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Chapter 1 
  
GENERAL INTRODUCTION
   
1. NORMAL HEMATOPOIESIS 
The blood of vertebrates is composed of different cell types that circulate in a fluid extracellular 
matrix called plasma. These cell types comprise erythrocytes (or red blood cells, RBC), that 
provide O2/CO2 transport, thrombocytes (or platelets, PLT), involved in hemostasis, and 
leukocytes (white blood cells, WBC), which protect the organism from infections. The lifespan of 
most blood cells is short compared to the organism they supply, with certain WBC populations 
having a half-life of 5 hours or less.1 The lifelong production of new blood cells, or hematopoiesis, 
is guaranteed by a pool of pluripotent cells that in adult mammals reside in the bone marrow 
(Figure 1). These cells, referred to as hematopoietic stem cells (HSCs), are able to divide and 
generate both differentiation-committed cells (called progenitors) and other pluripotent HSCs, 
virtually identical to the parent cell, which will preserve the hematopoietic capacity of the bone 
marrow over time. Proof that a single HSC can both differentiate and self-renew has been 
provided in different vertebrate models, showing that asymmetrical division of HSCs results from 
the specific orientation of cell fate determinants relative to the mitotic spindle.2-4 However, in 
homeostatic conditions most HSCs are not actively dividing, but rather preserved in a quiescent 
state, which is believed to be essential to maintain the genetic integrity of HSCs.5 
The differentiation of HSCs into mature blood cells occurs in a multistep process in which lineage 
maturation is associated with progressive restriction of multi-lineage cell potential. HSCs first 
differentiate into multipotent progenitors (MPPs), which lack self-renewal capacity but retain 
multi-lineage potential. MPPs further differentiate into oligopotent progenitors, namely the 
common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). CLPs are 
required to produce lymphoid cells, including natural killer (NK) cells, B and T lymphocytes and 
immature plasmacytoid dendritic cells (DC), which will complete their maturation outside of the 
blood stream. CMPs, on the other hand, differentiate into either megakaryocyte-erythroid 
progenitors (MEPs) or granulocyte-macrophage progenitors (GMPs). MEPs can further 
differentiate into RBCs or megakaryocytes (from which PLTs are produced), whereas GMPs give 
rise to immature myeloid DCs, monocytes/macrophages and granulocytes. The latter are immune 
cells characterized by the presence of cytoplasmic granules. Based on how such granules react to 
histochemical dyes (e.g. May-Grünwald-Giemsa or Wright’s staining), granulocytes are further 
classified into basophils, eosinophils and neutrophils.6 
 
Neutrophil maturation 
Neutrophilic granulocytes, or neutrophils, represent the most abundant WBC in the human blood 
and play a central role in the innate immune system, representing the first line of defense in the 
acute phase of inflammation. In response to chemotactic stimuli, neutrophils migrate from the  
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 Figure 1. Schematic view of hematopoiesis. Adapted from Reya et al.7 The production of blood cells 
requires the expansion and differentiation of otherwise quiescent HSCs. Through progressive 
differentiation into more committed progenitors, different blood cells are produced in the bone marrow 
and enter the blood stream. Myeloid cells (blue box) derive from CMPs, whereas lymphoid cells (orange 
box) originate from CLPs. Note that DCs can differentiate from either CMP or CLP, depending on their 
subtype. Eosinophils, neutrophils and basophils are collectively referred to as granulocytes (green box), 
and together with monocytes/macrophages, DCs and lymphoid cells constitute the different subtypes of 
WBCs (grey box).  
 
blood stream to the inflamed tissues. Here, they participate to the immune defense by different 
means, that include the degranulation and secretion of antimicrobial peptides, the phagocytosis 
of opsonized bacteria, the release of cytokines to amplify the immune response, and the secretion 
of the so-called neutrophil-extracellular traps (NETs), networks of chromatin and proteases that 
allow the physical containment of pathogens and their killing.8 
The differentiation of neutrophils from GMPs is associated with nuclear and cytoplasmic changes 
that morphologically define different maturation stages (Figure 2). Myeloblasts are the most 
primitive cells of the granulocytic lineage and are characterized by loose chromatin and visible 
nucleoli. The production of primary or azurophilic granules defines the promyelocyte stage: these 
granules contain different antimicrobial peptides, including myeloperoxidase, elastase, 
cathepsins and defensins. At the stage of myelocytes, secondary or specific granules are formed, 
which contain cytotoxic molecules such as lactoferrin and lysozyme. Myelocytes have a 
pronounced Golgi apparatus and represent the last dividing cell in the neutrophil maturation 
lineage. Metamyelocytes are post-mitotic cells with an eccentric, indented nucleus and more 
condensed chromatin. They are characterized by the production of tertiary granules (gelatinase), 
containing matrix remodeling enzymes such as MMP8 and MMP9. In humans, band cells have a 
typical horse-shoe shaped nucleus and a mature cytoplasm. They further differentiate into 
mature neutrophils, which present a segmented nucleus in humans and a donut-shaped one in 
mice.9 
Although in normal myelopoiesis only mature cells are released from the bone marrow into the 
blood, in case of infections and in certain bone marrow disorders immature myeloid cells circulate 
in the peripheral blood (left shift). Hematological disorders can also be characterized by dysplastic 
neutrophil morphology, with hypo- or hypersegmented nuclei, hypogranularity and presence of 
cytoplasmic inclusions.10 
 
 
Figure 2. Morphological staging of neutrophil development. Adapted from Pillay et al.11 Schematic 
representation of the morphological changes observed during neutrophil development in humans and 
mice. 
 
2. REGULATION OF HEMATOPOIETIC STEM CELLS BY THE BONE MARROW NICHE 
Whether a HSC will proliferate, differentiate or be kept quiescent depends on both cell intrinsic 
cues, such as the expression of lineage-instructive transcription factors, and extrinsic signals, 
including growth factors, cytokines, reactive oxygen species, and factors derived from the HSC 
niche.12,13 
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The HSC niche is defined as the local microenvironment that maintains and regulates HSCs. The 
supporting nature of the HSC microenvironment was first demonstrated in the late 1970s with 
seminal work of Michael Dexter, showing that the bone marrow stroma is able to support long-
term cultures of hematopoietic cells.14 The concept of the niche was next formulated by Ray 
Schofield, who hypothesized the existence of a “fixed tissue” where non-hematopoietic cells 
maintain HSCs and prevent their differentiation.15 
The supporting role of the niche results both from the physical interaction with HSCs, and 
consequently their retention in the microenvironment, and the active secretion of soluble factors 
that regulate HSC function. The physical adhesion to the niche depends on different proteins, 
expressed on the HSC plasma membrane, able to bind niche cells or components of the 
extracellular matrix; these proteins comprise VCAM1,16 CD4417 and the integrins α4β1, α6β1 and 
α9β1.18-21 Niche cells also secrete cytokines, chemokines and other molecules to maintain HSCs 
and keep them quiescent. The chemokine CXCL12 (or stromal cell-derived factor 1, SDF-1) binds 
to the receptor CXCR4 to keep HSCs quiescent and non-motile; its expression is increased by the 
stromal cells in the presence of different DNA damaging agents and upon parathyroid hormone 
(PTH) signaling.22,23 Stem cell factor (SCF, or Kit ligand) is expressed either in a soluble or in a 
membrane-bound form, the latter being required for HSC maintenance in vivo.24 Other important 
stroma-derived molecules regulating HSCs are angiopoietin 1, Notch and Wnt ligands and 
thrombopoietin.25-28 
The development of transgenic mouse models and the identification of HSC surface markers have 
contributed to define the cellular components of the bone marrow niche. Emerging data supports 
a view where different cell types may regulate HSCs both directly and indirectly, i.e. by signaling 
to other niche components, thus reshaping the definition of niche as a complex network rather 
than a single cellular entity.29 
 
Composition of the bone marrow niche 
While the cell types within the hematopoietic lineage and their hierarchy are relatively well 
defined (Figure 1), our understanding of the HSC niche composition is significantly more limited, 
mostly due to the rarity of HSCs and the difficulty in their identification in situ. 
The earliest attempts to define the microenvironment of primitive hematopoietic cells relied on 
fractionation experiments in mice, consisting in separating different areas of the bone marrow 
and evaluating the frequency of hematopoietic colony-forming units within each fraction.30 This 
led to the observation that primitive hematopoietic cells localize preferentially at the endosteum, 
and suggested that factors or cells located at the bone surface are important to sustain 
hematopoiesis.30  
This concept found further support in the early 2000s, with studies defining bone depositing cells 
(osteoblasts) as candidate components of the HSC niche. In one of these studies, inducing 
osteoblast proliferation through the activation of the parathyroid hormone receptor signaling 
resulted in the expansion of the hematopoietic stem and progenitor cell (HSPC) compartment.26 
The same result was achieved in a second study, in which osteoblast proliferation was 
experimentally induced through the conditional inactivation of the bone morphogenetic protein 
receptor type IA.31 Conversely, in a third study, ablating osteoblasts resulted in a severe yet 
reversible pancytopenia, with reduced numbers of primitive hematopoietic cells.32 
Collectively, these early reports indicated that osteoblasts influence the HSPC pool size in mice 
and suggested their role as niche components. In line with this view, cells of the osteoblastic 
lineage were shown to secrete important niche factors such as CXCL12,22,33 angiopoietin 1,25 
thrombopoietin28 and the Notch ligand Jagged-1.26 Finally, transplanting fetal bone cell 
populations under the mouse kidney capsule was sufficient to produce ectopic donor-derived 
niches for the recipient’s HSCs, niches that could not be formed by suppressing the expression of 
the osteogenic transcription factor osterix.34 
Further advances in the understanding of the niche composition followed the improvements in 
the HSC identification. The introduction of SLAM family receptors as HSC markers allowed a more 
accurate definition of the primitive hematopoietic compartment, with one in every 2.1 SLAM-
defined cells (CD48- CD150+ Lin- c-Kit+ Sca-1+) predicted to be a long term-HSC.35 The availability 
of these novel markers enabled a better  histological assessment of the spatial relationship 
between HSCs and their microenvironment. In contrast with earlier reports,30 SLAM marker-based 
imaging studies revealed that only 14% of the HSCs localized at the endosteum, while 60% were 
in contact with the sinusoidal endothelium.35 This opened the possibility that perivascular or 
endothelial cells could play a role in maintaining HSCs.  
Numerous studies supported this concept. First, a population of stromal cells was described that 
localized both at the endosteum and close to bone marrow sinusoids and expressed high amounts 
of the HSC supporting factor CXCL12; these cells were renamed CXCL12-abundant reticular (CAR) 
cells.36 Other perivascular cells identified by the expression of the intermediate filament Nestin 
were later found to produce CXCL12 and to be required for homing and maintenance of HSCs.37 
Additionally, endothelial cells seemed to regulate directly HSC expansion and self-renewal via 
Notch ligands and E-selectin signaling.38-40 To complete this complex scenario, other cell types in 
the bone marrow were demonstrated to regulate at different levels HSCs, among which 
osteoclasts,41 adipocytes42 and cells of the nervous system.42-45 
In an attempt to reach a unifying view among these different (and sometimes discrepant)47 niche 
models (Figure 3), researchers started interrogating the relative importance of different stromal 
components by systematically depleting key niche factors from each population and evaluating 
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the effects of such depletion on HSC biology. Endothelial and perivascular mesenchymal cells, 
defined respectively by the expression of the angiopoietin- (Tie2) and leptin receptor (Lepr), were 
in this way demonstrated to be essential sources of SCF. Deficiency of the ligand in Tie2+ and Lepr+ 
cells caused depletion of transplantable HSCs. No effect was observed instead by deleting Scf in 
other cell types, namely hematopoietic (Vav1+) cells, Nestin (Nes) expressing mesenchymal cells 
and osteoblasts (identified by expression of the marker Col2.3).48 Similarly, deficiency of CXCL12 
in perivascular or endothelial cells had dramatic effects on HSC maintenance, and resulted 
respectively in HSC mobilization (Lepr-cre mice), reduced frequency of HSCs (Tie2-cre model), and 
compromised HSC reconstitution capacity (deletion in Prx1+ perivascular mesenchymal cells).49,50 
Conversely, HSC frequencies were not affected when abrogating CXCL12 expression in Vav1+, Nes+ 
and osteolineage (Col2.3+ and osterix+) cells.49,50 
While these studies seem to converge on endothelial and perivascular cells as the main producers 
of key HSC niche factors, they do not formally exclude that other cell types contribute - at least 
indirectly - to HSC maintenance. This could explain the apparent discrepancy with earlier reports 
indicating bone lineage cells as essential niche components. In addition, recent data suggests that 
different putative niche cell types may be connected through unexpected differentiation 
hierarchies. For instance, perinatal osterix-expressing cells (Osx+), traditionally thought to 
represent osteoblast progenitors, were found to be a long-lived source of different stromal cell 
types, including adventitial and Nes+ perivascular cells51,52 (Figure 3). 
In conclusion, data derived from experiments in mice depicts a complex scenario where the 
identity and relative importance of the cell types composing the niche remains incompletely 
understood. Moreover, there is still little knowledge about how these results in mice rely to 
human biology. 
Few studies have analyzed the HSC niche composition in humans to date. An important one 
identified the adhesion molecule CD146 as marker of a population of perivascular and bone-
forming cells that express SCF and CXCL12.53 More recently, Tormin and colleagues showed that 
non-hematopoietic cells marked by the nerve growth factor receptor (CD271) are able to support 
hematopoiesis. This population comprises CD146+ perivascular and CD146- endosteal subsets, 
both localizing in proximity to human CD34+ hematopoietic stem and progenitor cells (HSPCs) in 
vivo.54 The transcriptional study of CD271+ cells confirmed the hematopoietic supporting activity 
of this population, as shown by the expression of angiopoietin-1 and CXCL12. Transcriptional 
analysis also indicated that CD271+ cells express markers for different mesenchymal fates, 
including pericytes (ACTA2, CSPG4, PDGFRA), osteoblasts (osterix, osteonectin, osteopontin, 
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the effects of such depletion on HSC biology. Endothelial and perivascular mesenchymal cells, 
defined respectively by the expression of the angiopoietin- (Tie2) and leptin receptor (Lepr), were 
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system. Alterations of this delicate balance may lead to disorders of hematopoiesis, such as acute 
myeloid leukemia and bone marrow failure. 
Acute myeloid leukemia (AML) is a form of hematopoietic malignancy characterized by 
uncontrolled proliferation of immature myeloid cells with impaired differentiation capacity. The 
expanding leukemic clone rapidly outgrows normal HSPCs, leading to decreased production of 
normal mature blood elements. Clinically, this translates in impaired blood function, with 
symptoms such as fatigue, increased risk of infections or bleeding episodes, and in the 
accumulation of myeloblasts in the blood and bone marrow of leukemic patients. The risk of 
developing acute myeloid leukemia is higher in patients affected by bone marrow failure 
syndromes.56 
Bone marrow failure (BMF) is defined as the impaired production of one or multiple 
hematopoietic lineages. Usually BMF presents itself as a deficiency in one specific blood cell type 
but can progress to involve all lineages. BMF can be acquired or genetically transmitted; the 
myelodysplastic syndromes represent the most common forms of acquired BMF syndromes.57 
 
Acquired BMF: the myelodysplastic syndromes 
The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic 
stem cells disorders characterized by ineffective, dysplastic hematopoiesis and a variable risk of 
progression to acute myeloid leukemia. Its etiology is largely unknown, but MDS can occur as a 
result of environmental exposure to chemotherapy and other mutagenic agents. In addition, MDS 
may develop in patients suffering from congenital BMF disorders, such as Fanconi anemia and 
Shwachman-Diamond syndrome.58 
Clinically, MDS is characterized by cytopenias, which include macro- or normocytic anemia, 
thrombocytopenia and neutropenia. Based on the presence of uni- or multilineage cytopenia, 
karyotypic changes and the percentage of circulating blasts, the International Prognostic Scoring 
System (IPSS) classifies the outcome of newly-diagnosed MDS patients into low, intermediate or 
high risk of acute myeloid leukemia (AML) development.59 
The molecular basis of MDS remains incompletely understood. More than 40 recurrent somatic 
mutations have so far been associated with MDS, implicating - among others - RNA splicing, 
epigenetics, transcription factor activation and ribosome biogenesis pathways in its 
pathogenesis.60 Although these molecular insights may instruct MDS research and potentially 
suggest novel treatments, it needs to be pointed out that clonal, MDS-associated mutations have 
been described in otherwise healthy individuals.61,62 At the same time, patients with idiopatic 
cytopenia and idiopatic dysplasia often evolve to MDS in the absence of the genetic mutations or 
aberrant karyotypes typically associated with MDS.63 Disease progression in these patients may 
depend on the acquisition of unknown mutations, but it could also indicate that the pathogenesis 
of MDS may be complex, with the HSC genetic make-up being an important, but not exclusive 
determinant factor for MDS development. 
 
Inherited forms of bone marrow failure: the ribosomopathies 
Inherited bone marrow failure syndromes (IBMFS) include, among others, Fanconi anemia, severe 
congenital neutropenia and the disease family of so-called ribosomopathies. 
Ribosomopathies are diseases caused by mutations affecting the biogenesis of ribosomes, cellular 
ribonucleoprotein complexes required for protein translation. In eukaryotes, the biosynthesis of 
ribosomes is a complex multistep event that requires four types of ribosomal RNA (rRNA), over 
80 ribosomal structural proteins, more than 150 different assembly proteins and around 70 small 
nucleolar RNAs (snoRNA), which cooperate to produce the small (40S) and the large (60S) subunit 
of ribosomes. 
The biogenesis of ribosomes is schematically represented in Figure 4. Briefly, rRNAs are first 
transcribed as precursors by RNA polymerases: in particular, RNA polymerase I (Pol-I) transcribes 
the 45S multicistronic pre-rRNA, which will generate the 5.8S, 18S and 28S rRNA species, while 
RNA polymerase III (Pol-III) transcribes the 5S pre-rRNA. These rRNA precursors are further 
processed in the nucleolus (45S) or in the cytoplasm (pre-5S) to generate the final rRNA 
components of the ribosomes. Next, the ribosomal proteins are imported in the nucleus and 
assembled onto rRNAs to form the pre-40S and pre-60S subunits. These precursor subunits are 
then exported in the cytoplasm to generate the mature 40S and 60S subunits, ready to be 
assembled in a translation-competent 80S ribosome. 
Despite the large number of genes involved in ribosome biogenesis, relatively few have been 
found mutated in ribosomopathies (Figure 4 and Table 1), probably because a strong selective 
pressure exists to remove malfunctioning ribosomes. Most of the different ribosomopathies 
described to date are inherited, but sporadic mutations of ribosomal genes RPL5, RPL10 and 
RPL22 have been observed in patients suffering from T cell acute lymphoblastic leukemia,64,65 and 
a causative link with impaired ribosome biogenesis has been demonstrated for the 5q- 
syndrome.66,67 This acquired disorder of hematopoietic cells is characterized by a monosomy 
involving all or part of the long arm of human chromosome 5 and is associated with development 
of low-risk MDS.66 Haploinsufficiency of RPS24, mapping on 5q, has been demonstrated to 
participate in the pathogenesis of the macrocytic anemia in 5q- syndrome patients.67,68 
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Figure 4. Impairment of ribosome biogenesis in ribosomopathies. Schematic representation of ribosomal 
biogenesis and indication of the steps affected in different ribosomopathies. TCS: Treacher Collins 
syndrome. X-DC: X-linked dyskeratosis congenita. CHH: cartilage hair hypoplasia. AD: anauxetic dysplasia. 
NAIC: North American Indian childhood cirrhosis. BCS: Bowen-Conradi syndrome. SDS: Shwachman-
Diamond syndrome. DBA: Diamond-Blackfan anemia. ICA: isolated congenital asplenia. 
 
Interestingly, predisposition to MDS characterizes other (inherited) ribosomopathies, suggesting 
a specific dependency of myeloid lineage cells for efficient ribosomal biogenesis. An increased 
risk to develop MDS and progress to AML is observed in patients suffering from X-linked 
dyskeratosis congenita, Diamond-Blackfan anemia and Shwachman-Diamond syndrome, albeit 
malignancy occurs in these disorders at different frequencies. Predisposition to cancer, including 
MDS/AML, is observed in around 4% of Diamond Blackfan anemia patients, less than in other 
IBMFS.69 
Perhaps the inherited ribosomopathy with the highest degree of genetic heterogeneity (Table 1), 
Diamond Blackfan anemia (DBA) is a pure RBC aplasia disorder characterized by macrocytic 
anemia, reticulocytopenia and decreased erythroid precursors in the bone marrow.70 Genetically, 
DBA is a heterogeneous disease. The first ribosomal gene discovered to be mutated in DBA was 
RPS19, which is indeed mutated in around 25% of patients.71 Since then, mutations or deletions 
in other genes encoding for large or small subunit ribosomal proteins have been discovered (Table 
1), which globally affect more than 50% of all DBA patients.72 Mutations in the erythroid 
transcription factor GATA1 have also been found in rare DBA cases, leading to reduced expression 
of full length GATA1 isoforms.73 Interestingly, it has been shown that haploinsufficiency of 
ribosomal protein genes in DBA leads to reduced GATA1 translation, thus impaired GATA1 activity 
may represent a common mechanism underlying RBC aplasia in DBA.74,75 Moreover, reduced 
translation of specific genes characterized by internal ribosomal entry sites (IRES), some of which  
known to be required for erythropoiesis (Bag1, Csde1), could contribute to the pathogenesis of 
DBA.93 
 
Table 1. Inherited ribosomopathies. 
Disease Mutated gene Non hematological features Hematologic 
defects 
Cancer 
predisposition 
Treacher Collins 
syndrome 
TCOF1,76 
POLR1D,77 
POLR1C77 
Craniofacial deformities, 
abnormal airways, ear 
anomalies 
None None 
X-linked 
dyskeratosis 
congenita 
DKC178 Skin hyperpigmentation, nail 
dystrophy, oral leukoplakia 
Progressive BMF MDS, AML, head 
and neck tumors 
Diamond-
Blackfan anemia 
RPS7,79 RPS10,80 
RPS17,81 RPS19,71 
RPS24,82 RPS26,80 
RPL5,83 RPL11,83 
RPL26,84 RPL35A85 
Craniofacial and thumb 
abnormalities, cardiac 
defects, growth retardation 
Red cell aplasia Osteosarcoma, 
MDS and AML 
(low frequency) 
Cartilage hair 
hypoplasia 
RMRP86 Short limb dwarfism, sparse 
hair, malabsorption 
Lympho- and 
neutropenia, 
macrocytic anemia 
Non-Hodgkin 
lymphoma, basal 
cell carcinoma 
North American 
Indian childhood 
cirrhosis 
CIRH1A87 Transient neonatal jaundice 
progressing to biliary 
cirrhosis 
None None 
Shwachman-
Diamond 
syndrome 
SBDS88 Exocrine pancreas 
insufficiency, short stature, 
early onset osteoporosis, 
metaphyseal dysostosis 
Neutropenia, 
anemia, 
thrombocytopenia 
MDS and AML 
(high frequency) 
Anauxetic 
dysplasia 
RMRP89 Severe short stature, 
hypodontia, 
mentalretardation 
None None 
Bowen-Conradi 
syndrome 
EMG190 Severe growth retardation, 
craniofacial defects, 
rockerbottom feet 
None None 
Isolated 
congenital 
asplenia 
RPSA91 None Agenesis or 
hypoplasia of 
spleen leading to 
immunodeficiency, 
Howell-Jolly bodies 
None 
Aplasia cutis 
congenita 
BMS192 Local agenesis of skin None None 
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Tissue specificity in inherited ribosomopathies  
While the sporadic nature of T-ALL and 5q- syndrome naturally limits the symptoms of this disease 
to a single tissue, it would be intuitive to think that a congenital ribosomal defect should 
homogeneously affect all organs, as protein translation is equally required in every cell of our 
body. On the contrary, the symptoms of inherited ribosomopathies are rather limited to few or 
even one tissue, as it is the case for North American Indian childhood cirrhosis, isolated congenital 
asplenia and aplasia cutis congenita (Table 1). Moreover, although affecting the same metabolic 
process, different ribosomopathies do not share the same tissue specificity, albeit many are 
associated with development of BMF and increased risk of developing blood cancers (Table 1). 
Solving the central enigma of tissue specificity in ribosomopathies is crucial to the field as it may 
result in more efficient therapies and perhaps preventive treatments against cancer development 
in these conditions. 
A theory frequently proposed to explain this conundrum considers the symptoms of 
ribosomopathies as resulting from defects of cell proliferation. In particular, ribosomopathies 
would affect tissues with a high proliferative rate, like the bone marrow, leading to their aplasia. 
This concept derives from the regulatory role of ribosome biogenesis in cell cycle progression. In 
yeast, most of the translational machinery is devoted to the production of ribosomes, thus 
ribosome biogenesis itself competes with the translation of cell cycle regulators, often 
characterized by complex mRNA structures and high protein turnover, until threshold 
concentrations of ribosomes are reached.94 This represents a control system that couples mitosis 
with cell growth, allowing the cell to divide only after a sufficient level of protein synthesis. 
Evidence of impaired cell division upon deficit of ribosomal components is found in metazoans. 
Haploinsufficiency of ribosomal protein genes in Drosophila “minute” mutants induces a 
developmental delay with an overall decrease in cell mitotic rate, while conditional deletion of 
ribosomal protein S6 in mouse liver compromises hepatic cell proliferation and thus organ 
regeneration.95,96 
While impaired proliferation could explain the hypoplastic phenotypes often observed in 
ribosomopathies, the limitations of considering this phenomenon as the sole pathogenic factor 
underlying these diseases should be considered. First, this view would predict that every organ 
system should be equally compromised during embryogenesis, since at this stage every tissue is 
rapidly proliferating. Moreover, according to this theory, different ribosomopathies should affect 
the same tissues (those with the highest proliferative rates), which is in contrast with the 
heterogeneity of clinical symptoms in ribosomopathies. In the context of hematopoiesis, one 
would imagine that all blood lineages should be affected by ribosomal biogenesis defects, as all 
hematopoietic progenitors are fast dividing, while distinct ribosomopathies show different blood 
cell lineage proclivity. 
Alternative explanations for tissue specificity in ribosomopathies have been proposed. First, in 
contrast with the view of ribosomes as “housekeeping” entities, with constant composition in 
every cell, the existence of “specialized” ribosomes, different in composition or in mRNA 
targeting, has been reported. The haploinsufficiency of ribosomal gene Rpl38 in mouse results in 
homeotic transformation of distinct axial skeleton regions.97 Interestingly, the expression pattern 
of Rpl38 in mouse embryos is enriched in the same regions and is locally required to translate 
Homeobox A (HoxA) gene transcripts from IRES elements localized in their 5’ untranslated regions 
(5’-UTR).97,98 As previously indicated, reduced IRES-mediated translation of Bag1 and Csde1 has 
been observed in mouse erythroblast cell lines haploinsufficient for DBA-related genes, leading 
to impaired erythroid differentiation.76 Defective translation from IRES has been shown also in 
primary lymphoblasts and fibroblasts from individuals affected by X-linked dyskeratosis 
congenita.99 
Finally, it is possible that ribosomopathy-associated genes may have extra-ribosomal functions 
restricted to specific cell types. In this regard, it is interesting to note how both cartilage hair 
hypoplasia (CHH) and anauxetic dysplasia (AD) are caused by mutations in the RMRP gene, 
required for 5.8S rRNA cleavage, albeit only CHH is associated with bone marrow failure and 
cancer predisposition. Interestingly, RMRP is also required for cell cycle regulation by mediating 
cyclin B degradation, but accumulation of cyclin B is observed only in CHH, perhaps explaining 
cancer predisposition in this ribosomopathy. 
 
Role of p53 in ribosomopathies 
The tumor suppressor protein p53 is a master regulator of cell fate and induces programs of cell 
cycle arrest, senescence and apoptosis in response to different stressors. It has emerged that 
impaired ribosome biogenesis can activate the p53 pathway, resulting in programmed cell death. 
In healthy cells, the concentration of p53 is kept low by continuous proteasome degradation, 
which requires p53 ubiquitination by MDM2. Perturbation of ribosome biogenesis uncouples 
rRNA transcription and protein synthesis, leading to nucleolar stress and accumulation of 
unincorporated ribosomal proteins. Several of these proteins (RPL11,100 RPL23,101,102 RPL5,103 
RPS7,104 RPL26105, and RPS3106) have been shown to bind and segregate MDM2, thus inducing 
activation of the p53 pathway. 
Animal models have shown that p53 activation may functionally underlie the pathogenesis of 
ribosomopathies. Monoallelic loss of Trp53 rescues craniofacial anomalies in a mouse model of 
Treacher Collins syndrome by preventing apoptosis of neural crest cells.107 Similarly, reduced dose 
of Trp53 ameliorates RBC counts in mice with heterozygous mutations of Rps19 and rescues 
macrocytic anemia in a mouse model of 5q- syndrome.68,108 
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even one tissue, as it is the case for North American Indian childhood cirrhosis, isolated congenital 
asplenia and aplasia cutis congenita (Table 1). Moreover, although affecting the same metabolic 
process, different ribosomopathies do not share the same tissue specificity, albeit many are 
associated with development of BMF and increased risk of developing blood cancers (Table 1). 
Solving the central enigma of tissue specificity in ribosomopathies is crucial to the field as it may 
result in more efficient therapies and perhaps preventive treatments against cancer development 
in these conditions. 
A theory frequently proposed to explain this conundrum considers the symptoms of 
ribosomopathies as resulting from defects of cell proliferation. In particular, ribosomopathies 
would affect tissues with a high proliferative rate, like the bone marrow, leading to their aplasia. 
This concept derives from the regulatory role of ribosome biogenesis in cell cycle progression. In 
yeast, most of the translational machinery is devoted to the production of ribosomes, thus 
ribosome biogenesis itself competes with the translation of cell cycle regulators, often 
characterized by complex mRNA structures and high protein turnover, until threshold 
concentrations of ribosomes are reached.94 This represents a control system that couples mitosis 
with cell growth, allowing the cell to divide only after a sufficient level of protein synthesis. 
Evidence of impaired cell division upon deficit of ribosomal components is found in metazoans. 
Haploinsufficiency of ribosomal protein genes in Drosophila “minute” mutants induces a 
developmental delay with an overall decrease in cell mitotic rate, while conditional deletion of 
ribosomal protein S6 in mouse liver compromises hepatic cell proliferation and thus organ 
regeneration.95,96 
While impaired proliferation could explain the hypoplastic phenotypes often observed in 
ribosomopathies, the limitations of considering this phenomenon as the sole pathogenic factor 
underlying these diseases should be considered. First, this view would predict that every organ 
system should be equally compromised during embryogenesis, since at this stage every tissue is 
rapidly proliferating. Moreover, according to this theory, different ribosomopathies should affect 
the same tissues (those with the highest proliferative rates), which is in contrast with the 
heterogeneity of clinical symptoms in ribosomopathies. In the context of hematopoiesis, one 
would imagine that all blood lineages should be affected by ribosomal biogenesis defects, as all 
hematopoietic progenitors are fast dividing, while distinct ribosomopathies show different blood 
cell lineage proclivity. 
Alternative explanations for tissue specificity in ribosomopathies have been proposed. First, in 
contrast with the view of ribosomes as “housekeeping” entities, with constant composition in 
every cell, the existence of “specialized” ribosomes, different in composition or in mRNA 
targeting, has been reported. The haploinsufficiency of ribosomal gene Rpl38 in mouse results in 
homeotic transformation of distinct axial skeleton regions.97 Interestingly, the expression pattern 
of Rpl38 in mouse embryos is enriched in the same regions and is locally required to translate 
Homeobox A (HoxA) gene transcripts from IRES elements localized in their 5’ untranslated regions 
(5’-UTR).97,98 As previously indicated, reduced IRES-mediated translation of Bag1 and Csde1 has 
been observed in mouse erythroblast cell lines haploinsufficient for DBA-related genes, leading 
to impaired erythroid differentiation.76 Defective translation from IRES has been shown also in 
primary lymphoblasts and fibroblasts from individuals affected by X-linked dyskeratosis 
congenita.99 
Finally, it is possible that ribosomopathy-associated genes may have extra-ribosomal functions 
restricted to specific cell types. In this regard, it is interesting to note how both cartilage hair 
hypoplasia (CHH) and anauxetic dysplasia (AD) are caused by mutations in the RMRP gene, 
required for 5.8S rRNA cleavage, albeit only CHH is associated with bone marrow failure and 
cancer predisposition. Interestingly, RMRP is also required for cell cycle regulation by mediating 
cyclin B degradation, but accumulation of cyclin B is observed only in CHH, perhaps explaining 
cancer predisposition in this ribosomopathy. 
 
Role of p53 in ribosomopathies 
The tumor suppressor protein p53 is a master regulator of cell fate and induces programs of cell 
cycle arrest, senescence and apoptosis in response to different stressors. It has emerged that 
impaired ribosome biogenesis can activate the p53 pathway, resulting in programmed cell death. 
In healthy cells, the concentration of p53 is kept low by continuous proteasome degradation, 
which requires p53 ubiquitination by MDM2. Perturbation of ribosome biogenesis uncouples 
rRNA transcription and protein synthesis, leading to nucleolar stress and accumulation of 
unincorporated ribosomal proteins. Several of these proteins (RPL11,100 RPL23,101,102 RPL5,103 
RPS7,104 RPL26105, and RPS3106) have been shown to bind and segregate MDM2, thus inducing 
activation of the p53 pathway. 
Animal models have shown that p53 activation may functionally underlie the pathogenesis of 
ribosomopathies. Monoallelic loss of Trp53 rescues craniofacial anomalies in a mouse model of 
Treacher Collins syndrome by preventing apoptosis of neural crest cells.107 Similarly, reduced dose 
of Trp53 ameliorates RBC counts in mice with heterozygous mutations of Rps19 and rescues 
macrocytic anemia in a mouse model of 5q- syndrome.68,108 
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Nevertheless, the relation between p53 and ribosomopathies may be more complex. First, 
accumulation of p53 protein is not a necessary consequence of ribosomal stress. Heterozygous 
mutations in 17 different zebrafish ribosomal proteins lead to poor p53 translation rather than its 
accumulation and induced the formation of tumors similar to those developing upon loss-of-
function mutation of p53.109 Second, the activation of p53 may not be required for disease 
pathogenesis. For instance, the skeletal patterning defect of Rpl38 haploinsufficient mice is not 
rescued by reduced dosage of Trp53.97 Interestingly, alternative models of Rps19 deficiency in 
zebrafish and in murine cell lines showed p53-independent defects of erythropoiesis.76,110 Finally, 
distinct models of SBDS deficiency reached opposite conclusions about the requirements of p53 
activation for pancreatic insufficiency in Shwachman Diamond syndrome.111,112 
 
Shwachman-Diamond syndrome 
Shwachman-Diamond syndrome (SDS) is an autosomal recessive genetic disease caused by 
mutation in the gene SBDS and characterized by exocrine pancreatic insufficiency, skeletal 
abnormalities, bone marrow failure (in particular neutropenia), and a strong predisposition to 
develop MDS and AML.113,114 The disease occurs with an incidence of around 1:77,000115 and is 
typically diagnosed in the first year of life based on the pancreatic phenotype (steatorrhea and 
nutrient malabsorption) and the recurrence of infections. Differential diagnosis, including genetic 
testing, is necessary to exclude cystic fibrosis and Pearson disease, also characterized by 
pancreatic failure and frequent infection episodes. 
 
Clinical manifestations and treatment 
Bone defects are common in SDS patients and include short stature, delayed dentition, 
metaphysial and thoracic dysplasia, and early onset low-turnover osteoporosis, defined as 
osteopenia caused by a reduced number of osteoblasts and osteoclasts.116,117 Skeletal defects 
may regress in time or progress and cause limb deformity and fracturing of the femoral necks.116 
Orthopedic intervention is however rarely required and surgery is mostly limited to cases of rib 
cage defects impairing the patient’s respiratory capacity. 
Although severe pancreatic insufficiency is a major concern in newborn and infant SDS patients, 
this condition often improves with age and pancreatic enzyme supplementation treatment can 
be stopped in half of the patients at the age of 4.118 However, it must be pointed out that a 
progressive involvement of the gastrointestinal tract is possible, most notably diagnosed as 
hepatic disorders.119 Neurocognitive deficits have been described in some SDS patients, albeit 
symptoms varied widely.120 
The hematological features of SDS are the main cause of morbidity and mortality in the disease. 
The hallmark of BMF in SDS is neutropenia, observed in at least 90% of the patients.121 Beside 
having reduced counts, neutrophils can also show defects of chemotaxis.122,123 Adaptive immunity 
may be compromised in SDS, probably contributing to the high frequency of infections in these 
patients. Different degrees of B and T cell defects have been registered, including low number of 
B cells and reduced production of antibodies.124 Anemia and thrombocytopenia are observed in 
many patients, although they are often intermittent or asymptomatic.125,126 The bone marrow of 
SDS patients is often hypocellular, and left-shifted myelopoiesis is a common finding, with 24.7-
30% of patients presenting myeloid maturation arrest in the bone marrow.126,127 Increased 
vascularity can be observed upon progression to MDS/AML.128  
Malignant progression of the hematological disease is a major concern in SDS. The estimated 
cumulative risk of leukemia in SDS patients varies in different reports between 20 and 70%, with 
higher risk in case MDS is diagnosed.116,129 The bone marrow cytogenetic abnormalities i(7q) and 
del(20q), typical of MDS/AML, are often observed in SDS patients in the absence of overt MDS 
and they largely persist without progressing to malignancy.121 
The treatment of hematological defects in SDS is typically limited to oral antibiotics, in case of 
infections, and monitoring of the disease. Patients with anemia or thrombocytopenia rarely 
require blood transfusions and G-CSF treatment is usually not prescribed for neutropenia, but can 
be beneficial in case of recurrent infections. Bone marrow smears and biopsies are recommended 
at the time of diagnosis and every 1-3 years to monitor progression to MDS and AML. HSC 
transplantation is the elected treatment in case of severe aplastic anemia or leukemia, while 
chemotherapy is usually not recommended.114   
 
Molecular genetics 
SDS is considered a monogenic genetic disease, as 90% of patients show mutations in the 
Shwachman-Bodian-Diamond syndrome gene (SBDS), mapping on chromosome 7q11.89 The two 
most common mutations, c.183-184TA>CT and c.258+2T>C, are thought to arise from 
recombination events (gene conversion) between SBDS and its paralogous pseudogene copy 
SBDSP, located 5.8 Mb distally from SBDS.89 Patients are mostly compound heterozygous for the 
two mutations, however other mutations can be observed, resulting in deletions/insertions, 
premature truncations, frameshifts or amino acidic substitutions.89,130  
The c.183-184TA>CT mutation introduces an in-frame premature stop (K62X) in SBDS mRNA, 
while c.258+2T>C disrupts the donor splice site of intron 2, and promotes the use of a cryptic 
upstream donor site at position 251-252.89 This ultimately results in an 8 bp deletion and a 
consequent frameshift (C84fsX3), with creation of a premature stop codon (UAA codon at 
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Nevertheless, the relation between p53 and ribosomopathies may be more complex. First, 
accumulation of p53 protein is not a necessary consequence of ribosomal stress. Heterozygous 
mutations in 17 different zebrafish ribosomal proteins lead to poor p53 translation rather than its 
accumulation and induced the formation of tumors similar to those developing upon loss-of-
function mutation of p53.109 Second, the activation of p53 may not be required for disease 
pathogenesis. For instance, the skeletal patterning defect of Rpl38 haploinsufficient mice is not 
rescued by reduced dosage of Trp53.97 Interestingly, alternative models of Rps19 deficiency in 
zebrafish and in murine cell lines showed p53-independent defects of erythropoiesis.76,110 Finally, 
distinct models of SBDS deficiency reached opposite conclusions about the requirements of p53 
activation for pancreatic insufficiency in Shwachman Diamond syndrome.111,112 
 
Shwachman-Diamond syndrome 
Shwachman-Diamond syndrome (SDS) is an autosomal recessive genetic disease caused by 
mutation in the gene SBDS and characterized by exocrine pancreatic insufficiency, skeletal 
abnormalities, bone marrow failure (in particular neutropenia), and a strong predisposition to 
develop MDS and AML.113,114 The disease occurs with an incidence of around 1:77,000115 and is 
typically diagnosed in the first year of life based on the pancreatic phenotype (steatorrhea and 
nutrient malabsorption) and the recurrence of infections. Differential diagnosis, including genetic 
testing, is necessary to exclude cystic fibrosis and Pearson disease, also characterized by 
pancreatic failure and frequent infection episodes. 
 
Clinical manifestations and treatment 
Bone defects are common in SDS patients and include short stature, delayed dentition, 
metaphysial and thoracic dysplasia, and early onset low-turnover osteoporosis, defined as 
osteopenia caused by a reduced number of osteoblasts and osteoclasts.116,117 Skeletal defects 
may regress in time or progress and cause limb deformity and fracturing of the femoral necks.116 
Orthopedic intervention is however rarely required and surgery is mostly limited to cases of rib 
cage defects impairing the patient’s respiratory capacity. 
Although severe pancreatic insufficiency is a major concern in newborn and infant SDS patients, 
this condition often improves with age and pancreatic enzyme supplementation treatment can 
be stopped in half of the patients at the age of 4.118 However, it must be pointed out that a 
progressive involvement of the gastrointestinal tract is possible, most notably diagnosed as 
hepatic disorders.119 Neurocognitive deficits have been described in some SDS patients, albeit 
symptoms varied widely.120 
The hematological features of SDS are the main cause of morbidity and mortality in the disease. 
The hallmark of BMF in SDS is neutropenia, observed in at least 90% of the patients.121 Beside 
having reduced counts, neutrophils can also show defects of chemotaxis.122,123 Adaptive immunity 
may be compromised in SDS, probably contributing to the high frequency of infections in these 
patients. Different degrees of B and T cell defects have been registered, including low number of 
B cells and reduced production of antibodies.124 Anemia and thrombocytopenia are observed in 
many patients, although they are often intermittent or asymptomatic.125,126 The bone marrow of 
SDS patients is often hypocellular, and left-shifted myelopoiesis is a common finding, with 24.7-
30% of patients presenting myeloid maturation arrest in the bone marrow.126,127 Increased 
vascularity can be observed upon progression to MDS/AML.128  
Malignant progression of the hematological disease is a major concern in SDS. The estimated 
cumulative risk of leukemia in SDS patients varies in different reports between 20 and 70%, with 
higher risk in case MDS is diagnosed.116,129 The bone marrow cytogenetic abnormalities i(7q) and 
del(20q), typical of MDS/AML, are often observed in SDS patients in the absence of overt MDS 
and they largely persist without progressing to malignancy.121 
The treatment of hematological defects in SDS is typically limited to oral antibiotics, in case of 
infections, and monitoring of the disease. Patients with anemia or thrombocytopenia rarely 
require blood transfusions and G-CSF treatment is usually not prescribed for neutropenia, but can 
be beneficial in case of recurrent infections. Bone marrow smears and biopsies are recommended 
at the time of diagnosis and every 1-3 years to monitor progression to MDS and AML. HSC 
transplantation is the elected treatment in case of severe aplastic anemia or leukemia, while 
chemotherapy is usually not recommended.114   
 
Molecular genetics 
SDS is considered a monogenic genetic disease, as 90% of patients show mutations in the 
Shwachman-Bodian-Diamond syndrome gene (SBDS), mapping on chromosome 7q11.89 The two 
most common mutations, c.183-184TA>CT and c.258+2T>C, are thought to arise from 
recombination events (gene conversion) between SBDS and its paralogous pseudogene copy 
SBDSP, located 5.8 Mb distally from SBDS.89 Patients are mostly compound heterozygous for the 
two mutations, however other mutations can be observed, resulting in deletions/insertions, 
premature truncations, frameshifts or amino acidic substitutions.89,130  
The c.183-184TA>CT mutation introduces an in-frame premature stop (K62X) in SBDS mRNA, 
while c.258+2T>C disrupts the donor splice site of intron 2, and promotes the use of a cryptic 
upstream donor site at position 251-252.89 This ultimately results in an 8 bp deletion and a 
consequent frameshift (C84fsX3), with creation of a premature stop codon (UAA codon at 
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position 267-269 of the wild type mRNA).89 Both the truncating and the frameshift mutations 
have been shown to induce reduction or complete absence of detectable protein levels in patient-
derived WBCs, while missense mutations have been proposed to affect the stability and the 
conformation of SBDS protein.131,132 
 
Function of SBDS 
Since its association with SDS, it was observed that SBDS represented a highly conserved gene 
with orthologs in archaea, plants and vertebrates.89 The archaeal SBDS ortholog clusters in an 
operon encoding predicted RNA-processing exosome components and proteins of the large 
ribosomal subunit.133 The bona fide function of SBDS protein in ribosome biogenesis (Figure 5) 
was first described in yeast, where the SBDS ortholog SDO1 was shown to mediate the release of 
the nucleolar shuttling factor TIF6 (ortholog of mammalian eukaryotic initiating factor 6, eIF6) 
from pre-60S ribosomes, allowing the recycling of TIF6, the full maturation of the large subunit 
and its binding to the 40S.134 Studies in Sbds inducible knock-out mouse models later elucidated 
the mechanisms of eIF6 release and proved that SBDS couples the GTPase activity of elongation 
factor-like 1 (EFL1) to a structural conformational change that induces eIF6 release.132 Reduced 
ribosomal subunit joining was observed in SDS patients, indicating that SBDS mutations impair 
the eIF6 releasing function of SBDS.135,136  
 
 
Figure 5. SBDS induces eIF6 release in ribosome biogenesis. Adapted from Menne et al.134 and Finch et 
al.132 SBDS and EFL1 are recruited on the pre-60S subunit. Upon GTPase activity of EFL1, SBDS changes 
conformation, allowing the release of eIF6 and its recycling in the nucleus, where it works as a shuttling 
factor for pre-60S. 
Beside its role in ribosome biogenesis, other functions have been suggested for SBDS protein. 
Based on SBDS localization at the mitotic spindle and its binding to microtubules, it was proposed 
that SBDS is required in mitosis.137,138 Other studies showed colocalization of SBDS with F-actin 
and Rac2 in neutrophil cellular protrusions and disruption of actin polarization in SDS neutrophils, 
indicating a possible role for SBDS in the metabolism of the cytoskeleton.139 However, it needs to 
be pointed out that SBDS localization at the cytoskeleton may also reflect localized translation of 
cytoskeleton proteins. Finally, SBDS may have a general function in the context of cellular stress, 
as it was shown to improve cellular survival after DNA damage and endoplasmic reticulum stress, 
perhaps through its binding to RPA70 and DNA-PK.140 
 
Pathogenesis of bone marrow failure in SDS 
While there is increasing knowledge on the function of SBDS, the consequences of its mutations 
for BMF pathogenesis remain poorly elucidated, partly due to the difficulties in obtaining viable 
in vivo models of SBDS deficiency. Homozygous deletion of Sbds in mice induces embryonic death 
before the time of gastrulation.141 The missense mutation R126T, rarely associated with SDS, is 
similarly lethal in homozygous embryos, although it was predicted to be a hypomorphic rather 
than null mutation.89,112,142 Transplantation of bone marrow cells after robust lentiviral vector-
mediated Sbds knock down is equally associated with lethality due to a lack of engraftment, while 
reducing the viral load during transduction preserves recipient viability but fails to significantly 
reproduce SDS-associated neutropenia in mice.143 
Zebrafish models have been used to investigate the consequences of Sbds deficiency for 
development. Impairing sbds translation or splicing with morpholinos induced exocrine 
pancreatic hypoplasia, chondro-osseous abnormalities and reduced numbers of myeloid cells.121 
While it was possible to explain the pancreatic phenotype in terms of reduced expansion of ptf1a-
expressing progenitors, the mechanisms behind impaired myelopoiesis remained unclear. 
Moreover, a preferential expression of sbds in the gastrointestinal tract could explain the 
pancreas but not the hematopoietic defects in this model.144 With respect to tissue specificity, it 
is also interesting to note that different models of Sbds deficiency showed an overall impairment 
of hematopoiesis but failed to reproduce the neutrophil specificity observed in the clinical 
spectrum of many SDS patients. The embryonic lethal SbdsR126T mouse model showed similar 
reduction of granulocytic, monocytic and erythroid progenitors by colony-forming unit (CFU) 
assay.112 Hematopoietic differentiation of SDS patient-derived induced pluripotent stem cells 
(iPSCs) similarly failed to show lineage-skewed defects, while an overall reduction in CFU numbers 
was observed.145 
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position 267-269 of the wild type mRNA).89 Both the truncating and the frameshift mutations 
have been shown to induce reduction or complete absence of detectable protein levels in patient-
derived WBCs, while missense mutations have been proposed to affect the stability and the 
conformation of SBDS protein.131,132 
 
Function of SBDS 
Since its association with SDS, it was observed that SBDS represented a highly conserved gene 
with orthologs in archaea, plants and vertebrates.89 The archaeal SBDS ortholog clusters in an 
operon encoding predicted RNA-processing exosome components and proteins of the large 
ribosomal subunit.133 The bona fide function of SBDS protein in ribosome biogenesis (Figure 5) 
was first described in yeast, where the SBDS ortholog SDO1 was shown to mediate the release of 
the nucleolar shuttling factor TIF6 (ortholog of mammalian eukaryotic initiating factor 6, eIF6) 
from pre-60S ribosomes, allowing the recycling of TIF6, the full maturation of the large subunit 
and its binding to the 40S.134 Studies in Sbds inducible knock-out mouse models later elucidated 
the mechanisms of eIF6 release and proved that SBDS couples the GTPase activity of elongation 
factor-like 1 (EFL1) to a structural conformational change that induces eIF6 release.132 Reduced 
ribosomal subunit joining was observed in SDS patients, indicating that SBDS mutations impair 
the eIF6 releasing function of SBDS.135,136  
 
 
Figure 5. SBDS induces eIF6 release in ribosome biogenesis. Adapted from Menne et al.134 and Finch et 
al.132 SBDS and EFL1 are recruited on the pre-60S subunit. Upon GTPase activity of EFL1, SBDS changes 
conformation, allowing the release of eIF6 and its recycling in the nucleus, where it works as a shuttling 
factor for pre-60S. 
Beside its role in ribosome biogenesis, other functions have been suggested for SBDS protein. 
Based on SBDS localization at the mitotic spindle and its binding to microtubules, it was proposed 
that SBDS is required in mitosis.137,138 Other studies showed colocalization of SBDS with F-actin 
and Rac2 in neutrophil cellular protrusions and disruption of actin polarization in SDS neutrophils, 
indicating a possible role for SBDS in the metabolism of the cytoskeleton.139 However, it needs to 
be pointed out that SBDS localization at the cytoskeleton may also reflect localized translation of 
cytoskeleton proteins. Finally, SBDS may have a general function in the context of cellular stress, 
as it was shown to improve cellular survival after DNA damage and endoplasmic reticulum stress, 
perhaps through its binding to RPA70 and DNA-PK.140 
 
Pathogenesis of bone marrow failure in SDS 
While there is increasing knowledge on the function of SBDS, the consequences of its mutations 
for BMF pathogenesis remain poorly elucidated, partly due to the difficulties in obtaining viable 
in vivo models of SBDS deficiency. Homozygous deletion of Sbds in mice induces embryonic death 
before the time of gastrulation.141 The missense mutation R126T, rarely associated with SDS, is 
similarly lethal in homozygous embryos, although it was predicted to be a hypomorphic rather 
than null mutation.89,112,142 Transplantation of bone marrow cells after robust lentiviral vector-
mediated Sbds knock down is equally associated with lethality due to a lack of engraftment, while 
reducing the viral load during transduction preserves recipient viability but fails to significantly 
reproduce SDS-associated neutropenia in mice.143 
Zebrafish models have been used to investigate the consequences of Sbds deficiency for 
development. Impairing sbds translation or splicing with morpholinos induced exocrine 
pancreatic hypoplasia, chondro-osseous abnormalities and reduced numbers of myeloid cells.121 
While it was possible to explain the pancreatic phenotype in terms of reduced expansion of ptf1a-
expressing progenitors, the mechanisms behind impaired myelopoiesis remained unclear. 
Moreover, a preferential expression of sbds in the gastrointestinal tract could explain the 
pancreas but not the hematopoietic defects in this model.144 With respect to tissue specificity, it 
is also interesting to note that different models of Sbds deficiency showed an overall impairment 
of hematopoiesis but failed to reproduce the neutrophil specificity observed in the clinical 
spectrum of many SDS patients. The embryonic lethal SbdsR126T mouse model showed similar 
reduction of granulocytic, monocytic and erythroid progenitors by colony-forming unit (CFU) 
assay.112 Hematopoietic differentiation of SDS patient-derived induced pluripotent stem cells 
(iPSCs) similarly failed to show lineage-skewed defects, while an overall reduction in CFU numbers 
was observed.145 
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Why does Sbds deficiency result in neutropenia? Insights from in vitro studies suggest that 
reduced SBDS levels induce programmed cell death. Yamaguchi and colleagues reported that Sbds 
RNA interference induced apoptosis of 32Dcl3 cells upon G-CSF culture, while no effect was 
observed growing cells in IL-3 proliferation medium.146 Similarly, primary CD34+ HSPCs from SDS 
patients were found hypersensitive to proapoptotic Fas stimulation and had increased baseline 
rates of apoptosis when grown in semisolid differentiation medium.147,148 While this data suggests 
that Sbds deficiency elicits a stress response in hematopoietic cells, how this general response 
leads to selective neutrophil defects in SDS has not been clarified yet. 
 
Cancer predisposition in SDS 
Another unclear aspect of SDS pathogenesis is how SBDS mutations confer increased risk of 
myeloid malignancies. Because multipolar spindles were found in primary bone marrow stromal 
cells from SDS patients, it was proposed that SBDS mutation may lead to genomic instability.137 
Nevertheless, to date no in vivo model has shown development of MDS/AML-like diseases upon 
hematopoietic cell-restricted SBDS deficiency,143,149 contradicting the view of SBDS as a bona fide 
DNA repair gene. At the same time, the models argue against a solely cell-autonomous 
pathogenesis of hematopoietic defects in SDS and open the possibility that extrinsic cues from 
the microenvironment could contribute to cancer predisposition in this disease. 
 
4. NICHE CONTRIBUTION TO MYELOID DISORDERS 
As previously indicated, the bone marrow niche plays an essential role in regulating the number 
and fate of HSCs. Given its function in ensuring the homeostasis of the hematopoietic tissue, it 
appears plausible that dysfunctional HSC niches could contribute to hematological disorders, thus 
changing the traditional view of leukemogenesis as an event solely dependent on intrinsic, 
genetically-determined characteristics of leukemic cells. 
Indeed, intriguing observations in human disease support the importance of the niche for 
hematologic malignancies. A first example is the inability to obtain engraftment of certain 
leukemias,150 as well as human MDS,151-153 in immunodeficient mice, suggesting that species- or 
disease-specific states of the bone marrow microenvironment are required for diseased clones to 
thrive in an otherwise healthy organism. Another observation challenging the view of 
hematologic malignancies as solely cell-autonomously determined is the emergence of the so-
called ‘donor cell-derived leukemia’ (DCL).154,155 The term refers to a rare but growingly 
recognized phenomenon observed upon allogeneic HSC transplantation, a common treatment 
for hematologic malignancies. While leukemia often relapses in transplanted patients because of 
the incomplete eradication of pre-existing malignant clones, rarely it emerges upon 
transformation of wild-type, grafted hematopoietic cells, while donor individuals seem to remain 
healthy. Although the persistence of chemotherapy agents or radiation-induced soluble damage 
signals in the bone marrow have been proposed to explain DCL,154 a role for the 
microenvironment in driving this phenomenon is possible. Occult leukemic and pre-leukemic 
clones may be in fact already present in the graft, and while the efficient immune system in the 
donor bone marrow can easily eradicate them, this negative selection could be compromised in 
a dysfunctional HSC niche. 
Additionally, it is tempting to hypothesize that the bone marrow microenvironment, profoundly 
changed by the exposure to primary leukemic cells or by the effect of chemo/radiotherapy, 
promotes accumulation of genetic mutations in HSC, potentially leading to full-blown malignant 
transformation. Indeed, chemo- and radiotherapy inflict considerable damage to stromal cells,156 
and stromal layers from MDS/AML display altered transcriptional profile with increased 
expression of proinflammatory cytokines such as IL-6 and TNF-α.157,158 Whether a niche-derived 
proinflammatory environment exists in vivo and is relevant for human leukemogenesis remains 
to be tested. 
To summarize, observations in human disease suggest two different, not mutually exclusive 
models of stromal contribution to hematological malignancies (Figure 6). In the first scenario 
(niche as a facilitating factor), the primary event is the occurrence of a malignant or premalignant 
HSC clone, which actively modifies the microenvironment in order to obtain a selective advantage 
over the normal HSCs. Conceptually, this could result either by limiting the niche supporting 
capacity of normal HSCs or improving that of malignant hematopoiesis. Indeed, mouse models of 
MLL-AF9+ AML and myeloproliferative neoplasms (BCR-ABL+ and JAK2(V617F)+ inducible knock-
in) support this concept. Specifically, they indicated that aberrant HSCs induce depletion of niche 
cells or downregulation of key niche factors such as CXCL12,159-161 thus compromising normal 
hematopoiesis, while maintaining deregulated, diseased HSCs.159,161 
The second, more provocative scenario considers the bone marrow niche as a true disease 
initiator, even in the absence of primary genetic events in the hematopoietic compartment. 
Evidence in support of this theory started accumulating with the observation that mice deficient 
for the retinoic acid receptor γ developed a myeloproliferative phenotype only when the 
deficiency involved the bone marrow stroma.162 Subsequently, a mouse model of primary niche- 
restricted genetic modification demonstrated that mesenchymal cells can drive 
leukemogenesis.163 Targeted deletion of Dicer1 was induced in osterix-expressing mesenchymal 
progenitors to achieve broad alteration of the expression landscape in specific cells within the 
bone marrow niche. This primary genetic alteration was sufficient to induce an MDS-like 
phenotype, which was reverted by transplanting HSCs from the aberrant niche into wild type 
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Why does Sbds deficiency result in neutropenia? Insights from in vitro studies suggest that 
reduced SBDS levels induce programmed cell death. Yamaguchi and colleagues reported that Sbds 
RNA interference induced apoptosis of 32Dcl3 cells upon G-CSF culture, while no effect was 
observed growing cells in IL-3 proliferation medium.146 Similarly, primary CD34+ HSPCs from SDS 
patients were found hypersensitive to proapoptotic Fas stimulation and had increased baseline 
rates of apoptosis when grown in semisolid differentiation medium.147,148 While this data suggests 
that Sbds deficiency elicits a stress response in hematopoietic cells, how this general response 
leads to selective neutrophil defects in SDS has not been clarified yet. 
 
Cancer predisposition in SDS 
Another unclear aspect of SDS pathogenesis is how SBDS mutations confer increased risk of 
myeloid malignancies. Because multipolar spindles were found in primary bone marrow stromal 
cells from SDS patients, it was proposed that SBDS mutation may lead to genomic instability.137 
Nevertheless, to date no in vivo model has shown development of MDS/AML-like diseases upon 
hematopoietic cell-restricted SBDS deficiency,143,149 contradicting the view of SBDS as a bona fide 
DNA repair gene. At the same time, the models argue against a solely cell-autonomous 
pathogenesis of hematopoietic defects in SDS and open the possibility that extrinsic cues from 
the microenvironment could contribute to cancer predisposition in this disease. 
 
4. NICHE CONTRIBUTION TO MYELOID DISORDERS 
As previously indicated, the bone marrow niche plays an essential role in regulating the number 
and fate of HSCs. Given its function in ensuring the homeostasis of the hematopoietic tissue, it 
appears plausible that dysfunctional HSC niches could contribute to hematological disorders, thus 
changing the traditional view of leukemogenesis as an event solely dependent on intrinsic, 
genetically-determined characteristics of leukemic cells. 
Indeed, intriguing observations in human disease support the importance of the niche for 
hematologic malignancies. A first example is the inability to obtain engraftment of certain 
leukemias,150 as well as human MDS,151-153 in immunodeficient mice, suggesting that species- or 
disease-specific states of the bone marrow microenvironment are required for diseased clones to 
thrive in an otherwise healthy organism. Another observation challenging the view of 
hematologic malignancies as solely cell-autonomously determined is the emergence of the so-
called ‘donor cell-derived leukemia’ (DCL).154,155 The term refers to a rare but growingly 
recognized phenomenon observed upon allogeneic HSC transplantation, a common treatment 
for hematologic malignancies. While leukemia often relapses in transplanted patients because of 
the incomplete eradication of pre-existing malignant clones, rarely it emerges upon 
transformation of wild-type, grafted hematopoietic cells, while donor individuals seem to remain 
healthy. Although the persistence of chemotherapy agents or radiation-induced soluble damage 
signals in the bone marrow have been proposed to explain DCL,154 a role for the 
microenvironment in driving this phenomenon is possible. Occult leukemic and pre-leukemic 
clones may be in fact already present in the graft, and while the efficient immune system in the 
donor bone marrow can easily eradicate them, this negative selection could be compromised in 
a dysfunctional HSC niche. 
Additionally, it is tempting to hypothesize that the bone marrow microenvironment, profoundly 
changed by the exposure to primary leukemic cells or by the effect of chemo/radiotherapy, 
promotes accumulation of genetic mutations in HSC, potentially leading to full-blown malignant 
transformation. Indeed, chemo- and radiotherapy inflict considerable damage to stromal cells,156 
and stromal layers from MDS/AML display altered transcriptional profile with increased 
expression of proinflammatory cytokines such as IL-6 and TNF-α.157,158 Whether a niche-derived 
proinflammatory environment exists in vivo and is relevant for human leukemogenesis remains 
to be tested. 
To summarize, observations in human disease suggest two different, not mutually exclusive 
models of stromal contribution to hematological malignancies (Figure 6). In the first scenario 
(niche as a facilitating factor), the primary event is the occurrence of a malignant or premalignant 
HSC clone, which actively modifies the microenvironment in order to obtain a selective advantage 
over the normal HSCs. Conceptually, this could result either by limiting the niche supporting 
capacity of normal HSCs or improving that of malignant hematopoiesis. Indeed, mouse models of 
MLL-AF9+ AML and myeloproliferative neoplasms (BCR-ABL+ and JAK2(V617F)+ inducible knock-
in) support this concept. Specifically, they indicated that aberrant HSCs induce depletion of niche 
cells or downregulation of key niche factors such as CXCL12,159-161 thus compromising normal 
hematopoiesis, while maintaining deregulated, diseased HSCs.159,161 
The second, more provocative scenario considers the bone marrow niche as a true disease 
initiator, even in the absence of primary genetic events in the hematopoietic compartment. 
Evidence in support of this theory started accumulating with the observation that mice deficient 
for the retinoic acid receptor γ developed a myeloproliferative phenotype only when the 
deficiency involved the bone marrow stroma.162 Subsequently, a mouse model of primary niche- 
restricted genetic modification demonstrated that mesenchymal cells can drive 
leukemogenesis.163 Targeted deletion of Dicer1 was induced in osterix-expressing mesenchymal 
progenitors to achieve broad alteration of the expression landscape in specific cells within the 
bone marrow niche. This primary genetic alteration was sufficient to induce an MDS-like 
phenotype, which was reverted by transplanting HSCs from the aberrant niche into wild type 
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Figure 6. Models of niche contribution to leukemogenesis. (A) Primary event in a HSC. Aberrant HSCs may 
signal to the niche (A1) causing depletion of stromal cells or modification of their support capacity (A2). 
While normal hematopoiesis is thus impaired, aberrant HSC expand and their leukemic transformation is 
facilitated by the niche (A3). (B) Primary event in the niche. Aberrant niche cells (B1) may signal to HSCs 
and induce a preleukemic transformation (B2). Persistent dysfunction in the niche may facilitate expansion 
of the preleukemic clone and/or emergence of leukemia (B3). 
 
mice. Notably, AML occurred in a minority of mice, which presented anemia, accumulation of 
blasts, splenomegaly and sarcomas harboring distinct cytogenetic abnormalities, including 
monosomies of regions homologous to human 5q. More recently, it was shown that the 
osteoblast-specific constitutive activation of β-catenin in mice is sufficient to induce AML with 
common chromosomal aberrations.164 
While the theory of niche-induced leukemogenesis was proved to be valid in experimental animal 
models, data supporting its relevance for human disease remain limited. Nuclear accumulation of 
β-catenin was observed in osteoblasts from MDS/AML patients, reminiscent of the constitutive 
activation in the mouse model,164  but the importance of this phenomenon for progression of 
human disease was not otherwise demonstrated. On the other hand, the relevance of the niche 
for a leukemia-predisposing syndrome was suggested in the afore-mentioned study of niche-
restricted deletion of Dicer1. The study showed that aberrant osterix+ cells significantly 
downregulate the expression of Sbds, whose deficiency characterizes the human disease SDS.163 
Indeed, several features of human SDS were recapitulated by conditionally deleting Sbds in Osx+ 
cells.163 First, Sbds deficiency in mesenchymal progenitors altered the bone marrow architecture, 
with increased vasculature and altered cortical bone texture. Second, dysplastic features of the 
myeloid lineage were observed, while no evidence of dysplasia was previously reported in 
hematopoietic-restricted mouse models of SDS.143 Dysplastic morphology was associated with an 
increased frequency of myeloid and a reduced number of B cells. Finally, a high rate of apoptosis 
was observed in hematopoietic progenitor cells, similar to what reported in SDS patients.165 
Altogether, the data suggested that extrinsic cues from the niche contribute to disease 
pathogenesis in SDS. How Sbds deficiency in the niche alters HSC biology remained to be 
investigated.  
 
4. AIM OF THE DISSERTATION 
The easiness to isolate hematopoietic cells, including HSPCs, from the peripheral blood and the 
bone marrow has greatly facilitated the study of human leukemia. Remarkable progress was 
achieved by analyzing hematopoietic cells alone. Nevertheless, this reductionist approach fails to 
fully explain the pathogenesis of certain hematopoietic conditions, including cancer 
predisposition in ribosomopathies.  
Recently, the bone marrow microenvironment was recognized as a critical player in blood cancer 
development and maintenance, suggesting that cell extrinsic cues may underlie leukemogenesis. 
This dissertation aims at exploring possible contributions of the bone marrow microenvironment 
to cancer predisposition in preleukemic disorders and identifying candidate underlying 
mechanisms. 
Shwachman-Diamond syndrome was chosen as ‘index disease’ to study the role of the HSC niche 
in leukemogenesis based on these considerations: 
1. SDS confers a striking predisposition for the development of MDS and AML. 
2. SDS is a congenital (constitutive) syndrome, thus both hematopoietic and stromal cells 
harbor the disease-initiating mutations. 
3. Its monogenic nature makes SDS amenable to experimentation. 
4. Bone and hematopoietic symptoms coexist in SDS, thus both blood- and bone-lineage 
niche cells are affected in this disease.  
5. While Sbds deficiency in hematopoietic cells alone failed to reproduce hematological 
features of SDS, niche-targeted knock out mice develop a MDS-like disease.  
6. The disease belongs to the larger family of ribosomopathies, thus insights on SDS 
pathology may be relevant for a broader set of illnesses. 
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To dissect cellular intrinsic and extrinsic contributions to hematological disease in SDS, 
hematopoietic- and niche-targeted Sbds conditional knock out models were obtained in mice 
based on tissue-selective expression of cre recombinase. In chapter 2, the Cebpa-cre model 
targets Sbds deletion in murine HSPCs, thus allowing the evaluation of cell intrinsic contributions 
of hematopoietic cells to bone marrow failure in SDS. In chapter 3, the niche-targeting Osx-cre 
model is used to obtain insights both on the pathogenesis of bone defects in SDS and on the cell 
extrinsic regulation of HSPCs in this disease, with the hypothesis that the bone marrow 
microenvironment contributes to SDS progression to MDS/AML. The relevance of the findings for 
human disease is then evaluated in SDS and MDS patients. 
While SDS offers a unique opportunity to study niche contribution to leukemogenesis, it remains 
a condition affecting a minority of individuals. In contrast, MDS is a more prevalent preleukemic 
disorder. Moreover, being a disease of the elderly, its incidence is expected to increase in the 
years to come. Current studies on the MDS niche have largely relied on long term cultures of 
mesenchymal cells, but analyses of primary cells have not been performed yet, thus whether the 
niche really contributes to patients disease in vivo is still unknown. In chapter 4, 
immunophenotypically-defined HSC niche cells are prospectively isolated from the bone marrow 
of low-risk MDS patients. RNA sequencing profiling is used to gain insights on possible 
contributions of stromal cells to MDS. Finally, the results of this thesis are summarized and their 
importance for the hematologic oncology field is discussed in chapter 5.  
  
REFERENCES 
1. Tak T, Tesselaar K, Pillay J, Borghans JA, Koenderman L. What's your age again? Determination of 
human neutrophil half-lives revisited. J Leukoc Biol. 2013;94(4):595-601. 
2. Wu M, Kwon HY, Rattis F, et al. Imaging hematopoietic precursor division in real time. Cell Stem Cell. 
2007;1(5):541-554. 
3. Zimdahl B, Ito T, Blevins A, et al. Lis1 regulates asymmetric division in hematopoietic stem cells and 
in leukemia. Nat Genet. 2014;46(3):245-252. 
4. Tamplin OJ, Durand EM, Carr LA, et al. Hematopoietic stem cell arrival triggers dynamic remodeling 
of the perivascular niche. Cell. 2015;160(1-2):241-252. 
5. Nakamura-Ishizu A, Takizawa H, Suda T. The analysis, roles and regulation of quiescence in 
hematopoietic stem cells. Development. 2014;141(24):4656-4666. 
6. Beck WS, Leukocytes I. Physiology. In: Beck WS, ed. Hematology, 5th edition. Cambridge MA: The 
MIT Press; 1998:339-350. 
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 
2001;414(6859):105-111. 
8. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 
2004;303:1532–1535. 
9. Provencher Bolliger A, Everds N. Haematology of the mouse. In: Hedrich H, ed. The Laboratory 
Mouse, 2nd edition. London UK: Academic Press; 2012:331-348. 
10. Marionneaux S. Nonmalignant leukocyte disorders. In: Keohane E, Smith L, Walenga J, eds. Rodak’s 
Hematology: Clinical Principles and Applications, 5th edition. St. Louis MO: Elsevier Saunders; 
2016:475-497.  
11. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic 
myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70(20):3813-
3827. 
12. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. 
Oncogene. 2002;21(21):3295-3313. 
13. Krause DS. Regulation of hematopoietic stem cell fate. Oncogene. 2002;21(21):3262-3269. 
14. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells 
in vitro. J Cell Physiol. 1977;91(3):335-344. 
15. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem 
cell. Blood Cells. 1978;4(1-2):7-25. 
16. Imai K, Kobayashi M, Wang J, et al. Selective transendothelial migration of hematopoietic progenitor 
cells: a role in homing of progenitor cells. Blood. 1999;93(1):149-156. 
17. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the 
trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103(8):2981-2989. 
18. Potocnik AJ, Brakebusch C, Fassler R. Fetal and adult hematopoietic stem cells require beta1 integrin 
function for colonizing fetal liver, spleen, and bone marrow. Immunity. 2000;12(6):653-663. 
19. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Alpha4 integrins regulate the proliferation/differentiation 
balance of multilineage hematopoietic progenitors in vivo. Immunity. 1999;11(5):555-566. 
33
General introduction
C
ha
pt
er
 1
To dissect cellular intrinsic and extrinsic contributions to hematological disease in SDS, 
hematopoietic- and niche-targeted Sbds conditional knock out models were obtained in mice 
based on tissue-selective expression of cre recombinase. In chapter 2, the Cebpa-cre model 
targets Sbds deletion in murine HSPCs, thus allowing the evaluation of cell intrinsic contributions 
of hematopoietic cells to bone marrow failure in SDS. In chapter 3, the niche-targeting Osx-cre 
model is used to obtain insights both on the pathogenesis of bone defects in SDS and on the cell 
extrinsic regulation of HSPCs in this disease, with the hypothesis that the bone marrow 
microenvironment contributes to SDS progression to MDS/AML. The relevance of the findings for 
human disease is then evaluated in SDS and MDS patients. 
While SDS offers a unique opportunity to study niche contribution to leukemogenesis, it remains 
a condition affecting a minority of individuals. In contrast, MDS is a more prevalent preleukemic 
disorder. Moreover, being a disease of the elderly, its incidence is expected to increase in the 
years to come. Current studies on the MDS niche have largely relied on long term cultures of 
mesenchymal cells, but analyses of primary cells have not been performed yet, thus whether the 
niche really contributes to patients disease in vivo is still unknown. In chapter 4, 
immunophenotypically-defined HSC niche cells are prospectively isolated from the bone marrow 
of low-risk MDS patients. RNA sequencing profiling is used to gain insights on possible 
contributions of stromal cells to MDS. Finally, the results of this thesis are summarized and their 
importance for the hematologic oncology field is discussed in chapter 5.  
  
REFERENCES 
1. Tak T, Tesselaar K, Pillay J, Borghans JA, Koenderman L. What's your age again? Determination of 
human neutrophil half-lives revisited. J Leukoc Biol. 2013;94(4):595-601. 
2. Wu M, Kwon HY, Rattis F, et al. Imaging hematopoietic precursor division in real time. Cell Stem Cell. 
2007;1(5):541-554. 
3. Zimdahl B, Ito T, Blevins A, et al. Lis1 regulates asymmetric division in hematopoietic stem cells and 
in leukemia. Nat Genet. 2014;46(3):245-252. 
4. Tamplin OJ, Durand EM, Carr LA, et al. Hematopoietic stem cell arrival triggers dynamic remodeling 
of the perivascular niche. Cell. 2015;160(1-2):241-252. 
5. Nakamura-Ishizu A, Takizawa H, Suda T. The analysis, roles and regulation of quiescence in 
hematopoietic stem cells. Development. 2014;141(24):4656-4666. 
6. Beck WS, Leukocytes I. Physiology. In: Beck WS, ed. Hematology, 5th edition. Cambridge MA: The 
MIT Press; 1998:339-350. 
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 
2001;414(6859):105-111. 
8. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 
2004;303:1532–1535. 
9. Provencher Bolliger A, Everds N. Haematology of the mouse. In: Hedrich H, ed. The Laboratory 
Mouse, 2nd edition. London UK: Academic Press; 2012:331-348. 
10. Marionneaux S. Nonmalignant leukocyte disorders. In: Keohane E, Smith L, Walenga J, eds. Rodak’s 
Hematology: Clinical Principles and Applications, 5th edition. St. Louis MO: Elsevier Saunders; 
2016:475-497.  
11. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic 
myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70(20):3813-
3827. 
12. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. 
Oncogene. 2002;21(21):3295-3313. 
13. Krause DS. Regulation of hematopoietic stem cell fate. Oncogene. 2002;21(21):3262-3269. 
14. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells 
in vitro. J Cell Physiol. 1977;91(3):335-344. 
15. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem 
cell. Blood Cells. 1978;4(1-2):7-25. 
16. Imai K, Kobayashi M, Wang J, et al. Selective transendothelial migration of hematopoietic progenitor 
cells: a role in homing of progenitor cells. Blood. 1999;93(1):149-156. 
17. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the 
trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103(8):2981-2989. 
18. Potocnik AJ, Brakebusch C, Fassler R. Fetal and adult hematopoietic stem cells require beta1 integrin 
function for colonizing fetal liver, spleen, and bone marrow. Immunity. 2000;12(6):653-663. 
19. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Alpha4 integrins regulate the proliferation/differentiation 
balance of multilineage hematopoietic progenitors in vivo. Immunity. 1999;11(5):555-566. 
34
Chapter 1
C
ha
pt
er
 1
20. Qian H, Tryggvason K, Jacobsen SE, Ekblom M. Contribution of alpha6 integrins to hematopoietic 
stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood. 
2006;107(9):3503-3510. 
21. Schreiber TD, Steinl C, Essl M, et al. The integrin alpha9beta1 on hematopoietic stem and progenitor 
cells: involvement in cell adhesion, proliferation and differentiation. Haematologica. 
2009;94(11):1493-1501. 
22. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following 
DNA damage improves human stem cell function. J Clin Invest. 2000;106(11):1331-1339. 
23. Tzeng YS, Li H, Kang YL, Chen WC, Cheng WC, Lai DM. Loss of Cxcl12/Sdf-1 in adult mice decreases 
the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic 
regeneration after myelosuppression. Blood. 2011;117(2):429-439. 
24. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90(4):1345-1364. 
25. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 
quiescence in the bone marrow niche. Cell. 2004;118(2):149-161. 
26. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell 
niche. Nature. 2003;425(6960):841-846. 
27. Kim JA, Kang YJ, Park G, et al. Identification of a stroma-mediated Wnt/beta-catenin signal 
promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells. 
2009;27(6):1318-1329. 
28. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem 
cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. 
29. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 
2014;505(7483):327-34. 
30. Lord BI, Testa NG, Hendry JH. The relative spatial distributions of CFUs and CFUc in the normal 
mouse femur. Blood. 1975;46(1):65-72. 
31. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the 
niche size. Nature. 2003;425(6960):836-841. 
32. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in 
mice with an induced osteoblast deficiency. Blood. 2004;103(9):3258-3264. 
33. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a 
possible mechanism for stem cell homing. Bone. 2006;38(4):497-508. 
34. Chan CFK, Chen CC, Luppen CA, et al. Endochondral ossification is required for haematopoietic stem-
cell niche formation. Nature. 2009;457(7228):490-494. 
35. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish 
hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 
2005;121(7):1109-1121. 
36. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by 
CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977-
988. 
37. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form 
a unique bone marrow niche. Nature. 2010;466(7308):829-834. 
38. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and 
repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6(3):251-264. 
39. Poulos MG, Guo P, Kofler NM, et al. Endothelial Jagged-1 is necessary for homeostatic and 
regenerative hematopoiesis. Cell Rep. 2013;4(5):1022-1034. 
40. Winkler IG, Barbier V, Nowlan B, et al. Vascular niche E-selectin regulates hematopoietic stem cell 
dormancy, self renewal and chemoresistance. Nat Med. 2012;18(11):1651-1657. 
41. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote 
mobilization of hematopoietic progenitor cells. Nat Med. 2006;12(6):657-664. 
42. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as 
negative regulators of the haematopoietic microenvironment. Nature. 2009;460(7252):259-263. 
43. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate 
hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407-421. 
44. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by 
circadian oscillations. Nature. 2008;452(7186):442-447. 
45. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem 
cell hibernation in the bone marrow niche. Cell. 2011;147(5):1146-1158. 
46. Lucas D, Scheiermann C, Chow A, et al. Chemotherapy-induced bone marrow nerve injury impairs 
hematopoietic regeneration. Nat Med. 2013;19(6):695-703. 
47. Li P, Zon Li. Resolving the controversy about N-cadherin and hematopoietic stem cells. Cell Stem 
Cell. 2010;6(3):199-202. 
48. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain 
haematopoietic stem cells. Nature. 2012;481(7382):457-462. 
49. Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for 
haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227-230. 
50. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone 
marrow niches. Nature. 2013;495(7440):231-235. 
51. Liu Y, Strecker S, Wang L, et al. Osterix-cre labeled progenitor cells contribute to the formation and 
maintenance of the bone marrow stroma. PLoS One. 2013;8(8):e71318. 
52. Mizoguchi T, Pinho S, Ahmed J, et al. Osterix marks distinct waves of primitive and definitive stromal 
progenitors during bone marrow development. Dev Cell. 2014;29(3):340-349. 
53. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids 
can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336. 
54. Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow stem 
cells is correlated with in situ localization. Blood. 2011;117(19):5067-5077. 
55. Churchman SM, Ponchel F, Boxall SA, et al. Transcriptional profile of native CD271+ multipotential 
stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling 
activity. Arthritis Rheum. 2012;64(8):2632-2643. 
56. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: prospects for 
leukemia prevention. Hematology Am Soc Hematol Educ Program. 2007:40-46. 
57. Gerds AT, Scott BL. Last marrow standing: bone marrow transplantation for acquired bone marrow 
failure conditions. Curr Hematol Malig Rep. 2012;7(4):292-299. 
35
General introduction
C
ha
pt
er
 1
20. Qian H, Tryggvason K, Jacobsen SE, Ekblom M. Contribution of alpha6 integrins to hematopoietic 
stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood. 
2006;107(9):3503-3510. 
21. Schreiber TD, Steinl C, Essl M, et al. The integrin alpha9beta1 on hematopoietic stem and progenitor 
cells: involvement in cell adhesion, proliferation and differentiation. Haematologica. 
2009;94(11):1493-1501. 
22. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following 
DNA damage improves human stem cell function. J Clin Invest. 2000;106(11):1331-1339. 
23. Tzeng YS, Li H, Kang YL, Chen WC, Cheng WC, Lai DM. Loss of Cxcl12/Sdf-1 in adult mice decreases 
the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic 
regeneration after myelosuppression. Blood. 2011;117(2):429-439. 
24. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90(4):1345-1364. 
25. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 
quiescence in the bone marrow niche. Cell. 2004;118(2):149-161. 
26. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell 
niche. Nature. 2003;425(6960):841-846. 
27. Kim JA, Kang YJ, Park G, et al. Identification of a stroma-mediated Wnt/beta-catenin signal 
promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells. 
2009;27(6):1318-1329. 
28. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem 
cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. 
29. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 
2014;505(7483):327-34. 
30. Lord BI, Testa NG, Hendry JH. The relative spatial distributions of CFUs and CFUc in the normal 
mouse femur. Blood. 1975;46(1):65-72. 
31. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the 
niche size. Nature. 2003;425(6960):836-841. 
32. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in 
mice with an induced osteoblast deficiency. Blood. 2004;103(9):3258-3264. 
33. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a 
possible mechanism for stem cell homing. Bone. 2006;38(4):497-508. 
34. Chan CFK, Chen CC, Luppen CA, et al. Endochondral ossification is required for haematopoietic stem-
cell niche formation. Nature. 2009;457(7228):490-494. 
35. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish 
hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 
2005;121(7):1109-1121. 
36. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by 
CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977-
988. 
37. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form 
a unique bone marrow niche. Nature. 2010;466(7308):829-834. 
38. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and 
repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6(3):251-264. 
39. Poulos MG, Guo P, Kofler NM, et al. Endothelial Jagged-1 is necessary for homeostatic and 
regenerative hematopoiesis. Cell Rep. 2013;4(5):1022-1034. 
40. Winkler IG, Barbier V, Nowlan B, et al. Vascular niche E-selectin regulates hematopoietic stem cell 
dormancy, self renewal and chemoresistance. Nat Med. 2012;18(11):1651-1657. 
41. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote 
mobilization of hematopoietic progenitor cells. Nat Med. 2006;12(6):657-664. 
42. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as 
negative regulators of the haematopoietic microenvironment. Nature. 2009;460(7252):259-263. 
43. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate 
hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407-421. 
44. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by 
circadian oscillations. Nature. 2008;452(7186):442-447. 
45. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem 
cell hibernation in the bone marrow niche. Cell. 2011;147(5):1146-1158. 
46. Lucas D, Scheiermann C, Chow A, et al. Chemotherapy-induced bone marrow nerve injury impairs 
hematopoietic regeneration. Nat Med. 2013;19(6):695-703. 
47. Li P, Zon Li. Resolving the controversy about N-cadherin and hematopoietic stem cells. Cell Stem 
Cell. 2010;6(3):199-202. 
48. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain 
haematopoietic stem cells. Nature. 2012;481(7382):457-462. 
49. Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for 
haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227-230. 
50. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone 
marrow niches. Nature. 2013;495(7440):231-235. 
51. Liu Y, Strecker S, Wang L, et al. Osterix-cre labeled progenitor cells contribute to the formation and 
maintenance of the bone marrow stroma. PLoS One. 2013;8(8):e71318. 
52. Mizoguchi T, Pinho S, Ahmed J, et al. Osterix marks distinct waves of primitive and definitive stromal 
progenitors during bone marrow development. Dev Cell. 2014;29(3):340-349. 
53. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids 
can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336. 
54. Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow stem 
cells is correlated with in situ localization. Blood. 2011;117(19):5067-5077. 
55. Churchman SM, Ponchel F, Boxall SA, et al. Transcriptional profile of native CD271+ multipotential 
stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling 
activity. Arthritis Rheum. 2012;64(8):2632-2643. 
56. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: prospects for 
leukemia prevention. Hematology Am Soc Hematol Educ Program. 2007:40-46. 
57. Gerds AT, Scott BL. Last marrow standing: bone marrow transplantation for acquired bone marrow 
failure conditions. Curr Hematol Malig Rep. 2012;7(4):292-299. 
36
Chapter 1
C
ha
pt
er
 1
58. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure 
syndromes. Blood Rev. 2010;24(3):101-122. 
59. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in 
myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. 
60. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver 
mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627; quiz 3699. 
61. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion 
and malignancies. Nat Med. 2014;20(12):1472-1478. 
62. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly 
individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181. 
63. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its 
distinction from myelodysplastic syndromes. Blood. 2015. 
64. Rao S, Lee SY, Gutierrez A, et al. Inactivation of ribosomal protein L22 promotes transformation by 
induction of the stemness factor, Lin28B. Blood. 2012;120(18):3764-3773. 
65. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and 
ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013;45(2):186-
190. 
66. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the 
myeloid neoplasms. Blood. 2002;100(7):2292-2302. 
67. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference 
screen. Nature. 2008;451(7176):335-339. 
68. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia 
in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59-66. 
69. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond 
Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815-
3819. 
70. Flygare J, Karlsson S. Diamond-Blackfan anemia: erythropoiesis lost in translation. Blood. 
2007;109(8):3152-3154. 
71. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is 
mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175. 
72. Horos R, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan 
Anaemia. Br J Haematol. 2012;159(5):514-527. 
73. Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in 
Diamond-Blackfan anemia. J Clin Invest. 2012;122(7):2439-2443. 
74. Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat 
Med. 2014;20(7):748-753. 
75. Chlon TM, McNulty M, Goldenson B, Rosinski A, Crispino JD. Global transcriptome and chromatin 
occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and 
gene expression. Haematologica. 2015;100(5):575-584. 
76. Dixon MJ. Treacher Collins syndrome. Hum Mol Genet. 1996;5:1391-6. 
77. Dauwerse JG, Dixon J, Seland S, et al. Mutations in genes encoding subunits of RNA polymerases I 
and III cause Treacher Collins syndrome. Nat Genet. 2011;43(1):20-2. 
78. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a 
highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32-8. 
79. Gerrard G, Valgañón M, Foong HE, et al. Target enrichment and high-throughput sequencing of 80 
ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia. Br J 
Haematol. 2013;162(4):530-6. 
80. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly 
mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010;86(2):222-8. 
81. Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is 
mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28(12):1178-82. 
82. Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-
Blackfan anemia. Am J Hum Genet. 2006;79(6):1110-8. 
83. Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with 
cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 
2008;83(6):769-80. 
84. Gazda HT, Preti M, Sheen MR, et al. Frameshift mutation in p53 regulator RPL26 is associated with 
multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-
blackfan anemia. Hum Mutat. 2012;33(7):1037-44. 
85. Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, 
in Diamond-Blackfan anemia. Blood. 2008;112(5):1582-92. 
86. Ridanpää M, van Eenennaam H, Pelin K, et al. Mutations in the RNA component of RNase MRP cause 
a pleiotropic human disease, cartilage-hair hypoplasia. Cell. 2001;104(2):195-203. 
87. Chagnon P, Michaud J, Mitchell G, et al. A missense mutation (R565W) in cirhin (FLJ14728) in North 
American Indian childhood cirrhosis. Am J Hum Genet. 2002;71(6):1443-9. 
88. Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-
Diamond syndrome. Nat Genet. 2003;33(1):97-101. 
89. Thiel CT, Horn D, Zabel B, et al. Severely incapacitating mutations in patients with extreme short 
stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. Am J 
Hum Genet. 2005;77(5):795-806. 
90. Armistead J, Khatkar S, Meyer B, et al. Mutation of a gene essential for ribosome biogenesis, EMG1, 
causes Bowen-Conradi syndrome. Am J Hum Genet. 2009;84(6):728-39. 
91. Bolze A, Mahlaoui N, Byun M, et al. Ribosomal protein SA haploinsufficiency in humans with isolated 
congenital asplenia. Science. 2013;340(6135):976-8. 
92. Marneros AG. BMS1 is mutated in aplasia cutis congenita. PLoS Genet. 2013;9(6):e1003573.     
93. Horos R, Ijspeert H, Pospisilova D, et al. Ribosomal deficiencies in Diamond-Blackfan anemia impair 
translation of transcripts essential for differentiation of murine and human erythroblasts. Blood. 
2012;119(1):262-272. 
94. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat Cell Biol. 
2000;2(5):E71-72. 
95. Morata G, Ripoll P. Minutes: mutants of drosophila autonomously affecting cell division rate. Dev 
Biol. 1975;42(2):211-221. 
96. Volarevic S, Stewart MJ, Ledermann B, et al. Proliferation, but not growth, blocked by conditional 
deletion of 40S ribosomal protein S6. Science. 2000;288(5473):2045-2047. 
37
General introduction
C
ha
pt
er
 1
58. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure 
syndromes. Blood Rev. 2010;24(3):101-122. 
59. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in 
myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. 
60. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver 
mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627; quiz 3699. 
61. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion 
and malignancies. Nat Med. 2014;20(12):1472-1478. 
62. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly 
individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181. 
63. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its 
distinction from myelodysplastic syndromes. Blood. 2015. 
64. Rao S, Lee SY, Gutierrez A, et al. Inactivation of ribosomal protein L22 promotes transformation by 
induction of the stemness factor, Lin28B. Blood. 2012;120(18):3764-3773. 
65. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and 
ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013;45(2):186-
190. 
66. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the 
myeloid neoplasms. Blood. 2002;100(7):2292-2302. 
67. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference 
screen. Nature. 2008;451(7176):335-339. 
68. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia 
in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59-66. 
69. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond 
Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815-
3819. 
70. Flygare J, Karlsson S. Diamond-Blackfan anemia: erythropoiesis lost in translation. Blood. 
2007;109(8):3152-3154. 
71. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is 
mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175. 
72. Horos R, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan 
Anaemia. Br J Haematol. 2012;159(5):514-527. 
73. Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in 
Diamond-Blackfan anemia. J Clin Invest. 2012;122(7):2439-2443. 
74. Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat 
Med. 2014;20(7):748-753. 
75. Chlon TM, McNulty M, Goldenson B, Rosinski A, Crispino JD. Global transcriptome and chromatin 
occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and 
gene expression. Haematologica. 2015;100(5):575-584. 
76. Dixon MJ. Treacher Collins syndrome. Hum Mol Genet. 1996;5:1391-6. 
77. Dauwerse JG, Dixon J, Seland S, et al. Mutations in genes encoding subunits of RNA polymerases I 
and III cause Treacher Collins syndrome. Nat Genet. 2011;43(1):20-2. 
78. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a 
highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32-8. 
79. Gerrard G, Valgañón M, Foong HE, et al. Target enrichment and high-throughput sequencing of 80 
ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia. Br J 
Haematol. 2013;162(4):530-6. 
80. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly 
mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010;86(2):222-8. 
81. Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is 
mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28(12):1178-82. 
82. Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-
Blackfan anemia. Am J Hum Genet. 2006;79(6):1110-8. 
83. Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with 
cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 
2008;83(6):769-80. 
84. Gazda HT, Preti M, Sheen MR, et al. Frameshift mutation in p53 regulator RPL26 is associated with 
multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-
blackfan anemia. Hum Mutat. 2012;33(7):1037-44. 
85. Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, 
in Diamond-Blackfan anemia. Blood. 2008;112(5):1582-92. 
86. Ridanpää M, van Eenennaam H, Pelin K, et al. Mutations in the RNA component of RNase MRP cause 
a pleiotropic human disease, cartilage-hair hypoplasia. Cell. 2001;104(2):195-203. 
87. Chagnon P, Michaud J, Mitchell G, et al. A missense mutation (R565W) in cirhin (FLJ14728) in North 
American Indian childhood cirrhosis. Am J Hum Genet. 2002;71(6):1443-9. 
88. Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-
Diamond syndrome. Nat Genet. 2003;33(1):97-101. 
89. Thiel CT, Horn D, Zabel B, et al. Severely incapacitating mutations in patients with extreme short 
stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. Am J 
Hum Genet. 2005;77(5):795-806. 
90. Armistead J, Khatkar S, Meyer B, et al. Mutation of a gene essential for ribosome biogenesis, EMG1, 
causes Bowen-Conradi syndrome. Am J Hum Genet. 2009;84(6):728-39. 
91. Bolze A, Mahlaoui N, Byun M, et al. Ribosomal protein SA haploinsufficiency in humans with isolated 
congenital asplenia. Science. 2013;340(6135):976-8. 
92. Marneros AG. BMS1 is mutated in aplasia cutis congenita. PLoS Genet. 2013;9(6):e1003573.     
93. Horos R, Ijspeert H, Pospisilova D, et al. Ribosomal deficiencies in Diamond-Blackfan anemia impair 
translation of transcripts essential for differentiation of murine and human erythroblasts. Blood. 
2012;119(1):262-272. 
94. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat Cell Biol. 
2000;2(5):E71-72. 
95. Morata G, Ripoll P. Minutes: mutants of drosophila autonomously affecting cell division rate. Dev 
Biol. 1975;42(2):211-221. 
96. Volarevic S, Stewart MJ, Ledermann B, et al. Proliferation, but not growth, blocked by conditional 
deletion of 40S ribosomal protein S6. Science. 2000;288(5473):2045-2047. 
38
Chapter 1
C
ha
pt
er
 1
97. Kondrashov N, Pusic A, Stumpf CR, et al. Ribosome-mediated specificity in Hox mRNA translation 
and vertebrate tissue patterning. Cell. 2011;145(3):383-397. 
98. Xue S, Tian S, Fujii K, Kladwang W, Das R, Barna M. RNA regulons in Hox 5' UTRs confer ribosome 
specificity to gene regulation. Nature. 2015;517(7532):33-38. 
99. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated translation in X-linked 
dyskeratosis congenita. Science. 2006;312(5775):902-906. 
100. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and 
mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23(23):8902-
8912. 
101. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting 
MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell 
Biol. 2004;24(17):7654-7668. 
102. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein 
L23. Mol Cell Biol. 2004;24(17):7669-7680. 
103. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal 
protein L5. J Biol Chem. 2004;279(43):44475-44482. 
104. Chen D, Zhang Z, Li M, et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: 
binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 
2007;26(35):5029-5037. 
105. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M. Mdm2 regulates p53 mRNA translation 
through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32(2):180-189. 
106. Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA. Ribosomal protein S3: A multi-
functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair 
(Amst). 2009;8(10):1215-1224. 
107. Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome 
through inhibition of p53 function. Nat Med. 2008;14(2):125-133. 
108. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and 
pleiotropic effects. Nat Genet. 2008;40(8):963-970. 
109. MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA. Loss of p53 synthesis in zebrafish 
tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A. 2008;105(30):10408-
10413. 
110. Torihara H, Uechi T, Chakraborty A, Shinya M, Sakai N, Kenmochi N. Erythropoiesis failure due to 
RPS19 deficiency is independent of an activated Tp53 response in a zebrafish model of Diamond-
Blackfan anaemia. Br J Haematol. 2011;152(5):648-654. 
111. Provost E, Wehner KA, Zhong XG, et al. Ribosomal biogenesis genes play an essential and p53-
independent role in zebrafish pancreas development. Development. 2012;139(17):3232-3241. 
112. Tourlakis ME, Zhang S, Ball HL, et al. In Vivo Senescence in the Sbds-Deficient Murine Pancreas: Cell-
Type Specific Consequences of Translation Insufficiency. PLoS Genet. 2015;11(6):e1005288. 
113. Shwachman H, Diamond LK, Oski FA, Khaw KT. The Syndrome of Pancreatic Insufficiency and Bone 
Marrow Dysfunction. J Pediatr. 1964;65:645-663. 
114. Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for diagnosis and treatment of 
Shwachman-Diamond syndrome. Ann N Y Acad Sci. 2011;1242:40-55. 
115. Goobie S, Popovic M, Morrison J, et al. Shwachman-Diamond syndrome with exocrine pancreatic 
dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum 
Genet. 2001;68(4):1048-1054. 
116. Mäkitie O, Ellis L, Durie PR, et al. Skeletal phenotype in patients with Shwachman-Diamond 
syndrome and mutations in SBDS. Clinical Genetics. 2004;65(2):101-112. 
117. Toiviainen-Salo S, Mayranpaa MK, Durie PR, et al. Shwachman-Diamond syndrome is associated 
with low-turnover osteoporosis. Bone. 2007;41(6):965-972. 
118. Mack DR, Forstner GG, Wilschanski M, Freedman MH, Durie PR. Shwachman syndrome: Exocrine 
pancreatic dysfunction and variable phenotypic expression. Gastroenterology. 1996;111(6):1593-
1602. 
119. Toiviainen-Salo S, Durie PR, Numminen K, et al. The natural history of Shwachman-Diamond 
syndrome-associated liver disease from childhood to adulthood. J Pediatr. 2009;155(6):807-811 
e802. 
120. Kerr EN, Ellis L, Dupuis A, Rommens JM, Durie PR. The behavioral phenotype of school-age children 
with shwachman diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman-
Bodian-Diamond syndrome gene function. J Pediatr. 2010;156(3):433-438. 
121. Myers KC, Bolyard AA, Otto B, et al. Variable Clinical Presentation of Shwachman-Diamond 
Syndrome: Update from the North American Shwachman-Diamond Syndrome Registry. Journal of 
Pediatrics. 2014;164(4):866-870. 
122. Aggett PJ, Harries JT, Harvey BA, Soothill JF. An inherited defect of neutrophil mobility in Shwachman 
syndrome. J Pediatr. 1979;94(3):391-394. 
123. Rothbaum RJ, Williams DA, Daugherty CC. Unusual surface distribution of concanavalin A reflects a 
cytoskeletal defect in neutrophils in Shwachman's syndrome. Lancet. 1982;2(8302):800-801. 
124. Dror Y, Ginzberg H, Dalal I, et al. Immune function in patients with Shwachman-Diamond syndrome. 
Br J Haematol. 2001;114(3):712-717. 
125. Dror Y. Shwachman-Diamond syndrome. Pediatr Blood & Cancer. 2005;45(7):892-901. 
126. Donadieu J, Fenneteau O, Beaupain B, et al. Classification of and risk factors for hematologic 
complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. 
Haematologica. 2012;97(9):1312-1319. 
127. Aggett PJ, Cavanagh NPC, Matthew DJ, Pincott JR, Sutcliffe J, Harries JT. Shwachmans Syndrome - a 
Review of 21 Cases. Archives of Disease in Childhood. 1980;55(5):331-347. 
128. Leung EW, Rujkijyanont P, Beyene J, et al. Shwachman-Diamond syndrome: an inherited model of 
aplastic anaemia with accelerated angiogenesis. Br J Haematol. 2006;133(5):558-561. 
129. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. 
Hematology Am Soc Hematol Educ Program. 2007:29-39. 
130. Nicolis E, Bonizzato A, Assael BM, Cipolli M. Identification of novel mutations in patients with 
Shwachman-Diamond syndrome. Hum Mutat. 2005;25(4):410. 
131. Woloszynek JR, Rothbaum RJ, Rawls AS, et al. Mutations of the SBDS gene are present in most 
patients with Shwachman-Diamond syndrome. Blood. 2004;104(12):3588-3590. 
132. Finch AJ, Hilcenko C, Basse N, et al. Uncoupling of GTP hydrolysis from eIF6 release on the ribosome 
causes Shwachman-Diamond syndrome. Genes Dev. 2011;25(9):917-929. 
39
General introduction
C
ha
pt
er
 1
97. Kondrashov N, Pusic A, Stumpf CR, et al. Ribosome-mediated specificity in Hox mRNA translation 
and vertebrate tissue patterning. Cell. 2011;145(3):383-397. 
98. Xue S, Tian S, Fujii K, Kladwang W, Das R, Barna M. RNA regulons in Hox 5' UTRs confer ribosome 
specificity to gene regulation. Nature. 2015;517(7532):33-38. 
99. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated translation in X-linked 
dyskeratosis congenita. Science. 2006;312(5775):902-906. 
100. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and 
mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23(23):8902-
8912. 
101. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting 
MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell 
Biol. 2004;24(17):7654-7668. 
102. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein 
L23. Mol Cell Biol. 2004;24(17):7669-7680. 
103. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal 
protein L5. J Biol Chem. 2004;279(43):44475-44482. 
104. Chen D, Zhang Z, Li M, et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: 
binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 
2007;26(35):5029-5037. 
105. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M. Mdm2 regulates p53 mRNA translation 
through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32(2):180-189. 
106. Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA. Ribosomal protein S3: A multi-
functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair 
(Amst). 2009;8(10):1215-1224. 
107. Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome 
through inhibition of p53 function. Nat Med. 2008;14(2):125-133. 
108. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and 
pleiotropic effects. Nat Genet. 2008;40(8):963-970. 
109. MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA. Loss of p53 synthesis in zebrafish 
tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A. 2008;105(30):10408-
10413. 
110. Torihara H, Uechi T, Chakraborty A, Shinya M, Sakai N, Kenmochi N. Erythropoiesis failure due to 
RPS19 deficiency is independent of an activated Tp53 response in a zebrafish model of Diamond-
Blackfan anaemia. Br J Haematol. 2011;152(5):648-654. 
111. Provost E, Wehner KA, Zhong XG, et al. Ribosomal biogenesis genes play an essential and p53-
independent role in zebrafish pancreas development. Development. 2012;139(17):3232-3241. 
112. Tourlakis ME, Zhang S, Ball HL, et al. In Vivo Senescence in the Sbds-Deficient Murine Pancreas: Cell-
Type Specific Consequences of Translation Insufficiency. PLoS Genet. 2015;11(6):e1005288. 
113. Shwachman H, Diamond LK, Oski FA, Khaw KT. The Syndrome of Pancreatic Insufficiency and Bone 
Marrow Dysfunction. J Pediatr. 1964;65:645-663. 
114. Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for diagnosis and treatment of 
Shwachman-Diamond syndrome. Ann N Y Acad Sci. 2011;1242:40-55. 
115. Goobie S, Popovic M, Morrison J, et al. Shwachman-Diamond syndrome with exocrine pancreatic 
dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum 
Genet. 2001;68(4):1048-1054. 
116. Mäkitie O, Ellis L, Durie PR, et al. Skeletal phenotype in patients with Shwachman-Diamond 
syndrome and mutations in SBDS. Clinical Genetics. 2004;65(2):101-112. 
117. Toiviainen-Salo S, Mayranpaa MK, Durie PR, et al. Shwachman-Diamond syndrome is associated 
with low-turnover osteoporosis. Bone. 2007;41(6):965-972. 
118. Mack DR, Forstner GG, Wilschanski M, Freedman MH, Durie PR. Shwachman syndrome: Exocrine 
pancreatic dysfunction and variable phenotypic expression. Gastroenterology. 1996;111(6):1593-
1602. 
119. Toiviainen-Salo S, Durie PR, Numminen K, et al. The natural history of Shwachman-Diamond 
syndrome-associated liver disease from childhood to adulthood. J Pediatr. 2009;155(6):807-811 
e802. 
120. Kerr EN, Ellis L, Dupuis A, Rommens JM, Durie PR. The behavioral phenotype of school-age children 
with shwachman diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman-
Bodian-Diamond syndrome gene function. J Pediatr. 2010;156(3):433-438. 
121. Myers KC, Bolyard AA, Otto B, et al. Variable Clinical Presentation of Shwachman-Diamond 
Syndrome: Update from the North American Shwachman-Diamond Syndrome Registry. Journal of 
Pediatrics. 2014;164(4):866-870. 
122. Aggett PJ, Harries JT, Harvey BA, Soothill JF. An inherited defect of neutrophil mobility in Shwachman 
syndrome. J Pediatr. 1979;94(3):391-394. 
123. Rothbaum RJ, Williams DA, Daugherty CC. Unusual surface distribution of concanavalin A reflects a 
cytoskeletal defect in neutrophils in Shwachman's syndrome. Lancet. 1982;2(8302):800-801. 
124. Dror Y, Ginzberg H, Dalal I, et al. Immune function in patients with Shwachman-Diamond syndrome. 
Br J Haematol. 2001;114(3):712-717. 
125. Dror Y. Shwachman-Diamond syndrome. Pediatr Blood & Cancer. 2005;45(7):892-901. 
126. Donadieu J, Fenneteau O, Beaupain B, et al. Classification of and risk factors for hematologic 
complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. 
Haematologica. 2012;97(9):1312-1319. 
127. Aggett PJ, Cavanagh NPC, Matthew DJ, Pincott JR, Sutcliffe J, Harries JT. Shwachmans Syndrome - a 
Review of 21 Cases. Archives of Disease in Childhood. 1980;55(5):331-347. 
128. Leung EW, Rujkijyanont P, Beyene J, et al. Shwachman-Diamond syndrome: an inherited model of 
aplastic anaemia with accelerated angiogenesis. Br J Haematol. 2006;133(5):558-561. 
129. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. 
Hematology Am Soc Hematol Educ Program. 2007:29-39. 
130. Nicolis E, Bonizzato A, Assael BM, Cipolli M. Identification of novel mutations in patients with 
Shwachman-Diamond syndrome. Hum Mutat. 2005;25(4):410. 
131. Woloszynek JR, Rothbaum RJ, Rawls AS, et al. Mutations of the SBDS gene are present in most 
patients with Shwachman-Diamond syndrome. Blood. 2004;104(12):3588-3590. 
132. Finch AJ, Hilcenko C, Basse N, et al. Uncoupling of GTP hydrolysis from eIF6 release on the ribosome 
causes Shwachman-Diamond syndrome. Genes Dev. 2011;25(9):917-929. 
40
Chapter 1
C
ha
pt
er
 1
133. Koonin EV, Wolf YI, Aravind L. Prediction of the archaeal exosome and its connections with the 
proteasome and the translation and transcription machineries by a comparative-genomic approach. 
Genome Res. 2001;11(2):240-252. 
134. Menne TF, Goyenechea B, Sanchez-Puig N, et al. The Shwachman-Bodian-Diamond syndrome 
protein mediates translational activation of ribosomes in yeast. Nat Genet. 2007;39(4):486-495. 
135. Wong CC, Traynor D, Basse N, Kay RR, Warren AJ. Defective ribosome assembly in Shwachman-
Diamond syndrome. Blood. 2011;118(16):4305-4312. 
136. Burwick N, Coats SA, Nakamura T, Shimamura A. Impaired ribosomal subunit association in 
Shwachman-Diamond syndrome. Blood. 2012;120(26):5143-5152. 
137. Austin KM, Gupta ML, Jr., Coats SA, et al. Mitotic spindle destabilization and genomic instability in 
Shwachman-Diamond syndrome. J Clin Invest. 2008;118(4):1511-1518. 
138. Orelio C, Verkuijlen P, Geissler J, van den Berg TK, Kuijpers TW. SBDS expression and localization at 
the mitotic spindle in human myeloid progenitors. Plos One. 2009;4(9):e7084. 
139. Orelio C, Kuijpers TW. Shwachman-Diamond syndrome neutrophils have altered chemoattractant-
induced F-actin polymerization and polarization characteristics. Haematologica. 2009;94(3):409-
413. 
140. Ball HL, Zhang B, Riches JJ, et al. Shwachman-Bodian Diamond syndrome is a multi-functional protein 
implicated in cellular stress responses. Hum Mol Genet. 2009;18(19):3684-3695. 
141. Zhang S, Shi M, Hui CC, Rommens JM. Loss of the mouse ortholog of the shwachman-diamond 
syndrome gene (Sbds) results in early embryonic lethality. Mol Cell Biol. 2006;26(17):6656-6663. 
142. Shammas C, Menne TF, Hilcenko C, et al. Structural and mutational analysis of the SBDS protein 
family. Insight into the leukemia-associated Shwachman-Diamond Syndrome. J Biol Chem. 
2005;280(19):19221-19229. 
143. Rawls AS, Gregory AD, Woloszynek JR, Liu FL, Link DC. Lentiviral-mediated RNAi inhibition of Sbds in 
murine hematopoietic progenitors impairs their hematopoietic potential. Blood. 2007;110(7):2414-
2422. 
144. Venkatasubramani N, Mayer AN. A zebrafish model for the Shwachman-Diamond syndrome (SDS). 
Pediatr Res. 2008;63(4):348-352. 
145. Tulpule A, Kelley JM, Lensch MW, et al. Pluripotent stem cell models of Shwachman-Diamond 
syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem 
Cell. 2013;12(6):727-736. 
146. Yamaguchi M, Fujimura K, Toga H, Khwaja A, Okamura N, Chopra R. Shwachman-Diamond syndrome 
is not necessary for the terminal maturation of neutrophils but is important for maintaining viability 
of granulocyte precursors. Exp Hematol. 2007;35(4):579-586. 
147. Watanabe K, Ambekar C, Wang H, Ciccolini A, Schimmer AD, Dror Y. SBDS-deficiency results in 
specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. 
Apoptosis. 2009;14(1):77-89. 
148. Sen S, Wang H, Nghiem CL, et al. The ribosome-related protein, SBDS, is critical for normal 
erythropoiesis. Blood. 2011;118(24):6407-6417. 
149. Leung R, Cuddy K, Wang Y, Rommens J, Glogauer M. Sbds is required for Rac2-mediated monocyte 
migration and signaling downstream of RANK during osteoclastogenesis. Blood. 2011;117(6):2044-
2053. 
150. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment 
potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera 
model. Leukemia. 2000;14(5):889-897. 
151. Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the 
CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. 
Blood. 2002;100(1):259-267. 
152. Benito AI, Bryant E, Loken MR, et al. NOD/SCID mice transplanted with marrow from patients with 
myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human 
precursors. Leuk Res. 2003;27(5):425-436. 
153. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-
beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic 
syndrome. Blood. 2004;103(11):4285-4293. 
154. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17(6):771-789. 
155. Flynn CM, Kaufman DS. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. 
Blood. 2007;109(7):2688-2692. 
156. Greenberger JS, Anderson J, Berry LA, Epperly M, Cronkite EP, Boggs SS. Effects of irradiation of 
CBA/CA mice on hematopoietic stem cells and stromal cells in long-term bone marrow cultures. 
Leukemia. 1996;10(3):514-527. 
157. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro 
characterization of hematopoietic microenvironment cells from patients with myelodysplastic 
syndrome. Leuk Res. 2002;26(7):677-686. 
158. Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal 
stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 
2014;14(6):824-837. 
159. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone 
marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285-299. 
160. Arranz L, Sanchez-Aguilera A, Martin-Perez D, et al. Neuropathy of haematopoietic stem cell niche 
is essential for myeloproliferative neoplasms. Nature. 2014;512(7512):78-81. 
161. Hanoun M, Zhang D, Mizoguchi T, et al. Acute myelogenous leukemia-induced sympathetic 
neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 
2014;15(3):365-375. 
162. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome 
caused by retinoic acid receptor gamma deficiency. Cell. 2007;129(6):1097-1110. 
163. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia 
and secondary leukaemia. Nature. 2010;464(7290):852-857. 
164. Kode A, Manavalan JS, Mosialou I, et al. Leukaemogenesis induced by an activating beta-catenin 
mutation in osteoblasts. Nature. 2014;506(7487):240-244. 
165. Rujkijyanont P, Adams SL, Beyene J, Dror Y. Bone marrow cells from patients with Shwachman-
Diamond syndrome abnormally express genes involved in ribosome biogenesis and RNA processing. 
Br J Haematol. 2009;145(6):806-815. 
41
General introduction
C
ha
pt
er
 1
133. Koonin EV, Wolf YI, Aravind L. Prediction of the archaeal exosome and its connections with the 
proteasome and the translation and transcription machineries by a comparative-genomic approach. 
Genome Res. 2001;11(2):240-252. 
134. Menne TF, Goyenechea B, Sanchez-Puig N, et al. The Shwachman-Bodian-Diamond syndrome 
protein mediates translational activation of ribosomes in yeast. Nat Genet. 2007;39(4):486-495. 
135. Wong CC, Traynor D, Basse N, Kay RR, Warren AJ. Defective ribosome assembly in Shwachman-
Diamond syndrome. Blood. 2011;118(16):4305-4312. 
136. Burwick N, Coats SA, Nakamura T, Shimamura A. Impaired ribosomal subunit association in 
Shwachman-Diamond syndrome. Blood. 2012;120(26):5143-5152. 
137. Austin KM, Gupta ML, Jr., Coats SA, et al. Mitotic spindle destabilization and genomic instability in 
Shwachman-Diamond syndrome. J Clin Invest. 2008;118(4):1511-1518. 
138. Orelio C, Verkuijlen P, Geissler J, van den Berg TK, Kuijpers TW. SBDS expression and localization at 
the mitotic spindle in human myeloid progenitors. Plos One. 2009;4(9):e7084. 
139. Orelio C, Kuijpers TW. Shwachman-Diamond syndrome neutrophils have altered chemoattractant-
induced F-actin polymerization and polarization characteristics. Haematologica. 2009;94(3):409-
413. 
140. Ball HL, Zhang B, Riches JJ, et al. Shwachman-Bodian Diamond syndrome is a multi-functional protein 
implicated in cellular stress responses. Hum Mol Genet. 2009;18(19):3684-3695. 
141. Zhang S, Shi M, Hui CC, Rommens JM. Loss of the mouse ortholog of the shwachman-diamond 
syndrome gene (Sbds) results in early embryonic lethality. Mol Cell Biol. 2006;26(17):6656-6663. 
142. Shammas C, Menne TF, Hilcenko C, et al. Structural and mutational analysis of the SBDS protein 
family. Insight into the leukemia-associated Shwachman-Diamond Syndrome. J Biol Chem. 
2005;280(19):19221-19229. 
143. Rawls AS, Gregory AD, Woloszynek JR, Liu FL, Link DC. Lentiviral-mediated RNAi inhibition of Sbds in 
murine hematopoietic progenitors impairs their hematopoietic potential. Blood. 2007;110(7):2414-
2422. 
144. Venkatasubramani N, Mayer AN. A zebrafish model for the Shwachman-Diamond syndrome (SDS). 
Pediatr Res. 2008;63(4):348-352. 
145. Tulpule A, Kelley JM, Lensch MW, et al. Pluripotent stem cell models of Shwachman-Diamond 
syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem 
Cell. 2013;12(6):727-736. 
146. Yamaguchi M, Fujimura K, Toga H, Khwaja A, Okamura N, Chopra R. Shwachman-Diamond syndrome 
is not necessary for the terminal maturation of neutrophils but is important for maintaining viability 
of granulocyte precursors. Exp Hematol. 2007;35(4):579-586. 
147. Watanabe K, Ambekar C, Wang H, Ciccolini A, Schimmer AD, Dror Y. SBDS-deficiency results in 
specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. 
Apoptosis. 2009;14(1):77-89. 
148. Sen S, Wang H, Nghiem CL, et al. The ribosome-related protein, SBDS, is critical for normal 
erythropoiesis. Blood. 2011;118(24):6407-6417. 
149. Leung R, Cuddy K, Wang Y, Rommens J, Glogauer M. Sbds is required for Rac2-mediated monocyte 
migration and signaling downstream of RANK during osteoclastogenesis. Blood. 2011;117(6):2044-
2053. 
150. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment 
potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera 
model. Leukemia. 2000;14(5):889-897. 
151. Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the 
CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. 
Blood. 2002;100(1):259-267. 
152. Benito AI, Bryant E, Loken MR, et al. NOD/SCID mice transplanted with marrow from patients with 
myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human 
precursors. Leuk Res. 2003;27(5):425-436. 
153. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-
beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic 
syndrome. Blood. 2004;103(11):4285-4293. 
154. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17(6):771-789. 
155. Flynn CM, Kaufman DS. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. 
Blood. 2007;109(7):2688-2692. 
156. Greenberger JS, Anderson J, Berry LA, Epperly M, Cronkite EP, Boggs SS. Effects of irradiation of 
CBA/CA mice on hematopoietic stem cells and stromal cells in long-term bone marrow cultures. 
Leukemia. 1996;10(3):514-527. 
157. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro 
characterization of hematopoietic microenvironment cells from patients with myelodysplastic 
syndrome. Leuk Res. 2002;26(7):677-686. 
158. Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal 
stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 
2014;14(6):824-837. 
159. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone 
marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285-299. 
160. Arranz L, Sanchez-Aguilera A, Martin-Perez D, et al. Neuropathy of haematopoietic stem cell niche 
is essential for myeloproliferative neoplasms. Nature. 2014;512(7512):78-81. 
161. Hanoun M, Zhang D, Mizoguchi T, et al. Acute myelogenous leukemia-induced sympathetic 
neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 
2014;15(3):365-375. 
162. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome 
caused by retinoic acid receptor gamma deficiency. Cell. 2007;129(6):1097-1110. 
163. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia 
and secondary leukaemia. Nature. 2010;464(7290):852-857. 
164. Kode A, Manavalan JS, Mosialou I, et al. Leukaemogenesis induced by an activating beta-catenin 
mutation in osteoblasts. Nature. 2014;506(7487):240-244. 
165. Rujkijyanont P, Adams SL, Beyene J, Dror Y. Bone marrow cells from patients with Shwachman-
Diamond syndrome abnormally express genes involved in ribosome biogenesis and RNA processing. 
Br J Haematol. 2009;145(6):806-815. 
    
Chapter 2 
    
Deficiency of  the ribosome biogenesis 
gene Sbds in hematopoietic stem and 
progenitor cells causes neutropenia in 
mice by attenuating lineage  
progression in myelocytes
Noemi A. Zambetti,1 Eric M. J. Bindels,1 Paulina M. H. Van Strien, 
1 Marijke G. Valkhof,1,2 Maria N. Adisty,1 Remco M. Hoogenboezem, 
1 Mathijs A. Sanders,1 Johanna M. Rommens,3 Ivo P. Touw,1 and
Marc H. G. P. Raaijmakers1
1Department of  Hematology, Erasmus Medical Center Cancer Institute, Rotterdam,  
The Netherlands 
2Current address: Laboratory for Cell Therapy, Sanquin Research  
and Landsteiner Laboratory, Amsterdam, The Netherlands 
3Program in Genetics & Genome Biology, Peter Gilgan Centre  
for Research and Learning, The Hospital for Sick Children, Department  
of  Molecular Genetics, University of  Toronto, Toronto, ON, Canada
Haematologica. 2015 Oct;100(10):1285-93
44
Chapter 2
C
ha
pt
er
 2
ABSTRACT 
Shwachman-Diamond syndrome is a congenital bone marrow failure disorder characterized by 
debilitating neutropenia. The disease is associated with loss-of-function mutations in the SBDS 
gene, implicated in ribosome biogenesis, but the cellular and molecular events driving cell specific 
phenotypes in ribosomopathies remain poorly defined. Here, we established, to our knowledge, 
the first mammalian model of neutropenia in Shwachman-Diamond syndrome through targeted 
downregulation of Sbds in hematopoietic stem and progenitor cells expressing the myeloid 
transcription factor CCAAT/enhancer binding protein α (Cebpa). Sbds deficiency in the myeloid 
lineage specifically affected myelocytes and their downstream progeny while, unexpectedly, it 
was well tolerated by rapidly cycling hematopoietic progenitor cells. Molecular insights provided 
by massive parallel sequencing supported cellular observations of impaired cell cycle exit and 
formation of secondary granules associated with the defect of myeloid lineage progression in 
myelocytes. Mechanistically, Sbds deficiency activated the p53 tumor suppressor pathway and 
induced apoptosis in these cells. Collectively, the data reveal a previously unanticipated, selective 
dependency of myelocytes and downstream progeny, but not rapidly cycling progenitors, on this 
ubiquitous ribosome biogenesis protein, thus providing a cellular basis for the understanding of 
myeloid lineage biased defects in Shwachman-Diamond syndrome. 
 
  
INTRODUCTION 
Shwachman-Diamond syndrome (SDS; OMIM 260400) is a rare congenital multi-systemic disorder 
characterized by exocrine pancreatic insufficiency, skeletal defects and bone marrow failure.1-3 
The hematological hallmark of the disease is neutropenia, which affects 88% to 98% of patients4,5 
and represents, together with leukemic evolution, the main cause of morbidity and mortality in 
SDS.1,6-8 Other, less common manifestations are anemia, thrombocytopenia and pancytopenia.6,7 
The disease is caused by biallelic loss of function mutations in the Shwachman-Bodian-Diamond 
Syndrome gene (SBDS).9 The two most common mutations, 258+2T→C and 183-184TA→CT, 
result in impaired splicing and a premature stop codon, respectively, and are associated with 
reduced protein levels of SBDS.9,10  
SBDS plays an essential role in ribosome biogenesis. In particular, the concerted activity of SBDS 
and elongation factor-like 1 (EFL1) mediates the removal of eukaryotic initiation factor 6 (eIF6) 
during the cytoplasmic maturation of the pre-60S subunit, allowing the formation of the 80S 
ribosome.10-12 Consistent with this notion, impaired ribosome subunit joining has been 
demonstrated in SDS patients12,13 and reduced overall translation was detected in yeast models 
of SDS.11 Defects in ribosome biogenesis define a group of pathologies collectively known as 
ribosomopathies. Causative mutations in genes linked to ribosome biogenesis have been 
identified in several congenital diseases including Diamond-Blackfan anemia (DBA), dyskeratosis 
congenita and cartilage-hair hypoplasia. While the hematopoietic system is affected in most of 
these conditions, leading to some degree of bone marrow failure, pronounced vulnerability of 
specific cell lineages discerns these disorders, with neutropenia being the specific hallmark of SDS. 
This reflects the central enigma in the understanding of human congenital ribosomopathies, i.e. 
how disruption of ribosome biogenesis, a process occurring in all tissues with a proposed generic 
role in protein synthesis, results in cell and tissue specific disease phenotypes.  
It is thought that ribosomes, and hence the proteins related to their biogenesis,  are critically 
important for fast cycling cells, thus leading to impaired function of hematopoietic progenitor 
cells, resulting in cytopenia, but this view provides no explanation for cell type specificity 
(neutropenia) in SDS.14,15  
Identification of the cell types specifically affected by dysfunction of ribosomal genes will thus be 
critical in deciphering the underlying molecular mechanisms driving disease pathology, ultimately 
enabling targeted therapies. However, progress in understanding the pathophysiology of SDS is 
limited by the lack of a robust mammalian model faithfully recapitulating neutropenia. Deficiency 
of Sbds leads to embryonic lethality in full knockout mice10,16 and transplantation of shRNA-
transduced, Sbds-deficient murine hematopoietic cells in wild type recipient mice did not result 
in overt neutropenia, although it impaired myeloid progenitor generation.17 Targeting Sbds in the 
hematopoietic system via poly(I:C) treatment of Sbdsfl/-Tg:Mx1-cre mice resulted in a severe 
45
Sbds deficiency in HSPCs causes neutropenia in mice
C
h
ap
te
r 
2
ABSTRACT 
Shwachman-Diamond syndrome is a congenital bone marrow failure disorder characterized by 
debilitating neutropenia. The disease is associated with loss-of-function mutations in the SBDS 
gene, implicated in ribosome biogenesis, but the cellular and molecular events driving cell specific 
phenotypes in ribosomopathies remain poorly defined. Here, we established, to our knowledge, 
the first mammalian model of neutropenia in Shwachman-Diamond syndrome through targeted 
downregulation of Sbds in hematopoietic stem and progenitor cells expressing the myeloid 
transcription factor CCAAT/enhancer binding protein α (Cebpa). Sbds deficiency in the myeloid 
lineage specifically affected myelocytes and their downstream progeny while, unexpectedly, it 
was well tolerated by rapidly cycling hematopoietic progenitor cells. Molecular insights provided 
by massive parallel sequencing supported cellular observations of impaired cell cycle exit and 
formation of secondary granules associated with the defect of myeloid lineage progression in 
myelocytes. Mechanistically, Sbds deficiency activated the p53 tumor suppressor pathway and 
induced apoptosis in these cells. Collectively, the data reveal a previously unanticipated, selective 
dependency of myelocytes and downstream progeny, but not rapidly cycling progenitors, on this 
ubiquitous ribosome biogenesis protein, thus providing a cellular basis for the understanding of 
myeloid lineage biased defects in Shwachman-Diamond syndrome. 
 
  
INTRODUCTION 
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reduced protein levels of SBDS.9,10  
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these conditions, leading to some degree of bone marrow failure, pronounced vulnerability of 
specific cell lineages discerns these disorders, with neutropenia being the specific hallmark of SDS. 
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how disruption of ribosome biogenesis, a process occurring in all tissues with a proposed generic 
role in protein synthesis, results in cell and tissue specific disease phenotypes.  
It is thought that ribosomes, and hence the proteins related to their biogenesis,  are critically 
important for fast cycling cells, thus leading to impaired function of hematopoietic progenitor 
cells, resulting in cytopenia, but this view provides no explanation for cell type specificity 
(neutropenia) in SDS.14,15  
Identification of the cell types specifically affected by dysfunction of ribosomal genes will thus be 
critical in deciphering the underlying molecular mechanisms driving disease pathology, ultimately 
enabling targeted therapies. However, progress in understanding the pathophysiology of SDS is 
limited by the lack of a robust mammalian model faithfully recapitulating neutropenia. Deficiency 
of Sbds leads to embryonic lethality in full knockout mice10,16 and transplantation of shRNA-
transduced, Sbds-deficient murine hematopoietic cells in wild type recipient mice did not result 
in overt neutropenia, although it impaired myeloid progenitor generation.17 Targeting Sbds in the 
hematopoietic system via poly(I:C) treatment of Sbdsfl/-Tg:Mx1-cre mice resulted in a severe 
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hepatic phenotype, precluding a thorough investigation of the hematological consequences of 
Sbds deficiency in adult hematopoietic stem cells (HSCs).10 Thus, in vivo targeting of Sbds in 
postnatal mammalian hematopoiesis remains a key challenge for the field. 
The basic leucine zipper transcription factor CCAAT/Enhancer-Binding Protein α (C/EBPα) is 
expressed in a fraction of HSCs and throughout the myeloid lineage,18-20 thus offering an 
alternative approach to target hematopoietic stem and progenitor cells and their downstream 
myeloid lineage progeny in adult mammals. 
Here, we generated a novel mouse model of genetic Sbds deletion through targeted 
downregulation of the gene in Cebpa-expressing cells, resulting in profound neutropenia. We 
show that loss of Sbds is well tolerated by rapidly cycling myeloid progenitor cells and identify 
myelocytes and their downstream progeny as the cell types within the hematopoietic hierarchy 
critically affected by Sbds deficiency through induction of cellular stress and apoptosis, thus 
providing a cellular and molecular basis for neutropenia in SDS. 
 
METHODS 
Additional information is provided in the Supplemental Methods. 
Mice and Genotyping 
Cebpacre/+ R26 EYFP mice and Sbdsf/+ mice have been previously described.19,21 B6.SJL-
PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased from Charles River. Mice and embryos were 
genotyped by PCR on DNA isolated from toes and forelimbs, respectively, using the primers listed 
in Table S1 (Life Technologies). Animals were maintained in specific pathogen free conditions in 
the Experimental Animal Center of Erasmus MC (EDC) and sacrificed by cervical dislocation. All 
animal work was approved by the Animal Welfare/Ethics Committee of the EDC in accordance 
with legislation in the Netherlands. 
 
Fetal Liver Cell Transplantation 
Fetal livers were isolated from E14.5 embryos. Cell suspensions were centrifuged, resuspended 
in a minimal volume of ACK lysing buffer (Lonza) and incubated on ice for 4 min to eliminate red 
blood cells. After centrifugation, cells were resuspended in PBS+0.5% FCS. 7-10-week-old, lethally 
irradiated (8.5Gy) B6.SJL mice were transplanted with 3x105 fetal liver cells by tail vein injection. 
Recipients received antibiotics in the drinking water for 2 weeks after transplantation.  
RNA Sequencing and GSEA Analysis 
cDNA was synthesized and amplified using SMARTer Ultra Low RNA kit (Clontech Laboratories) 
following the manufacturer’s protocol. Amplified cDNA was further processed according to 
TruSeq Sample Preparation v2 Guide (Illumina) and paired end-sequenced (2x75 bp) on the HiSeq 
2500 (Illumina). Demultiplexing was performed using CASAVA software (Illumina) and the adaptor 
sequences were trimmed with Cutadapt (http://code.google.com/p/cutadapt/). Alignments 
against the mouse genome (mm10) and analysis of differential expressed genes were performed 
as previously described.22 Cufflinks software was used to calculate the number of fragments per 
kilobase of exon per million fragments mapped (FPKM) for each gene. FPKM values of Sbds f/f 
and +/+ recipients were then compared to the curated gene sets (C2) and the Gene Ontology 
gene sets (C5) of the Molecular Signature Database (MSigDB) by GSEA23 (Broad Institute), using 
the Signal2Noise metric and 1000 phenotype-based permutations. 
 
Statistical Analysis 
Unless otherwise specified, statistical analysis was performed by an unpaired, 2-tailed Student’s 
t test or 1-way analysis of variance. All results in bar graphs are reported as mean value ± standard 
error of the mean.  
 
RESULTS 
Cebpa-driven deletion of Sbds in the hematopoietic system 
To address the functional consequences of Sbds deficiency in early hematopoietic progenitors, 
we crossed Sbds-conditional knock-out mice, with loxP sites flanking the second exon of Sbds,21 
with Cebpacre/+ R26 EYFP mice19 (Figure 1A). In this approach, Cre-mediated deletion of Sbds exon 
2 in Cebpa-expressing cells results in a frameshift and consequently generates a premature stop 
codon, thus mimicking the effects of the 183-184TA→CT mutation in the human disease.9 In 
addition, the R26 EYFP element enables the tracing of Sbds-depleted cells and their progeny 
based on enhanced yellow fluorescent protein (EYFP) expression.  
Intercrossings of Sbdsf/+;Cebpacre/+;R26EYFP/+ mice failed to generate any Sbdsf/f;Cebpacre/+ viable 
offspring (Table S2). This, together with the small litter sizes, suggested that deficiency of Sbds in 
Cebpa-expressing cells is lethal in mice. Because Cebpa is expressed in non-hematopoietic tissues, 
like liver and lungs,24 we analyzed E14.5 embryos from  Sbdsf/+;Cebpacre/+ R26EYFP/+ intercrosses to 
assess whether the lethal phenotype directly reflected hematopoietic dysfunction. Interestingly, 
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at this gestational age, Sbdsf/f;Cebpacre/+;R26EYFP/+ (hereafter Sbds f/f or mutants) offspring was 
found at Mendelian frequencies (Table S2) and these embryos were morphologically 
indistinguishable from their littermates. Genomic PCR indicated effective deletion of exon 2 in 
Sbds f/f embryos (Figure 1A, Figure 1B). We next compared hematopoiesis in Sbds f/f embryos 
with that of Cebpacre/+;R26EYFP/+ controls (hence Sbds +/+) and found that Sbds recombination was 
associated with overall conservation of normal hematopoietic architecture in the fetal liver 
(Figure 1C). This suggests that embryonic lethality in this model is not caused by impaired blood 
cell production. The proportion of EYFP+, Cre-targeted cells in each hematopoietic compartment 
was also similar in Sbds f/f and +/+ embryos, with the majority of GMPs and Gr1+Mac1+ mature 
granulocytes expressing EYFP (>90% and >60% of cells, respectively, Figure 1D). As expected,19,20 
a small fraction of immunophenotypically defined HSCs, multipotent progenitors (MPPs),  
 
 
Figure 1. Sbds-deletion from myeloid progenitor cells does not perturb the architecture of fetal liver 
hematopoiesis. (A) Schematic representation of the targeting vectors and the primers used in the study. 
Primer sequences are listed in Table S1. (B) Genomic analysis of E14.5 embryos confirmed excision of Sbds 
in f/f mice. a + b, genotyping primers. c + d, deletion primers. (C-D) Normal composition of fetal liver (Sbds 
+/+, n = 4; Sbds f/f, n = 6). (C) Frequency of hematopoietic subsets in live cells (7AAD-). (D) Proportion of 
EYFP+ cells in each hematopoietic population. Data is mean ± s.e.m. Differences between Sbds +/+ and f/f 
mice are not significant. HSC, Lin- c-Kit+ Sca1+ (LKS) CD48- CD150+ cells. Multipotent progenitors (MPP), LKS 
CD48- CD150- cells. Common myeloid progenitor (CMP), Lin- c-Kit+ Sca1- CD34+ CD16/32- cells. Granulocyte-
macrophage progenitor (GMP), Lin- c-Kit+ Sca1- CD34+ CD16/32+ cells. 
megakaryocyte-erythroid progenitors (MEPs) and B220+ lymphocytes also expressed EYFP, 
indicating targeting of multilineage progenitors in this model. 
 
Transplantation of Sbds-deleted fetal hematopoietic cells in adult mice results in 
neutropenia  
To assess whether the deletion of Sbds in fetal hematopoietic progenitors would compromise 
postnatal hematopoiesis, we transplanted fetal liver cells from of E14.5 (CD45.2+) Sbds f/f or +/+ 
embryos into lethally irradiated (CD45.1+) B6.SJL mice (Figure 2A) and monitored hematopoiesis 
by peripheral blood analysis every 4 weeks. In both Sbds f/f and +/+ recipients more than 90% of 
circulating blood cells were CD45.2+, indicating high chimerism in reconstituted mice. Mice 
transplanted with Sbds-deficient cells developed profound neutropenia, with an average 5.9-fold 
reduction of Gr1+ Mac1+ cells in the peripheral blood 5 weeks after transplantation (Figure 2B). 
Neutropenia was stable and persisted during the entire follow-up, i.e. 4 months after 
transplantation. Consistent with the hypothesis that loss of Sbds impairs myelopoiesis, the 
proportion of EYFP+, Cre-targeted cells in Sbds f/f recipients (47.4±10.2%) was lower than that in  
 
 
Figure 2. Loss of Sbds from C/EBPα-expressing cells causes neutropenia in mice. (A) Experimental design. 
300 000 fetal liver cells from either Sbds +/+ or f/f embryos (E14.5) were transplanted into 7 to 10-week-
old lethally irradiated CD45.1+ B6.SJL mice (n = 7 per group). (B) Peripheral blood analysis at 5 and 16 weeks 
after transplantation showed severe reduction of granulocytes (Gr1+ Mac1+ cells) upon Sbds deletion. Each 
circle represents one mouse. The horizontal line depicts average values. WBC, white blood cells. ** P < 
0.01, ***P <  0.001. 
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controls (75.6±17.3%). In addition, numbers of circulating erythrocytes and B-cells were unaltered 
in steady state hematopoiesis after transplantation, while platelet numbers were increased in 
transplanted mice (Figure S1). Overall, the data indicates that Sbds is essential to maintain 
postnatal granulopoiesis and neutrophil homeostasis.  
 
Sbds-deficiency in the myeloid lineage arrests differentiation at the myelocyte-
metamyelocyte stage 
To obtain insight into the cellular events caused by Sbds deficiency driving the defect in neutrophil 
development, we sacrificed mice 17 to 19 weeks after transplantation. Cebpa is expressed in 
myeloid progenitor cells and in a subpopulation of early progenitors that retain multilineage 
differentiation capacity.19,20 In line with this, EYFP expression was found in a small fraction of 
immunophenotypically defined hematopoietic stem and progenitor cells (HSPCs) and in all blood 
lineages (Gr1+Mac1+ myeloid, Ter119+ erythroid and B220+ lymphoid) at varying frequencies 
(Table 1; Figure 3A). 
The bone marrow of mice transplanted with Sbds f/f fetal liver cells was hypocellular, a common 
finding in SDS patients7,25 (Figure 3B). Hypocellularity resulted mostly from a marked reduction in 
EYFP+ Gr1+ Mac1+ neutrophils (86 437 ± 33 601 cells per femur/body gram in Sbds f/f recipients 
and 316 442 ± 47 984 in controls), although also the number of EYFP+ lymphoid and Ter119+ 
erythroid cells was modestly decreased in mutant mice (Figure 3C, Figure 3D). Of note, 
myelodysplastic features were not observed in Sbds f/f recipients in the current model, suggesting 
that hematopoietic cell-extrinsic factors may contribute to myelodysplasia in SDS.26 
 
Table 1. Frequency of EYFP+ cells within hematopoietic subsets in the bone marrow.  
Population Sbds +/+ a Sbds f/f a 
LKSb  3.3% (1.61% - 5.82%) 7.4% (1.67% - 11.5%) 
CMPb 31.2% (24.0% - 41.6%) 22.5% (16.3% - 31.6%) 
MEPb 8.2% (6.3% - 10.2%) 5.8% (4.92% - 6.79%) 
GMPb 72.3% (63.7% - 77.6%) 67.7% (62.6% - 72.3%) 
Gr1+ Mac1+ c 87.9% (86.2% - 89.1%) 76.1% (74.3% - 77.7%) 
B220+ c 8.8% (5.4% - 13.2%) 4.4% (3.3% - 5.9%) 
Ter119+ d 3.0% (2.2% - 4.1%) 1.8% (0.7% - 3.2%) 
aThe percentage of EYFP+ cells in different hematopoietic populations is indicated as mean frequency 
(range). bn = 7. cSbds +/+, n = 7; Sbds f/f, n=6. dSbds +/+, n = 5; Sbds f/f, n = 4. 
 
Having established that Sbds deletion from multilineage hematopoietic progenitors results in 
neutropenia, we next sought to define the stages in myeloid lineage progression that were 
affected by loss of Sbds. It is generally assumed that loss of ribosome biogenesis genes affects 
rapidly proliferating progenitor cells with increased protein translation rates, although in vivo 
experimental support for this view has been lacking in the absence of a mammalian model of Sbds 
deficiency resulting in stable neutropenia. Efficient Sbds gene knockdown in EYFP+ cells was first 
confirmed by quantitative RT-PCR throughout myeloid lineage development (Figure 3E), showing 
near complete deletion of Sbds expression at all stages of myeloid development (LKS, CMP, GMP, 
immature and mature neutrophils). Interestingly, Sbds deficiency did not result in reduced 
numbers of hematopoietic progenitor cells along the myeloid lineage (Figure 3C, Figure 3D). 
Rather, a compensatory expansion of some progenitors was observed with numbers of both 
EYFP+ and EYFP- GMPs dramatically increased in mice transplanted with Sbds f/f cells (average 
fold change, FC: 5.8 in EYFP+ compartment and 5.9 in EYFP- cells; Figure 3D; Figure S2), suggesting 
the emergence of reactive granulopoiesis in this cohort, defined as adaptation of the 
hematopoietic system to the increased demand through enhanced myeloid precursor cell 
proliferation in the bone marrow.27 
We next aimed to further define the specific cell type in myeloid development that is critically 
dependent on Sbds function. FACS analysis revealed an increased frequency of c-Kitint Gr1low cells, 
previously identified as myelocytes and metamyelocytes (MC-MMs, Figure 3F).28 Both frequency 
and absolute count of more mature myeloid cells, characterized by loss of c-Kit expression and 
bright Gr1 staining, were lower, suggesting an arrest of lineage progression at the MC-MM stage. 
Morphological assessment of the bone marrow confirmed that terminal granulopoiesis is severely 
affected in Sbds f/f recipients, with accumulation of MC-MMs and reduced frequency of 
segmented neutrophils (Figure 3G; Figure S3). Together, the data demonstrates that Sbds 
deletion from hematopoietic progenitor cells critically and specifically affects late stages of 
myeloid development, in particular the transition MC-MM to mature neutrophils. 
 
Deficiency of Sbds deregulates myeloid differentiation programs and prevents 
cell-cycle-exit in myelocytes and metamyelocytes 
To gain insight into the molecular programs associated with the proposed block of myeloid 
lineage progression at the MC-MM stage, the transcriptome of prospectively FACS-isolated EYFP+ 
c-Kitint Gr1low (MC-MM) cells was investigated by massive parallel RNA sequencing (RNA-Seq). As 
expected, Sbds expression in this population was significantly reduced in Sbds f/f recipients (log2 
FC = -2.39, False Discovery Rate, FDR=6.6x10-9, Figure 4A). Consistent with its postulated function 
in ribosome biogenesis, Sbds deficiency significantly (FDR<0.25) affected transcriptional  
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Table 1. Frequency of EYFP+ cells within hematopoietic subsets in the bone marrow.  
Population Sbds +/+ a Sbds f/f a 
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CMPb 31.2% (24.0% - 41.6%) 22.5% (16.3% - 31.6%) 
MEPb 8.2% (6.3% - 10.2%) 5.8% (4.92% - 6.79%) 
GMPb 72.3% (63.7% - 77.6%) 67.7% (62.6% - 72.3%) 
Gr1+ Mac1+ c 87.9% (86.2% - 89.1%) 76.1% (74.3% - 77.7%) 
B220+ c 8.8% (5.4% - 13.2%) 4.4% (3.3% - 5.9%) 
Ter119+ d 3.0% (2.2% - 4.1%) 1.8% (0.7% - 3.2%) 
aThe percentage of EYFP+ cells in different hematopoietic populations is indicated as mean frequency 
(range). bn = 7. cSbds +/+, n = 7; Sbds f/f, n=6. dSbds +/+, n = 5; Sbds f/f, n = 4. 
 
Having established that Sbds deletion from multilineage hematopoietic progenitors results in 
neutropenia, we next sought to define the stages in myeloid lineage progression that were 
affected by loss of Sbds. It is generally assumed that loss of ribosome biogenesis genes affects 
rapidly proliferating progenitor cells with increased protein translation rates, although in vivo 
experimental support for this view has been lacking in the absence of a mammalian model of Sbds 
deficiency resulting in stable neutropenia. Efficient Sbds gene knockdown in EYFP+ cells was first 
confirmed by quantitative RT-PCR throughout myeloid lineage development (Figure 3E), showing 
near complete deletion of Sbds expression at all stages of myeloid development (LKS, CMP, GMP, 
immature and mature neutrophils). Interestingly, Sbds deficiency did not result in reduced 
numbers of hematopoietic progenitor cells along the myeloid lineage (Figure 3C, Figure 3D). 
Rather, a compensatory expansion of some progenitors was observed with numbers of both 
EYFP+ and EYFP- GMPs dramatically increased in mice transplanted with Sbds f/f cells (average 
fold change, FC: 5.8 in EYFP+ compartment and 5.9 in EYFP- cells; Figure 3D; Figure S2), suggesting 
the emergence of reactive granulopoiesis in this cohort, defined as adaptation of the 
hematopoietic system to the increased demand through enhanced myeloid precursor cell 
proliferation in the bone marrow.27 
We next aimed to further define the specific cell type in myeloid development that is critically 
dependent on Sbds function. FACS analysis revealed an increased frequency of c-Kitint Gr1low cells, 
previously identified as myelocytes and metamyelocytes (MC-MMs, Figure 3F).28 Both frequency 
and absolute count of more mature myeloid cells, characterized by loss of c-Kit expression and 
bright Gr1 staining, were lower, suggesting an arrest of lineage progression at the MC-MM stage. 
Morphological assessment of the bone marrow confirmed that terminal granulopoiesis is severely 
affected in Sbds f/f recipients, with accumulation of MC-MMs and reduced frequency of 
segmented neutrophils (Figure 3G; Figure S3). Together, the data demonstrates that Sbds 
deletion from hematopoietic progenitor cells critically and specifically affects late stages of 
myeloid development, in particular the transition MC-MM to mature neutrophils. 
 
Deficiency of Sbds deregulates myeloid differentiation programs and prevents 
cell-cycle-exit in myelocytes and metamyelocytes 
To gain insight into the molecular programs associated with the proposed block of myeloid 
lineage progression at the MC-MM stage, the transcriptome of prospectively FACS-isolated EYFP+ 
c-Kitint Gr1low (MC-MM) cells was investigated by massive parallel RNA sequencing (RNA-Seq). As 
expected, Sbds expression in this population was significantly reduced in Sbds f/f recipients (log2 
FC = -2.39, False Discovery Rate, FDR=6.6x10-9, Figure 4A). Consistent with its postulated function 
in ribosome biogenesis, Sbds deficiency significantly (FDR<0.25) affected transcriptional  
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signatures related to translation and ribosome biogenesis (Figure 4B; Table S3 and S4). Gene set 
enrichment analysis (GSEA) highlighted the enrichment of relatively immature hematopoietic 
signatures in Sbds f/f MC-MMs, whereas data sets associated with cell differentiation were 
enriched in controls, consistent with a defect in maturation (Figure 4C; Table S3). To specifically 
define the stage in which myeloid differentiation is impaired, we examined the expression of 
transcripts encoding constituents of myeloid granules. In myeloid development, primary granules 
are produced in promyelocytes, whereas secondary granule production starts in myelocytes and 
gelatinase-containing tertiary granules become apparent in metamyelocytes and in band 
cells.29,30 Transcript analysis showed significantly reduced expression of secondary and tertiary 
granule components, whereas transcripts encoding constituents of primary granules were 
significantly enriched, indicating that development is specifically arrested in myelocytes, 
consistent with flow-cytometric findings (Figure 4D). 
To definitively establish the myelocyte as the cell type in the myeloid lineage critically depending 
on Sbds expression, we next performed cell cycle analysis. Myelocytes represent the last cell in 
myeloid differentiation capable of mitotic division31 and cell cycle exit is a required process for 
terminal granulopoiesis32. Ki67 analysis by FACS demonstrated that c-Kitint Gr1low cells indeed 
failed to exit the cell cycle, congruent with the notion that Sbds deficiency attenuates lineage 
progression in myelocytes (Figure 4E, Figure 4F). Molecularly, this failure to exit the cell cycle was 
associated with significant reduced expression of the transcription factor retinoic acid receptor α 
(RARα) and its downstream transcriptional targets Itgb2 and p27 (Cdkn1b),33,34 key activators of 
the terminal myeloid differentiation program and cell cycle exit (Figure 4G).  
Together, the data demonstrates that loss of Sbds from hematopoietic progenitors results in 
failure of lineage progression specifically in myelocytes, which is associated with attenuation of  
 
Figure 3. Sbds-deficiency in hematopoiesis attenuates myeloid lineage progression at the myelocyte-
metamyelocyte stage. (A) Donut chart illustrating the percentage of different hematopoietic subsets 
within the EYFP+ compartment in the bone marrow of Sbds +/+ and f/f recipients. (B) Decreased cellularity 
upon transplantation of Sbds-deficient cells. (C-D) Absolute number of EYFP+ cells in different 
hematopoietic populations in the bone marrow (Sbds +/+, n = 7; Sbds f/f, n = 6, data is mean ± s.e.m). (C) 
LKS subsets. (D) Reduction of EYFP+ mature granulocytes in Sbds f/f-transplanted mice is associated with 
an increase of granulocyte-macrophage progenitors. (E) Deletion efficacy. Expression of Sbds is reduced in 
LKS and throughout the myeloid differentiation stages in Sbds f/f EYFP+ cells. (F) Loss of late myeloid cells 
in Sbds f/f mice. Upper panel, representative plots of EYFP+ cells. Lower panel, percentage of c-Kit+ Gr1- 
myeloblasts and promyelocytes (i), c-Kitint Gr1low myelocytes and metamyelocytes (ii) and c-Kit- Gr1+ band 
and segmented cells (iii) in EYFP+ cells from Sbds +/+ and f/f cohorts. (G) Accumulation of myelocytes and 
metamyelocytes (black arrows) in Sbds-deficient bone marrow (original magnification x63). * P < 0.05, ** 
P < 0.01, ***P < 0.001.  
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myeloid differentiation signatures and cellular events. 
 
Loss of Sbds results in activation of the p53 tumor suppressor pathway and 
apoptosis in late stage myeloid cells 
Finally, we shought to better define the underlying cellular and molecular mechanisms of the 
arrest in lineage progression at the stage of myelocytes. Activation of p53 has been proposed as 
a common mechanism in the pathogenesis of different ribosomopathies, including DBA, Treacher 
Collins syndrome and 5q- syndrome35. In SDS, overexpression of p53 in immature cells has been 
described in bone marrow biopsies from SDS patients36 but the consequences of p53 activation 
for disease pathogenesis have not been experimentally defined. Transcriptional activation of the 
p53 pathway was observed in Sbds f/f MC-MMs by GSEA analysis (Figure 5A). Specifically, RNA 
sequencing demonstrated a significant increase in transcripts for p53 itself and many of its 
downstream targets, including the cell cycle regulators Cdkn1a (p21) and Zmat3 (Wig1) and the 
pro-apoptotic genes Bbc3 (PUMA), Bax, Tnfrsf10b (Death Receptor 5) and Cycs (cytochrome c, 
somatic) (Figure 5B). FACS analysis confirmed intracellular accumulation of the p53 protein, 
specifically at late stages of myelopoiesis (MC-MM and c-Kit - EYFP+ populations) in Sbds f/f 
recipients (FC = 1.78 and 1.53, respectively, Figure 5C). In line with this activation of the p53 tumor 
suppressor pathway and increased expression of pro-apoptotic genes, an increased rate of 
apoptosis (annexin V+ 7AAD- cells) was found in p53-overexpressing c-Kitint and c-Kit- EYFP+ 
populations (Figure 5D). Of note, no significant p53 accumulation or apoptosis was observed in  
 
Figure 4. Sbds deficiency results in failure of cell cycle exit and secondary granule formation in 
myelopoiesis. (A) Expression of Sbds in c-Kitint Gr1low EYFP+ cells by RNA-Seq (n = 4). Each circle represents 
one mouse. (B-C) GSEA plots showing enrichment of data sets relating to translation (B) and immature 
hematopoietic features (Ci) in c-Kitint Gr1low EYFP+ cells from Sbds f/f recipients and enrichment of 
maturation signatures in the Sbds +/+ group (Cii). Genes in the datasets are represented by black bars 
distributed according to their differential expression between Sbds f/f and Sbds +/+ cohorts. NES: 
Normalized Enrichment Score. (D) Reduced expression of genes encoding secondary and tertiary granule 
proteins in Sbds f/f c-Kitint Gr1low EYFP+ cells with enrichment of transcripts encoding primary granules 
components. (E-F) Sbds deficiency impairs cell cycle exit in myelopoiesis (Sbds +/+, n = 5; Sbds f/f, n = 4). 
(E) Gating strategy in representative FACS plots. (F) Percentage of cells in G0 (Ki67- 7AADlow), G1 (Ki67+ 
7AADlow) and S-G2-M (Ki67+ 7AADhigh) in each YFP+ population. (G) Downregulation of Rara, Cdkn1b (p27) 
and Itgb2 in recipients of Sbds-deficient cells (n = 4). Data is mean ± s.e.m. * P < 0.05, ** P < 0.01, ***P <  
0.001.  † FDR < 0.05, †† FDR < 0.01, †††FDR < 0.001. 
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Figure 5. Activation of p53 and apoptosis in late stages of Sbds-deficient myeloid development. (A) 
Enrichment of p53 signatures in the transcriptome of MC-MMs from Sbds f/f recipients (n = 4). (B) 
Increased transcript levels of Trp53 and its downstream transcriptional targets in RNA-Seq data. (C) 
Accumulation of p53 protein in late stages of myelopoiesis. Left, representative histograms. Right, mean 
fluorescence intensities in different EYFP+ populations (Sbds +/+, n = 5; Sbds f/f, n = 4). (D) Increased rates 
of apoptosis in late myeloid cells upon Sbds deletion (n = 4). Left, representative plot. Right, frequency of 
annexin V+ 7AAD- apoptotic cells in different stages of myelopoiesis. Data in bar graphs is mean ± s.e.m. 
*P < 0.05, ***P < 0.001. †FDR < 0.05, †††FDR < 0.001. 
 
 
more immature progenitors (cKit+ EYFP+ cells). Collectively, the findings indicate that Sbds 
deficiency in the myeloid lineage specifically attenuates lineage progression at the myelocyte 
stage through activation of cellular stress pathways and induction of p53-associated apoptosis. 
 
DISCUSSION 
Neutropenia is the principal hematological manifestation of SDS, but the cellular and molecular 
mechanisms underlying this specific disease phenotype remain poorly understood. Here, we 
established a mammalian model of Sbds deficiency-induced neutropenia, revealing a critical 
dependency of myelocytes and their downstream progeny on the function of this ribosomal 
biogenesis gene through induction of p53-associated apoptosis, thus providing a cellular and 
molecular basis for the understanding of neutropenia in this disease. 
Several findings in our study point towards myelocytes as the differentiation stage critically 
impaired by Sbds deficiency. First, the data indicates that myelocytes accumulate in Cebpa-cre 
Sbds mutant mice and fail to exit the cell cycle, a process typically occurring at the myelocyte 
stage and required for terminal differentiation towards mature neutrophils.31,32 Secondly, 
massive parallel transcriptional profiling of prospectively isolated MC-MMs revealed specifically 
reduced expression of genes encoding constituents of secondary and tertiary granule proteins, 
the production of which specifically marks the transition from promyelocytes to myelocytes in 
myeloid development.29,30 Finally, Sbds deficiency in myelocytes was associated with reduced 
expression of the myeloid transcription factor RARα and its downstream transcriptional targets. 
RARα is an important regulator of myelopoiesis with a putative role in terminal granulocyte 
differentiation.37 In vitro differentiation studies show that RAR deficiency blocks lineage 
progression at the myelocyte stage38 and in vivo inhibition of endogenous retinoids results in 
accumulation of immature myeloid cells in wild type mice.37  
While Sbds deletion in the myeloid lineage specifically attenuated lineage progression 
downstream of myelocytes, deficiency of Sbds did not functionally affect rapidly cycling 
hematopoietic progenitor cells (HPCs). This finding was initially unanticipated since HPCs are 
thought to have a relatively high rate of protein synthesis in comparison to HSCs and other cells 
of the hematopoietic hierarchy39 and it seemed therefore reasonable to predict that rapidly 
cycling progenitors are more sensitive to defects of ribosome biogenesis and protein translation. 
In line with this view, reduced frequency or altered activity of HPCs have been previously 
suggested to drive cytopenia in both DBA and SDS,40-42 albeit this does not provide a satisfactory 
explanation for lineage specificity in these diseases. In our model, the efficacy of Sbds deletion 
was comparable throughout myeloid development (Cebpa-expressing LKS, CMP, GMP and the 
myelocyte compartment), yet the size of the progenitor pool in the bone marrow increased, while 
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explanation for lineage specificity in these diseases. In our model, the efficacy of Sbds deletion 
was comparable throughout myeloid development (Cebpa-expressing LKS, CMP, GMP and the 
myelocyte compartment), yet the size of the progenitor pool in the bone marrow increased, while 
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the number of mature neutrophils was reduced. This finding seems congruent with observations 
in zebrafish, where deletion of Sbds induces loss of neutrophils, but does not affect spi1 (PU.1) 
positive progenitors.43 
The resulting left-shifted myelopoiesis in our model is reminiscent of that observed in vitro upon 
granulocytic differentiation of Sbds-knockdown hematopoietic cells, resulting in an accumulation 
of MC-MMs,17 and of the maturation defect that characterizes a subset of SDS patients.5,7,25,44 
While our findings provide a basis for understanding the myeloid lineage specificity of ribosomal 
dysfunction in SDS, in translating these findings to human disease it is important to point out that 
pluripotent hematopoietic stem cells are incompletely targeted in this model. Cebpa-driven 
deletion of Sbds occurred in a small subset of immunophenotypically defined, multipotent HSCs, 
reflected in a modest decrease in erythroid and lymphoid cells in the EYFP+ compartment of 
mutant mice. It is therefore reasonable to assume that Sbds deficiency in the hematopoietic 
system does not exclusively, but rather predominantly, affects the myeloid lineage. It is 
conceivable that in human disease composite effects of Sbds deficiency in pluripotent HSCs, 
potentially reducing numbers of (normally functioning) hematopoietic progenitor cells,42,44,45 
synergize with a specific impairment of lineage progression in late myeloid differentiation phases 
to impair granulopoiesis. Incomplete HSC targeting may also explain the apparent absence of 
homing defects, previously reported in a transplant model of Sbds downregulation in HSC.17 This 
notion may help understand why we have been able to establish a stable model of neutropenia, 
where incomplete targeting of HSCs allowed durable and robust engraftment of hematopoiesis 
enabling the detailed analysis of long-term myeloid lineage progression in mutant mice. 
Identification of the cells driving neutropenia within the Sbds-deficient hematopoietic hierarchy 
allowed us to begin defining the cellular and molecular events underlying neutropenia in SDS. Our 
study describes activation of the p53 pathway and an associated increase in apoptotic rates 
specifically in myelocytes and their downstream progeny. The data seems congruent with 
observations in human disease where an intrinsic propensity for apoptosis is seen in 
hematopoietic cells after 7-day culture of CD34+ cells in medium containing G-CSF46 with a lack 
of correlation between colony numbers and apoptosis rate, indicating that the number of CFU-C 
is not affected in SDS patients. Activation of the p53 pathway has been suggested to represent a 
molecular commonality in ribosomopathies and perhaps congenital neutropenias47 but 
experimental support for this view in SDS has been lacking. Our findings do not, however, exclude 
the possibility that other mechanisms are involved in the failure in cell cycle progression and 
neutropenia in SDS. 
It is conceivable that the loss of function of Sbds affects the translation of specific transcription 
factors driving terminal myeloid differentiation, including those upstream of RARα. In particular, 
the mRNA of specific transcription factor isoforms may be characterized by distinct 5’-UTRs, some 
of them predicted to have a complex secondary structure.48 These complex 5’-UTRs are typically 
associated with high demands for translation initiation factors and may thus confer particular 
sensitivity to conditions of translational stress. Such a mechanism of reduced translation 
efficiency has recently been shown to affect GATA1 protein levels in the pathogenesis of DBA.49 
Alternatively, the high and specific demand of protein synthesis and cotranslational assembly into 
secretory granules, which characterizes and defines myelocytes and their downstream progeny, 
may cause specific translational stress, resulting in activation of cellular alarm pathways and 
downstream events including impaired differentiation. In this context, it is interesting to note 
previous observations in induced pluripotent stem cell models of SDS, indicating granule 
abnormalities in pancreatic and myeloid cells,50 and in a mouse model of pancreatic-specific Sbds 
deficiency, showing reduced in vivo zymogen granule formation in acinar cells,21 perhaps pointing 
towards impaired secretory granule maturation as a common mechanism underlying tissue 
specificity in SDS.50 Our current model will allow the interrogation of these potential mechanisms 
which is ultimately anticipated to result in novel, targeted therapeutic strategies for SDS. 
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The resulting left-shifted myelopoiesis in our model is reminiscent of that observed in vitro upon 
granulocytic differentiation of Sbds-knockdown hematopoietic cells, resulting in an accumulation 
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pluripotent hematopoietic stem cells are incompletely targeted in this model. Cebpa-driven 
deletion of Sbds occurred in a small subset of immunophenotypically defined, multipotent HSCs, 
reflected in a modest decrease in erythroid and lymphoid cells in the EYFP+ compartment of 
mutant mice. It is therefore reasonable to assume that Sbds deficiency in the hematopoietic 
system does not exclusively, but rather predominantly, affects the myeloid lineage. It is 
conceivable that in human disease composite effects of Sbds deficiency in pluripotent HSCs, 
potentially reducing numbers of (normally functioning) hematopoietic progenitor cells,42,44,45 
synergize with a specific impairment of lineage progression in late myeloid differentiation phases 
to impair granulopoiesis. Incomplete HSC targeting may also explain the apparent absence of 
homing defects, previously reported in a transplant model of Sbds downregulation in HSC.17 This 
notion may help understand why we have been able to establish a stable model of neutropenia, 
where incomplete targeting of HSCs allowed durable and robust engraftment of hematopoiesis 
enabling the detailed analysis of long-term myeloid lineage progression in mutant mice. 
Identification of the cells driving neutropenia within the Sbds-deficient hematopoietic hierarchy 
allowed us to begin defining the cellular and molecular events underlying neutropenia in SDS. Our 
study describes activation of the p53 pathway and an associated increase in apoptotic rates 
specifically in myelocytes and their downstream progeny. The data seems congruent with 
observations in human disease where an intrinsic propensity for apoptosis is seen in 
hematopoietic cells after 7-day culture of CD34+ cells in medium containing G-CSF46 with a lack 
of correlation between colony numbers and apoptosis rate, indicating that the number of CFU-C 
is not affected in SDS patients. Activation of the p53 pathway has been suggested to represent a 
molecular commonality in ribosomopathies and perhaps congenital neutropenias47 but 
experimental support for this view in SDS has been lacking. Our findings do not, however, exclude 
the possibility that other mechanisms are involved in the failure in cell cycle progression and 
neutropenia in SDS. 
It is conceivable that the loss of function of Sbds affects the translation of specific transcription 
factors driving terminal myeloid differentiation, including those upstream of RARα. In particular, 
the mRNA of specific transcription factor isoforms may be characterized by distinct 5’-UTRs, some 
of them predicted to have a complex secondary structure.48 These complex 5’-UTRs are typically 
associated with high demands for translation initiation factors and may thus confer particular 
sensitivity to conditions of translational stress. Such a mechanism of reduced translation 
efficiency has recently been shown to affect GATA1 protein levels in the pathogenesis of DBA.49 
Alternatively, the high and specific demand of protein synthesis and cotranslational assembly into 
secretory granules, which characterizes and defines myelocytes and their downstream progeny, 
may cause specific translational stress, resulting in activation of cellular alarm pathways and 
downstream events including impaired differentiation. In this context, it is interesting to note 
previous observations in induced pluripotent stem cell models of SDS, indicating granule 
abnormalities in pancreatic and myeloid cells,50 and in a mouse model of pancreatic-specific Sbds 
deficiency, showing reduced in vivo zymogen granule formation in acinar cells,21 perhaps pointing 
towards impaired secretory granule maturation as a common mechanism underlying tissue 
specificity in SDS.50 Our current model will allow the interrogation of these potential mechanisms 
which is ultimately anticipated to result in novel, targeted therapeutic strategies for SDS. 
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SUPPLEMENTAL METHODS 
Peripheral Blood Measurements 
Peripheral blood was collected by submandibular bleeding in K2EDTA-coated microtainers (BD). 
Hematological parameters were analyzed using a Vet ABC counter (Scil Animal Care). 
 
Flow Cytometry 
Bone marrow cells were isolated as previously reported.1 Red blood cells (RBC) from bone marrow 
and fetal liver were lysed with ACK lysing buffer (Lonza) before FACS staining. Peripheral blood 
cells were first stained for surface markers and next RBC-depleted using IOTest 3 Lysing Solution 
(Beckman Coulter). Bone marrow, blood and fetal liver cells were stained in PBS+0.5%FCS for 20 
min on ice. To identify bone marrow lineage positivity (Lin+), cells were co-stained with biotin-
labelled antibodies against Gr1 (RB6-8C5), Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), 
CD4 (GK1.5), CD8 (53-6.7) and B220 (RA3-6B2) (all from BD), followed by incubation with Pacific 
Orange-conjugated streptavidin (Life Technologies). For fetal liver analysis, anti-Mac1 was 
excluded from the lineage cocktail as this marker is expressed in fetal hematopoietic stem cells.2 
In addition to the lineage cocktail, the following antibodies were used to identify HSPCs: Pacific 
Blue anti-Sca1 (D7), AF700 or PE anti-CD48 (HM48-1), PE-Cy7 anti-CD150 (TC15-12F12.2), PE anti-
CD34 (HM34) (all from Biolegend), APC or PE-CF594 anti-c-Kit (2B8) and APC-Cy7 anti-CD16/32 
(2.4G2) (all from BD). To analyze differentiated cells, we used APC anti-Gr1 (RB6-8C5), PE-Cy7 
anti-Mac1 (M1/70) (both from Biolegend) and eFluor450 anti-B220 (RA3-6B2, eBioscience). 
Erythroid subsets were identified by staining with PE anti-CD71 (C2, BD) and Ter119 (TER-119, 
Biolegend). Dead cells were excluded based on 7-AAD staining (Biolegend). Apoptotic cells were 
identified with APC annexin V (BD) according to the manufacturer’s protocol. For cell cycle and 
p53 analysis, cells were stained for surface markers, then permeabilized using Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD) following the manufacturer's recommendations and 
finally stained with PE anti-Ki67 (B56, BD) and 7-AAD (cell cycle analysis) or with AF647 anti-p53 
(1C12, Cell Signaling Technology). For all FACS analysis, events were recorded using a BD LSR II 
Flow Cytometer and analyzed with FlowJo 7.6.5 software (Tree Star). Cells were sorted with a BD 
FACSAria III.  
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Flow Cytometry 
Bone marrow cells were isolated as previously reported.1 Red blood cells (RBC) from bone marrow 
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(2.4G2) (all from BD). To analyze differentiated cells, we used APC anti-Gr1 (RB6-8C5), PE-Cy7 
anti-Mac1 (M1/70) (both from Biolegend) and eFluor450 anti-B220 (RA3-6B2, eBioscience). 
Erythroid subsets were identified by staining with PE anti-CD71 (C2, BD) and Ter119 (TER-119, 
Biolegend). Dead cells were excluded based on 7-AAD staining (Biolegend). Apoptotic cells were 
identified with APC annexin V (BD) according to the manufacturer’s protocol. For cell cycle and 
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Bone Marrow Morphology  
For morphological studies, cytospin preparations were obtained from 5x105 bone marrow cells 
per transplanted mouse and stained with May-Grünwald-Giemsa as previously reported.3  
 
Quantitative PCR 
Cells were sorted in TRIzol Reagent (Life Technologies) and RNA was extracted following the 
manufacturer's instructions, with addition of 25 µg linear polyacrylamide (Genelute LPA; Sigma 
Aldrich) as RNA carrier. Genomic DNA was eliminated by treatment with RQ1 RNase-free DNase 
(Promega). First strand cDNA was synthesized from poly(A)+-selected RNA using SuperScript III 
First-Strand Synthesis System (Life Technologies). Real-Time PCR reactions were prepared with 
Fast SYBR Green Master Mix (Life Technologies) using the primers listed in Online Supplementary 
Table S1 and run on a 7500 Fast Real-Time PCR System (Life Technologies). 
 
  
SUPPLEMENTAL TABLES 
Table S1. Oligonucleotide primers used in this study. 
Application Target Allele Primer 
ID 
Sequence Amplicon 
size (bp) 
Genotyping Sbds Wild type a CCAGGGTCACGTTAATACAAACC 329 
   b TGAGTTTCAATCCTCAGCATCC  
  Floxed a CCAGGGTCACGTTAATACAAACC 450 
   b TGAGTTTCAATCCTCAGCATCC  
  Recombined c TAAAACAAAGCTGCGGTCAAGA 319 
   d ATCCTCAGCATCCCGAACAA  
 Cebpa Wild type e GCTCTAAGACCCAGCAGGC 272 
   f CGGCTCCACCTCGTAGAAGTC  
  Cre g CGCTAAGGATGACTCTGGT 487 
   h GTCTCAAGGAGAAACCACCAC  
 Rosa26 Wild type i ACCTTTCTGGGAGTTCTCTGCTG 488 
   j GGAGCGGGAGAAATGGATATG  
  EYFP i ACCTTTCTGGGAGTTCTCTGCTG 200 
   k GCGAAGAGTTTGTCCTCAACC  
  Recombined i ACCTTTCTGGGAGTTCTCTGCTG 400 
   l GCTCCTCGCCCTTGCTCA  
Quantitative RT-PCR Gapdh N/A m AGGTCGGTGTGAACGGATTTG 123 
   n TGTAGACCATGTAGTTGAGGTCA  
 Sbds N/A o GCGCTTCGAAATCGCCTG 167 
   p TCTGGTCGTCTGTCCCAAATG  
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Table S2. Complete loss of Sbds in Cebpa-expressing cells is lethal during mouse development. 
Crossing Time of DNA 
isolation 
Genotype Expected 
frequency† 
No. of 
pups 
Sbdsf/+ Cebpacre/+ x Sbdsf/+ Cebpacre/+ 
P = 0.0018 
11 crossings 
Average litter size = 5.36 
P7 Sbds+/+ Cebpa+/+ 
Sbds+/+ Cebpacre/+ 
Sbdsf/+ Cebpa+/+ 
Sbdsf/+ Cebpacre/+ 
Sbdsf/f Cebpa+/+ 
Sbdsf/f Cebpacre/+ 
1/12 
1/6 
1/6 
1/3 
1/12 
1/6 
7/59 
18/59 
8/59 
23/59 
3/59 
0/59 
Sbdsf/f Cebpa+/+ x Sbdsf/+ Cebpacre/+ 
P = 0.0043 
5 crossings 
Average litter size = 6.25 
P7 Sbdsf/+ Cebpa+/+ 
Sbdsf/+ Cebpacre/+ 
Sbdsf/f Cebpa+/+ 
Sbdsf/f Cebpacre/+ 
1/4 
1/4 
1/4 
1/4 
11/33 
8/33 
14/33 
0/33 
Sbdsf/+ Cebpacre/+ x Sbdsf/+ Cebpa+/+ 
P = 0.1047 
5 crossings 
Average litter size = 7.20 
P7 Sbds+/+ Cebpa+/+ 
Sbds+/+ Cebpacre/+ 
Sbdsf/+ Cebpa+/+ 
Sbdsf/+ Cebpacre/+ 
Sbdsf/f Cebpa+/+ 
Sbdsf/f Cebpacre/+ 
1/8 
1/8 
1/4 
1/4 
1/8 
1/8 
5/36 
4/36 
9/36 
9/36 
9/36 
0/36 
Sbdsf/+ Cebpacre/+ x Sbdsf/+ Cebpacre/+ 
P = 0.018 
5 crossings 
Average litter size = 9.80 
E14.5 Sbdsf/+ Cebpa+/+ 
Sbdsf/+ Cebpacre/+ 
Sbdsf/f Cebpa+/+ 
Sbdsf/f Cebpacre/+ 
1/4 
1/4 
1/4 
1/4 
12/49 
9/49 
17/49 
11/49 
 
Cumulative frequencies of litters obtained from intercrossing Sbdsf/+ Cebpacre/+ R26YFP/+ mice. The genotype 
of the parents and the offspring is shown. The R26 genotype is omitted for simplicity. †Cebpacre/cre mice 
are not viable due to the complete absence of Cebpa coding sequence in the Cre allele4. P values refer to 
Pearson’s chi-squared test. 
  
Table S3. Transcriptional signatures for translation and lineage progression in Sbds-deficient MC-MMs.  
 Data set Enrichment Size ES NES NOM 
p-val 
FDR 
q-val 
Translation       
BILANGES_RAPAMYCIN_SENSITIVE_VIA_ 
TSC1_AND_TSC2 
Mutants 72 0.698 1.611 <0.001 0.232 
BILANGES_SERUM_RESPONSE_ 
TRANSLATION 
Mutants 35 0.701 1.550 0.035 0.166 
PENG_RAPAMYCIN_RESPONSE_DN Mutants 243 0.613 1.511 <0.001 0.175 
REACTOME_TRANSLATION Mutants 140 0.788 1.477 <0.001 0.193 
BILANGES_SERUM_AND_RAPAMYCIN_ 
SENSITIVE_GENES 
Mutants 64 0.79 1.431 0.021 0.210 
MENSSEN_MYC_TARGETS Mutants 52 0.676 1.397 <0.001 0.245 
REACTOME_SRP_DEPENDENT_ 
COTRANSLATIONAL_PROTEIN_TARGETIN
G_TO_MEMBRANE 
Mutants 102 0.826 1.391 0.021 0.248 
REACTOME_ACTIVATION_OF_THE_MRNA
_UPON_BINDING_OF_ 
THE_CAP_BINDING_COMPLEX_AND_EIFS
_AND_ SUBSEQUENT_BINDING_TO_43S 
Mutants 54 0.759 1.390 <0.001 0.246 
Undifferentiated state       
BHATTACHARYA_EMBRYONIC_STEM_ 
CELL 
Mutants 85 0.575 1.601 <0.001 0.203 
JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN Mutants 90 0.582 1.572 <0.001 0.154 
MUELLER_PLURINET Mutants 295 0.535 1.539 <0.001 0.157 
PARK_HSC_AND_MULTIPOTENT_ 
PROGENITORS 
Mutants 50 0.504 1.480 0.086 0.192 
IVANOVA_HEMATOPOIESIS_ 
INTERMEDIATE_PROGENITOR 
Mutants 147 0.637 1.469 <0.001 0.193 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL
_AND_BRAIN_QTL_CIS 
Mutants 64 0.524 1.403 <0.001 0.240 
SCHURINGA_STAT5A_TARGETS_DN Mutants 15 0.478 1.397 0.026 0.246 
RAMALHO_STEMNESS_UP Mutants 207 0.531 1.386 <0.001 0.249 
XU_RESPONSE_TO_TRETINOIN_AND_ 
NSC682994_DN 
Mutants 15 0.750 1.383 <0.001 0.246 
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Table S3. Transcriptional signatures for translation and lineage progression in Sbds-deficient MC-MMs. 
(Continued) 
 Data set Enrichment Size ES NES NOM 
p-val 
FDR 
q-val 
Myeloid differentiation       
LIAN_NEUTROPHIL_GRANULE_ 
CONSTITUENTS 
Controls 24 -0.556 -1.719 <0.001 0.062 
JAATINEN_HEMATOPOIETIC_STEM_CELL_
DN 
Controls 214 -0.561 -1.718 <0.001 0.061 
IVANOVA_HEMATOPOIESIS_MATURE_ 
CELL 
Controls 294 -0.582 -1.644 <0.001 0.082 
PID_AMB2_NEUTROPHILS_PATHWAY Controls 40 -0.532 -1.612 <0.001 0.108 
REACTOME_DEGRADATION_OF_THE_ 
EXTRACELLULAR_MATRIX 
Controls 27 -0.529 -1.601 <0.001 0.110 
BROWN_MYELOID_CELL_DEVELOPMENT
_UP 
Controls 168 -0.665 -1.590 <0.001 0.122 
TAVOR_CEBPA_TARGETS_UP Controls 49 -0.503 -1.580 <0.001 0.123 
PID_INTEGRIN_A9B1_PATHWAY Controls 25 -0.575 -1.567 <0.001 0.137 
KEGG_HEMATOPOIETIC_CELL_LINEAGE Controls 80 -0.460 -1.557 <0.001 0.144 
SA_MMP_CYTOKINE_CONNECTION Controls 15 -0.629 -1.542 <0.001 0.160 
XU_RESPONSE_TO_TRETINOIN_UP Controls 15 -0.605 -1.478 <0.001 0.188 
NAKAJIMA_EOSINOPHIL Controls 27 -0.640 -1.477 0.027 0.189 
BIOCARTA_CCR3_PATHWAY Controls 23 -0.670 -1.467 <0.001 0.193 
ZHOU_INFLAMMATORY_RESPONSE_LPS_
UP 
Controls 373 -0.380 -1.443 <0.001 0.224 
KAMIKUBO_MYELOID_CEBPA_NETWORK Controls 80 -0.457 -1.417 <0.001 0.249 
Curated data sets significantly enriched in Sbds f/f (mutants) or +/+ (controls) are shown (FDR<0.25, GSEA 
comparison to the C2 MSigDB collection). ES: enrichment score. NES: normalized enrichment score. NOM 
p-val: nominal p-value. FDR q-val: False Discovery Rate q-value. 
  
  
Table S4. Enrichment of GO-terms for ribosome biogenesis in Sbds-deficient MC-MMs.  
 Data set Enrichment Size ES NES NOM 
p-val 
FDR 
q-val 
REGULATION_OF_TRANSLATIONAL_ 
INITIATION 
Mutants 28 0.681 1.520 <0.001 0.183 
TRANSCRIPTION_FROM_RNA_ 
POLYMERASE_III_PROMOTER 
Mutants 17 0.703 1.523 0.032 0.187 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY Mutants 17 0.859 1.525 <0.001 0.201 
NUCLEOLUS Mutants 119 0.700 1.551 <0.001 0.207 
RIBONUCLEOPROTEIN_COMPLEX Mutants 141 0.672 1.589 <0.001 0.213 
RIBONUCLEOPROTEIN_COMPLEX_ 
BIOGENESIS_AND_ASSEMBLY 
Mutants 83 0.664 1.552 <0.001 0.217 
PROTEIN_RNA_COMPLEX_ASSEMBLY Mutants 64 0.601 1.492 <0.001 0.217 
RRNA_METABOLIC_PROCESS Mutants 15 0.845 1.589 <0.001 0.231 
TRANSLATIONAL_INITIATION Mutants 36 0.640 1.455 <0.001 0.237 
NUCLEOLAR_PART Mutants 17 0.783 1.467 <0.001 0.241 
RIBOSOME Mutants 38 0.825 1.435 <0.001 0.242 
 GO gene sets related to ribosome maturation and translation are significantly enriched in Sbds f/f 
(mutants) (FDR<0.25, GSEA comparison to the C5 MSigDB collection). ES: enrichment score. NES: 
normalized enrichment score. NOM p-val: nominal p-value. FDR q-val: False Discovery Rate q-value. 
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SUPPLEMENTAL FIGURES 
 
Figure S1. Effects of Sbds deletion from Cebpa-expressing hematopoietic cells on peripheral blood cell 
numbers. (A) Normal levels of red blood cells counts (RBC), hemoglobin (HGB) and mean corpuscular 
volume (MCV) in mice injected with Sbds +/+ or f/f cells. (B) Platelet counts (PLT) in the peripheral blood. 
(C) Numbers of B220+ lymphocytes (B cells) in the peripheral blood. Each circle represents one recipient 
mouse. Data is presented at 5 and 16 weeks after transplantation. *P < 0.05. ***P < 0.001.  
 
Figure S2. Expansion of EYFP- progenitors in Sbds f/f recipients. Absolute counts of EYFP- progenitors in 
transplanted mice. Data is mean ± s.e.m. **P < 0.01. 
 
 
Figure S3. Increased frequency of MC-MMs and loss of mature neutrophils in Sbds f/f recipients. 
Evaluation of myeloid differentiation stages in bone marrow cytospins from Sbds f/f and +/+  recipients (n 
= 2). MB-PM: myeloblasts-promyelocytes. MC-MM: myelocytes-metamyelocytes. BC-SC: band cells-
segmented cells. Data is mean ± s.e.m. 
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SUPPLEMENTAL FIGURES 
 
Figure S1. Effects of Sbds deletion from Cebpa-expressing hematopoietic cells on peripheral blood cell 
numbers. (A) Normal levels of red blood cells counts (RBC), hemoglobin (HGB) and mean corpuscular 
volume (MCV) in mice injected with Sbds +/+ or f/f cells. (B) Platelet counts (PLT) in the peripheral blood. 
(C) Numbers of B220+ lymphocytes (B cells) in the peripheral blood. Each circle represents one recipient 
mouse. Data is presented at 5 and 16 weeks after transplantation. *P < 0.05. ***P < 0.001.  
 
Figure S2. Expansion of EYFP- progenitors in Sbds f/f recipients. Absolute counts of EYFP- progenitors in 
transplanted mice. Data is mean ± s.e.m. **P < 0.01. 
 
 
Figure S3. Increased frequency of MC-MMs and loss of mature neutrophils in Sbds f/f recipients. 
Evaluation of myeloid differentiation stages in bone marrow cytospins from Sbds f/f and +/+  recipients (n 
= 2). MB-PM: myeloblasts-promyelocytes. MC-MM: myelocytes-metamyelocytes. BC-SC: band cells-
segmented cells. Data is mean ± s.e.m. 
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SUMMARY 
Mesenchymal niche cells may drive tissue failure and malignant transformation in the 
hematopoietic system but the molecular mechanisms and their relevance to human disease 
remain poorly defined. Here, we show that perturbation of mesenchymal cells in a mouse model 
of the preleukemic disorder Shwachman-Diamond syndrome induces mitochondrial dysfunction, 
oxidative stress and activation of DNA damage responses in hematopoietic stem and progenitor 
cells. Massive parallel RNA sequencing of highly purified mesenchymal cells in the mouse model 
and a range of human preleukemic syndromes identified S100A8/9-TLR4 inflammatory signaling 
as a common driving mechanism of genotoxic stress, which could be attenuated by TLR4 
blockade. S100A8/9 expression in mesenchymal cells predicted outcome in myelodysplastic 
syndromes, the principal human preleukemic condition, independent of known prognostic 
variables. Collectively, findings reveal a concept of mesenchymal niche-induced genotoxic stress 
in heterotypic stem and progenitor cells through inflammatory signaling as an actionable 
determinant of disease outcome in human preleukemia. 
 
GRAPHICAL ABSTRACT 
 
INTRODUCTION 
Genotoxic stress results in the accumulation of DNA lesions in hematopoietic stem and progenitor 
cells (HSPCs) over the lifespan of an organism, contributing to tissue failure and malignant 
transformation.1,2 The pathophysiological insults underlying genomic stress in HSPCs, however, 
remain incompletely understood. Perturbed signaling from their surrounding microenvironment 
may be implicated, but this has not been experimentally defined.  
Components of the bone marrow microenvironment have emerged as key regulators of normal 
and malignant hematopoiesis.3-7 We, and others, have shown that primary alterations of the 
mesenchymal niche can induce myelodysplasia and promote the emergence of acute myeloid 
leukemia (AML) with cytogenetic abnormalities in HSPCs,8,9 thus introducing a concept of niche-
driven oncogenesis in the hematopoietic system.  
To provide insights into the mechanisms that underlie this concept, as well as their relevance for 
human disease, we modeled the human leukemia predisposition disorder Shwachman-Diamond 
syndrome (SDS), caused by constitutive homozygous or compound heterozygous loss of function 
mutations in the SBDS gene, required for ribosome biogenesis.10,11 SDS is characterized by skeletal 
defects in conjunction with a striking propensity to develop myelodysplastic syndrome (MDS) and 
AML at a young age, with a cumulative probability of >30% at the age of 30 years and a median 
onset at 18 years.12,13 Hematopoietic cell intrinsic loss of Sbds does not result in MDS or 
leukemia,14,15 supporting the notion that cell-extrinsic factors contribute to malignant 
transformation. Deletion of Sbds from mesenchymal cells in the bone marrow induced apoptosis 
in HSPCs and myelodysplasia, but the molecular mechanisms driving these observations and their 
relevance for human disease remained to be defined.8 
Here, we identify the endogenous damage-associated molecular pattern (DAMP) molecules 
S100A8 and S100A9, secreted from mesenchymal niche cells, as drivers of mitochondrial 
dysfunction, oxidative stress and DDR activation in HSPCs, with clinical relevance to the 
pathogenesis and prognosis of human bone marrow failure and leukemia predisposition 
syndromes. 
 
RESULTS 
Deletion of Sbds from mesenchymal progenitor cells (MPCs) recapitulates skeletal 
abnormalities of human SDS 
SDS is characterized by bone abnormalities including low-turnover osteoporosis with reduced 
trabecular bone volume, low numbers of osteoblasts, and reduced amount of osteoid, leading to 
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increased risk of fractures.16 The cellular subsets driving these abnormalities and the underlying 
molecular mechanisms have remained largely undefined. We have previously shown that Cre-
mediated deletion of Sbds from osterix+ MPCs (Sbdsf/f Osxcre/+ mice, hereafter OCSf/f or mutants) 
disrupts the architecture of the marrow and cortical bone.8 Here, we first sought to better define 
the skeletal defects in these mice and their relevance to human disease.  
OCSf/f mice presented growth retardation and reduced femur length compared to control Sbdsf/+ 
Osxcre/+ (OCSf/+) mice (Figure 1A and 1B) as observed in human patients.17,18 The runted phenotype 
was associated with a significantly limited lifespan, with lethality observed after the age of 4 
weeks. Analyses were therefore performed in three week-old mice. The femur trabecular area 
was profoundly reduced in OCSf/f mice, with decreased bone volume, low number of trabeculae, 
increased trabecular spacing and reduced numbers of osteoblasts compared to controls (Figure 
1C-1G, and 1I). The cortical bone of OCS mutants was also affected, as indicated by low bone 
mineral density values (Figure 1C-1D and 1H), attenuating the mechanical properties of the bone, 
which was found less resistant to fracture in three-point bending tests (Figure 1J). A tendency for 
reduced stiffness in the long bones was also observed (Figure 1K). Taken together, the structural 
and mechanical defects indicate that Sbds deficiency in MPCs causes osteoporosis with a 
propensity for fracturing, in line with observations in SDS patients.16,18,19 Impaired osteogenesis 
did not reflect a contraction of the bone progenitor cell pool as shown by frequency of CFU-F and 
Osx::GFP+ cells (Figure S1A and S1B), but rather impairment of terminal osteogenic differentiation 
as suggested by transcriptional profiling of prospectively isolated osterix-expressing (GFP+) cells 
(Figure S1C). Transcriptional data confirmed deregulated expression of genes related to 
ribosomal biogenesis and translation (Figure S1D and S1E), in line with the established role of 
Sbds in ribosome biogenesis. Collectively, this data supports a view in which bone abnormalities 
in SDS are caused by deficiency of Sbds in MPCs, which attenuates terminal differentiation 
towards matrix-depositing osteoblastic cells with a compensatory increase in the most primitive 
mesenchymal compartment. 
 
Sbds deficiency in the hematopoietic niche induces mitochondrial dysfunction, 
oxidative stress and activation of the DNA damage response in HSPCs 
Having established that the OCS mice represent a bona fide model for bone abnormalities in 
human disease, we next investigated the hematopoietic consequences of these environmental 
alterations. HSPC number was unaltered in OCS mice (Figure S2A-S2C) and HSPCs displayed global 
preservation of their transcriptional landscape after exposure to the Sbds-deficient environment 
(Figure S2D-S2F).  
Transcriptional network analysis, however, revealed significant overlap with signatures previously  
 
Figure 1. Deletion of Sbds in MPCs recapitulates skeletal defects in human SDS. (A-B) Impaired growth in 
OCSf/f mice: (A) body weight (n = 9) and (B) femur length (n = 5). (C-H) Femur μCT analysis of OCSf/+ (n = 5) 
and OCSf/f (n = 4) mice. (C) Representative 2D-images. Left: longitudinal view. Right: cortical bone. (D) 3D-
image. (E) Bone volume per tissue volume (BV/TV). (F) Trabecular number (Tb. N). (G) Trabecular spacing 
(Tb. Sp). (H) Cortical bone mineral density (BMD). (I) Goldner osteoblast staining (OCSf/+, n = 6; OCSf/f, n = 
8). Left: representative images (arrows: osteoblasts; with white dashed line in the magnified region). Right: 
number of osteoblasts per bone perimeter (N.Ob/B.Pm). (J-K) 3-point bending test indicating (J) reduced 
resistant to fracture and (K) increased stiffness of OCSf/f bone (OCSf/+, n = 5; OCSf/f, n = 4). *P<0.05. **P< 
0.01. ***P<0.001. Data are mean ± SEM. See also Figure S1. 
 
defined as predicting leukemic evolution of human CD34+ cells,20 including pathways signaling 
mitochondrial abnormalities (Figure 2A; Table S1). Mitochondrial dysfunction was confirmed by 
measuring the mitochondrial membrane potential (Δψ), indicating hyperpolarization of the  
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defined as predicting leukemic evolution of human CD34+ cells,20 including pathways signaling 
mitochondrial abnormalities (Figure 2A; Table S1). Mitochondrial dysfunction was confirmed by 
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mitochondria (Figure 2B and 2C). Mitochondrial hyperpolarization can result in reverse electron 
transfer, leading to the production of superoxide radicals, which can be further converted into 
other reactive oxygen species (ROS).21 In line with this, a marked increase in intracellular ROS 
levels was found in OCS mutant HSPCs (Figure 2D). ROS can undermine the genomic integrity of 
HSPCs by inducing DNA damage,22-24 to which normal HSPCs react by activating the DNA damage 
response (DDR) and repair pathways.1 Indeed, CD48+ LKS cells from OCSf/f mice displayed 
increased foci of Ser139-phosphorylated H2AX histone (γH2AX), which form at the sites of DNA 
damage (Figure 2E). Congruent with genotoxic effects of the mutant microenvironment, HSPCs 
displayed transcriptional modulation of DDR and DNA repair pathways (Table S2), including 
nucleotide excision repair programs, associated with ROS-induced lesions25 and signatures 
related to the master regulator of DDR and cell checkpoint activation ataxia telangiectasia and 
Rad3-related (ATR). Activation of the G1-S cell cycle checkpoint, resulting in cell cycle arrest, was 
further demonstrated by depletion of G1-S transcriptional signatures (Figure 2F; Table S1), in vivo 
BrdU labeling (Figure 2G and 2H) and downregulation of the Myc pathway, a critical regulator for 
this restriction point and the coordination of S–G2–M progression (Figure 2I; Table S3). Apoptosis 
of mutant HSPCs, as an alternative outcome of checkpoint activation, was earlier demonstrated.8 
Together, the data indicate that the Sbds-deficient environment induces mitochondrial 
dysfunction, oxidative stress, DNA damage and genotoxic stress in HSPCs leading to activation of 
DDR pathways and G1-S checkpoint activation, reminiscent of a model in which mitochondrial 
dysfunction underlies an escalating cycle of increased ROS and genotoxic damage.26 
Short term exposure to the genotoxic environment did not attenuate HSPC function in DNA repair 
proficient cells, as demonstrated by competitive transplantation experiments (Figure S3A-S3C), 
suggesting efficient DNA-repair or elimination of functionally impaired HSPCs by DDR-driven 
apoptosis and cell cycle arrest. Congruent with this notion, alkaline comet assays on sorted HSPCs 
failed to demonstrate structural DNA damage (Figure S3D and S3E). 
 
Figure 2. Sbds-deficient mesenchymal cells induce genotoxic stress in HSPCs. (A) Transcriptional network 
analysis indicating mitochondrial dysregulation in mutant HSPCs. NES: Normalized Enrichment Score. (B-
C) Increased mitochondrial potential (TMRM) in HSPCs: (B) representative plots; (C) mean fluorescence 
intensity (MFI) (n = 3). (D) ROS quantification by CM-H2DCFDA (OCSf/+, n = 6; OCSf/f, n = 7). (E) γH2AX foci 
quantification in HSPCs from mutants (n = 2; pooled data). (F-I) Activation of DNA damage response in 
mutant HSPCs. (F) Transcriptional repression of G1-S checkpoint progression. (G, H) In vivo BrdU staining 
confirming impaired S-phase transition (n = 4). (I) Downregulation of Myc signaling. GSEA data shown is 
from CD48- LKS cells †††FDR<0.001. *P<0.05. **P<0.01. ***P<0.001. Data in bar graphs are mean± SEM. 
See also Figure S2, S3 and Table S1, S2 and S3. 
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Activation of the p53 pathway drives bone abnormalities but not genotoxic stress 
in OCS mice 
Next, we sought to define the molecular programs underlying the bone and hematopoietic 
alterations in OCS mice. A proposed common molecular mechanism for the pathogenesis of 
ribosomopathies involves activation of the p53 tumor suppressor pathway.27 The p53 protein was 
overexpressed in GFP+ MPCs in OCS mutants, with activation of downstream transcriptional 
pathways and upregulation of canonical targets (Figure 3A-3C).  
To assess the pathophysiological role of p53 activation in MPCs, we intercrossed OCS with Trp53-
floxed mice,28 generating a double conditional knock-out model where the deletion of p53 is 
localized in the Sbds-deleted stromal compartment (Sbdsf/f Trp53f/f Osxcre/+ mice; hence OCSf/f 
p53Δ) (Figure 3D). Genetic recombination of the Trp53 locus was detected only in bone cells-
containing samples, demonstrating the tissue specificity of p53 deletion in this model (Figure 3E). 
Genetic deletion of p53 from Sbds-deficient MPCs rescued the osteoporotic phenotype (Figure 
3F-3J), but not cortical bone mineralization, growth, or hematopoietic parameters (Figure 3K and 
data not shown), implicating p53-independent molecular mechanisms in the induction of cellular 
stress in HSPCs.  
 
Identification of the damage-associated molecular pattern genes S100A8 and 
S100A9 as candidate niche factors driving genotoxic stress in human leukemia 
predisposition syndromes  
To identify human disease-relevant niche factors driving genomic stress in HSPCs, we compared 
the transcriptomes of GFP+ MPCs from OCS mice to those from prospectively FACS-isolated 
mesenchymal CD271+ niche cells29 from human SDS patients (Figure 4A; Table S4). The 
mesenchymal nature of CD271+ cells was confirmed by CFU-F capacity and differential expression 
of mesenchymal, osteolineage and HSPC-regulatory genes (chapter 4).  
RNA sequencing showed the presence of SBDS mutations (Figure 4B; Figure S4; Table S4) 
associated with reduced SBDS expression (Figure 4C), confirming molecular aspects of SDS in 
previous studies.11,30 Identical transcriptional signatures of disrupted ribosome biogenesis and 
translation were found in human niche cells (Figure 4D) and in GFP+ cells from OCS mice (Figure 
S1E), confirming faithful recapitulation of human molecular disease characteristics in the mouse 
model. Forty genes were differentially expressed both in the mouse model and human SDS, 25 of 
which were overexpressed, with a remarkable abundance of genes encoding proteins implicated 
in inflammation and innate immunity (Figure 4E). 
 
Figure 3. Activation of p53 in MPCs drives skeletal abnormalities in OCS mutants. (A) p53 protein (FACS) 
accumulates in GFP+ cells from OCSf/f mice (n = 3). (B-C) Activation of p53 in mutant GFP+ cells as 
demonstrated by (B) enrichment of a p53 GSEA signature and (C) overexpression of canonical p53 targets 
(n = 3). (D) Schematic representation of the p53 floxed allele with indication of primers used to assess 
genotypes (p10.1-p10.2) and genomic deletion (p1.1-p10.2). (E) Specific deletion of p53 in bone-containing 
tissue in OCSf/f p53Δ mice (genomic PCR). (F-J) µCT analysis indicating normalization of bone mass in OCSf/f 
mice upon genetic deletion of p53 (p53+, n = 3; p53Δ, n = 5). Tb. Pf , Trabecular bone pattern factor. (K) 
Bone mineral density in OCSf/f mice is not rescued by p53 deletion. MFI: mean fluorescence intensity. *P < 
0.05. ***P <0.001. Data are mean ± SEM. 
 
To further delineate candidate genes driving genomic stress and leukemic evolution from this 
gene set, we performed whole transcriptome sequencing of CD271+ cells in two related human 
bone marrow failure and leukemia predisposition disorders: (1) low-risk MDS, the principal 
human preleukemic disorder in which cell cycle exit (senescence), accumulation of ROS, DNA 
damage and apoptosis have been described,31-33 reminiscent of HSPC phenotypes in OCS mice, 
and (2) DBA, like SDS, a ribosomopathy characterized by bone marrow failure, but with a much 
lower propensity to evolve into AML (<1% with longer latency than observed in SDS and MDS)34 
(Table S4). We reasoned that genes specifically overexpressed in mesenchymal niche cells from  
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overexpressed in GFP+ MPCs in OCS mutants, with activation of downstream transcriptional 
pathways and upregulation of canonical targets (Figure 3A-3C).  
To assess the pathophysiological role of p53 activation in MPCs, we intercrossed OCS with Trp53-
floxed mice,28 generating a double conditional knock-out model where the deletion of p53 is 
localized in the Sbds-deleted stromal compartment (Sbdsf/f Trp53f/f Osxcre/+ mice; hence OCSf/f 
p53Δ) (Figure 3D). Genetic recombination of the Trp53 locus was detected only in bone cells-
containing samples, demonstrating the tissue specificity of p53 deletion in this model (Figure 3E). 
Genetic deletion of p53 from Sbds-deficient MPCs rescued the osteoporotic phenotype (Figure 
3F-3J), but not cortical bone mineralization, growth, or hematopoietic parameters (Figure 3K and 
data not shown), implicating p53-independent molecular mechanisms in the induction of cellular 
stress in HSPCs.  
 
Identification of the damage-associated molecular pattern genes S100A8 and 
S100A9 as candidate niche factors driving genotoxic stress in human leukemia 
predisposition syndromes  
To identify human disease-relevant niche factors driving genomic stress in HSPCs, we compared 
the transcriptomes of GFP+ MPCs from OCS mice to those from prospectively FACS-isolated 
mesenchymal CD271+ niche cells29 from human SDS patients (Figure 4A; Table S4). The 
mesenchymal nature of CD271+ cells was confirmed by CFU-F capacity and differential expression 
of mesenchymal, osteolineage and HSPC-regulatory genes (chapter 4).  
RNA sequencing showed the presence of SBDS mutations (Figure 4B; Figure S4; Table S4) 
associated with reduced SBDS expression (Figure 4C), confirming molecular aspects of SDS in 
previous studies.11,30 Identical transcriptional signatures of disrupted ribosome biogenesis and 
translation were found in human niche cells (Figure 4D) and in GFP+ cells from OCS mice (Figure 
S1E), confirming faithful recapitulation of human molecular disease characteristics in the mouse 
model. Forty genes were differentially expressed both in the mouse model and human SDS, 25 of 
which were overexpressed, with a remarkable abundance of genes encoding proteins implicated 
in inflammation and innate immunity (Figure 4E). 
 
Figure 3. Activation of p53 in MPCs drives skeletal abnormalities in OCS mutants. (A) p53 protein (FACS) 
accumulates in GFP+ cells from OCSf/f mice (n = 3). (B-C) Activation of p53 in mutant GFP+ cells as 
demonstrated by (B) enrichment of a p53 GSEA signature and (C) overexpression of canonical p53 targets 
(n = 3). (D) Schematic representation of the p53 floxed allele with indication of primers used to assess 
genotypes (p10.1-p10.2) and genomic deletion (p1.1-p10.2). (E) Specific deletion of p53 in bone-containing 
tissue in OCSf/f p53Δ mice (genomic PCR). (F-J) µCT analysis indicating normalization of bone mass in OCSf/f 
mice upon genetic deletion of p53 (p53+, n = 3; p53Δ, n = 5). Tb. Pf , Trabecular bone pattern factor. (K) 
Bone mineral density in OCSf/f mice is not rescued by p53 deletion. MFI: mean fluorescence intensity. *P < 
0.05. ***P <0.001. Data are mean ± SEM. 
 
To further delineate candidate genes driving genomic stress and leukemic evolution from this 
gene set, we performed whole transcriptome sequencing of CD271+ cells in two related human 
bone marrow failure and leukemia predisposition disorders: (1) low-risk MDS, the principal 
human preleukemic disorder in which cell cycle exit (senescence), accumulation of ROS, DNA 
damage and apoptosis have been described,31-33 reminiscent of HSPC phenotypes in OCS mice, 
and (2) DBA, like SDS, a ribosomopathy characterized by bone marrow failure, but with a much 
lower propensity to evolve into AML (<1% with longer latency than observed in SDS and MDS)34 
(Table S4). We reasoned that genes specifically overexpressed in mesenchymal niche cells from  
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disorders with as strong propensity for leukemic evolution (SDS and MDS) might represent strong 
candidate drivers of genotoxic stress. Eleven such genes were found (Figure 4F), among which 
the damage-associated molecular pattern (DAMPs) S100A8 and S100A9, significantly (P<0.05) 
differentially expressed in GFP+ cells from OCS mutant mice (Figure 4E-4G).   
 
S100A8/9 induces genotoxic stress in murine and human HSPCs  
S100A8 and S100A9 belong to a subclass of proinflammatory molecules referred to as damage-
associated molecular pattern (DAMP) or alarmins. DAMPs are endogenous danger signals that are 
passively released or actively secreted in the microenvironment after cell death, damage or stress 
and bind pattern recognition receptors (PRR) to regulate inflammation and tissue repair.35  
S100A8 and S100A9 proteins were overexpressed in mouse Sbds-deficient MPCs (Figure 5A and 
5B) and increased plasma concentration of S100A8/9 indicated secretion of the heterodimer 
(Figure 5C). Its canonical receptor TLR436 is expressed in murine HSPCs (Figure S2G) and the 
canonical downstream signaling NF-κB and MAPK pathways were activated in HSPCs from OCSf/f 
mice (Figure S2H). Exposure of HSPCs (LKS) cells to recombinant murine S100A8/9 resulted in a 
replication-independent increase in DNA damage (number of γH2AX foci) (Figure 5D and 5E) and 
apoptosis (Figure 5F), associated with activation of TLR signaling (Figure 5G; Table S5), 
recapitulating the in vivo HSPC phenotype.8 In vivo, blockage of TLR4 by neutralizing antibodies 
resulted in a reduction of γH2AX foci in LKS cells (Figure 5H). Translating these findings to human 
disease, exposure of human cord blood CD34+ HSPCs to human recombinant S100A8/9 at 
clinically relevant concentrations37 (Supplemental Experimental Procedures) resulted in DNA 
damage (increased γH2AX foci), apoptosis and impaired HSPC function (CFU-C) (Figure S5).  
 
Figure 4. Identification of S100A8 and S100A9 as candidate drivers of genotoxic stress in leukemia 
predisposition syndromes. (A) Representative mesenchymal CD271+ FACS gating. (B) Pathognomonic 183-
184 TA>CT mutation in niche cells from a representative SDS patient (IGV plot). (C) Reduced SBDS 
expression in SDS niche cells. (D) Disruption of ribosome biogenesis and translation in SDS CD271+ cells 
(GSEA). (E) Inflammation-related transcripts are upregulated in niche cells from SDS patients and OCSf/f 
mice. (F) Significantly differentially expressed genes in SDS (n = 4), MDS (n = 9) and DBA (n = 3) in 
comparison to normal CD271+ cells. (G) Expression of S100A8 and S100A9 in mesenchymal cells from SDS, 
low-risk MDS, and DBA patients. *P<0.05. ***P<0.001. †††FDR-adjusted P<0.001. See also Figure S1, S4 and 
Table S4. 
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S100A8/9 expression in mesenchymal niche cells predicts clinical outcome in 
human low-risk MDS 
To further define the biologic and clinical significance of these findings, we performed 
transcriptome sequencing of CD271+ niche cells in a prospective, homogeneously treated cohort 
of low-risk MDS patients (n = 20, Figure 6A; Table S6). Expression of S100A8 and S100A9 was 
strongly correlated (Figure 6B), with a subgroup of MDS patients (6/20; 30%) demonstrating 
significant overexpression of S100A8 and S100A9 (Modified Thompson Tau outlier test) (Figure 
6B and 6C), independent of established prognostic factors as defined by the revised International 
Prognostic Scoring System (IPSS-R) and the MD Anderson risk score (LR-PSS) (Table S6). S100A8/9 
overexpression in niche cells was strongly predictive of overall survival (median survival 8.95 vs 
44.20 months) (Figure 6D and Table S6). All 6 patients in the S100A8/9+ group died of MDS-related 
pathology such as bleeding or infection. Bone marrow analysis upon the course of disease was 
available in only 1/6 patients demonstrating leukemic evolution. Leukemic evolution was not 
observed in patients without elevated S100A8/9 expression in niche cells (n = 14), despite 
considerably longer follow-up. 
 
DISCUSSION 
Genomic stress and the ensuing DNA damage play a pivotal role in the attenuation of normal 
hematopoiesis in ageing and disease. Mutations accumulate in HSPCs over the lifespan of an 
organism, but the (patho)physiological sources of genomic stress in HSPCs and their relationship 
with human bone marrow failure remain incompletely understood. Here, we show that specific 
inflammatory signals from the mesenchymal niche can induce genotoxic stress in heterotypic 
stem/progenitor cells and relate this concept to the pathogenesis of two human bone marrow 
failure and leukemia predisposition syndromes, SDS and MDS.  
 
Figure 5. S100A8/9 induces genotoxic stress in murine HSPCs through TLR4 signaling. (A-B) Increased 
S100A8 and S100A9 levels in OCSf/f GFP+ cells. (A) representative plots. (B) MFI values (n = 5). (C) Increased 
plasma concentration of S100A8/9 by ELISA (OCSf/+, n = 5; OCSf/f, n = 4). (D) Left: representative γH2AX 
pictures after HSPCs in vitro exposure. Positive control: 8-Gy irradiated Lin- c-Kit+ Sca-1- cells. Negative 
controls: heat-inactivated S100A8/9 (H.I. ctr). Right: number of γH2AX foci (n = 3). (E) S100A8/9 has no 
effect on cell cycle (n = 2). (F) Increased apoptosis in S100A8/9-exposed LKS (n = 3). (G) Activation of TLR 
signaling (GSEA). (H) TLR4-blocking antibodies limit DNA damage in OCSf/f mice (n = 4). *P<0.05. *P<0.01. 
***P<0.001. Data are mean ± SEM. See also Figure S2 and S5; Table S5.  
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strongly correlated (Figure 6B), with a subgroup of MDS patients (6/20; 30%) demonstrating 
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pathology such as bleeding or infection. Bone marrow analysis upon the course of disease was 
available in only 1/6 patients demonstrating leukemic evolution. Leukemic evolution was not 
observed in patients without elevated S100A8/9 expression in niche cells (n = 14), despite 
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DISCUSSION 
Genomic stress and the ensuing DNA damage play a pivotal role in the attenuation of normal 
hematopoiesis in ageing and disease. Mutations accumulate in HSPCs over the lifespan of an 
organism, but the (patho)physiological sources of genomic stress in HSPCs and their relationship 
with human bone marrow failure remain incompletely understood. Here, we show that specific 
inflammatory signals from the mesenchymal niche can induce genotoxic stress in heterotypic 
stem/progenitor cells and relate this concept to the pathogenesis of two human bone marrow 
failure and leukemia predisposition syndromes, SDS and MDS.  
 
Figure 5. S100A8/9 induces genotoxic stress in murine HSPCs through TLR4 signaling. (A-B) Increased 
S100A8 and S100A9 levels in OCSf/f GFP+ cells. (A) representative plots. (B) MFI values (n = 5). (C) Increased 
plasma concentration of S100A8/9 by ELISA (OCSf/+, n = 5; OCSf/f, n = 4). (D) Left: representative γH2AX 
pictures after HSPCs in vitro exposure. Positive control: 8-Gy irradiated Lin- c-Kit+ Sca-1- cells. Negative 
controls: heat-inactivated S100A8/9 (H.I. ctr). Right: number of γH2AX foci (n = 3). (E) S100A8/9 has no 
effect on cell cycle (n = 2). (F) Increased apoptosis in S100A8/9-exposed LKS (n = 3). (G) Activation of TLR 
signaling (GSEA). (H) TLR4-blocking antibodies limit DNA damage in OCSf/f mice (n = 4). *P<0.05. *P<0.01. 
***P<0.001. Data are mean ± SEM. See also Figure S2 and S5; Table S5.  
86
Chapter 3
C
ha
pt
er
 3
 
Figure 6. Expression of S100A8/9 in highly purified mesenchymal niche cells predicts clinical outcome in 
low-risk MDS. (A) Representative examples of FACS-isolated CD271+ niche cells in human MDS. (B) 
Correlation plot of S100A8 and S100A9 expression levels in human low-risk MDS (n = 20) and normal 
controls (n = 7). (C) Representative staining of S100A8 and S100A9 in endosteal (CD271+) stromal cells. 
Intramedullary staining reflects expression of S100A8/9 in myeloid cells. (D) Kaplan-Meier survival curve 
showing patient outcome. See also Table S6. 
 
The data indicate that the mesenchymal niche may actively contribute to the formation of a 
‘mutagenic’ environment, adding to our understanding of how a premalignant environment 
facilitates cancer initiation and evolution. The data argue that this may not only occur through 
facilitated selection and expansion of genetic clones that stochastically emerge in a permissive 
environment, but that the mesenchymal niche may be an active participant in driving the 
genotoxic stress underlying tissue failure and malignant transformation of parenchymal cells.  
Notably, leukemic transformation was not observed in mice with targeted deficiency of Sbds in 
mesenchymal cells. Earlier, in a related mouse model of targeted Dicer1 deletion in MPCs, 
leukemic transformation was a rare event.8 In the light of our current findings, these observations 
are likely explained by several factors. First, prolonged exposure to a mutagenic niche, beyond 
the limited lifespan of OCS mice, may be necessary for the accumulation of genetic damage 
required for full transformation. Additionally, the data argue that DNA repair-proficient HSPCs 
are able to cope with the mutagenic stress induced by their environment through activation of 
the DDR (as shown by molecular activation of cell cycle checkpoints and apoptosis), preventing 
the accumulation of stable genetic damage (as demonstrated by comet assays) and maintaining 
the functional integrity of HSPCs (as shown by repopulation assays). It will thus be of considerable 
interest to test the hypothesis that a mutagenic environment cooperates with aberrant HSPCs, 
compromised in their ability to cope with inflammatory genotoxic stress, in leukemic evolution.  
In this context, the propensity of Sbds-deficient cells to accumulate ROS38 and their reduced 
ability to cope with various cellular stressors, such as mitotic spindle destabilizing agents, 
endoplasmic reticulum stress activators, topoisomerase inhibitors and UV irradiation,39,40 is 
noteworthy.  
The current findings add to emerging insights into the role of innate immune TLR-signaling in the 
pathogenesis of human MDS. TLR4 and other TLRs are overexpressed in HSPCs from MDS 
patients41,42 and TLR4 expression was shown to correlate with apoptosis in CD34+ hematopoietic 
cells. TLR signaling is constitutively activated in MDS mice with deletion of chromosome 5 
(del5q)43 and multiple TLR downstream signaling pathways have been shown to be activated in 
MDS and related to loss of progenitor cell function.44 
Our findings implicate the DAMP S100A8/9 derived from the mesenchymal niche as a driver of 
TLR signaling in this disease. The unbiased identification of S100A8/9 seems to independently 
converge with an earlier report implicating S100A8/9 in the pathogenesis of MDS.37 In this study 
it was shown that the plasma concentration of S100A9 was significantly increased in MDS patients 
and S100A8/9 was shown to drive expansion and activation of myeloid-derived suppressor cells 
(MDSCs), which contributed to cytopenia and myelodysplasia in a murine model of S100A9 
overexpression through secretion of suppressive cytokines. It is therefore an intriguing possibility 
that additional, indirect, biologic effects of S100A8/9 contribute to the hematopoietic phenotype 
of OCS mice. This may include engagement of other cognate receptors of the protein, including 
expansion of MDSCs through CD33 signaling.37 Similarly, it is conceivable that other ligands 
secreted from mesenchymal cells contribute to the induction of DNA damage in HSPCs in the 
mouse model. We found a striking abundance of transcripts encoding other DAMPs and cytotoxic 
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Figure 6. Expression of S100A8/9 in highly purified mesenchymal niche cells predicts clinical outcome in 
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Correlation plot of S100A8 and S100A9 expression levels in human low-risk MDS (n = 20) and normal 
controls (n = 7). (C) Representative staining of S100A8 and S100A9 in endosteal (CD271+) stromal cells. 
Intramedullary staining reflects expression of S100A8/9 in myeloid cells. (D) Kaplan-Meier survival curve 
showing patient outcome. See also Table S6. 
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noteworthy.  
The current findings add to emerging insights into the role of innate immune TLR-signaling in the 
pathogenesis of human MDS. TLR4 and other TLRs are overexpressed in HSPCs from MDS 
patients41,42 and TLR4 expression was shown to correlate with apoptosis in CD34+ hematopoietic 
cells. TLR signaling is constitutively activated in MDS mice with deletion of chromosome 5 
(del5q)43 and multiple TLR downstream signaling pathways have been shown to be activated in 
MDS and related to loss of progenitor cell function.44 
Our findings implicate the DAMP S100A8/9 derived from the mesenchymal niche as a driver of 
TLR signaling in this disease. The unbiased identification of S100A8/9 seems to independently 
converge with an earlier report implicating S100A8/9 in the pathogenesis of MDS.37 In this study 
it was shown that the plasma concentration of S100A9 was significantly increased in MDS patients 
and S100A8/9 was shown to drive expansion and activation of myeloid-derived suppressor cells 
(MDSCs), which contributed to cytopenia and myelodysplasia in a murine model of S100A9 
overexpression through secretion of suppressive cytokines. It is therefore an intriguing possibility 
that additional, indirect, biologic effects of S100A8/9 contribute to the hematopoietic phenotype 
of OCS mice. This may include engagement of other cognate receptors of the protein, including 
expansion of MDSCs through CD33 signaling.37 Similarly, it is conceivable that other ligands 
secreted from mesenchymal cells contribute to the induction of DNA damage in HSPCs in the 
mouse model. We found a striking abundance of transcripts encoding other DAMPs and cytotoxic 
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proteins in both the mouse model and mesenchymal elements isolated from SDS patients. 
Ongoing investigations will have to assess whether other selected ligands can evoke genomic 
stress in heterotypic HSPCs and in such a fashion contribute to the generation of a mutagenic 
environment in these disorders. 
Finally, our findings establish molecular characteristics of the mesenchymal environment as an 
important determinant of disease outcome in humans. S100A8/9 expression in mesenchymal 
cells predicted overall survival in a cohort of homogeneously treated low-risk MDS patients. This 
is of considerable clinical relevance because low-risk MDS is a heterogeneous disease-entity with 
a subset of patients having a particular dismal prognosis not identified by current risk-
stratification strategies.45 Gene expression of S100A8/9 may identify a substantial subset of 
patients with an overall survival typically associated with ‘high-risk’ patients and, if confirmed in 
larger independent cohorts, could guide therapeutic decision making in MDS. The data thus 
provide a strong rationale for niche–instructed therapeutic targeting of inflammatory signaling in 
human preleukemic disease. 
 
EXPERIMENTAL PROCEDURES 
Mice and in vivo procedures 
OCS and Trp53f/f mice have been previously described.8,46 PtprcaPepcb/BoyCrl (B6.SJL) mice were 
purchased from Charles River. Animals were maintained in specific pathogen free conditions in 
the Experimental Animal Center of Erasmus MC (EDC). For in vivo cell cycle analysis, OCS mice 
received intraperitoneal injections of BrdU (1.5 mg in PBS, BD Biosciences) and sacrificed after 15 
h. For TLR4 studies, 2 week-old mice were intraperitoneally injected with a double dose (100 µg 
and 35 µg, 48 h interval) of TLR4-neutralizing antibody (clone MTS510, eBioscience) or isotype 
control (clone eBR2a, eBioscience) and sacrificed after 60h. All mice were sacrificed by cervical 
dislocation. Animal studies were approved by the Animal Welfare/Ethics Committee of the EDC 
in accordance with legislation in the Netherlands (Approval No. EMC 2067, 2714, 2892, 3062). 
 
μCT analysis 
Femur bones were isolated, fixated in 3% PFA/PBS for 24 h and stored in 70% ethanol. μCT 
analysis was performed using a SkyScan 1172 system (SkyScan) using previously described 
settings.47 Bone microarchitectural parameters relative to the trabecular and the cortical area 
were determined in the distal metaphysis and the mid-diaphysis of each femur, respectively, 
using software packages from Bruker MicroCT (NRecon, CtAn and Dataviewer).  
Patient material 
Bone marrow aspirates were obtained from SDS and DBA patients during routine follow-up. All 
low-risk MDS patients were treated with lenalidomide (10 mg/day, d 1-21 in a 4-week schedule) 
in the context of an ongoing prospective clinical trial (HOVON89; www.hovon.nl; 
www.trialregister.nl as NTR1825; EudraCT No. 2008-002195-10); bone marrow specimens were 
collected at study entry. As controls, bone marrow cells from allogeneic transplantation donors 
were used. Patients and healthy donor characteristics are described in Table S4 and S6. All 
specimens were collected with informed consent, in accordance with the Declaration of Helsinki. 
 
Gene expression profiling 
Osx::GFP cells from bone cell suspensions of OCS mice were sorted in TRIzol Reagent (Life 
Technologies) and RNA was extracted according to the manufacturer’s recommendations. Linear 
amplification of mRNA was performed using the Ovation Pico WTA System (NuGEN). cDNA was 
fragmented and labelled with Encore™ Biotin Module (NuGEN). The biotinylated cDNA was 
hybridized to the GeneChip Mouse Genome 430 2.0 Array (Affymetrix eBioscience). Signal was 
normalized and differential gene expression analysis was performed with the limma package.48 
RNA sequencing experiments were performed as previously described.15 Human transcripts were 
aligned to the Ref Seq transcriptome (hg19) and analyzed with DESeq2,49, while mouse transcripts 
were aligned to the Ensembl transcriptome (mm10) and analyzed with EdgeR50 in the R 
environment. FPKM values were calculated using Cufflinks.51 Principal component analysis was 
performed in the R environment on the raw fragment counts extracted from the BAM files by 
HTSeq-count.52 For Gene Set Enrichment Analysis53 (GSEA, Broad Institute), normalized intensity 
values (microarray data) and FPKM values (RNA sequencing) were compared to the curated gene 
sets (C2) and the Gene Ontology gene sets (C5) of the Molecular Signature Database (MsigDB) 
using the Signal2Noise metric and 1000 gene set-based permutations. For HSPCs GO-term 
analysis, genes with significantly differential expression (P<0.05) were interrogated using 
g:Profiler web-based software.54,55 
 
Immunofluorescence microscopy 
HSPCs were harvested in PBS+0.5%FBS, cytospun on a glass slide for 3 min at 500 rpm using a 
Cytospin 4 centrifuge (Thermo Scientific) and fixed in 3% PFA/PBS for 15 min on ice. After 3 
washing steps in PBS, cells were permeabilized for 2 min in 0.15% Triton-X100/PBS. Aspecific 
binding sites were blocked by incubation in 1%BSA/PBS for 1 h at room temperature. Cells were 
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larger independent cohorts, could guide therapeutic decision making in MDS. The data thus 
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h. For TLR4 studies, 2 week-old mice were intraperitoneally injected with a double dose (100 µg 
and 35 µg, 48 h interval) of TLR4-neutralizing antibody (clone MTS510, eBioscience) or isotype 
control (clone eBR2a, eBioscience) and sacrificed after 60h. All mice were sacrificed by cervical 
dislocation. Animal studies were approved by the Animal Welfare/Ethics Committee of the EDC 
in accordance with legislation in the Netherlands (Approval No. EMC 2067, 2714, 2892, 3062). 
 
μCT analysis 
Femur bones were isolated, fixated in 3% PFA/PBS for 24 h and stored in 70% ethanol. μCT 
analysis was performed using a SkyScan 1172 system (SkyScan) using previously described 
settings.47 Bone microarchitectural parameters relative to the trabecular and the cortical area 
were determined in the distal metaphysis and the mid-diaphysis of each femur, respectively, 
using software packages from Bruker MicroCT (NRecon, CtAn and Dataviewer).  
Patient material 
Bone marrow aspirates were obtained from SDS and DBA patients during routine follow-up. All 
low-risk MDS patients were treated with lenalidomide (10 mg/day, d 1-21 in a 4-week schedule) 
in the context of an ongoing prospective clinical trial (HOVON89; www.hovon.nl; 
www.trialregister.nl as NTR1825; EudraCT No. 2008-002195-10); bone marrow specimens were 
collected at study entry. As controls, bone marrow cells from allogeneic transplantation donors 
were used. Patients and healthy donor characteristics are described in Table S4 and S6. All 
specimens were collected with informed consent, in accordance with the Declaration of Helsinki. 
 
Gene expression profiling 
Osx::GFP cells from bone cell suspensions of OCS mice were sorted in TRIzol Reagent (Life 
Technologies) and RNA was extracted according to the manufacturer’s recommendations. Linear 
amplification of mRNA was performed using the Ovation Pico WTA System (NuGEN). cDNA was 
fragmented and labelled with Encore™ Biotin Module (NuGEN). The biotinylated cDNA was 
hybridized to the GeneChip Mouse Genome 430 2.0 Array (Affymetrix eBioscience). Signal was 
normalized and differential gene expression analysis was performed with the limma package.48 
RNA sequencing experiments were performed as previously described.15 Human transcripts were 
aligned to the Ref Seq transcriptome (hg19) and analyzed with DESeq2,49, while mouse transcripts 
were aligned to the Ensembl transcriptome (mm10) and analyzed with EdgeR50 in the R 
environment. FPKM values were calculated using Cufflinks.51 Principal component analysis was 
performed in the R environment on the raw fragment counts extracted from the BAM files by 
HTSeq-count.52 For Gene Set Enrichment Analysis53 (GSEA, Broad Institute), normalized intensity 
values (microarray data) and FPKM values (RNA sequencing) were compared to the curated gene 
sets (C2) and the Gene Ontology gene sets (C5) of the Molecular Signature Database (MsigDB) 
using the Signal2Noise metric and 1000 gene set-based permutations. For HSPCs GO-term 
analysis, genes with significantly differential expression (P<0.05) were interrogated using 
g:Profiler web-based software.54,55 
 
Immunofluorescence microscopy 
HSPCs were harvested in PBS+0.5%FBS, cytospun on a glass slide for 3 min at 500 rpm using a 
Cytospin 4 centrifuge (Thermo Scientific) and fixed in 3% PFA/PBS for 15 min on ice. After 3 
washing steps in PBS, cells were permeabilized for 2 min in 0.15% Triton-X100/PBS. Aspecific 
binding sites were blocked by incubation in 1%BSA/PBS for 1 h at room temperature. Cells were 
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next stained overnight at 4°C with anti-phospho-histone H2A.X (Ser139) mouse monoclonal 
antibody (clone JBW301, Merck Millipore, diluted 1:1000 in 1%BSA/PBS). Slides were washed 
twice in PBS for 5 min and incubated for 1 h at 37°C with Alexa Fluor 488-conjugated goat anti-
mouse antibody (Cat. A10667, Life Technologies, diluted 1:200 in 1%BSA/PBS). After 2 washes in 
PBS, slides were mounted in VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). Z-
series images were acquired with a Leica TCS SP5 confocal microscope (63X objective lens) using 
the LAS software (Leica Microsystems). γH2AX foci were counted manually from the maximum 
projection view. 
 
Survival analysis 
The low-risk MDS patient subgroup with S100 niche signature was defined by the Modified 
Thompson Tau test for outlier detection. In brief, S100A8 statistics from the control cases were 
combined to define the rejection region, demarcating FPKM values to be considered as outliers. 
MDS cases with S100A8 FPKM values within the rejection region were thus defined as niche-
signature+. Kaplan-Meier curves were next constructed for the two MDS patient subgroups with 
events defined as patient death or development of leukemia. Statistical significant difference was 
asserted with the log-rank test. 
 
Statistics 
Statistical analysis was performed using Prism 5 (GraphPad Software). Unless otherwise specified, 
unpaired, 2-tailed Student’s t test (single test) or 1-way analysis of variance (multiple 
comparisons) were used to evaluate statistical significance, defined as P<0.05. All results in bar 
graphs are mean value ± standard error of the mean. 
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SUPPLEMENTAL DATA ITEMS 
 
 
 
Figure S1. Related to Figure 1; Figure 4. Impairment of terminal osteogenic differentiation in OCSf/f mice. 
(A) Increased CFU-F numbers (n = 3) with (B) unaltered frequency of Osx::GFP+ cells (n = 4) in OCSf/f mice. 
(C) Depletion of transcripts defining terminal osteogenic differentiation (osteocalcin, Bglap) and dentin 
matrix acidic phosphoprotein 1 (Dmp1), critical for proper mineralization of bone, and enrichment of 
markers of bone progenitors cells or early osteoblasts (Runx2 and Col1a1) in GFP+ cells from OCSf/f mice. 
(D) Significant (FDR<0.25) enrichment of ribosome and peptide chain elongation signatures in OCSf/f GFP+ 
cells (GSEA) with (E) representative plots. *P<0.05. **P<0.01. Data are mean ± SEM. 
  
 
Figure S2. Related to Figure 2; Figure 5. Global preservation of the frequency and transcriptional 
landscape of HSPCs in OCSf/f mice. (A-C) unaltered HSPC numbers in OCSf/f mice: (A) representative FACS 
plots, (B) bone marrow cellularity and (C) subset frequency (OCSf/+, n = 8 A-B, n = 7 C; OCSf/f, n = 7). LK: Lin- 
c-Kit+ Sca-1- cells. LKS: Lin- c-Kit+ Sca-1+ cells. MPP: multipotent progenitors, CD48- CD150- LKS cells. SLAM: 
CD48- CD150+ LKS cells. (D) FACS isolation of CD48+ and CD48- HSPC subsets for RNA-seq (OCSf/+ CD48-, n = 
3; other groups, n = 4). (E) RNA-seq validation confirming CD48 and Ptprc (CD45) expression and the Sbds-
proficient status of HSPCs from mutant mice. (F) Principal component analysis indicating global 
preservation of the transcriptome in HSPCs from OCSf/f mice. (G) TLR4 expression. (H) Activation of NF-κB 
and MAPK pathways in mutant HSPCs (GSEA). NES: normalized enrichment score. †††FDR-adjusted P<0.001. 
Data are mean ± SEM. 
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Figure S3. Related to Figure 2. Niche-induced DNA damage does not affect HSPC function. (A) Schematic 
representation of the competitive transplantation. BM: bone marrow. (B) Peripheral blood frequency of 
CD45.2+ cells 16 weeks after transplantation. (C) Bone marrow frequency of CD45.2+ cells (21-32 weeks 
after transplantation). Every circle represents one recipient mouse. (D) Manual scoring system applied to 
comet assay analysis. (E) Comet assay showing similar frequency of highly damaged HSPCs in OCSf/+ and 
OCSf/f mice (n = 5). +IR: 8-10 Gy irradiated positive control (LK cells). ***P<0.001. Data are mean ± SEM. 
  
 
 
Figure S4. Related to Figure 4. SBDS mutations in mesenchymal cells from SDS patients. (A-B) Detection 
of 258+2 T>C mutation in SDS patients. (A) Representative IGV plot. Note that the coverage level after the 
cryptic site (dashed box) is reduced in SDS, indicating an 8-bp deletion. (B) Quantification of 258+2 T>C 
mutation as frequency of spliced reads with 8-bp deletion. Every circle represents a patient. (C) Nucleotide 
sequence in positions 183-184 from SDS patients and healthy donors.  
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Figure S5. Related to Figure 5. S100A8/9 drives genomic stress in human HSPCs. (A-C) Treatment of 
human CD34+ HSPCs with recombinant S100A8/9. (A) Induction of γH2AX foci (n = 3). (B-C) Increased 
frequency of apoptotic cells. (B) Representative plot. (C) Quantification (n = 3).  (D) Reduced colony forming 
capacity of HSPCs as assessed by CFU-C assay (n = 4 independent experiments in triplicate). Data are mean 
± SEM. *P<0.05. **P<0.01. ***P<0.001. 
  
Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution.  
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS mutants      
G-protein coupled receptors      
G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_ 
SIGNALING_PATHWAY 
C5   1.63 0.180 
Cell adhesion-communication      
REACTOME_GAP_JUNCTION_ASSEMBLY C2   1.84 0.170 
PID_INTEGRIN_CS_PATHWAY C2   1.78 0.213 
SA_MMP_CYTOKINE_CONNECTION C2   1.75 0.230 
KEGG_CELL_ADHESION_MOLECULES_CAMS C2   1.70 0.236 
Enriched in OCS controls      
Mitochondria and oxidative phosphorylation      
MOOTHA_VOXPHOS C2 -2.49 <0.001 -1.93 0.001 
WONG_MITOCHONDRIA_GENE_MODULE C2 -2.46 <0.001 -2.19 <0.001 
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_A
TP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_
HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS 
C2 -2.44 <0.001 -2.02 <0.001 
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT C2 -2.43 <0.001 -1.91 0.002 
KEGG_OXIDATIVE_PHOSPHORYLATION C2 -2.37 <0.001 -1.75 0.012 
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT C2 -2.13 <0.001 -1.95 0.001 
MOOTHA_MITOCHONDRIA C2 -2.12 <0.001 -1.96 0.001 
HOUSTIS_ROS C2 -1.58 0.047 -1.34 0.211 
REACTOME_RNA_POL_I_RNA_POL_III_AND_ 
MITOCHONDRIAL_TRANSCRIPTION 
C2 -1.50 0.076   
GARGALOVIC_RESPONSE_TO_OXIDIZED_ 
PHOSPHOLIPIDS_TURQUOISE_DN 
C2 -1.48 0.083   
MOOTHA_HUMAN_MITODB_6_2002 C2   -2.01 <0.001 
GALLUZZI_PREVENT_MITOCHONDIAL_ 
PERMEABILIZATION 
C2   -1.30 0.248 
MITOCHONDRIAL_MEMBRANE_PART C5 -2.21 <0.001 -1.83 0.016 
MITOCHONDRIAL_INNER_MEMBRANE C5 -2.15 <0.001 -1.99 0.003 
MITOCHONDRIAL_PART C5 -2.13 <0.001 -2.07 0.001 
MITOCHONDRIAL_MEMBRANE C5 -2.07 <0.001 -2.02 0.003 
MITOCHONDRIAL_ENVELOPE C5 -1.98 0.002 -2.01 0.003 
MITOCHONDRIAL_MATRIX C5 -1.97 0.002 -1.81 0.020 
MITOCHONDRIAL_LUMEN C5 -1.96 0.002 -1.81 0.019 
MITOCHONDRIAL_RIBOSOME C5 -1.87 0.008 -1.64 0.060 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Mitochondria and oxidative phosphorylation      
MITOCHONDRION C5 -1.85 0.010 -2.01 0.002 
MITOCHONDRIAL_RESPIRATORY_CHAIN C5 -1.81 0.015 -1.87 0.013 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS C5 -1.54 0.121 -1.50 0.133 
ELECTRON_CARRIER_ACTIVITY C5   -1.73 0.034 
MITOCHONDRIAL_TRANSPORT C5   -1.55 0.099 
Ribosomes      
BILANGES_SERUM_RESPONSE_TRANSLATION C2 -1.64 0.028   
REACTOME_DEADENYLATION_DEPENDENT_MRNA_ 
DECAY 
C2 -1.63 0.032   
REACTOME_ELONGATION_ARREST_AND_RECOVERY C2 -1.58 0.046   
REACTOME_TRANSLATION C2 -2.47 <0.001   
KEGG_RIBOSOME C2 -2.42 <0.001   
REACTOME_PEPTIDE CHAIN ELONGATION C2 -2.42 <0.001   
REACTOME_NONSENSE_MEDIATED_DECAY_ 
ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX 
C2 -2.37 <0.001   
REACTOME_FORMATION_OF_THE_TERNARY_ 
COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX 
C2 -2.19 <0.001   
MCGOWAN_RSP6_TARGETS_UP C2   -1.76 0.011 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME C5 -2.33 <0.001   
RIBOSOME C5 -2.04 0.001 -1.68 0.045 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY C5 -2.02 0.001 -1.78 0.023 
ORGANELLAR_RIBOSOME C5 -1.89 0.007 -1.63 0.067 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_
ASSEMBLY 
C5 -1.83 0.012 -2.11 0.002 
RIBOSOMAL_SUBUNIT C5 -1.78 0.019 -1.62 0.071 
TRANSLATION C5 -1.56 0.118   
PROTEIN_POLYMERIZATION C5 -1.53 0.126   
RIBONUCLEOPROTEIN_COMPLEX C5   -2.09 0.001 
PROTEIN_RNA_COMPLEX_ASSEMBLY C5   -1.98 0.003 
TRANSLATIONAL_INITIATION C5   -1.73 0.034 
TRANSLATION_REGULATOR_ACTIVITY C5   -1.71 0.039 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BIN
DING 
C5   -1.70 0.044 
TRANSLATION_INITIATION_FACTOR_ACTIVITY C5   -1.67 0.048 
Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Ribosomes      
REGULATION_OF_TRANSLATIONAL_INITIATION C5   -1.55 0.100 
tRNA biosynthesis      
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION C2   -1.85 0.004 
REACTOME_TRNA_AMINOACYLATION C2   -1.72 0.015 
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS C2   -1.64 0.030 
TRNA_METABOLIC_PROCESS C5   -1.69 0.044 
Proteasomal pathway      
KEGG_PROTEASOME C2 -2.18 <0.001 -1.99 0.001 
REACTOME_AUTODEGRADATION_OF_THE_E3_ 
UBIQUITIN_LIGASE_COP1 
C2 -2.07 <0.001 -2.01 <0.001 
BIOCARTA_PROTEASOME_PATHWAY C2 -1.92 0.002 -2.14 <0.001 
WONG_PROTEASOME_GENE_MODULE C2   -1.83 0.005 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION
_PROTEASOME_DEGRADATION 
C2   -1.42 0.138 
PROTEASOME_COMPLEX C5 -1.47 0.168 -1.52 0.113 
Cell cycle regulation      
REACTOME_SYNTHESIS_OF_DNA C2 -2.44 <0.001 -2.25 <0.001 
REACTOME_S_PHASE C2 -2.42 <0.001 -2.31 <0.001 
CHICAS_RB1_TARGETS_LOW_SERUM C2 -2.28 <0.001   
ISHIDA_E2F_TARGETS C2 -2.27 <0.001 -2.11 <0.001 
REACTOME_MITOTIC_G1_G1_S_PHASES C2 -2.27 <0.001 -2.37 <0.001 
REACTOME_G1_S_TRANSITION C2 -2.26 <0.001 -2.31 <0.001 
REACTOME_M_G1_TRANSITION C2 -2.26 <0.001 -2.17 <0.001 
REACTOME_DNA_STRAND_ELONGATION C2 -2.23 <0.001 -2.05 <0.001 
KEGG_DNA_REPLICATION C2 -2.21 <0.001 -2.02 <0.001 
RAHMAN_TP53_TARGETS_PHOSPHORYLATED C2 -2.18 <0.001 -1.90 0.002 
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_ 
AND_REMOVAL_OF_CDC6 
C2 -2.17 <0.001 -2.00 0.001 
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_ 
COMPLEX 
C2 -2.15 <0.001 -2.20 <0.001 
KONG_E2F3_TARGETS C2 -2.14 <0.001 -2.19 <0.001 
REACTOME_DNA_REPLICATION C2 -2.14 <0.001 -2.29 <0.001 
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ 
ORC_ORIGIN_COMPLEX 
C2 -2.13 <0.001 -2.10 <0.001 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Mitochondria and oxidative phosphorylation      
MITOCHONDRION C5 -1.85 0.010 -2.01 0.002 
MITOCHONDRIAL_RESPIRATORY_CHAIN C5 -1.81 0.015 -1.87 0.013 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS C5 -1.54 0.121 -1.50 0.133 
ELECTRON_CARRIER_ACTIVITY C5   -1.73 0.034 
MITOCHONDRIAL_TRANSPORT C5   -1.55 0.099 
Ribosomes      
BILANGES_SERUM_RESPONSE_TRANSLATION C2 -1.64 0.028   
REACTOME_DEADENYLATION_DEPENDENT_MRNA_ 
DECAY 
C2 -1.63 0.032   
REACTOME_ELONGATION_ARREST_AND_RECOVERY C2 -1.58 0.046   
REACTOME_TRANSLATION C2 -2.47 <0.001   
KEGG_RIBOSOME C2 -2.42 <0.001   
REACTOME_PEPTIDE CHAIN ELONGATION C2 -2.42 <0.001   
REACTOME_NONSENSE_MEDIATED_DECAY_ 
ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX 
C2 -2.37 <0.001   
REACTOME_FORMATION_OF_THE_TERNARY_ 
COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX 
C2 -2.19 <0.001   
MCGOWAN_RSP6_TARGETS_UP C2   -1.76 0.011 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME C5 -2.33 <0.001   
RIBOSOME C5 -2.04 0.001 -1.68 0.045 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY C5 -2.02 0.001 -1.78 0.023 
ORGANELLAR_RIBOSOME C5 -1.89 0.007 -1.63 0.067 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_
ASSEMBLY 
C5 -1.83 0.012 -2.11 0.002 
RIBOSOMAL_SUBUNIT C5 -1.78 0.019 -1.62 0.071 
TRANSLATION C5 -1.56 0.118   
PROTEIN_POLYMERIZATION C5 -1.53 0.126   
RIBONUCLEOPROTEIN_COMPLEX C5   -2.09 0.001 
PROTEIN_RNA_COMPLEX_ASSEMBLY C5   -1.98 0.003 
TRANSLATIONAL_INITIATION C5   -1.73 0.034 
TRANSLATION_REGULATOR_ACTIVITY C5   -1.71 0.039 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BIN
DING 
C5   -1.70 0.044 
TRANSLATION_INITIATION_FACTOR_ACTIVITY C5   -1.67 0.048 
Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Ribosomes      
REGULATION_OF_TRANSLATIONAL_INITIATION C5   -1.55 0.100 
tRNA biosynthesis      
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION C2   -1.85 0.004 
REACTOME_TRNA_AMINOACYLATION C2   -1.72 0.015 
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS C2   -1.64 0.030 
TRNA_METABOLIC_PROCESS C5   -1.69 0.044 
Proteasomal pathway      
KEGG_PROTEASOME C2 -2.18 <0.001 -1.99 0.001 
REACTOME_AUTODEGRADATION_OF_THE_E3_ 
UBIQUITIN_LIGASE_COP1 
C2 -2.07 <0.001 -2.01 <0.001 
BIOCARTA_PROTEASOME_PATHWAY C2 -1.92 0.002 -2.14 <0.001 
WONG_PROTEASOME_GENE_MODULE C2   -1.83 0.005 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION
_PROTEASOME_DEGRADATION 
C2   -1.42 0.138 
PROTEASOME_COMPLEX C5 -1.47 0.168 -1.52 0.113 
Cell cycle regulation      
REACTOME_SYNTHESIS_OF_DNA C2 -2.44 <0.001 -2.25 <0.001 
REACTOME_S_PHASE C2 -2.42 <0.001 -2.31 <0.001 
CHICAS_RB1_TARGETS_LOW_SERUM C2 -2.28 <0.001   
ISHIDA_E2F_TARGETS C2 -2.27 <0.001 -2.11 <0.001 
REACTOME_MITOTIC_G1_G1_S_PHASES C2 -2.27 <0.001 -2.37 <0.001 
REACTOME_G1_S_TRANSITION C2 -2.26 <0.001 -2.31 <0.001 
REACTOME_M_G1_TRANSITION C2 -2.26 <0.001 -2.17 <0.001 
REACTOME_DNA_STRAND_ELONGATION C2 -2.23 <0.001 -2.05 <0.001 
KEGG_DNA_REPLICATION C2 -2.21 <0.001 -2.02 <0.001 
RAHMAN_TP53_TARGETS_PHOSPHORYLATED C2 -2.18 <0.001 -1.90 0.002 
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_ 
AND_REMOVAL_OF_CDC6 
C2 -2.17 <0.001 -2.00 0.001 
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_ 
COMPLEX 
C2 -2.15 <0.001 -2.20 <0.001 
KONG_E2F3_TARGETS C2 -2.14 <0.001 -2.19 <0.001 
REACTOME_DNA_REPLICATION C2 -2.14 <0.001 -2.29 <0.001 
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ 
ORC_ORIGIN_COMPLEX 
C2 -2.13 <0.001 -2.10 <0.001 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING
_G1_S_TRANSITION_ 
C2 -2.13 <0.001 -2.13 <0.001 
MARKEY_RB1_ACUTE_LOF_DN C2 -2.11 <0.001 -2.27 <0.001 
REACTOME_CELL_CYCLE_CHECKPOINTS C2 -2.10 <0.001 -2.11 <0.001 
WHITFIELD_CELL_CYCLE_LITERATURE C2 -2.08 <0.001 -2.25 <0.001 
EGUCHI_CELL_CYCLE_RB1_TARGETS C2 -2.03 <0.001 -1.97 0.001 
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE C2 -2.03 <0.001   
REACTOME_CELL_CYCLE_MITOTIC C2 -2.02 <0.001 -2.34 <0.001 
REACTOME_LAGGING_STRAND_SYNTHESIS C2 -2.02 <0.001 -1.88 0.003 
REACTOME_CELL_CYCLE C2 -2.01 <0.001 -2.18 <0.001 
REACTOME_MITOTIC_M_M_G1_PHASES C2 -2.00 <0.001 -2.23 <0.001 
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_ 
DN 
C2 -1.98 0.001 -1.81 0.006 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR C2 -1.90 0.002 -2.12 <0.001 
KAUFFMANN_DNA_REPLICATION_GENES C2 -1.87 0.003 -1.96 0.001 
IGLESIAS_E2F_TARGETS_UP C2 -1.86 0.003 -1.32 0.235 
CHANG_CYCLING_GENES C2 -1.85 0.004 -2.10 <0.001 
TANG_SENESCENCE_TP53_TARGETS_DN C2 -1.82 0.006 -1.86 0.003 
MARKEY_RB1_CHRONIC_LOF_UP C2 -1.78 0.008 -1.42 0.134 
REACTOME_G2_M_CHECKPOINTS C2 -1.78 0.008 -1.71 0.017 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR C2 -1.77 0.009 -2.19 <0.001 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_ 
DURING_G2_M_TRANSITION 
C2 -1.68 0.022 -1.39 0.160 
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_
REPLICATION 
C2 -1.64 0.028 -1.88 0.003 
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN C2 -1.62 0.033 -2.32 <0.001 
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION C2 -1.62 0.034 -1.94 0.001 
BIOCARTA_P53_PATHWAY C2 -1.59 0.044 -1.31 0.246 
VERNELL_RETINOBLASTOMA_PATHWAY_UP C2 -1.58 0.045 -1.96 0.001 
REACTOME_MEIOTIC_RECOMBINATION C2 -1.57 0.049   
KANNAN_TP53_TARGETS_DN C2 -1.56 0.052   
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM C2 -1.54 0.059 -1.40 0.155 
KEGG_CELL_CYCLE C2 -1.51 0.068 -1.88 0.003 
BIOCARTA_MCM_PATHWAY C2 -1.49 0.079 -1.54 0.068 
Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
REACTOME_G0_AND_EARLY_G1 C2 -1.48 0.086 -1.86 0.003 
PID_E2F_PATHWAY C2 -1.47 0.088 -1.85 0.004 
MARKEY_RB1_CHRONIC_LOF_DN C2 -1.44 0.110   
CHICAS_RB1_TARGETS_GROWING C2 -1.42 0.121 -1.72 0.015 
REACTOME_MITOTIC_PROMETAPHASE C2 -1.38 0.153 -1.84 0.004 
REACTOME_G1_PHASE C2 -1.37 0.155 -1.65 0.030 
BIOCARTA_CELLCYCLE_PATHWAY C2 -1.35 0.173 -1.65 0.029 
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_ 
DN 
C2 -1.30 0.220   
WHITFIELD_CELL_CYCLE_G2 C2 -1.30 0.224 -1.60 0.044 
SANCHEZ_MDM2_TARGETS C2 -1.28 0.249   
BENPORATH_PROLIFERATION C2   -2.15 <0.001 
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_
P27_P21 
C2   -2.14 <0.001 
REACTOME_APC_C_CDC20_MEDIATED_ 
DEGRADATION_OF_MITOTIC_PROTEINS 
C2   -2.03 <0.001 
REN_BOUND_BY_E2F C2   -1.89 0.002 
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_ 
LAGGING_STRAND 
C2 -1.92 0.001 -1.72 0.016 
REACTOME_MITOTIC_G2_G2_M_PHASES C2   -1.69 0.021 
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_
COMPLEX 
C2 -1.93 0.001 -1.68 0.022 
CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP C2   -1.67 0.025 
REACTOME_RECRUITMENT_OF_MITOTIC_ 
CENTROSOME_PROTEINS_AND_COMPLEXES 
C2   -1.63 0.033 
REICHERT_MITOSIS_LIN9_TARGETS C2   -1.61 0.039 
PID_P53REGULATIONPATHWAY C2   -1.59 0.047 
BIOCARTA_G1_PATHWAY C2   -1.55 0.060 
SA_G1_AND_S_PHASES C2   -1.51 0.082 
WHITFIELD_CELL_CYCLE_G2_M C2   -1.48 0.099 
WHITFIELD_CELL_CYCLE_M_G1 C2   -1.48 0.099 
WHITFIELD_CELL_CYCLE_G1_S C2   -1.47 0.101 
BIOCARTA_G2_PATHWAY C2   -1.46 0.112 
GEORGES_CELL_CYCLE_MIR192_TARGETS C2   -1.45 0.116 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING
_G1_S_TRANSITION_ 
C2 -2.13 <0.001 -2.13 <0.001 
MARKEY_RB1_ACUTE_LOF_DN C2 -2.11 <0.001 -2.27 <0.001 
REACTOME_CELL_CYCLE_CHECKPOINTS C2 -2.10 <0.001 -2.11 <0.001 
WHITFIELD_CELL_CYCLE_LITERATURE C2 -2.08 <0.001 -2.25 <0.001 
EGUCHI_CELL_CYCLE_RB1_TARGETS C2 -2.03 <0.001 -1.97 0.001 
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE C2 -2.03 <0.001   
REACTOME_CELL_CYCLE_MITOTIC C2 -2.02 <0.001 -2.34 <0.001 
REACTOME_LAGGING_STRAND_SYNTHESIS C2 -2.02 <0.001 -1.88 0.003 
REACTOME_CELL_CYCLE C2 -2.01 <0.001 -2.18 <0.001 
REACTOME_MITOTIC_M_M_G1_PHASES C2 -2.00 <0.001 -2.23 <0.001 
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_ 
DN 
C2 -1.98 0.001 -1.81 0.006 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR C2 -1.90 0.002 -2.12 <0.001 
KAUFFMANN_DNA_REPLICATION_GENES C2 -1.87 0.003 -1.96 0.001 
IGLESIAS_E2F_TARGETS_UP C2 -1.86 0.003 -1.32 0.235 
CHANG_CYCLING_GENES C2 -1.85 0.004 -2.10 <0.001 
TANG_SENESCENCE_TP53_TARGETS_DN C2 -1.82 0.006 -1.86 0.003 
MARKEY_RB1_CHRONIC_LOF_UP C2 -1.78 0.008 -1.42 0.134 
REACTOME_G2_M_CHECKPOINTS C2 -1.78 0.008 -1.71 0.017 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR C2 -1.77 0.009 -2.19 <0.001 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_ 
DURING_G2_M_TRANSITION 
C2 -1.68 0.022 -1.39 0.160 
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_
REPLICATION 
C2 -1.64 0.028 -1.88 0.003 
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN C2 -1.62 0.033 -2.32 <0.001 
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION C2 -1.62 0.034 -1.94 0.001 
BIOCARTA_P53_PATHWAY C2 -1.59 0.044 -1.31 0.246 
VERNELL_RETINOBLASTOMA_PATHWAY_UP C2 -1.58 0.045 -1.96 0.001 
REACTOME_MEIOTIC_RECOMBINATION C2 -1.57 0.049   
KANNAN_TP53_TARGETS_DN C2 -1.56 0.052   
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM C2 -1.54 0.059 -1.40 0.155 
KEGG_CELL_CYCLE C2 -1.51 0.068 -1.88 0.003 
BIOCARTA_MCM_PATHWAY C2 -1.49 0.079 -1.54 0.068 
Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
REACTOME_G0_AND_EARLY_G1 C2 -1.48 0.086 -1.86 0.003 
PID_E2F_PATHWAY C2 -1.47 0.088 -1.85 0.004 
MARKEY_RB1_CHRONIC_LOF_DN C2 -1.44 0.110   
CHICAS_RB1_TARGETS_GROWING C2 -1.42 0.121 -1.72 0.015 
REACTOME_MITOTIC_PROMETAPHASE C2 -1.38 0.153 -1.84 0.004 
REACTOME_G1_PHASE C2 -1.37 0.155 -1.65 0.030 
BIOCARTA_CELLCYCLE_PATHWAY C2 -1.35 0.173 -1.65 0.029 
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_ 
DN 
C2 -1.30 0.220   
WHITFIELD_CELL_CYCLE_G2 C2 -1.30 0.224 -1.60 0.044 
SANCHEZ_MDM2_TARGETS C2 -1.28 0.249   
BENPORATH_PROLIFERATION C2   -2.15 <0.001 
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_
P27_P21 
C2   -2.14 <0.001 
REACTOME_APC_C_CDC20_MEDIATED_ 
DEGRADATION_OF_MITOTIC_PROTEINS 
C2   -2.03 <0.001 
REN_BOUND_BY_E2F C2   -1.89 0.002 
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_ 
LAGGING_STRAND 
C2 -1.92 0.001 -1.72 0.016 
REACTOME_MITOTIC_G2_G2_M_PHASES C2   -1.69 0.021 
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_
COMPLEX 
C2 -1.93 0.001 -1.68 0.022 
CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP C2   -1.67 0.025 
REACTOME_RECRUITMENT_OF_MITOTIC_ 
CENTROSOME_PROTEINS_AND_COMPLEXES 
C2   -1.63 0.033 
REICHERT_MITOSIS_LIN9_TARGETS C2   -1.61 0.039 
PID_P53REGULATIONPATHWAY C2   -1.59 0.047 
BIOCARTA_G1_PATHWAY C2   -1.55 0.060 
SA_G1_AND_S_PHASES C2   -1.51 0.082 
WHITFIELD_CELL_CYCLE_G2_M C2   -1.48 0.099 
WHITFIELD_CELL_CYCLE_M_G1 C2   -1.48 0.099 
WHITFIELD_CELL_CYCLE_G1_S C2   -1.47 0.101 
BIOCARTA_G2_PATHWAY C2   -1.46 0.112 
GEORGES_CELL_CYCLE_MIR192_TARGETS C2   -1.45 0.116 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
WHITFIELD_CELL_CYCLE_S C2   -1.40 0.155 
REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_ 
KINASE_ACTIVITY 
C5 -1.99 0.001   
REPLICATION_FORK C5 -1.85 0.010 -1.45 0.169 
DNA_REPLICATION C5 -1.83 0.012 -1.58 0.088 
CELL_CYCLE_PROCESS C5 -1.74 0.031 -1.51 0.127 
INTERPHASE C5 -1.67 0.057 -1.45 0.171 
CELL_CYCLE_PHASE C5 -1.64 0.070 -1.40 0.209 
CELL_CYCLE_GO_0007049 C5 -1.64 0.070 -1.43 0.174 
MITOTIC_CELL_CYCLE C5 -1.63 0.070 -1.51 0.122 
DNA_DEPENDENT_DNA_REPLICATION C5 -1.59 0.097 -1.52 0.113 
INTERPHASE_OF_MITOTIC_CELL_CYCLE C5 -1.58 0.104 -1.50 0.128 
M_PHASE C5 -1.54 0.122 -1.34 0.250 
M_PHASE_OF_MITOTIC_CELL_CYCLE C5 -1.52 0.125 -1.55 0.098 
CELL_PROLIFERATION_GO_0008283 C5 -1.46 0.176   
MITOSIS C5 -1.43 0.197 -1.56 0.096 
DNA_METABOLIC_PROCESS C5   -1.46 0.160 
Metabolism      
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ 
ELECTRON_TRANSPORT 
C2 -2.19 <0.001 -2.08 <0.001 
MOOTHA_TCA C2 -1.67 0.024 -1.78 0.008 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE C2 -1.61 0.037 -1.87 0.003 
KEGG_CITRATE_CYCLE_TCA_CYCLE C2 -1.55 0.054 -1.79 0.007 
REACTOME_GLUCOSE_METABOLISM C2 -1.33 0.190   
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ 
ACID_TCA_CYCLE 
C2   -1.71 0.017 
Hematopoietic stem cells      
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_ 
PROGENITOR 
C2 -1.67 0.023 -2.02 <0.001 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS C2 -1.45 0.103   
PARK_HSC_AND_MULTIPOTENT_PROGENITORS C2 -1.39 0.145 -1.53 0.070 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN
_QTL_CIS 
C2   -1.32 0.227 
 
Upregulation of G-protein-coupled receptors and cell adhesion-communication, and downregulation of 
mitochondrial oxidative phosphorylation, ribosome biogenesis, aminoacyl-tRNA synthetase activity, 
proteasomal degradation, citric acid cycle, cell cycle deregulation and hematopoietic stem cell programs. 
Normalized enrichment score (NES) and False Discovery Rate-adjusted q-value (FDR) are omitted when 
FDR > 0.25. 
 
Table S2. Related to Figure 2. Stress and DNA damage dysregulation in the transcriptome of HSPCs from 
OCSf/f mice.  
ID Description CD48- 
p-val 
CD48+ 
p-val 
GO:0006310 DNA recombination NS 4.68e-02 
GO:0006950 response to stress 4.69e-05 1.31e-10 
  GO:0080134 regulation of response to stress 2.25e-03 9.78e-04 
  GO:0033554 cellular response to stress 5.53e-06 9.15e-05 
    GO:0080135 regulation of cellular response to stress 2.82e-02 NS 
    GO:0006974 cellular response to DNA damage stimulus 4.11e-03 1.96e-03 
      GO:0006281 DNA repair 3.86e-02 NS 
        GO:0006301 postreplication repair NS 2.78e-02 
REAC:5956042 Cell Cycle Checkpoints 1.27e-04 2.86e-04 
    REAC:5956049 Activation of ATR in response to replication stress 2.89e-02 4.10e-02 
  REAC:5956279 Gap-filling DNA repair synthesis and ligation in GG-NER 2.01e-02 NS 
  REAC:5956420 Gap-filling DNA repair synthesis and ligation in TC-NER 2.01e-02 NS 
 
Genes with significantly different expression (P<0.05) between OCSf/+ and OCSf/f mice within the CD48- or 
CD48+ populations were interrogated for GO and Reactome term enrichment using g-profiler. P-val: p-
value. NS: not significant (P≥0.05). 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. (Continued) 
Gene set MSigDB 
collection 
CD48- 
NES 
CD48- 
FDR 
CD48+ 
NES 
CD48+ 
FDR 
Enriched in OCS controls      
Cell cycle regulation      
WHITFIELD_CELL_CYCLE_S C2   -1.40 0.155 
REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_ 
KINASE_ACTIVITY 
C5 -1.99 0.001   
REPLICATION_FORK C5 -1.85 0.010 -1.45 0.169 
DNA_REPLICATION C5 -1.83 0.012 -1.58 0.088 
CELL_CYCLE_PROCESS C5 -1.74 0.031 -1.51 0.127 
INTERPHASE C5 -1.67 0.057 -1.45 0.171 
CELL_CYCLE_PHASE C5 -1.64 0.070 -1.40 0.209 
CELL_CYCLE_GO_0007049 C5 -1.64 0.070 -1.43 0.174 
MITOTIC_CELL_CYCLE C5 -1.63 0.070 -1.51 0.122 
DNA_DEPENDENT_DNA_REPLICATION C5 -1.59 0.097 -1.52 0.113 
INTERPHASE_OF_MITOTIC_CELL_CYCLE C5 -1.58 0.104 -1.50 0.128 
M_PHASE C5 -1.54 0.122 -1.34 0.250 
M_PHASE_OF_MITOTIC_CELL_CYCLE C5 -1.52 0.125 -1.55 0.098 
CELL_PROLIFERATION_GO_0008283 C5 -1.46 0.176   
MITOSIS C5 -1.43 0.197 -1.56 0.096 
DNA_METABOLIC_PROCESS C5   -1.46 0.160 
Metabolism      
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ 
ELECTRON_TRANSPORT 
C2 -2.19 <0.001 -2.08 <0.001 
MOOTHA_TCA C2 -1.67 0.024 -1.78 0.008 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE C2 -1.61 0.037 -1.87 0.003 
KEGG_CITRATE_CYCLE_TCA_CYCLE C2 -1.55 0.054 -1.79 0.007 
REACTOME_GLUCOSE_METABOLISM C2 -1.33 0.190   
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ 
ACID_TCA_CYCLE 
C2   -1.71 0.017 
Hematopoietic stem cells      
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_ 
PROGENITOR 
C2 -1.67 0.023 -2.02 <0.001 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS C2 -1.45 0.103   
PARK_HSC_AND_MULTIPOTENT_PROGENITORS C2 -1.39 0.145 -1.53 0.070 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN
_QTL_CIS 
C2   -1.32 0.227 
 
Upregulation of G-protein-coupled receptors and cell adhesion-communication, and downregulation of 
mitochondrial oxidative phosphorylation, ribosome biogenesis, aminoacyl-tRNA synthetase activity, 
proteasomal degradation, citric acid cycle, cell cycle deregulation and hematopoietic stem cell programs. 
Normalized enrichment score (NES) and False Discovery Rate-adjusted q-value (FDR) are omitted when 
FDR > 0.25. 
 
Table S2. Related to Figure 2. Stress and DNA damage dysregulation in the transcriptome of HSPCs from 
OCSf/f mice.  
ID Description CD48- 
p-val 
CD48+ 
p-val 
GO:0006310 DNA recombination NS 4.68e-02 
GO:0006950 response to stress 4.69e-05 1.31e-10 
  GO:0080134 regulation of response to stress 2.25e-03 9.78e-04 
  GO:0033554 cellular response to stress 5.53e-06 9.15e-05 
    GO:0080135 regulation of cellular response to stress 2.82e-02 NS 
    GO:0006974 cellular response to DNA damage stimulus 4.11e-03 1.96e-03 
      GO:0006281 DNA repair 3.86e-02 NS 
        GO:0006301 postreplication repair NS 2.78e-02 
REAC:5956042 Cell Cycle Checkpoints 1.27e-04 2.86e-04 
    REAC:5956049 Activation of ATR in response to replication stress 2.89e-02 4.10e-02 
  REAC:5956279 Gap-filling DNA repair synthesis and ligation in GG-NER 2.01e-02 NS 
  REAC:5956420 Gap-filling DNA repair synthesis and ligation in TC-NER 2.01e-02 NS 
 
Genes with significantly different expression (P<0.05) between OCSf/+ and OCSf/f mice within the CD48- or 
CD48+ populations were interrogated for GO and Reactome term enrichment using g-profiler. P-val: p-
value. NS: not significant (P≥0.05). 
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Table S3. Related to Figure 2. Myc-related signatures depleted in OCSf/f HSPCs. 
Gene set Size CD48- 
NES 
CD48- 
FDR 
CD 48+ 
NES 
CD48+ 
FDR 
DANG_MYC_TARGETS_UP 140 -2.3691 <0.0001 -2.3219 <0.0001 
MENSSEN_MYC_TARGETS 52 -2.2803 <0.0001 -2.1716 <0.0001 
YU_MYC_TARGETS_UP 40 -2.1026 <0.0001 -2.2127 <0.0001 
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN 45 -1.9994 0.0004 -1.9883 0.0006 
CAIRO_PML_TARGETS_BOUND_BY_MYC_UP 23 -1.9161 0.0015 -1.6278 0.0344 
SCHUHMACHER_MYC_TARGETS_UP 80 -1.9014 0.0019 -2.2771 <0.0001 
SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM 153 -1.8948 0.0021 -2.1315 0.0001 
BENPORATH_MYC_TARGETS_WITH_EBOX 224 -1.8805 0.0025 -1.6005 0.0427 
SANSOM_APC_TARGETS_REQUIRE_MYC 195 -1.8271 0.0049 -1.6294 0.0340 
PID_MYC_ACTIVPATHWAY 77 -1.7735 0.0088 -1.7577 0.0107 
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_ 
UP 
102 -1.7638 0.0098 -1.9423 0.0012 
SCHLOSSER_MYC_AND_SERUM_RESPONSE_ 
SYNERGY 
32 -1.7246 0.0142 -1.5919 0.0448 
KIM_MYC_AMPLIFICATION_TARGETS_UP 192 -1.6787 0.0216 -1.8727 0.0027 
DANG_REGULATED_BY_MYC_UP 69 -1.5696 0.0484 -1.7749 0.0091 
COLLER_MYC_TARGETS_UP 25 -1.5656 0.0498 -2.0411 0.0003 
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_ 
TARGETS_UP 
77 -1.4380 0.1081 -1.4098 0.1455 
SCHLOSSER_MYC_TARGETS_AND_SERUM_ 
RESPONSE_DN 
47 -1.4123 0.1260 -1.9374 0.0012 
BILD_MYC_ONCOGENIC_SIGNATURE 193 -1.4101 0.1277 -1.3748 0.1735 
 
  
Table S4. Related to Figure 4. Human normal donor and patient characteristics. 
Sample ID Disease status Age Sex 
HD513 Healthy donor 40 y M 
HD723 Healthy donor 48 y F 
HD863 Healthy donor 42 y M 
HD237 Healthy donor 40 y M 
HD703 Healthy donor 39 y M 
HD066 Healthy donor 35 y M 
HD167 Healthy donor 48 y M 
SDS438 SDS patienta 9 y M 
SDS132 SDS patienta 14 y M 
SDS640 SDS patienta 4 y M 
SDS221 SDS patienta 18 y M 
MDS247 Low-risk MDS patientb 62 y M 
MDS006 Low-risk MDS patientb 63 y F 
MDS020 Low-risk MDS patientb 72 y F 
MDS159 Low-risk MDS patientb 75 y F 
MDS209 Low-risk MDS patientb 79 y F 
MDS222 Low-risk MDS patientb 66 y F 
MDS610 Low-risk MDS patientb 65 y F 
MDS627 Low-risk MDS patientb 80 y M 
MDS008 Low-risk MDS patientb 65 y F 
DBA044 DBA patient 1 y F 
DBA087 DBA patient 4 mo M 
DBA563 DBA patient 4 y F 
aAll SDS patients were genetically characterized by compound heterozygosity 
c.183_184TA>CT/c.258+2T>C. Patients did not receive G-CSF treatment and were not diagnosed with MDS 
or AML at the time of bone marrow sampling. All patients presented with pancreatic insufficiency (serum 
trypsinogen level <6 µg/L) and growth retardation (≤ 2 SD). All patients but SDS438 were neutropenic at 
sampling (absolute neutrophil counts, ANC < 1.5×109/l); SDS438 had ANC = 1.62×109/l). 
bSee Table S6 for further patient characteristics. 
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Table S3. Related to Figure 2. Myc-related signatures depleted in OCSf/f HSPCs. 
Gene set Size CD48- 
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HD723 Healthy donor 48 y F 
HD863 Healthy donor 42 y M 
HD237 Healthy donor 40 y M 
HD703 Healthy donor 39 y M 
HD066 Healthy donor 35 y M 
HD167 Healthy donor 48 y M 
SDS438 SDS patienta 9 y M 
SDS132 SDS patienta 14 y M 
SDS640 SDS patienta 4 y M 
SDS221 SDS patienta 18 y M 
MDS247 Low-risk MDS patientb 62 y M 
MDS006 Low-risk MDS patientb 63 y F 
MDS020 Low-risk MDS patientb 72 y F 
MDS159 Low-risk MDS patientb 75 y F 
MDS209 Low-risk MDS patientb 79 y F 
MDS222 Low-risk MDS patientb 66 y F 
MDS610 Low-risk MDS patientb 65 y F 
MDS627 Low-risk MDS patientb 80 y M 
MDS008 Low-risk MDS patientb 65 y F 
DBA044 DBA patient 1 y F 
DBA087 DBA patient 4 mo M 
DBA563 DBA patient 4 y F 
aAll SDS patients were genetically characterized by compound heterozygosity 
c.183_184TA>CT/c.258+2T>C. Patients did not receive G-CSF treatment and were not diagnosed with MDS 
or AML at the time of bone marrow sampling. All patients presented with pancreatic insufficiency (serum 
trypsinogen level <6 µg/L) and growth retardation (≤ 2 SD). All patients but SDS438 were neutropenic at 
sampling (absolute neutrophil counts, ANC < 1.5×109/l); SDS438 had ANC = 1.62×109/l). 
bSee Table S6 for further patient characteristics. 
 
 
  
110
Chapter 3
C
ha
pt
er
 3
Table S5. Related to Figure S5. In vitro exposure of HSPCs to S100A8/9 activates transcriptional 
signatures related to TLR signaling and cellular stress/apoptosis.  
Gene set NES P-val FDR 
q-val 
Toll-like receptor signaling    
BIOCARTA_TOLL_PATHWAY 1.60 0.014 0.404 
REACTOME_TOLL_RECEPTOR_CASCADES 1.53 0.005 0.365 
PID_TOLL_ENDOGENOUS_PATHWAY 0.043 1.49 0.043 0.380 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 1.46 0.012 0.428 
REACTOME_ACTIVATED_TLR4_SIGNALLING 1.44 0.025 0.444 
REACTOME_INNATE_IMMUNE_SYSTEM 1.56 0.0001 0.374 
Activation of p53 and apoptosis pathways    
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 1.52 0.017 0.364 
INGA_TP53_TARGETS 1.62 0.019 0.363 
RASHI_RESPONSE_TO_IONIZING_RADIATION_1 1.68 0.005 0.326 
DAZARD_UV_RESPONSE_CLUSTER_G2 1.69 0.006 0.314 
AMUNDSON_GAMMA_RADIATION_RESISTANCE 1.71 0.009 0.316 
KEGG_APOPTOSIS 1.74 0.001 0.260 
KEGG_P53_SIGNALING_PATHWAY 1.78 0.001 0.217 
 
  
Table S6. Related to Figure 6. MDS patient characteristics at beginning of treatment and clinical 
outcome. Provided as an Excel file. All patients were treated with lenalidomide in the context of an 
ongoing prospective clinical trial (details in Experimental Procedures). Patients were studied of which 
sufficient bone marrow material was available for analysis. Survival data are calculated from date of study-
entry. aNot calculated, missing cytogenetics. Hb, hemoglobin. PLT, platelets. WBC, white blood cells. ANC, 
absolute neutrophil count. S100A8 and S100A9 expression is obtained by RNA-sequencing data. P-values 
were calculated by Mann-Whitney test. 
 
Patient ID WHO Cytogenetics IPSS LR-PSS 
score 
LR-PSS 
category 
Outcome 
S100 niche signature+         
MDS020 RCMD-RS 46,XX[20] 0.5 4 2 Death 
MDS267 RCMD 46,XY[20] 0.5 4 2 Death 
MDS486 RAEB-1 46,XX,t(3;3)(q21;q26)[10] 0.5 4 2 Death 
MDS610 RCMD-RS 46,XX[20] 0.5 3 2 Leukemia 
MDS314 Del(5q) 46,XX,del(5)(q13q33)[25]/46,XX[5] 0 2 1 Death 
MDS008 RCMD 46,XX[20] 0 4 2 Death 
Mean (SD)         
S100 niche signature-         
MDS247 RCMD-RS 46,XY[20] 0 3 2 Alive 
MDS006 RAEB-1 46,XX[20] 1 5 3 Death 
MDS118 RARS 46,XX[20] 0 1 1 Alive 
MDS159 Del(5q) 46,XX,del(5)(q15q33)[10] 0 3 2 Death 
MDS222 RARS 46,XX[21] 0 4 2 Alive 
MDS209 RCMD-RS 46,XX[10] 0 3 2 Death 
MDS025 RCMD-RS 46,XY[20] 0.5 3 2 Death 
MDS146 RARS 46,XY[20] 0.5 4 2 Alive 
MDS433 RCMD-RS 45,X,-Y[10]/46,XY[10] 0 2 1 Alive 
MDS646 RAEB-1 46,yy[20] 1 5 3 Death 
MDS893 RARS 46,XX[20] 0 3 2 Death 
MDS111 RCMD 46,XX[20] 0.5 3 2 Alive 
MDS623 RCMD 46,XY[20] 0.5 4 2 Alive 
MDS067 RCMD-RS not available 1 a a Alive 
Mean (SD)         
MW P-value         
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Table S5. Related to Figure S5. In vitro exposure of HSPCs to S100A8/9 activates transcriptional 
signatures related to TLR signaling and cellular stress/apoptosis.  
Gene set NES P-val FDR 
q-val 
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BIOCARTA_TOLL_PATHWAY 1.60 0.014 0.404 
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KEGG_P53_SIGNALING_PATHWAY 1.78 0.001 0.217 
 
  
Table S6. Related to Figure 6. MDS patient characteristics at beginning of treatment and clinical 
outcome. Provided as an Excel file. All patients were treated with lenalidomide in the context of an 
ongoing prospective clinical trial (details in Experimental Procedures). Patients were studied of which 
sufficient bone marrow material was available for analysis. Survival data are calculated from date of study-
entry. aNot calculated, missing cytogenetics. Hb, hemoglobin. PLT, platelets. WBC, white blood cells. ANC, 
absolute neutrophil count. S100A8 and S100A9 expression is obtained by RNA-sequencing data. P-values 
were calculated by Mann-Whitney test. 
 
Patient ID WHO Cytogenetics IPSS LR-PSS 
score 
LR-PSS 
category 
Outcome 
S100 niche signature+         
MDS020 RCMD-RS 46,XX[20] 0.5 4 2 Death 
MDS267 RCMD 46,XY[20] 0.5 4 2 Death 
MDS486 RAEB-1 46,XX,t(3;3)(q21;q26)[10] 0.5 4 2 Death 
MDS610 RCMD-RS 46,XX[20] 0.5 3 2 Leukemia 
MDS314 Del(5q) 46,XX,del(5)(q13q33)[25]/46,XX[5] 0 2 1 Death 
MDS008 RCMD 46,XX[20] 0 4 2 Death 
Mean (SD)         
S100 niche signature-         
MDS247 RCMD-RS 46,XY[20] 0 3 2 Alive 
MDS006 RAEB-1 46,XX[20] 1 5 3 Death 
MDS118 RARS 46,XX[20] 0 1 1 Alive 
MDS159 Del(5q) 46,XX,del(5)(q15q33)[10] 0 3 2 Death 
MDS222 RARS 46,XX[21] 0 4 2 Alive 
MDS209 RCMD-RS 46,XX[10] 0 3 2 Death 
MDS025 RCMD-RS 46,XY[20] 0.5 3 2 Death 
MDS146 RARS 46,XY[20] 0.5 4 2 Alive 
MDS433 RCMD-RS 45,X,-Y[10]/46,XY[10] 0 2 1 Alive 
MDS646 RAEB-1 46,yy[20] 1 5 3 Death 
MDS893 RARS 46,XX[20] 0 3 2 Death 
MDS111 RCMD 46,XX[20] 0.5 3 2 Alive 
MDS623 RCMD 46,XY[20] 0.5 4 2 Alive 
MDS067 RCMD-RS not available 1 a a Alive 
Mean (SD)         
MW P-value         
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Table S6. Related to Figure 6. MDS patient characteristics at beginning of treatment and clinical 
outcome. Provided as an Excel file. (Continued) All patients were treated with lenalidomide in the context 
of an ongoing prospective clinical trial (details in Experimental Procedures). Patients were studied of which 
sufficient bone marrow material was available for analysis. Survival data are calculated from date of study-
entry. aNot calculated, missing cytogenetics. Hb, hemoglobin. PLT, platelets. WBC, white blood cells. ANC, 
absolute neutrophil count. S100A8 and S100A9 expression is obtained by RNA-sequencing data. P-values 
were calculated by Mann-Whitney test. 
 
Patient ID Age 
(y) 
Hb 
(mmol/l) 
PLT 
(x103/ul) 
WBC 
(x103/ul) 
ANC 
(/ul) 
Blasts (%) S100A8 
(FPKM) 
S100A9 
(FPKM) 
S100 niche signature+         
MDS020 72 8.1 69 5.5 76 1% 889 450 
MDS267 80 5.7 153 10.3 57 3% 724 293 
MDS486 66 5.3 530 12.4 65 1% 1016 436 
MDS610 65 5.9 249 4.2 27 3% 4853 1921 
MDS314 38 6.3 100 8.9 56 2% 2255 540 
MDS008 65 4.8 153 5.0 36 2% 2330 1029 
Mean (SD) 64 (14) 6.0 (1.1) 209 (169) 7.7 (3.3) 53 (18) 2% (0.9%) 2011 (1558) 778 (614) 
S100 niche signature-         
MDS247 62 4.0 587 4.0 56 0% 200 32 
MDS006 63 5.1 73 2.8 14 5% 277 186 
MDS118 56 4.3 391 3.8 39 0% 332 39 
MDS159 75 5.4 327 8.4 55 1% 398 154 
MDS222 66 5.0 185 15.7 70 2% 151 26 
MDS209 79 5.2 240 3.5 52 0% 314 105 
MDS025 85 5.4 264 2.6 50 1% 254 58 
MDS146 85 5.5 163 3.9 33 1% 0,6 0 
MDS433 58 4.8 248 4.5 56 1% 174 65 
MDS646 74 5.3 65 3.4 18 5% 158 80 
MDS893 85 6.0 501 5.3 59 1% 190 71 
MDS111 62 4.2 118 2.8 51 3% 116 34 
MDS623 73 5.8 74 7.6 83 2% 89 52 
MDS067 74 6.1 107 2.7 62 2% 361 333 
Mean (SD) 71 (10) 5.1 (0.6) 239 (163) 5.1 (3.5) 50 (19) 1.7%(1.6%) 215 (113) 88 (87) 
MW P-value 0.4556 0.1040 0.6459 0.0246 0.6011 0.665 <0.0001 <0.0001 
 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Mice genotyping and sample collection 
DNA was extracted from mouse toes with DirectPCR Lysis Reagent (Viagen Biotech). Genotyping 
and Cre-mediated recombination were verified on genomic DNA samples using the primers listed 
in the table below. Mouse bone marrow and bone fraction cells were isolated as previously 
described.1 Red blood cells (RBC) were lysed with ACK lysing buffer (Lonza) before surface markers 
staining. Peripheral blood was collected from the submandibular vein in K2EDTA-coated 
microtainers (BD) and analyzed using a Vet ABC counter (Scil Animal Care). 
 
Genotyping primers used in the study. 
Target Allele Primer ID Sequence Amplicon size 
(bp) 
Sbds Wild-type a CCAGGGTCACGTTAATACAAACC 329 
b TGAGTTTCAATCCTCAGCATCC 
Floxed a CCAGGGTCACGTTAATACAAACC 450 
b TGAGTTTCAATCCTCAGCATCC 
Recombined c TAAAACAAAGCTGCGGTCAAGA 319 
d ATCCTCAGCATCCCGAACAA 
Sp7 (Osx) Wild type e CTCTTCATGAGGAGGACCCT No band 
f GCCAGGCAGGTGCCTGGACAT 
Cre e CTCTTCATGAGGAGGACCCT 500 
f GCCAGGCAGGTGCCTGGACAT 
Trp53 Wild-type 10.1 GTTAAGGGGTATGAGGGACA 400 
10.2 GAAGACAGAAAAGGGGAGGG 
Floxed 10.1 GTTAAGGGGTATGAGGGACA 600 
10.2 GAAGACAGAAAAGGGGAGGG 
Recombined 1.1 CACAAAAACAGGTTAAACCCAG 612 
 
 
Bone mineral density and 3-point bending test analysis 
Cortical BMD was calculated from μCT cortical data on the basis of a calibration scanning obtained 
using two phantoms with known density (0.25 g/cm3 and 0.75 g/cm3; Bruker MicroCT) under 
identical conditions as for the femurs. For the bending test, femurs were placed in a custom-
modified Single Column Lloyd LRX System bending device (Lloyd Instruments) and analyzed as 
previously reported (van der Eerden et al., 2013) using CtAnalyzer software (Bruker MicroCT). 
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Table S6. Related to Figure 6. MDS patient characteristics at beginning of treatment and clinical 
outcome. Provided as an Excel file. (Continued) All patients were treated with lenalidomide in the context 
of an ongoing prospective clinical trial (details in Experimental Procedures). Patients were studied of which 
sufficient bone marrow material was available for analysis. Survival data are calculated from date of study-
entry. aNot calculated, missing cytogenetics. Hb, hemoglobin. PLT, platelets. WBC, white blood cells. ANC, 
absolute neutrophil count. S100A8 and S100A9 expression is obtained by RNA-sequencing data. P-values 
were calculated by Mann-Whitney test. 
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Mean (SD) 71 (10) 5.1 (0.6) 239 (163) 5.1 (3.5) 50 (19) 1.7%(1.6%) 215 (113) 88 (87) 
MW P-value 0.4556 0.1040 0.6459 0.0246 0.6011 0.665 <0.0001 <0.0001 
 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Mice genotyping and sample collection 
DNA was extracted from mouse toes with DirectPCR Lysis Reagent (Viagen Biotech). Genotyping 
and Cre-mediated recombination were verified on genomic DNA samples using the primers listed 
in the table below. Mouse bone marrow and bone fraction cells were isolated as previously 
described.1 Red blood cells (RBC) were lysed with ACK lysing buffer (Lonza) before surface markers 
staining. Peripheral blood was collected from the submandibular vein in K2EDTA-coated 
microtainers (BD) and analyzed using a Vet ABC counter (Scil Animal Care). 
 
Genotyping primers used in the study. 
Target Allele Primer ID Sequence Amplicon size 
(bp) 
Sbds Wild-type a CCAGGGTCACGTTAATACAAACC 329 
b TGAGTTTCAATCCTCAGCATCC 
Floxed a CCAGGGTCACGTTAATACAAACC 450 
b TGAGTTTCAATCCTCAGCATCC 
Recombined c TAAAACAAAGCTGCGGTCAAGA 319 
d ATCCTCAGCATCCCGAACAA 
Sp7 (Osx) Wild type e CTCTTCATGAGGAGGACCCT No band 
f GCCAGGCAGGTGCCTGGACAT 
Cre e CTCTTCATGAGGAGGACCCT 500 
f GCCAGGCAGGTGCCTGGACAT 
Trp53 Wild-type 10.1 GTTAAGGGGTATGAGGGACA 400 
10.2 GAAGACAGAAAAGGGGAGGG 
Floxed 10.1 GTTAAGGGGTATGAGGGACA 600 
10.2 GAAGACAGAAAAGGGGAGGG 
Recombined 1.1 CACAAAAACAGGTTAAACCCAG 612 
 
 
Bone mineral density and 3-point bending test analysis 
Cortical BMD was calculated from μCT cortical data on the basis of a calibration scanning obtained 
using two phantoms with known density (0.25 g/cm3 and 0.75 g/cm3; Bruker MicroCT) under 
identical conditions as for the femurs. For the bending test, femurs were placed in a custom-
modified Single Column Lloyd LRX System bending device (Lloyd Instruments) and analyzed as 
previously reported (van der Eerden et al., 2013) using CtAnalyzer software (Bruker MicroCT). 
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Goldner’s Masson trichrome staining 
Femurs were embedded in methylmetacrylate as indicated before.2 Sections of 6 μm were 
deacrylated, hydrated and stained accordingly to the previously described protocol.3 Images of 
the metaphysial area were captured with a Nikon Eclipse E400 system (Nikon) using a 20X 
objective lens. Data was analyzed using Image J software (http://imagej.nih.gov/ij/). Briefly, the 
bone surface was manually selected and the perimeter length calculated. Osteoblasts were 
manually identified based on staining and morphology. The frequency of osteoblasts was 
calculated as percentage of osteoblast area in the bone surface and as number of osteoblasts per 
mm of bone.  
 
CFU-F assay 
Primary bone fraction cells were resuspended in growth medium, consistent of αMEM, 20% FBS 
(Life Technologies), and Penicillin-Streptomycin solution (Life Technologies), and cultured under 
hypoxic conditions (5% O2, 5% CO2) in 24-well plates (seeding density: 6.5 x 104 cells/cm2). After 
24h, the medium was changed to eliminate non-adherent cells. Colonies were stained after 7 days 
of culture. Briefly, medium was removed and cells were fixed 5’ in methanol, stained in a 1:20 
dilution of Giemsa staining (Merck Millipore) in distilled water and rinsed with tap water. Colonies 
were counted with an Olympus CK2 inverted microscope, using a 10X magnification.  
 
Primary cell isolation and flow cytometry 
All FACS antibodies incubations were performed in PBS+0.5%FCS for 20 min on ice. To identify 
hematopoietic stem and progenitor cells (HSPCs), bone marrow cells were first co-stained with a 
cocktail of biotin-labelled antibodies against the following lineage (Lin) markers: Gr1 (RB6-8C5), 
Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), CD4 (GK1.5), CD8 (53-6.7) and B220 (RA3-
6B2) (all from BD Biosciences). After washing, cells were incubated with Pacific Orange-
conjugated streptavidin (Life Technologies) and the following antibodies: Pacific Blue anti-Sca1 
(D7), FITC or PE anti-CD48 (HM48-1), PE-Cy7 anti-CD150 (TC15-12F12.2) (all from Biolegend), APC 
anti-c-Kit (2B8, BD Biosciences).  
To analyze differentiated cells and define chimerism, we used FITC anti-Gr1 (RB6-8C5), APC anti-
Mac1 (M1/70), PE anti-B220 (RA3-6B2), APC-Cy7 anti-CD45.1 (A20), PE-Cy7 anti-CD45.2 (104), all 
from Biolegend. To identify stromal cells, bone fraction cell suspension was stained with the 
following antibodies: APC-Cy7 anti-CD45.2 (104), BV510 anti-Ter119 (TER-119), PE-Cy7 anti-
CD105 (MJ7/18) (all from Biolegend), PE-CF594 anti-CD31 (MEC 13.3, BD Biosciences).  
For human mesenchymal cell isolation, bone marrow aspirates were diluted 1:25 with red blood 
cell lysis solution (NH4Cl 0.155 M, KHCO3 0.01 M, EDTA-Na2.2H2O 0.1 M, pH 7.4) and incubated 
for 10 min at room temperature. Cells were collected by centrifugation and washed once with 
PBS+0.5%FBS. For FACS sorting, immunostaining was performed with the same protocol used for 
murine bone marrow, using PE CD271 (ME20.4) and PE-Cy7 CD45 (HI30) antibodies (Biolegend). 
CD271+ cells did not contain erythroid cells based on staining with BV421 CD235a (GA-R2, BD 
Biosciences). 
Apoptosis was assayed with FITC Annexin V Apoptosis Detection Kit I (BD Biosciences) according 
to the recommendation of the manufacturer. Dead cells were excluded based on 7AAD staining.  
The content of p53 in stromal cells was analyzed after cell surface antibody staining and cell 
permeabilization, obtained with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD 
Biosciences), by incubating cells with Alexa Fluor 647 anti-p53 (1C12) diluted in 1X Perm/Wash 
buffer (BD Biosciences).  
All FACS events were recorded using a BD LSR II Flow Cytometer and analyzed with FlowJo 7.6.5 
software (Tree Star). Cells were sorted with a BD FACSAria III. 
 
SBDS mutation analysis 
Mutations in SBDS were evaluated in the RNA sequencing data of SDS patients and healthy 
controls using the Integrative Genomics Viewer (IGV).4 The c.183_184TA>CT mutation was 
quantified by annotating the number of reads presenting each of the four different nucleotides 
for both the positions 183 and 184. Because of its intronic position, the c.258+2T>C mutation was 
assessed by quantifying the usage of the 251-252 cryptic donor site.5 Specifically, we quantified 
the fraction of spliced reads with an 8-bp deletion (nucleotides 251-258) as an indication of the 
mutated genotype. 
 
Mitochondrial membrane potential quantification 
After staining cells for surface antigens, cells were washed in PBS+0.5%FBS and centrifuged. Cells 
were resuspended in PBS+0.5%FBS  and tetramethylrhodamine methyl ester (TMRM, Life 
Technologies) was added from a 10 μM stock solution in DMSO to a final non-quenching 
concentration of 100 nM. After incubation for 20 min at 37°C, cells were washed with 
PBS+0.5%FBS  and analyzed. Cells treated with 1 μM p-trifluoromethoxy carbonyl cyanide phenyl 
hydrazone (FCCP) were used as positive control for membrane depolarization. 
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ROS detection 
After surface antigen staining, cells washed in PBS+0.5%FBS and centrifuged. A stock solution of 
2.5 μg/μl 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester (CM-
H2DCFDA, Life Technologies) in DMSO was diluted with PBS+0.5%FBS to a final concentration of 
3 μg/μl. Cells were resuspended with the CM-H2DCFDA solution and stained for 20 min at 37°C, 
washed in PBS+0.5%FBS and analyzed. 
 
Cell cycle analysis 
Mice labeled in vivo by BrdU were sacrificed and bone marrow cells were stained for surface 
antigen. BrdU staining was performed using the FITC BrdU Flow Kit (BD Biosciences) following the 
manufacturer’s instructions. 
For in vitro cell cycle analysis, cultured cells were first stained for surface markers and then fixed 
and permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD 
Biosciences). After washing, cells were incubated cells with FITC anti-Ki67 (B56, BD Biosciences) 
diluted in 1X Perm/Wash buffer (BD Biosciences) for 20 min and then washed. Cells were 
resuspended in PBS+0.5%FBS and 7AAD was added to detect DNA. 
 
Alkaline comet assay 
HSPCs were resuspended in 0.7% low melting agarose (Sigma-Aldrich) in PBS at a concentration 
of 105 cells/ml. 50 μl of cell suspension were spread on CometSlides (Trevigen) and the agarose 
was allowed to solidify for 30 min at 4°C. Slides were incubated for 1 h at 4°C in lysis buffer (1% 
Triton-X100 freshly added to 2.5M NaCl, 100 mM EDTA, 10 mM Tris/pH10 solution) protected 
from light and placed in an electrophoresis tray. After 20 min incubation in alkaline solution 
(200mM NaOH, 1mM EDTA, freshly prepared), unwound DNA was run in the same solution for 30 
min at 1 V/cm. After electrophoresis, slides were washed twice in distilled water for 5 min, fixated 
in 70% ethanol for 5 min and allowed to dry at 37°C. DNA was stained for 5 min in SYBR Gold (Life 
Technologies), washed in distilled water and allowed to dry in the dark. Images were captured 
with a Leica DMRXA fluorescent microscope (10X magnification). DNA damage severity was 
manually quantified according to the score system depicted in Figure S3D.  
 
 
Competitive transplantation  
Bone marrow cells from OCS and BL6.SJL mice were isolated and RBC-depleted as described 
above. BL6.SJL cells were mixed in a 1:1 ratio with cells from OCSf/+ of OCSf/f mice. 9 week-old 
B6.SJL mice were lethally irradiated (8.5Gy) and transplanted with a total of 106 bone marrow 
cells. Recipients received antibiotics in the drinking water for 2 weeks after transplantation. 
 
S100A8/9 measurements 
To quantify intracellular levels of S100A8/9 proteins, bone fraction cell suspensions were first 
stained for surface markers and next fixated and permeabilized with Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer’s 
instructions. Cells were then resuspended in 1X Perm/Wash buffer (BD Biosciences) and 
incubated for 20 min with polyclonal rabbit antibodies against mouse S100A8 or S100A9.6 After 
washing, cells were incubated for 20 min with Pacific Orange-labelled goat anti-rabbit secondary 
antibody (Life Technologies) diluted in 1X Perm/Wash buffer, washed and resuspended in 
PBS+0.5%FBS and analyzed by FACS. 
To analyze the concentration of S100A8/9 in the plasma, peripheral blood was collected in 
Microtainer PST tube (BD) and centrifuged to collect the plasma fraction. Samples were stored at  
-80°C until the moment of analysis. S100A8/9 was quantified by ELISA as previously described.6 
Immunohistochemical staining of low-risk MDS and age-matched controls (biopsies obtained for 
disease staging from lymphoma patients without evidence of intramedullary localization) were 
performed on 5 µm bone marrow sections, which were deparaffinized in xylene and hydrated in 
a graded series of alcohol. Antigen retrieval was achieved by microwave treatment in citrate 
buffer (10mM pH 6.0) and blocking of the endogenous peroxidases was performed with 3% H2O2 
in PBS. Sections were blocked using 10% normal human and goat serum (DAKO) in Teng-T solution 
followed by overnight incubation at 4°C with primary antibody anti-S100A8 and S100A96 diluted 
1:500, CD271 (Sigma Aldrich) diluted 1:200, or normal rabbit immunoglobulin (DAKO) diluted 
accordingly. Immunoreactions were detected using biotinylated secondary antibody (goat anti-
rabbit, 1:2000 dilution) with Vectastain ABC Elite Kit (Vector Laboratories) and 3,3’-
diaminobenzidine tetrahydrochloride (Sigma Aldrich). For all stainings, nuclei were 
counterstained with haematoxylin (Vector Laboratories). Images of the stained tissue were 
acquired using a Leica DM5500B upright microscope with 40x lenses and LAS-AF image acquisition 
software.  
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HSPCs in vitro culture, S100A8/A9 exposure and CFU-C assay 
LKS and Lin- c-Kit+ Sca-1- cells were sorted from wild type C57BL/6 mice and cultured in a serum-
free medium, with the following composition: X-Vivo 15 (Lonza), 1% detoxified BSA, 50 μM β-
mercaptoethanol (Life Technologies), 1:100 GlutaMAX™ Supplement (Life Technologies), 20 
ng/ml recombinant murine SCF (Peprotech), 100 ng/ml recombinant murine Flt3-Ligand 
(Peprotech), 1:100 penicillin-streptomycin mixture (Life Technologies). The medium was 
supplemented with recombinant murine S100A8/9, produced with the same methods described 
earlier,7 at a final, clinically relevant concentration of 25-50 μg/ml, in the range of concentrations 
measured in the bone marrow supernatants of MDS patients8. A heat-inactivated control was 
obtained by incubating S100A8/9 at 80°C for 30 min; the protein was cooled-down and next 
added to the HSPC medium with the same concentration and volume as S100A8/9. LKS and Lin- 
c-Kit+ Sca-1- cells were cultured in 96-well plates at a cell density of 2.5x104 cells/well. 
For human studies, cryopreserved CD34+ cells were used, which were isolated from cord blood 
obtained under informed consent by Ficoll gradient and MACS separation (Miltenyi Biotec). 
Thawed cells were resuspended in StemSpan SFEM II (STEMCELL Technologies) and recombinant 
human S100A8/9 was added (R&D systems) at a final concentration of 50 μg/ml. For the control 
medium, an equal volume of vehicle (PBS) was added. Cells were seeded in flat bottom 96 well-
plates (5x104 cells/well). 
For both mouse and human studies, cells were harvested at 4h for γH2AX and cell cycle studies 
and at 24 h for apoptosis assay. 
To assess the effect of S100A9 on HSPC function, CD34+ cord blood cells were resuspended in 
SFEM1 medium (Stemcell Technologies) containing SCF (50 ng/ml) and human recombinant 
S100A9 (2.5 μg/ml,ProSpec) or PBS control and seeded in 96-well plates (2x104 cells/well). After 
one week of preconditioning (37ºC, 5% CO2), cells were pooled. 2,000 cells per condition were 
resuspended in 400 µl IMDM and transferred to 3.6 ml of MethoCult H84434 (Stemcell 
Technologies). Cells were plated in triplicate on 1 cm² petri-dishes (1 ml/dish) and incubated at 
37ºC/5% CO2. Colonies were counted after 12-14 days. 
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ABSTRACT  
Myelodysplastic syndromes (MDS) have long been considered hematopoietic cell-autonomous 
disorders in which disease initiation and progression is exclusively driven by hematopoietic cell 
intrinsic genetic events. Recent experimental findings have challenged this view, implicating 
mesenchymal elements in the bone marrow microenvironment in disease pathogenesis. 
Translation of experimental findings to human disease is complicated by a lack of insight in the 
molecular wiring of primary, non-expanded, mesenchymal cells in MDS. Here, we describe 
massive parallel sequencing of prospectively isolated mesenchymal elements from human low-
risk MDS, revealing a common molecular signature, characterized by cellular stress, activation of 
the NF-κB inflammatory pathway and upregulation of senescence associated secreted factors, 
including known negative regulators of hematopoiesis. The data comprise, to our knowledge, the 
first comprehensive transcriptional network analysis of primary mesenchymal elements in a 
hematopoietic disorder. They provide human disease relevance to earlier findings in mouse 
models, implicating the mesenchyme in disease pathogenesis and stressing the relevance of 
considering the tissue context in understanding hematopoietic disease. 
  
INTRODUCTION 
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic disorders 
characterized by ineffective hematopoiesis and predisposition to leukemic transformation. 
Profiling of transcriptional, genetic and epigenetic events in hematopoietic cells has contributed 
markedly to the understanding and prognostication of these diseases, but their pathogenesis 
remains incompletely understood. The inability to faithfully recapitulate and propagate disease 
in xenograft models, as well as longstanding observations of abnormalities in ex vivo expanded 
bone marrow derived mesenchymal cells, have sparked a continuing debate about a potential 
facilitating role of accessory elements in disease pathogenesis.1 This notion has been 
substantiated by experimental support, providing proof of principle that components of the 
hematopoietic stem and progenitor cell (HSPC) niche have the ability to initiate and facilitate 
disease progression in mice.2-4 Specifically, genetic perturbation of mesenchymal bone lineage 
cells has the ability to induce MDS and AML, establishing an experimental concept of ‘niche-
induced’ oncogenesis.3,4 Alternatively, primary alterations in hematopoietic cells have the ability 
to alter mesenchymal niche components such that niche cells facilitate disease propagation in the 
context of xenograft transplantation.5 
Together, these observations challenge the view that ineffective hematopoiesis and leukemic 
progression is exclusively driven by hematopoietic cell-autonomous events in human MDS. 
Translating experimental concepts to human disease, however, critically depends on our ability 
to interrogate primary mesenchymal elements from the diseased marrow, which has hitherto not 
been performed. Molecular insights from mesenchymal cells in MDS have largely been derived 
from small-scale gene expression assessments in ex vivo expanded, plastic adherent 
mesenchymal cells with uncertain significance to in vivo hematopoiesis. Here, we describe 
massive parallel whole transcriptome sequencing of prospectively isolated primary mesenchymal 
elements from low-risk MDS. The data reveal a defining molecular signature of NF-κB-mediated 
inflammation, senescence and upregulation of known negative regulators of hematopoiesis, 
establishing human relevance to concepts and mechanisms proposed in mouse studies. 
 
 
MATERIALS AND METHODS 
Patient characteristics (median age: 65, range: 38-80) are shown in supplemental Table 1. Bone 
marrow was collected at diagnosis and control marrow was obtained from donors for allogeneic 
transplantation (median age: 45, range: 35-61), after written informed consent. The use of human 
samples was approved by the Institutional Review Board of Erasmus Medical Center, the 
Netherlands, in accordance with the declaration of Helsinki. 
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FACS data were acquired on FACSAria III systems (BDBioscience) and analyzed by FlowJo software 
(version 7). Gating strategy and antibodies used are described in the supplemental Methods. Cells 
were directly sorted in TRIzol (Ambion). Smarter Ultra Low RNA kit for Illumina Sequencing 
(Clonetech) was used for cDNA synthesis according to the manufacturer’s protocol. Sample 
preparation, sequencing, demultiplexing and alignment were performed as previously described 
with modifications specific to the application of Smarter kit (Supplemental Methods).6 
Immunohistochemistry was performed as previously described (Supplemental Methods).7  
 
RESULTS AND DISCUSSION 
Mesenchymal cells were prospectively FACS-isolated from bone marrow aspirates of low-risk 
MDS patients at diagnosis (n = 12, Table S1) and normal controls (n = 10) using previously 
established markers of primary bone marrow mesenchymal cells8 (Figure 1A). The frequency of 
CD45- 7AAD- CD235a- CD31- CD271+ CD105+ mesenchymal cells in MDS was not significantly 
different from normal bone marrow (Figure 1B) (0.019% ± 0.0086% of mononuclear cells (MNCs) 
vs. 0.022% ± 0.0066%, P = 0.819 by unpaired student t-test), and these cells comprised a small 
subset of CD45- 7AAD- CD235a- ‘niche’ cells (10.41% ± 4.086% vs. 12.30% ± 5.052, P = 0.771) with 
the major constituent being CD31+ endothelial cells (43.80% ± 7.243% vs. 38.28% ± 9.424%, P = 
0.816). Together, the data indicate that the cellular composition of the niche remains relatively 
intact in low-risk MDS in this particular experimental context. The mesenchymal nature of CD45- 
7AAD-CD235a- CD31- CD271+ CD105+ cells was confirmed molecularly by whole transcriptome 
analysis demonstrating significant abundance of transcripts encoding the defining membrane 
proteins (Figure 1C), established markers of mesenchymal stem cells (Figure 1D)8,9, essential 
‘niche’ factors governing the behavior of HSPCs (Figure 1E) and osteolineage markers (Figure 1F) 
compared to endothelial cells. Together, the data indicate the feasibility of prospective isolation 
and molecular characterization of highly purified primary mesenchymal elements in MDS using 
massive parallel sequencing.  
 
Figure 1. Prospective isolation and molecular characterization of mesenchymal cells in low-risk MDS. (A) 
Flow cytometry approach to identify and isolate 7AAD- CD45- CD235a- CD271+ CD105+ mesenchymal cells. 
(B) Frequency of mesenchymal cells in normal and MDS samples. (C-F) Transcriptional validation of the 
mesenchymal nature of 7AAD- CD45- CD235a- CD271+ CD105+ cells, showing differential  expression in 
comparison to endothelial subsets of (C) defining cell surface markers (CD271, CD105, CD31), (D) known 
mesenchymal markers (CD73, CD90, CD146), (E) established hematopoiesis-supporting cytokines (CXCL12, 
ANGPT1, KitL) and (F) bone lineage markers (BGLAP, RUNX2, SPP1 and ALPL). FPKM: fragments per kilobase 
of exon per million fragments mapped. Figure C to figure F: Normal samples (n = 10); MDS samples (n = 
12). Black bar: CD271+ mesenchymal cells; white bar: CD31+ endothelial cells. *FDR < 0.05; **FDR < 0.01; 
***FDR < 0.001. 
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Principle component analysis (PCA) of transcriptomes demonstrated uniform clustering of normal 
mesenchymal cells, indicating transcriptional homogeneity (Figure 2A). Strikingly, distinct and 
more heterogeneous clustering of mesenchymal transcriptomes was found in low-risk MDS 
revealing that these cells are transcriptionally distinct from their normal counterparts. Distinct 
clustering remained present in an age-matched cohort (Figure S1), excluding the potential effect 
of age differences. Gene set enrichment analysis (GSEA) was then performed to define the 
molecular networks underlying the distinct transcriptional landscape in low-risk MDS. Gene sets 
associated with cellular stress induced by UV and ionizing radiation were remarkably enriched in 
low-risk MDS (Figure 2B; Table S2).  
Cell cycle progression and metabolic signatures were significantly downregulated (Table S2), 
compatible with the view that these cells suffer from cellular stress, metabolic reprogramming, 
and may activate senescence programs. This notion is further supported by strong enrichment of 
transcriptional signatures of p53 activation and upregulation of several classic senescence-
associated genes, including CDKN1A (p21) and CDKN2D (p19) (Figure S2). 
Investigating potential pathways driving cellular stress, we found significant enrichment of 
inflammatory signatures (Figure 2C), in particular activation of the nuclear factor NF-κB family of 
transcription factors in low-risk MDS (Figure 2C-D; Table S3). Congruent with this finding, 
increased phosphorylation of p65, a component of the activated NF-κB complex, was found in 
bone-lining stromal cells, which were shown to be predominantly CD271+ (Figure S3). 
Importantly, NF-κB activation in non-hematopoietic cells has been shown to induce ‘MDS-like’ 
disease in mice through upregulation of the Notch ligand Jagged-12.  Jagged-1, which drives 
hematopoietic abnormalities in another niche-induced mouse model of myeloid neoplasia,4 was 
significantly overexpressed in mesenchymal cells from low-risk MDS (Figure 2E), thus directly 
relating mouse modeling to human disease. 
Activation of NF-κB has recently been identified as a major driver of cellular senescence10 and the 
senescence-associated secretory phenotype (SASP),11,12 implicated in alteration of the tumor 
microenvironment and progression of (pre)malignant phenotypes.13,14 Transcript abundance 
analysis revealed significant upregulation of numerous SASP factors (Table S4), such as the 
canonical IL-6 and IL-8 cytokines and a large number of other secreted factors including a wide 
variety of factors previously demonstrated to be negative regulators of hematopoiesis, in 
particular erythropoiesis and B-lymphopoiesis, cell lineages that are typically affected in low-risk 
MDS (Table S5 and references herein). 
The finding of NF-κB activation in mesenchymal cells complements recent findings implicating 
activation of the NF-κB pathway in CD34+ cells in the pathogenesis of low-risk MDS.15 The 
combined findings suggest that in low-risk MDS, activation of NF-κB occurs in both hematopoietic 
  
Figure 2. Mesenchymal cells in low-risk MDS display a distinct molecular signature characterized by 
cellular stress and NF-κB-mediated inflammation. (A) PCA based on the entire transcriptome of normal 
and low-risk MDS mesenchymal cells. Patient numbers in the figure refer to MDS patient IDs (supplemental 
Table 1). (B) Representative GSEA plot demonstrating cellular stress in response to UV in low-risk MDS 
mesenchymal cells. (C) Summary of gene sets indicating inflammatory response and NF-κB activation in 
low-risk MDS mesenchymal cells. (D) Example of GSEA plot revealing activation of NF-κB signaling in the 
mesenchymal cells from low-risk MDS. (E) Expression level of JAG1 (FPKM) in normal and low-risk MDS 
mesenchymal cells. Size: Data set gene size. NES: normalized enrichment score. FDR: false discovery rate. 
***FDR < 0.001 
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and mesenchymal cells, likely through autocrine and paracrine feedback signaling networks, 
leading to overexpression of a repertoire of secreted negative hematopoietic regulators (Figure 
S4). Of interest, NF-κB mediated chronic tissue inflammation drives cancer initiation and 
progression in other systems,16 warranting ongoing experiments defining the contribution of NF-
κB activation to ineffective hematopoiesis and leukemic evolution in MDS.  
Taken together, the data reveal a distinct transcriptional network of NF-κB activation-related 
inflammation and senescence characterizing the mesenchyme in low-risk MDS, translating 
findings in mouse models to human disease. The data comprises, to our knowledge, the first 
whole transcriptome analysis of highly purified, prospectively isolated, primary mesenchymal 
cells in a hematopoietic disorder, stressing its relevance in generating a comprehensive 
understanding of disease, considering the tissue context in addition to molecular and genetic 
events in hematopoietic cells. The findings further open the perspective that mesenchymal 
factors, in addition to hematopoietic cell autonomous characteristics, may be therapeutically 
targeted in low risk MDS. 
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SUPPLEMENTAL METHODS 
Flow Cytometry Procedure and Cell Sorting 
Bone marrow cells from patients and normal donors were stained on ice in dark with the following 
antibodies using optimized dilutions: CD45-PE-Cy7 (1:200), CD235a-BV421-A (1:100), CD271-PE 
(1:100), CD105-APC (1:50), CD31-APC-Cy7 (1:50). The indicated populations of interest were 
sorted using FACS ARIAIII Cell Sorter (BD) and the cells were directly sorted in Trizol (Ambion) (800 
µl) for RNA isolation step. The RNAse-free non-stick Eppendorf tubes (Ambion) were used to 
prevent pre-digestion of RNA. Dead cells were gated out using 7AAD (Stem-Kit Reagents) after 
mononuclear cell selection and doublets exclusion. 
 
RNA Extraction and RNA Quality Control 
Total sample RNA isolation was performed according to the standard protocol of RNA isolation 
with Trizol and GenElute LPA (Sigma). Next, the RNA pellet was resuspended in 7.5 µl RNAse free 
water (Qiagen) and 1.2 µl was taken to check the quality and quantity of the total RNA with 2100 
Bio-analyzer (Agilent) using the Agilent RNA 6000 Pico Kit. Samples were selected based on the 
quality of total RNA using Bio-analyzer RNA Integrity Number of 4 as cut-off. The whole procedure 
was performed in an RNAse free environment.  
 
RNA Sequencing and Gene Expression Profiling  
SMARTer Ultra Low RNA Kit (Clontech) for Illumina Sequencing was used to prepare the cDNA 
library. Before starting the library preparation, specific dilution of total RNA from each sample 
was carried out to ensure a comparable amount of starting material. cDNA library preparation 
steps were performed according to the user manual in a PCR-clean room to avoid contamination. 
The Agilent 2100 Bio-analyzer and the High Sensitivity DNA kit were applied to check the quality 
of the cDNA library. Once the cDNA libraries were obtained, the subsequent sample preparation 
steps, sequencing and alignments were performed as previously described.1 Prior to sequence 
alignment, the SMARTer adapters were trimmed using the cutadapt program.2 The resulting 
sequences were aligned to the human RefSeq transcriptome using TopHat2.3 Sequences that 
could not be aligned to the RefSeq transcriptome were aligned to the reference genome (hg19). 
Normalization and quantification was performed using Cufflinks.4 The resulting gene expression 
values are measured as FPKM. Differential expression analysis was performed on the fragment 
counts using the DESeq25 package in the R environment and the FDR multiple testing correction 
was applied. The required per-gene fragment counts were measured using the htseq-count 
program using the strict intersection option. Principle component analysis was also performed on 
the fragment counts using the R environment. For all of the mentioned analysis, the RefSeq gene 
database was used. Finally we also performed GSEA on the gene expression values using the 
curated C2 collection of MSigDB.6 
 
Immunohistochemistry  
Immunohistochemical staining of low-risk MDS and age-matched controls were performed on 5 
µm bone marrow sections, which were deparaffinized in xylene and hydrated in a graded series 
of alcohol. Antigen retrieval was achieved by microwave treatment in citrate buffer (10mM PH 
6.0) and blocking of the endogenous peroxidases was performed with 3% H2O2 in PBS. Sections 
were blocked using 10% normal human and goat serum (DAKO) in Teng-T solution followed by 
overnight incubation at 4°C with primary antibody: serine 276 phosphorylated p65 (p-p65, active 
form; Santa Cruze Biotechonology) diluted 1:400, CD271 (Sigma Aldrich) diluted 1:200, or normal 
rabbit immunoglobulin (DAKO) diluted accordingly. Immunoreactions were detected using 
biotinylated secondary antibody (goat anti-rabbit, 1:2000 dilution) with Vectastain ABC Elite Kit 
(Vector Laboratories) and 3,3’-diaminobenzidine tetrahydrochloride (Sigma Aldrich). In all 
stainings, nuclei were counterstained with haematoxylin (Vector Laboratories). Images of the 
stained tissue were acquired using a Leica DM5500B upright microscope with 40x lenses and LAS-
AF image acquisition software. The number of phospho-p65+ bone lining cells were manually 
quantitated using ImageJ software on x40 photomicrographs of blindly selected trabecular bone 
area. Unpaired t-test was performed and P < 0.05 was used to define significance.  
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SUPPLEMENTAL METHODS 
Flow Cytometry Procedure and Cell Sorting 
Bone marrow cells from patients and normal donors were stained on ice in dark with the following 
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(1:100), CD105-APC (1:50), CD31-APC-Cy7 (1:50). The indicated populations of interest were 
sorted using FACS ARIAIII Cell Sorter (BD) and the cells were directly sorted in Trizol (Ambion) (800 
µl) for RNA isolation step. The RNAse-free non-stick Eppendorf tubes (Ambion) were used to 
prevent pre-digestion of RNA. Dead cells were gated out using 7AAD (Stem-Kit Reagents) after 
mononuclear cell selection and doublets exclusion. 
 
RNA Extraction and RNA Quality Control 
Total sample RNA isolation was performed according to the standard protocol of RNA isolation 
with Trizol and GenElute LPA (Sigma). Next, the RNA pellet was resuspended in 7.5 µl RNAse free 
water (Qiagen) and 1.2 µl was taken to check the quality and quantity of the total RNA with 2100 
Bio-analyzer (Agilent) using the Agilent RNA 6000 Pico Kit. Samples were selected based on the 
quality of total RNA using Bio-analyzer RNA Integrity Number of 4 as cut-off. The whole procedure 
was performed in an RNAse free environment.  
 
RNA Sequencing and Gene Expression Profiling  
SMARTer Ultra Low RNA Kit (Clontech) for Illumina Sequencing was used to prepare the cDNA 
library. Before starting the library preparation, specific dilution of total RNA from each sample 
was carried out to ensure a comparable amount of starting material. cDNA library preparation 
steps were performed according to the user manual in a PCR-clean room to avoid contamination. 
The Agilent 2100 Bio-analyzer and the High Sensitivity DNA kit were applied to check the quality 
of the cDNA library. Once the cDNA libraries were obtained, the subsequent sample preparation 
steps, sequencing and alignments were performed as previously described.1 Prior to sequence 
alignment, the SMARTer adapters were trimmed using the cutadapt program.2 The resulting 
sequences were aligned to the human RefSeq transcriptome using TopHat2.3 Sequences that 
could not be aligned to the RefSeq transcriptome were aligned to the reference genome (hg19). 
Normalization and quantification was performed using Cufflinks.4 The resulting gene expression 
values are measured as FPKM. Differential expression analysis was performed on the fragment 
counts using the DESeq25 package in the R environment and the FDR multiple testing correction 
was applied. The required per-gene fragment counts were measured using the htseq-count 
program using the strict intersection option. Principle component analysis was also performed on 
the fragment counts using the R environment. For all of the mentioned analysis, the RefSeq gene 
database was used. Finally we also performed GSEA on the gene expression values using the 
curated C2 collection of MSigDB.6 
 
Immunohistochemistry  
Immunohistochemical staining of low-risk MDS and age-matched controls were performed on 5 
µm bone marrow sections, which were deparaffinized in xylene and hydrated in a graded series 
of alcohol. Antigen retrieval was achieved by microwave treatment in citrate buffer (10mM PH 
6.0) and blocking of the endogenous peroxidases was performed with 3% H2O2 in PBS. Sections 
were blocked using 10% normal human and goat serum (DAKO) in Teng-T solution followed by 
overnight incubation at 4°C with primary antibody: serine 276 phosphorylated p65 (p-p65, active 
form; Santa Cruze Biotechonology) diluted 1:400, CD271 (Sigma Aldrich) diluted 1:200, or normal 
rabbit immunoglobulin (DAKO) diluted accordingly. Immunoreactions were detected using 
biotinylated secondary antibody (goat anti-rabbit, 1:2000 dilution) with Vectastain ABC Elite Kit 
(Vector Laboratories) and 3,3’-diaminobenzidine tetrahydrochloride (Sigma Aldrich). In all 
stainings, nuclei were counterstained with haematoxylin (Vector Laboratories). Images of the 
stained tissue were acquired using a Leica DM5500B upright microscope with 40x lenses and LAS-
AF image acquisition software. The number of phospho-p65+ bone lining cells were manually 
quantitated using ImageJ software on x40 photomicrographs of blindly selected trabecular bone 
area. Unpaired t-test was performed and P < 0.05 was used to define significance.  
 
  
132
Chapter 4
C
ha
pt
er
 4
SUPPLEMENTAL TABLES 
Table S1. Patient Characteristics 
Patient ID Age WHO Cytogenetics BM blasts IPSS 
MDS01 62 RCMD-RS 46, XY[20] 0% 0 
MDS02 63 RAEB-1 46, XX[20] 5% 1 
MDS03 72 RCMD-RS 46, XX[20] 1% 0.5 
MDS04 75 Del(5q) 46, XX, del(5)(q15q33)[10] 1% 0 
MDS05 79 RCMD-RS 46, XX[10] 0% 0 
MDS06 66 RARS 46, XX[21] 2% 0 
MDS07 56 RARS 46, XX[20] 0% 0 
MDS08 80 RCMD 46, XY[20] 3% 0.5 
MDS09 65 RCMD-RS 46, XX[20] 3% 0.5 
MDS10 58 RCMD-RS 46, X, -Y[10]/46, XY[10] 1% 0 
MDS11 38 Del(5q) 46, XX, del(5)(q13q33)[25]/46, XX[5] 2% 0 
MDS12 65 RCMD 46, XX[20] 2% 0 
The patient ID, age, WHO category (MDS WHO classification 2008), cytogenetic abnormalities, level of 
bone marrow blasts and the international prognostic scoring system (IPSS) of each patient are listed above 
(n = 12). BM blasts: bone marrow blasts. 
 
  
Table S2. Transcriptional signatures reflecting cellular stress in mesenchymal cells from low-risk MDS 
patients 
Data Set Enrichment Size NES NOM 
p-val 
FDR 
q-val 
DNA Damage and Stress Response      
GHANDHI_DIRECT_IRRADIATION_UP MDS 106 2.40 <0.001 0.064 
GHANDHI_BYSTANDER_IRRADIATION_UP MDS 83 2.30 <0.001 0.001 
DAZARD_UV_RESPONSE_CLUSTER_G24 MDS 26 2.26 <0.001 0.001 
DAZARD_UV_RESPONSE_CLUSTER_G4 MDS 21 2.08 <0.001 0.006 
DAZARD_UV_RESPONSE_CLUSTER_G28 MDS 20 2.44 <0.001 0.004 
RASHI_RESPONSE_TO_IONIZING_RADIATION_1 MDS 45 1.68 <0.001 0.040 
RASHI_RESPONSE_TO_IONIZING_RADIATION_2 MDS 127 2.42 <0.001 0.006 
GENTILE_UV_LOW_DOSE_UP MDS 27 2.68 <0.001 <0.001 
GENTILE_UV_HIGH_DOSE_UP MDS 25 2.26 <0.001 0.001 
SESTO_RESPONSE_TO_UV_C3 MDS 20 2.13 <0.001 0.004 
SESTO_RESPONSE_TO_UV_C1 MDS 72 1.95 <0.001 0.011 
SESTO_RESPONSE_TO_UV_C5 MDS 46 1.79 <0.001 0.026 
SESTO_RESPONSE_TO_UV_C0  MDS 107 1.42 <0.001 0.126 
SMIRNOV_RESPONSE_TO_IR_2HR_UP MDS 50 2.62 <0.001 0.049 
SMIRNOV_RESPONSE_TO_IR_6HR_UP MDS 163 1.65 <0.001 <0.001 
MURAKAMI_UV_RESPONSE_6HR_UP MDS 37 1.35 0.09 0.159 
TSAI_RESPONSE_TO_RADIATION_THERAPY MDS 32 2.25 <0.001 0.002 
TSAI_RESPONSE_TO_IONIZING_RADIATION MDS 149 1.81 <0.001 0.024 
Cell Cycle and DNA Replication      
KEGG_DNA_REPLICATION Normal 36 -1.67 <0.001 0.030 
REACTOME_G2_M_CHECKPOINTS Normal 41 -1.68 0.001 0.035 
REACTOME_M_G1_TRANSITION Normal 78 -1.67 <0.001 0.041 
REACTOME_MITOTIC_M_M_G1_PHASES Normal 169 -1.63 <0.001 0.057 
REACTOME_DNA_REPLICATION Normal 189 -1.63 <0.001 0.060 
REACTOME_CELL_CYCLE_CHECKPOINTS Normal 112 -1.60 0.002 0.075 
REACTOME_REGULATION_OF_MITOTIC_CELL_ 
CYCLE 
Normal 77 -1.58 <0.001 0.096 
REACTOME_CELL_CYCLE_MITOTIC Normal 312 -1.50 <0.001 0.177 
REACTOME_S_PHASE Normal 106 -1.50 0.005 0.178 
REACTOME_G1_S_TRANSITION Normal 107 -1.48 0.005 0.203 
 
The size of each individual gene set, normalized enrichment score (NES), nominal p-value (NOM p-val) and 
false discovery rate (FDR q-val) values are as listed. 
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SUPPLEMENTAL TABLES 
Table S1. Patient Characteristics 
Patient ID Age WHO Cytogenetics BM blasts IPSS 
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MDS02 63 RAEB-1 46, XX[20] 5% 1 
MDS03 72 RCMD-RS 46, XX[20] 1% 0.5 
MDS04 75 Del(5q) 46, XX, del(5)(q15q33)[10] 1% 0 
MDS05 79 RCMD-RS 46, XX[10] 0% 0 
MDS06 66 RARS 46, XX[21] 2% 0 
MDS07 56 RARS 46, XX[20] 0% 0 
MDS08 80 RCMD 46, XY[20] 3% 0.5 
MDS09 65 RCMD-RS 46, XX[20] 3% 0.5 
MDS10 58 RCMD-RS 46, X, -Y[10]/46, XY[10] 1% 0 
MDS11 38 Del(5q) 46, XX, del(5)(q13q33)[25]/46, XX[5] 2% 0 
MDS12 65 RCMD 46, XX[20] 2% 0 
The patient ID, age, WHO category (MDS WHO classification 2008), cytogenetic abnormalities, level of 
bone marrow blasts and the international prognostic scoring system (IPSS) of each patient are listed above 
(n = 12). BM blasts: bone marrow blasts. 
 
  
Table S2. Transcriptional signatures reflecting cellular stress in mesenchymal cells from low-risk MDS 
patients 
Data Set Enrichment Size NES NOM 
p-val 
FDR 
q-val 
DNA Damage and Stress Response      
GHANDHI_DIRECT_IRRADIATION_UP MDS 106 2.40 <0.001 0.064 
GHANDHI_BYSTANDER_IRRADIATION_UP MDS 83 2.30 <0.001 0.001 
DAZARD_UV_RESPONSE_CLUSTER_G24 MDS 26 2.26 <0.001 0.001 
DAZARD_UV_RESPONSE_CLUSTER_G4 MDS 21 2.08 <0.001 0.006 
DAZARD_UV_RESPONSE_CLUSTER_G28 MDS 20 2.44 <0.001 0.004 
RASHI_RESPONSE_TO_IONIZING_RADIATION_1 MDS 45 1.68 <0.001 0.040 
RASHI_RESPONSE_TO_IONIZING_RADIATION_2 MDS 127 2.42 <0.001 0.006 
GENTILE_UV_LOW_DOSE_UP MDS 27 2.68 <0.001 <0.001 
GENTILE_UV_HIGH_DOSE_UP MDS 25 2.26 <0.001 0.001 
SESTO_RESPONSE_TO_UV_C3 MDS 20 2.13 <0.001 0.004 
SESTO_RESPONSE_TO_UV_C1 MDS 72 1.95 <0.001 0.011 
SESTO_RESPONSE_TO_UV_C5 MDS 46 1.79 <0.001 0.026 
SESTO_RESPONSE_TO_UV_C0  MDS 107 1.42 <0.001 0.126 
SMIRNOV_RESPONSE_TO_IR_2HR_UP MDS 50 2.62 <0.001 0.049 
SMIRNOV_RESPONSE_TO_IR_6HR_UP MDS 163 1.65 <0.001 <0.001 
MURAKAMI_UV_RESPONSE_6HR_UP MDS 37 1.35 0.09 0.159 
TSAI_RESPONSE_TO_RADIATION_THERAPY MDS 32 2.25 <0.001 0.002 
TSAI_RESPONSE_TO_IONIZING_RADIATION MDS 149 1.81 <0.001 0.024 
Cell Cycle and DNA Replication      
KEGG_DNA_REPLICATION Normal 36 -1.67 <0.001 0.030 
REACTOME_G2_M_CHECKPOINTS Normal 41 -1.68 0.001 0.035 
REACTOME_M_G1_TRANSITION Normal 78 -1.67 <0.001 0.041 
REACTOME_MITOTIC_M_M_G1_PHASES Normal 169 -1.63 <0.001 0.057 
REACTOME_DNA_REPLICATION Normal 189 -1.63 <0.001 0.060 
REACTOME_CELL_CYCLE_CHECKPOINTS Normal 112 -1.60 0.002 0.075 
REACTOME_REGULATION_OF_MITOTIC_CELL_ 
CYCLE 
Normal 77 -1.58 <0.001 0.096 
REACTOME_CELL_CYCLE_MITOTIC Normal 312 -1.50 <0.001 0.177 
REACTOME_S_PHASE Normal 106 -1.50 0.005 0.178 
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The size of each individual gene set, normalized enrichment score (NES), nominal p-value (NOM p-val) and 
false discovery rate (FDR q-val) values are as listed. 
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Table S2. Transcriptional signatures reflecting cellular stress in mesenchymal cells from low-risk MDS 
patients (Continued) 
Data Set Enrichment Size NES NOM 
p-val 
FDR 
q-val 
Metabolic Activities      
KEGG_PROPANOATE_METABOLISM Normal 32 -1.52 0.011 0.152 
KEGG_CITRATE_CYCLE_TCA_CYCLE Normal 30 -1.52 0.029 0.155 
KEGG_PYRIMIDINE_METABOLISM Normal 97 -1.50 0.001 0.179 
KEGG_FATTY_ACID_METABOLISM Normal 42 -1.88 <0.001 0.002 
KEGG_TRYPTOPHAN_METABOLISM Normal 40 -1.70 0.001 0.030 
KEGG_BUTANOATE_METABOLISM Normal 34 -1.70 0.001 0.031 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE Normal 20 -1.59 0.010 0.082 
REACTOME_SULFUR_AMINO_ACID_METABOLISM Normal 24 -1.56 0.020 0.110 
The size of each individual gene set, normalized enrichment score (NES), nominal p-value (NOM p-val) and 
false discovery rate (FDR q-val) values are as listed. 
  
Table S3. Differential expression of bona fide downstream targets of NF-κB signaling in low-risk MDS 
mesenchymal cells 
NF-κB target gene Signature Fold-change FDR/Pa 
CXCL3 GSEA-Derived NF-κB Targets7-12 6.21 0.026 
CXCL10 GSEA-Derived NF-κB Targets7-12 4.00 0.034 
CCL5 GSEA-Derived NF-κB Targets7-12 2.71 0.036 
CD83 GSEA-Derived NF-κB Targets7-12 4.27 0.034 
CEACAM6 GSEA-Derived NF-κB Targets7-12 -2.48 0.024* 
DUSP6 GSEA-Derived NF-κB Targets7-12 2.58 <0.001 
DAPK1 GSEA-Derived NF-κB Targets7-12 -1.78 0.016* 
FN1 GSEA-Derived NF-κB Targets7-12 2.00 0.037 
GADD45A GSEA-Derived NF-κB Targets7-12 1.80 0.010 
IER3 GSEA-Derived NF-κB Targets7-12 3.60 0.020 
IL8 GSEA-Derived NF-κB Targets7-12 7.24 <0.001 
IL6 GSEA-Derived NF-κB Targets7-12 5.09 0.005 
LITAF GSEA-Derived NF-κB Targets7-12 407 <0.001 
MAP3K8 GSEA-Derived NF-κB Targets7-12 2.18 0.001 
NFKBIA GSEA-Derived NF-κB Targets7-12 4.47 <0.001 
NFKBIE GSEA-Derived NF-κB Targets7-12 2.88 0.036 
PLK2 GSEA-Derived NF-κB Targets7-12 2.16 0.020 
SERPINB1 GSEA-Derived NF-κB Targets7-12 2.75 0.006 
SOD2 GSEA-Derived NF-κB Targets7-12 3.18 0.002 
VEGFA GSEA-Derived NF-κB Targets7-12 2.67 <0.001 
VIM GSEA-Derived NF-κB Targets7-12 -1.93 0.028 
BCL2L11 Online Database13 2.90 0.034 
BMP2 Online Database13 4.83 0.017 
BCL3 Online Database13 2.35 0.026 
CD44 Online Database13 3.90 0.002 
CCL3 Online Database13 4.21 0.022 
CXCL9 Online Database13 6.73 0.023 
CD69 Online Database13 6.26 0.023 
EMR1 Online Database13 6.06 0.006* 
FTH1 Online Database13 2.02 0.015 
HIF1A Online Database13 4.54 <0.001 
IER2 Online Database13 3.60 0.020 
Significantly differentially expressed genes in low-risk MDS mesenchyme were compared to 
experimentally defined NF-κB targets derived from GSEA signatures listed in Figure 2C7-12 and online 
database.13 FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
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Table S2. Transcriptional signatures reflecting cellular stress in mesenchymal cells from low-risk MDS 
patients (Continued) 
Data Set Enrichment Size NES NOM 
p-val 
FDR 
q-val 
Metabolic Activities      
KEGG_PROPANOATE_METABOLISM Normal 32 -1.52 0.011 0.152 
KEGG_CITRATE_CYCLE_TCA_CYCLE Normal 30 -1.52 0.029 0.155 
KEGG_PYRIMIDINE_METABOLISM Normal 97 -1.50 0.001 0.179 
KEGG_FATTY_ACID_METABOLISM Normal 42 -1.88 <0.001 0.002 
KEGG_TRYPTOPHAN_METABOLISM Normal 40 -1.70 0.001 0.030 
KEGG_BUTANOATE_METABOLISM Normal 34 -1.70 0.001 0.031 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE Normal 20 -1.59 0.010 0.082 
REACTOME_SULFUR_AMINO_ACID_METABOLISM Normal 24 -1.56 0.020 0.110 
The size of each individual gene set, normalized enrichment score (NES), nominal p-value (NOM p-val) and 
false discovery rate (FDR q-val) values are as listed. 
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CXCL10 GSEA-Derived NF-κB Targets7-12 4.00 0.034 
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CD83 GSEA-Derived NF-κB Targets7-12 4.27 0.034 
CEACAM6 GSEA-Derived NF-κB Targets7-12 -2.48 0.024* 
DUSP6 GSEA-Derived NF-κB Targets7-12 2.58 <0.001 
DAPK1 GSEA-Derived NF-κB Targets7-12 -1.78 0.016* 
FN1 GSEA-Derived NF-κB Targets7-12 2.00 0.037 
GADD45A GSEA-Derived NF-κB Targets7-12 1.80 0.010 
IER3 GSEA-Derived NF-κB Targets7-12 3.60 0.020 
IL8 GSEA-Derived NF-κB Targets7-12 7.24 <0.001 
IL6 GSEA-Derived NF-κB Targets7-12 5.09 0.005 
LITAF GSEA-Derived NF-κB Targets7-12 407 <0.001 
MAP3K8 GSEA-Derived NF-κB Targets7-12 2.18 0.001 
NFKBIA GSEA-Derived NF-κB Targets7-12 4.47 <0.001 
NFKBIE GSEA-Derived NF-κB Targets7-12 2.88 0.036 
PLK2 GSEA-Derived NF-κB Targets7-12 2.16 0.020 
SERPINB1 GSEA-Derived NF-κB Targets7-12 2.75 0.006 
SOD2 GSEA-Derived NF-κB Targets7-12 3.18 0.002 
VEGFA GSEA-Derived NF-κB Targets7-12 2.67 <0.001 
VIM GSEA-Derived NF-κB Targets7-12 -1.93 0.028 
BCL2L11 Online Database13 2.90 0.034 
BMP2 Online Database13 4.83 0.017 
BCL3 Online Database13 2.35 0.026 
CD44 Online Database13 3.90 0.002 
CCL3 Online Database13 4.21 0.022 
CXCL9 Online Database13 6.73 0.023 
CD69 Online Database13 6.26 0.023 
EMR1 Online Database13 6.06 0.006* 
FTH1 Online Database13 2.02 0.015 
HIF1A Online Database13 4.54 <0.001 
IER2 Online Database13 3.60 0.020 
Significantly differentially expressed genes in low-risk MDS mesenchyme were compared to 
experimentally defined NF-κB targets derived from GSEA signatures listed in Figure 2C7-12 and online 
database.13 FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
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Table S3. Differential expression of bona fide downstream targets of NF-κB signaling in low-risk MDS 
mesenchymal cells (Continued) 
NF-κB target gene Signature Fold-change FDR/Pa 
INHBA Online Database13 8.08 0.026 
KDM6B (JMJD3) Online Database13 5.21 <0.001 
NR4A2 Online Database13 2.11 0.030 
LTF Online Database13 6.58 0.017 
MYC Online Database13 3.66 0.010 
SLC16A1 Online Database13 3.24 0.012 
S100A10 Online Database13 2.95 <0.001 
S100A6 Online Database13 3.06 0.006 
SOX9 Online Database13 6.11 0.001 
SLC3A2 Online Database13 2.64 0.008 
TMOD2 Online Database13 2.00 0.004 
Significantly differentially expressed genes in low-risk MDS mesenchyme were compared to 
experimentally defined NF-κB targets derived from GSEA signatures listed in Figure 2C7-12 and online 
database.13 FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
  
Table S4. Upregulation of SASP factors in low-risk MDS mesenchymal cells 
SASP factor gene Fold-change FDR/Pa 
Soluble factors and chemokines (CXCL, CCL)   
IL6 (interleukin 6) 5.10 0.005* 
IL8 (interleukin 8) 7.24 <0.001 
CCL3 (chemokine C-C motif ligand 3, MIP-1a) 4.21 0.022 
CCL7 (chemokine C-C motif ligand 7, MCP-3) 9.65 0.006* 
CXCL4 (chemokine C-X-C motif ligand 4, PF4) 6.96 0.005 
CXCL14 (chemokine C-X-C motif ligand 14) 5.54 0.023 
CXCL3 (chemokine C-X-C motif ligand 3) 6.23 0.026 
Growth factors and regulators   
VEGFA (vascular endothelial growth factor A) 6.36 <0.001 
IGFBP3 (insulin-like growth factor binding protein 3) 2.53 0.010* 
IGFBP4 (insulin-like growth factor binding protein 4) 2.17 0.004* 
IGFBP7 (insulin-like growth factor binding protein 7) 2.00 0.016* 
Proteases and regulators   
TIMP1 (tissue inhibitor of metalloproteinases 1) 2.22 0.012 
ISG15 (ISG15 ubiquitin-like modifier) 2.45 0.014* 
SERPINB2 (serpin peptidase inhibitor, member 2) 4.11 0.029* 
SMURF2 (SMAD specific E3 ubiquitin protein ligase 2) 2.46 0.029* 
Soluble or shed receptors and ligands   
ICAM1 (intercellular adhesion molecule 1) 2.51 0.010 
PLAUR (plasminogen activator, urokinase receptor, uPAR) 3.36 <0.001 
Insoluble factors (ECM)   
FN1 (fibronectin 1) 2.00 0.037* 
COL1A1 (collagen, type 1, alpha 2) 3.27 0.005 
Other   
CLTB (clathrin, light chain, Lcb) 3.20 0.009* 
CRYAB (crystalline, alpha B) 3.18 0.012 
CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1) 2.22 0.004* 
MAP1LC3B (microtubule-associated protein 1 light chain 3, beta) 2.75 0.016 
NME2 (NME/NM23 nucleus diphosphate kinase 2) 1.83 0.020 
RAC1 (Ras-related C3 botulinum toxin substrate 1, Rho family, small GTP 
binding protein) 
1.75 0.020* 
VIM (vimentin) 2.00 0.003* 
MDM2 (Mdm2 p53 binding protein homolog) 2.13 0.029* 
The differential expression of canonical SASP factors14-16 is listed. FDR: false discovery rate. aThe differential 
expression of these genes is P-significant instead of FDR-significant.  
137
Stromal inflammation in MDS
C
ha
pt
er
 4
Table S3. Differential expression of bona fide downstream targets of NF-κB signaling in low-risk MDS 
mesenchymal cells (Continued) 
NF-κB target gene Signature Fold-change FDR/Pa 
INHBA Online Database13 8.08 0.026 
KDM6B (JMJD3) Online Database13 5.21 <0.001 
NR4A2 Online Database13 2.11 0.030 
LTF Online Database13 6.58 0.017 
MYC Online Database13 3.66 0.010 
SLC16A1 Online Database13 3.24 0.012 
S100A10 Online Database13 2.95 <0.001 
S100A6 Online Database13 3.06 0.006 
SOX9 Online Database13 6.11 0.001 
SLC3A2 Online Database13 2.64 0.008 
TMOD2 Online Database13 2.00 0.004 
Significantly differentially expressed genes in low-risk MDS mesenchyme were compared to 
experimentally defined NF-κB targets derived from GSEA signatures listed in Figure 2C7-12 and online 
database.13 FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
  
Table S4. Upregulation of SASP factors in low-risk MDS mesenchymal cells 
SASP factor gene Fold-change FDR/Pa 
Soluble factors and chemokines (CXCL, CCL)   
IL6 (interleukin 6) 5.10 0.005* 
IL8 (interleukin 8) 7.24 <0.001 
CCL3 (chemokine C-C motif ligand 3, MIP-1a) 4.21 0.022 
CCL7 (chemokine C-C motif ligand 7, MCP-3) 9.65 0.006* 
CXCL4 (chemokine C-X-C motif ligand 4, PF4) 6.96 0.005 
CXCL14 (chemokine C-X-C motif ligand 14) 5.54 0.023 
CXCL3 (chemokine C-X-C motif ligand 3) 6.23 0.026 
Growth factors and regulators   
VEGFA (vascular endothelial growth factor A) 6.36 <0.001 
IGFBP3 (insulin-like growth factor binding protein 3) 2.53 0.010* 
IGFBP4 (insulin-like growth factor binding protein 4) 2.17 0.004* 
IGFBP7 (insulin-like growth factor binding protein 7) 2.00 0.016* 
Proteases and regulators   
TIMP1 (tissue inhibitor of metalloproteinases 1) 2.22 0.012 
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COL1A1 (collagen, type 1, alpha 2) 3.27 0.005 
Other   
CLTB (clathrin, light chain, Lcb) 3.20 0.009* 
CRYAB (crystalline, alpha B) 3.18 0.012 
CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1) 2.22 0.004* 
MAP1LC3B (microtubule-associated protein 1 light chain 3, beta) 2.75 0.016 
NME2 (NME/NM23 nucleus diphosphate kinase 2) 1.83 0.020 
RAC1 (Ras-related C3 botulinum toxin substrate 1, Rho family, small GTP 
binding protein) 
1.75 0.020* 
VIM (vimentin) 2.00 0.003* 
MDM2 (Mdm2 p53 binding protein homolog) 2.13 0.029* 
The differential expression of canonical SASP factors14-16 is listed. FDR: false discovery rate. aThe differential 
expression of these genes is P-significant instead of FDR-significant.  
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Table S5 Negative regulators of hematopoiesis upregulated in low-risk MDS mesenchymal cells  
Gene name Effect on hematopoiesis FC FDR/Pa 
TGFB1 Negative Regulator of Hematopoiesis17 4.44 0.048 
S100A8 Negative Regulator of Erythropoiesis18-19, 24 4.44 0.024 
S100A9 Negative Regulator of Erythropoiesis18-19, 24 4.56 0.028 
CCL3 Negative Regulator of Erythropoiesis18-19, 24 4.21 0.022 
IL8 Negative Regulator of Erythropoiesis18-19, 24 7.24 <0.001 
INHBA Negative Regulator of B-lymphopoiesis20 8.08 0.026 
FTH1 Myelosuppressive Effects21 2.02 0.015 
LTF Myelosuppressive Effects21 6.58 0.017 
CCL5 Myelosuppressive Effects21 2.71 0.036* 
IL8 Myelosuppressive Effects21 7.24 <0.001 
PF4 (CXCL4) Negative Regulator of Megakaryopoiesis and HSCs activity22-23 6.96 0.005 
The differential expression of known secreted negative regulators of hematopoiesis17-24 is listed. FC: Fold 
change; FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
  
SUPPLEMENTAL FIGURES 
 
Figure S1. Principle component analysis (PCA) of an age-matched cohort of low-risk MDS and normal 
mesenchymal cells. (A) Patient and control characteristics. (B) PCA plot. 
139
Stromal inflammation in MDS
C
ha
pt
er
 4
Table S5 Negative regulators of hematopoiesis upregulated in low-risk MDS mesenchymal cells  
Gene name Effect on hematopoiesis FC FDR/Pa 
TGFB1 Negative Regulator of Hematopoiesis17 4.44 0.048 
S100A8 Negative Regulator of Erythropoiesis18-19, 24 4.44 0.024 
S100A9 Negative Regulator of Erythropoiesis18-19, 24 4.56 0.028 
CCL3 Negative Regulator of Erythropoiesis18-19, 24 4.21 0.022 
IL8 Negative Regulator of Erythropoiesis18-19, 24 7.24 <0.001 
INHBA Negative Regulator of B-lymphopoiesis20 8.08 0.026 
FTH1 Myelosuppressive Effects21 2.02 0.015 
LTF Myelosuppressive Effects21 6.58 0.017 
CCL5 Myelosuppressive Effects21 2.71 0.036* 
IL8 Myelosuppressive Effects21 7.24 <0.001 
PF4 (CXCL4) Negative Regulator of Megakaryopoiesis and HSCs activity22-23 6.96 0.005 
The differential expression of known secreted negative regulators of hematopoiesis17-24 is listed. FC: Fold 
change; FDR: false discovery rate. aThe differential expression of these genes is P-significant instead of 
FDR-significant. 
  
SUPPLEMENTAL FIGURES 
 
Figure S1. Principle component analysis (PCA) of an age-matched cohort of low-risk MDS and normal 
mesenchymal cells. (A) Patient and control characteristics. (B) PCA plot. 
140
Chapter 4
C
ha
pt
er
 4
 
 
Figure S2 (up). Transcriptional activation of p53 and senescence pathways in mesenchymal cells from 
low-risk MDS. (A-B) Representative GSEA plot of gene sets demonstrating enrichment of senescence 
programs (A) and p53 activation (B). (C) Significantly upregulated gene sets indicating activation of p53 
signaling. (D) Expression level of senescence marker p19 and canonical downstream p53-mediated 
senescence markers p21 and DEC1.25 NES: normalized enrichment score; FDR: false discovery rate. *FDR < 
0.05; **FDR < 0.01; ***FDR < 0.001.  
Figure S3 (right). NF-κB activation in CD271+ endosteal cells in low-risk MDS. (A) Representative 
photomicrographs (original magnification x40) of the distribution of CD271+ mesenchymal cells identified 
by immunohistochemistry (brown). CD271+ cells are enriched at the endosteal surface and have a spindle-
shaped morphology. (B) Representative immune-histochemical analysis (original magnification x40) of 
phospho-p65 (brown) in low-risk MDS (n = 2) (bottom panel) and age-matched controls (n = 2) (top panel), 
demonstrating NF-κB activation of spindle-shaped endosteal cells in low-risk MDS. (C) The percentage of 
phospho-p65+ bone lining cells as a fraction of the total bone lining cells in low-risk MDS compared to age-
matched controls. *P < 0.05 
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Figure S4. A working model of mesenchyme involvement in low-risk MDS pathogenesis: integration of 
transcriptional networking in human disease and mouse modeling. Activation of NF-κB in mesenchymal 
cells induces ineffective hematopoiesis and promotes malignant transformation through secretion of 
Jagged-1 and senescence associated factors, negatively affecting hematopoiesis and driving leukemic 
transformation. NF-κB activation may be maintained by autocrine/paracrine feedback signaling networks.  
 
  
SUPPLEMENTAL REFERENCES 
1. Groschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes 
concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369-381. 
2. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet 
journal. 2011;17:pp. 10-12. 
3. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of 
transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36. 
4. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq 
experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562-578. 
5. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 
2010;11:R106. 
6. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 
2005;102:15545-15550. 
7. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Divergent gene regulation and growth effects by 
NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene. 2003;22:1955-1964. 
8. Hanson JL, Hawke NA, Kashatus D, Baldwin AS. The nuclear factor kappaB subunits RelA/p65 and c-
Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 
2004;64:7248-7255. 
9. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic targets 
downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor 
signaling. J Biol Chem. 2005;280:17435-17448. 
10. Rashi-Elkeles S, Elkon R, Weizman N, et al. Parallel induction of ATM-dependent pro- and 
antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. Oncogene. 
2006;25:1584-1592. 
11. Schon M, Wienrich BG, Kneitz S, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the 
susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst. 2008;100:862-875. 
12. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. 
Oncogene. 2006;25:6685-6705. 
13. Boston University Gene Source: NF-kB Target Genes. http://www.bu.edu/nf-kb/gene-
resources/target-genes/. Accessed January 2, 2015 
14. Coppe JP, Patil CK, Rodier F, et al. A human-like senescence-associated secretory phenotype is 
conserved in mouse cells dependent on physiological oxygen. PLoS One. 2010;5:e9188. 
15. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853-
2868. 
16. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the 
dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118. 
17. Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant 
hematopoiesis. Leukemia. 2003;17:1731-1737. 
143
Stromal inflammation in MDS
C
ha
pt
er
 4
 
 
 
Figure S4. A working model of mesenchyme involvement in low-risk MDS pathogenesis: integration of 
transcriptional networking in human disease and mouse modeling. Activation of NF-κB in mesenchymal 
cells induces ineffective hematopoiesis and promotes malignant transformation through secretion of 
Jagged-1 and senescence associated factors, negatively affecting hematopoiesis and driving leukemic 
transformation. NF-κB activation may be maintained by autocrine/paracrine feedback signaling networks.  
 
  
SUPPLEMENTAL REFERENCES 
1. Groschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes 
concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369-381. 
2. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet 
journal. 2011;17:pp. 10-12. 
3. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of 
transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36. 
4. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq 
experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562-578. 
5. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 
2010;11:R106. 
6. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 
2005;102:15545-15550. 
7. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Divergent gene regulation and growth effects by 
NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene. 2003;22:1955-1964. 
8. Hanson JL, Hawke NA, Kashatus D, Baldwin AS. The nuclear factor kappaB subunits RelA/p65 and c-
Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 
2004;64:7248-7255. 
9. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic targets 
downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor 
signaling. J Biol Chem. 2005;280:17435-17448. 
10. Rashi-Elkeles S, Elkon R, Weizman N, et al. Parallel induction of ATM-dependent pro- and 
antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. Oncogene. 
2006;25:1584-1592. 
11. Schon M, Wienrich BG, Kneitz S, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the 
susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst. 2008;100:862-875. 
12. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. 
Oncogene. 2006;25:6685-6705. 
13. Boston University Gene Source: NF-kB Target Genes. http://www.bu.edu/nf-kb/gene-
resources/target-genes/. Accessed January 2, 2015 
14. Coppe JP, Patil CK, Rodier F, et al. A human-like senescence-associated secretory phenotype is 
conserved in mouse cells dependent on physiological oxygen. PLoS One. 2010;5:e9188. 
15. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853-
2868. 
16. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the 
dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118. 
17. Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant 
hematopoiesis. Leukemia. 2003;17:1731-1737. 
144
Chapter 4
C
ha
pt
er
 4
18. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. 
J Clin Invest. 2013;123:4595-4611. 
19. Broxmeyer HE, Cooper S, Lu L, Miller ME, Langefeld CD, Ralph P. Enhanced stimulation of human 
bone marrow macrophage colony formation in vitro by recombinant human macrophage colony-
stimulating factor in agarose medium and at low oxygen tension. Blood. 1990;76:323-329. 
20. Nishihara T, Ohsaki Y, Ueda N, Koseki T, Eto Y. Induction of apoptosis in B lineage cells by activin A 
derived from macrophages. J Interferon Cytokine Res. 1995;15:509-516. 
21. Broxmeyer HE, Cooper S, Hangoc G, Kim CH. Stromal cell-derived factor-1/CXCL12 selectively 
counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell 
proliferation in vitro. Stem Cells Dev. 2005;14:199-203. 
22. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a 
negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. 
Blood. 2007;110:1153-1160. 
23. Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell quiescence 
through CXCL4 secretion. Nat Med. 2014;20:1315-1320. 
24. Dimicoli S, Wei Y, Bueso-Ramos C, et al. Overexpression of the toll-like receptor (TLR) signaling 
adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One. 
2013;8:e71120. 
25. Qian Y, Zhang J, Yan B, Chen X. DEC1, a basic helix-loop-helix transcription factor and a novel target 
gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem. 
2008;283:2896-2905. 
  
  
18. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. 
J Clin Invest. 2013;123:4595-4611. 
19. Broxmeyer HE, Cooper S, Lu L, Miller ME, Langefeld CD, Ralph P. Enhanced stimulation of human 
bone marrow macrophage colony formation in vitro by recombinant human macrophage colony-
stimulating factor in agarose medium and at low oxygen tension. Blood. 1990;76:323-329. 
20. Nishihara T, Ohsaki Y, Ueda N, Koseki T, Eto Y. Induction of apoptosis in B lineage cells by activin A 
derived from macrophages. J Interferon Cytokine Res. 1995;15:509-516. 
21. Broxmeyer HE, Cooper S, Hangoc G, Kim CH. Stromal cell-derived factor-1/CXCL12 selectively 
counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell 
proliferation in vitro. Stem Cells Dev. 2005;14:199-203. 
22. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a 
negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. 
Blood. 2007;110:1153-1160. 
23. Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell quiescence 
through CXCL4 secretion. Nat Med. 2014;20:1315-1320. 
24. Dimicoli S, Wei Y, Bueso-Ramos C, et al. Overexpression of the toll-like receptor (TLR) signaling 
adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One. 
2013;8:e71120. 
25. Qian Y, Zhang J, Yan B, Chen X. DEC1, a basic helix-loop-helix transcription factor and a novel target 
gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem. 
2008;283:2896-2905. 
  
  
 
  
 
  
    
Chapter 5
 
  
 
  
    
SUMMARY AND GENERAL 
DISCUSSION
   
1. SUMMARY OF THE RESULTS 
The bone marrow microenvironment supports and regulates the activity of hematopoietic stem 
cells (HSCs). Recent work in experimental mouse models has shown that genetic manipulation of 
mesenchymal elements within the niche is sufficient for the development of leukemia.1,2 
However, the molecular mechanisms underlying the concept of niche-induced leukemogenesis 
and their relevance for human disease have remained elusive. This thesis adopted the human 
leukemia predisposition disorder Shwachman-Diamond syndrome (SDS) as a model disease to 
address these open questions, as an involvement of the HSC niche in the pathogenesis of this 
disease could be hypothesized based on several aspects. These included the presence of 
pathognomonic mutations in mesenchymal cells (due to the congenital nature of SDS), the 
existence of skeletal defects in SDS patients, and the lack of leukemic transformation in mice with 
hematopoietic-restricted Sbds deficiency.3 
To unravel niche contributions to SDS hematological phenotypes, two tissue-specific conditional 
knock-out mouse models were used, which allowed to dissect hematopoietic cell intrinsic and 
extrinsic effects of Sbds deficiency. In chapter 2, the cell intrinsic effects were considered. The 
chapter described the generation and characterization of the first mouse model of neutropenia 
in SDS, obtained by targeted deletion of Sbds in Cebpa+ hematopoietic stem and progenitor cells 
(HSPCs). Although homozygous deletion of Sbds produced a lethal phenotype, transplantation of 
fetal liver cells from Sbdsf/f Cebpacre/+ R26EYFP/+ embryos into lethally irradiated recipients induced 
profound neutropenia. Bone marrow analysis revealed that progression through the myelocyte 
stage was impaired in Sbdsf/f Cebpacre/+ recipients, leading to decreased numbers of terminally 
differentiated neutrophils with a reactive expansion of myeloid progenitor cells. Molecularly, 
activation of the p53 tumor suppressor pathway and increased apoptosis characterized late 
stages of myelopoiesis. The data revealed a critical dependency of a specific cell type in the 
hematopoietic hierarchy on SBDS, while, unanticipatedly, rapidly cycling progenitor populations 
were not functionally affected by loss of the protein. 
While intrinsic Sbds deficiency in hematopoietic cells was sufficient to recapitulate SDS-associated 
bone marrow failure (BMF) in this model, no clear indication of myelodysplasia and no signs of 
leukemia were observed in the transplanted mice throughout the experimental follow-up. 
Conversely, myelodysplastic features were previously described in Sbdsf/f Osx-cre mice (OCSf/f), in 
which Sbds is deleted from osterix-expressing mesenchymal progenitor cells, suggesting that the 
progression of SDS to myelodysplasia (MDS) and acute myeloid leukemia (AML) may depend on 
specific cues from the bone marrow microenvironment.1 
Consequently, in chapter 3, the OCS mouse model was used to investigate how HSPC biology is 
influenced by a Sbds-deficient niche. First, it was shown that OCSf/f mice, like SDS patients, 
develop low-turnover osteoporosis, associated with impaired terminal differentiation in the bone 
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lineage. Further, exposure to the Sbds-deficient microenvironment altered specific aspects of 
HSPC biology. In particular, mitochondrial dysfunction and accumulation of reactive oxygen 
species (ROS) were observed in OCSf/f-derived HSPCs. Oxidative stress was associated with DNA 
damage (accumulation of γH2AX foci) and related cell cycle arrest, revealing a novel concept of 
niche-induced DNA damage in the hematopoietic system. However, the attenuation of HSPCs 
genomic integrity did not affect their function in competitive transplantation assays, suggesting 
that a Sbds-deficient niche is not sufficient for the malignant transformation of DNA-repair 
proficient HSPCs. Searching for the molecular events underlying the phenotype of OCSf/f mice, 
two putative mechanisms were evaluated: the activation of the p53 pathway in Osx+ cells (and 
their progeny) and the secretion of inflammatory ligands. Genetic deletion of p53 from Osx+ cells 
rescued osteoporosis, but it did not alter ROS accumulation in HSPCs. To discover candidate 
secreted proteins driving the hematopoietic stress, an unbiased whole transcriptome analysis of 
niche cells was subsequently employed in search for molecular overlaps between the mouse 
model and human SDS. This identified the alarmins S100A8 and S100A9 as proteins capable to 
elicit DNA damage repair programs in murine and human HSPCs, suggesting a functional link 
between alarmin-mediated stress signaling from the niche and establishment of a HSPC-
genotoxic environment. Importantly, abundant S100A8 and S100A9 transcript levels also 
identified a subgroup of low-risk MDS patients with significantly impaired survival. Globally, the 
results in this chapter provide evidence for a direct role of Sbds-deficient niche cells in driving 
osteoporosis in SDS, and reveal a concept of mesenchymal niche-induced attenuation of genomic 
integrity through inflammatory S100A8/9 signaling in the context of human preleukemic disease. 
After having examined how mesenchymal cells can induce hematopoietic dysfunction in 
preleukemic syndromes, chapter 4 describes the first transcriptome-wide analysis of primary 
mesenchymal cells in the human preleukemic condition MDS. Immunophenotypical analysis of 
bone marrow samples from 12 low-risk MDS patients revealed global preservation of the niche 
architecture. However, gene expression profiles obtained by massive parallel RNA sequencing 
distinguished prospectively isolated mesenchymal cells from normal and MDS individuals in 
hierarchical clustering, unveiling a profound alteration in the transcriptional programs of stromal 
cells in MDS, with enrichment of signatures for cellular stress, DNA damage and p53 activation. 
Transcriptional evidence for senescence (GSEA data) was congruent with upregulated 
senescence-associated secretory phenotype (SASP) genes in MDS CD271+ cells and with the 
enrichment of signatures for cell cycle progression and metabolic activity in control samples, 
derived from healthy individuals. In line with its proposed role as driver of SASP,4 activation of 
NF-κB was observed, as indicated by supporting transcriptional data and by increased phospho-
p65 staining in bone lining stromal cells. Finally, increased expression of the Notch ligand Jagged-
1 and of a group of negative regulators of hematopoiesis were observed in the MDS niche. In 
conclusion, impaired hematopoiesis in low-risk MDS is associated with a remarkable molecular 
alteration of the microenvironment. While the functional relevance of this changes remains to be 
shown, previous literature suggests a possible implication of NF-κB,5,6 senescence7,8 and Jagged-
12,9 pathways in the progression of MDS to overt cancer, while the expression of negative 
regulators of hematopoiesis by CD271+ cells indicates that the niche may contribute to cytopenias 
in MDS. 
  
2. NOVEL INSIGHTS ON THE PATHOGENESIS OF SDS 
The first chapters of this dissertation focused on SDS, chosen as model disease to study the role 
of the HSC niche in BMF and leukemogenesis. Much of the current knowledge on SDS 
pathogenesis has been generated in the last decade, starting with the identification of loss-of-
function mutations in the ribosome biogenesis gene SBDS as drivers of this disease.10 In spite of 
several in vitro and few in vivo studies, little is known about the cellular and molecular events 
leading to bone marrow failure and MDS/AML predisposition in this syndrome, with main 
proposed mechanisms being cellular stress in rapidly cycling progenitors in association to some 
cytoskeletal dysfunction.11 Even more obscure is the reason behind tissue specificity of symptoms 
in this ribosomopathy. The findings illustrated in chapters 2 and 3 provide new insights on SDS 
pathogenesis while offering possible explanations to the conundrum of ribosomopathies tissue 
specificity. 
 
Molecular mechanisms in SDS: activation of p53 tumor suppressor pathway 
As indicated in chapter 1, experimental data supports the view that ribosome biogenesis defects 
determine activation of the p53 tumor suppressor pathway due to the inhibitory binding of free 
ribosomal proteins to the p53 negative regulator, MDM2. Activation of p53 could explain the 
hypoplastic phenotypes observed in ribosomopathies as it induces transcriptional programs of 
cell cycle arrest, cellular senescence or apoptosis, limiting cell proliferation. In the context of SDS, 
the contribution of p53 to disease pathogenesis is still controversial. While a developmental 
model of SDS in zebrafish showed no rescue of pancreatic hypoplasia and myeloid defects upon 
loss of p53 function,12 the genetic ablation of Trp53 in mouse models of Sbds deficiency partially 
restored the exocrine pancreatic function by blocking cellular senescence programs.13 Deficiency 
of p53 also determined an increase in the number of hematopoietic progenitors in SbdsR126T/R126T 
embryos.13 
In this dissertation, the activation of the p53 pathway was analyzed in both hematopoietic 
(chapter 2) and stromal (chapter3) cells in the context of disease-relevant mouse models. The 
data demonstrates that Sbds deficiency in myeloid and mesenchymal cells equally determines an 
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Transcriptional evidence for senescence (GSEA data) was congruent with upregulated 
senescence-associated secretory phenotype (SASP) genes in MDS CD271+ cells and with the 
enrichment of signatures for cell cycle progression and metabolic activity in control samples, 
derived from healthy individuals. In line with its proposed role as driver of SASP,4 activation of 
NF-κB was observed, as indicated by supporting transcriptional data and by increased phospho-
p65 staining in bone lining stromal cells. Finally, increased expression of the Notch ligand Jagged-
1 and of a group of negative regulators of hematopoiesis were observed in the MDS niche. In 
conclusion, impaired hematopoiesis in low-risk MDS is associated with a remarkable molecular 
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leading to bone marrow failure and MDS/AML predisposition in this syndrome, with main 
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cytoskeletal dysfunction.11 Even more obscure is the reason behind tissue specificity of symptoms 
in this ribosomopathy. The findings illustrated in chapters 2 and 3 provide new insights on SDS 
pathogenesis while offering possible explanations to the conundrum of ribosomopathies tissue 
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As indicated in chapter 1, experimental data supports the view that ribosome biogenesis defects 
determine activation of the p53 tumor suppressor pathway due to the inhibitory binding of free 
ribosomal proteins to the p53 negative regulator, MDM2. Activation of p53 could explain the 
hypoplastic phenotypes observed in ribosomopathies as it induces transcriptional programs of 
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model of SDS in zebrafish showed no rescue of pancreatic hypoplasia and myeloid defects upon 
loss of p53 function,12 the genetic ablation of Trp53 in mouse models of Sbds deficiency partially 
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accumulation of the p53 protein and the upregulation of its transcriptional targets, indicating 
activation of this tumor suppressor pathway. In the Cebpa-Cre model, p53 activation was further 
experimentally supported by an increased frequency of apoptotic cells at late stages of 
myelopoiesis, characterized by p53 accumulation, with a corresponding dramatic loss of 
terminally differentiated neutrophils (chapter 2). The finding is consistent with previous in vitro 
data showing high apoptotic rates upon Sbds knockdown in human CD34+ cells14 and in different 
cell lines (32Dcl3,15 TF-1,16 K56214 and Hela16,17), as well as in SDS patient-derived iPSC lines 
differentiated towards the pancreatic or the hematopoietic lineage.18 
To assess whether p53 activation is critical for the pathogenesis of SDS, genetic and 
pharmacological inhibition of this tumor suppressor pathway were considered. Deletion of Trp53 
in mesenchymal cells rescued the osteoporotic phenotype of OCS mice (chapter 3), providing 
direct experimental support for a role of p53 in SDS bone pathology. Concerning bone marrow 
failure, due to the genetic complexity of the Sbds-flox Cebpa-Cre R26EYFP model, crossings with 
Trp53-flox mice are still ongoing while this thesis is being written. A pharmacological approach 
was however tested to preliminarily assess the relevance of p53 activation in this model. Pifithrin 
α (PFTα) is a small molecule which blocks p53-mediated transcriptional activation.19 A two month-
treatment of Sbds f/f recipients with PFTα partially rescued bone marrow cellularity, but failed to 
ameliorate the progression through the myelocyte stage and thus the production of mature 
neutrophils (Figure 1 A-C). Of note, while the lack of effects on p53 protein levels (Figure 1D) was 
predicted (PFTα targets p53 transcriptional activity rather than its stability),20 the expression of 
p53 downstream targets was unexpectedly not or modestly reduced (Figure 1E) and the apoptotic 
phenotype was not rescued (Figure 1F). An incomplete targeting of p53 transcriptional activity by 
PFTα treatment likely explains the findings, and compels the use of genetic models to clearly 
define whether p53 activation is necessary for development of neutropenia in SDS. 
In conclusion, mouse models investigated here highlight clear activation of p53 by Sbds 
deficiency, but the functional relevance of this tumor suppressor pathway for SDS pathogenesis 
needs further assessment. At the same time, data from this thesis also indicate that some aspects 
of disease pathology may be p53-independent. Specifically, the abnormal regulation of HSPCs by 
Sbds-deficient niche cells did not appear to be – at least completely – dependent on p53 
activation, as no rescue of oxidative stress was observed in p53f/f OCSf/f mice (chapter 3). A more 
complex model where p53 activation is necessary for some, but not all, aspects of SDS 
pathogenesis may also help explaining the conflicting results of studies targeting p53 activation 
in SDS models previously reported in literature.12,13 
 
 
Figure 1. Treatment with pifithrin α does not rescue neutropenia in Sbdsf/f Cebpacre/+ recipients. (A) 
Partial increase in cellularity in PFTα treated Sbds f/f recipients. Treatment with PFTα does not rescue (B) 
neutropenia or (C) arrest of myeloid lineage progression (n = 5). (D) PFTα does not alter the protein levels 
of p53 (n = 4). (E) Quantitative RT-PCR shows decreased mRNA levels of Bax but not p21 in Sbds deficient, 
PFTα treated myelocytes (n = 5).  (F) PFTα treatment is not sufficient to limit apoptosis rate in Sbds f/f 
recipients (n = 4). Data in bar graph is mean ± s.e.m. *P < 0.05. **P < 0.01. ***P < 0.001. 
 
Cytotoxic granules: a common theme in SDS tissue specificity? 
While functioning ribosomes are required in every cells of the body, ribosomal defects in SDS 
seem to specifically affect the exocrine pancreas, the skeleton and the bone marrow. Similar to 
other ribosomopathies, the cellular and molecular determinants of this specificity have remained 
elusive. For SDS, a major obstacle in the study of tissue specificity has been the limited availability 
of models recapitulating the hallmarks of this disease. In particular, while Ptf1a-cre Sbds-flox mice 
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accumulation of the p53 protein and the upregulation of its transcriptional targets, indicating 
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data showing high apoptotic rates upon Sbds knockdown in human CD34+ cells14 and in different 
cell lines (32Dcl3,15 TF-1,16 K56214 and Hela16,17), as well as in SDS patient-derived iPSC lines 
differentiated towards the pancreatic or the hematopoietic lineage.18 
To assess whether p53 activation is critical for the pathogenesis of SDS, genetic and 
pharmacological inhibition of this tumor suppressor pathway were considered. Deletion of Trp53 
in mesenchymal cells rescued the osteoporotic phenotype of OCS mice (chapter 3), providing 
direct experimental support for a role of p53 in SDS bone pathology. Concerning bone marrow 
failure, due to the genetic complexity of the Sbds-flox Cebpa-Cre R26EYFP model, crossings with 
Trp53-flox mice are still ongoing while this thesis is being written. A pharmacological approach 
was however tested to preliminarily assess the relevance of p53 activation in this model. Pifithrin 
α (PFTα) is a small molecule which blocks p53-mediated transcriptional activation.19 A two month-
treatment of Sbds f/f recipients with PFTα partially rescued bone marrow cellularity, but failed to 
ameliorate the progression through the myelocyte stage and thus the production of mature 
neutrophils (Figure 1 A-C). Of note, while the lack of effects on p53 protein levels (Figure 1D) was 
predicted (PFTα targets p53 transcriptional activity rather than its stability),20 the expression of 
p53 downstream targets was unexpectedly not or modestly reduced (Figure 1E) and the apoptotic 
phenotype was not rescued (Figure 1F). An incomplete targeting of p53 transcriptional activity by 
PFTα treatment likely explains the findings, and compels the use of genetic models to clearly 
define whether p53 activation is necessary for development of neutropenia in SDS. 
In conclusion, mouse models investigated here highlight clear activation of p53 by Sbds 
deficiency, but the functional relevance of this tumor suppressor pathway for SDS pathogenesis 
needs further assessment. At the same time, data from this thesis also indicate that some aspects 
of disease pathology may be p53-independent. Specifically, the abnormal regulation of HSPCs by 
Sbds-deficient niche cells did not appear to be – at least completely – dependent on p53 
activation, as no rescue of oxidative stress was observed in p53f/f OCSf/f mice (chapter 3). A more 
complex model where p53 activation is necessary for some, but not all, aspects of SDS 
pathogenesis may also help explaining the conflicting results of studies targeting p53 activation 
in SDS models previously reported in literature.12,13 
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While functioning ribosomes are required in every cells of the body, ribosomal defects in SDS 
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were described as consistently developing exocrine pancreatic failure,13,21 a model of SDS 
neutropenia in vivo was lacking,3 and the skeletal phenotype observed in SDS patients was only 
partially recapitulated in a LysM-cre-based model of Sbds deficiency,22 with complete absence of 
SDS-associated growth defects. This dissertation addressed these experimental gaps by 
introducing the first mouse model of Sbds deficiency-induced neutropenia (chapter 2) and 
defining skeletal abnormalities in the previously described Sbds-flox Osx-cre mice1 (chapter 3). 
With the whole spectrum of SDS symptoms modeled, it is now possible to compare findings and 
advance hypotheses on the mechanisms underlying tissue specificity in SDS symptoms. 
The Cebpa-cre model presented in chapter 2 indicates that Sbds deficiency critically affects 
myeloid lineage development at the myelocyte-to-metamyelocyte transition. This developmental 
stage is characterized by the production of so-called secondary and tertiary granules, which 
contain a number of cytotoxic molecules and matrix-remodeling peptidases essential for the 
immune function of neutrophils. Transcript levels for these granules components were found 
reduced in Sbds-deficient c-Kitint cells, while transcripts for primary granule components – 
produced from promyelocytes – were enriched, likely reflecting arrested lineage progression at 
the myelocyte stage. Interestingly, the exocrine function of the pancreas also includes the 
secretion of potentially cytotoxic molecules, among which proteases, lipases and the pancreatic 
amylase, produced by acinar pancreatic cells. Similar to myelocytes/metamyelocytes, acinar cells 
coordinate the production of pancreatic enzymes and their storage in (zymogen) granules, thus 
preventing cellular digestion and severe organ damage. Defective zymogen granule production 
was described in different in vitro and in vivo model of SDS pancreatic disease.12,18,21 
Unexpectedly, the transcriptional analysis of Osx::GFP+ cells showed that Sbds-deficient 
mesenchymal progenitor cells, critical for the osteoporotic phenotype of OCS mice, overexpress 
genes implicated in inflammation and innate immunity (chapter 3). These genes included 
cytotoxic molecules, metallopeptidases and transmembrane proteins typically found in the 
membrane of myeloid granules (Table 1). Indeed, transcriptional analysis revealed enriched 
signatures for myeloid granules in OCSf/f-derived Osx::GFP+ cells (Figure 2A). Staining of sorted 
Osx::GFP+ cells confirmed the existence of a mesenchymal subpopulation characterized by 
cytoplasmic granules (Figure 2B), although their exact content still needs to be assessed. 
Given their ‘osteoblast-like’ morphology (eccentric nucleus, prominent Golgi apparatus, 
eosinophilic cytoplasm), and because they were observed both in OCS mutants and controls, it is 
attractive to hypothesize that granule-containing Osx::GFP+ cells represent a naturally occurring 
stage in osteoblast differentiation, perhaps with a particular sensitivity to ribosomal stress. In line 
with this, it is interesting to point out that some granule components were proposed to play a 
role in bone metabolism (Table 2), and thus their production may be functional for bone-
depositing cells. If this were the case, the granule component signature in OCSf/f Osx::GFP+ cells  
Table 1. Transcripts for myeloid granule components are increased in Osx+ cells from OCSf/f mice. 
Gene Description Myeloid 
granule 
P value FC MNI 
OCSf/f 
MNI 
OCSf/+ 
Fpr2 formyl peptide receptor 2 SG, GG 0.000001 14.20 4785.48 1892.93 
Lcn2 lipocalin 2 SG  0.000284 7.50 4180.05 1948.51 
Prg2 proteoglycan 2 EG 0.000307 11.81 1686.42 698.49 
Ear2 eosinophil-associated, ribonuclease A 
family, member 2 
EG 0.000599 7.83 5028.02 2302.59 
Slpi secretory leukocyte peptidase inhibitor SG 0.002701 2.09 515.44 247.14 
Cybb cytochrome b-245, beta polypeptide SG, GG 0.000364 6.64 2147.14 1031.02 
Lyz2 lysozyme 2 AG, SG; 
GG 
0.003925 5.52 11836.58 6011.45 
Fpr1 formyl peptide receptor 1 SG, GG 0.010926 3.94 270.92 155.68 
Ctsg cathepsin G AG 0.014213 15.08 3748.10 1483.49 
Ltf lactoferrin SG 0.017512 4.29 4808.99 2694.00 
Mmp8 matrix metallopeptidase 8 SG, GG 0.019802 13.95 1055.14 417.60 
Prg3 proteoglycan 3 EG 0.021057 32.59 131.89 46.55 
Elane elastase, neutrophil expressed AG 0.035623 9.37 693.25 290.65 
Ear1 eosinophil-associated, ribonuclease A 
family, member 1 
EG 0.039260 19.61 2875.52 1085.90 
Ear3 eosinophil-associated, ribonuclease A 
family, member 3 
EG 0.039671 16.83 407.79 159.07 
Itgama integrin, alpha M  0.130952 2.62 44.30 16,94 
Sp7b Sp7 transcription factor 7  0.161034 1.23 2979.80 2428.06 
Microarray data from Osx+ cells (n = 3); the typical myeloid granule localization is indicated. aCD11b (Itgam) 
is shown as negative control. bOsx (Sp7) expression serves as positive control. Experimental details are 
described in chapter 3. FC: fold change. MNI: mean normalized intensity. AG: azurophilic granules. SG: 
specific granules. GG: gelatinase granules. EG: eosinophilic granules. 
155
Summary and general discussion
C
ha
pt
er
 5
were described as consistently developing exocrine pancreatic failure,13,21 a model of SDS 
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With the whole spectrum of SDS symptoms modeled, it is now possible to compare findings and 
advance hypotheses on the mechanisms underlying tissue specificity in SDS symptoms. 
The Cebpa-cre model presented in chapter 2 indicates that Sbds deficiency critically affects 
myeloid lineage development at the myelocyte-to-metamyelocyte transition. This developmental 
stage is characterized by the production of so-called secondary and tertiary granules, which 
contain a number of cytotoxic molecules and matrix-remodeling peptidases essential for the 
immune function of neutrophils. Transcript levels for these granules components were found 
reduced in Sbds-deficient c-Kitint cells, while transcripts for primary granule components – 
produced from promyelocytes – were enriched, likely reflecting arrested lineage progression at 
the myelocyte stage. Interestingly, the exocrine function of the pancreas also includes the 
secretion of potentially cytotoxic molecules, among which proteases, lipases and the pancreatic 
amylase, produced by acinar pancreatic cells. Similar to myelocytes/metamyelocytes, acinar cells 
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mesenchymal progenitor cells, critical for the osteoporotic phenotype of OCS mice, overexpress 
genes implicated in inflammation and innate immunity (chapter 3). These genes included 
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membrane of myeloid granules (Table 1). Indeed, transcriptional analysis revealed enriched 
signatures for myeloid granules in OCSf/f-derived Osx::GFP+ cells (Figure 2A). Staining of sorted 
Osx::GFP+ cells confirmed the existence of a mesenchymal subpopulation characterized by 
cytoplasmic granules (Figure 2B), although their exact content still needs to be assessed. 
Given their ‘osteoblast-like’ morphology (eccentric nucleus, prominent Golgi apparatus, 
eosinophilic cytoplasm), and because they were observed both in OCS mutants and controls, it is 
attractive to hypothesize that granule-containing Osx::GFP+ cells represent a naturally occurring 
stage in osteoblast differentiation, perhaps with a particular sensitivity to ribosomal stress. In line 
with this, it is interesting to point out that some granule components were proposed to play a 
role in bone metabolism (Table 2), and thus their production may be functional for bone-
depositing cells. If this were the case, the granule component signature in OCSf/f Osx::GFP+ cells  
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GG 
0.003925 5.52 11836.58 6011.45 
Fpr1 formyl peptide receptor 1 SG, GG 0.010926 3.94 270.92 155.68 
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Figure 2. Molecular and morphological analysis suggests the presence of granules in a subpopulation of 
Osx+ cells. (A) GSEA data showing enrichment of signatures for neutrophil granule constituents in 
Osx::GFP+ cells from OCSf/f mice. NES: normalized enrichment score. FDR: false discovery rate. (B) Sorted 
GFP+ cells were cytospun and stained (May-Grünwald Giemsa). GFP+ cells have an osteoblast/progenitor-
like phenotype with granular morphology observed in 10-33% of cells (n = 3). 
 
Table 2. Myeloid granule constituents in mesenchymal cell biology 
Gene Expression Function 
Fpr1 Human MSC23   
 
Expression increases upon osteogenesis24 
Mobilization intracellular calcium; cell adhesion 
and chemotaxis23 
Promotes osteoblast differentiation.25 
Fpr2 Human MSC23 Mobilization intracellular calcium; cell adhesion 
and chemotaxis23 
Lcn2 Human MSC under oxidative stress26  
BMSC of mice subjected to reduced bone 
load27 
Increases human MSC proliferation26 
Inhibits mouse osteogenesis27 
Ltf Human fetal osteoblasts28 Promotes bone anabolism29 
Mmp8 Rat embryonic osteolineage cells30 Not characterized 
Slpi Decreased expression in osteoblasts in a 
mouse model of impaired osteoblast 
differentiation (Bgn-/-)31 
Not characterized 
 
Experimental evidence of myeloid granule components expression from literature (references are in apex). 
MSC: plastic adherent mesenchymal stromal cells. 
 
could be explained by an impairment in bone lineage progression with enrichment of transcripts 
for earlier stages of differentiation, reminiscent of the imbalance between transcripts for primary 
and secondary/tertiary granules in Sbds-deficient cKitint cells (chapter 2). Indeed, a terminal 
osteogenic differentiation defect was proposed in OCSf/f mice based on the reduced expression 
of late- and the increased expression of early osteolineage markers (chapter 3). While surely 
intriguing, this hypothesis awaits a formal experimental validation. 
In conclusion, data from this thesis suggest that Sbds deficiency critically impairs lineage 
progression through granule production stages in each of the tissues affected in SDS, perhaps 
explaining tissue specificity in this ribosomopathy (Figure 3). This notion is supported by our 
experimental data in myelopoiesis, while its validity for bone lineage cells remains to be formally 
demonstrated. Likewise, more experimental insight is needed to understand what are the 
molecular consequences of Sbds deficiency in granule-producing cells, although it was earlier 
proposed that this may lead to the activation of cytotoxic molecules with consequent organ 
damage.18,21 Further exploring these concepts is of utmost importance for the field, as it could 
instruct tailored therapeutic strategies targeting at once all tissues specifically affected by SDS. 
 
 
Figure 3. A working model for tissue specificity in SDS. Data from this thesis and previously published 
work suggest that Sbds deficiency impairs lineage progression at stages characterized by the production 
of granules containing cytotoxic molecules. Unanticipatedly, this concept may apply not only to the 
pancreatic and myeloid, but also to the osteoblastic lineage.  
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Experimental evidence of myeloid granule components expression from literature (references are in apex). 
MSC: plastic adherent mesenchymal stromal cells. 
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Unfolded protein response as a novel candidate mechanism in SDS pathogenesis 
When postulating lineage progression arrest at granule producing-stages as a common feature of 
cells critically affected in SDS, a fundamental question that arises is how Sbds deficiency would 
affect such granule-containing cells. 
The production of granules and secretory vesicles is a complex process that involves several 
organelles. Nascent proteins destined for secretion translocate co-translationally from ribosomes  
to the lumen of the endoplasmic reticulum (ER), a specialized environment for protein folding. 
Next, they move to the Golgi apparatus, where a sorting takes place between constitutively 
secreted proteins and those routed for the regulated secretory pathway, which will be eventually 
stored in granules. The whole process of granule production is tightly regulated, and a crucial 
quality control exists for protein folding in the ER. Accumulation of unfolded proteins determines 
the activation of three main sensors, namely inositol-requiring protein 1α (IRE1α), protein kinase 
RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6). The so-called ‘unfolded 
protein response’ (UPR) thus activated allows buffering of the ER stress by improving ER folding 
capacity, reducing the translation and folding load, degrading misfolded proteins, and inducing 
the digestion of malfunctioning ERs by autophagy. 
Unfolded or misfolded proteins may accumulate in the ER in different conditions, including 
nutrient deprivation, impaired redox balance, and increased secretory protein synthesis.32 
Specialized secretory cells show in fact a natural propensity for protein folding stress.33 
Importantly, UPR in granule-producing cells underlies another inherited bone marrow failure 
syndrome, i.e. severe congenital neutropenia (SCN). Like SDS, SCN is characterized by a profound 
decrease in mature neutrophil counts due to different inherited mutations, of which the most 
common affect the gene encoding the neutrophil elastase (ELANE).34 In SCN, myeloid 
differentiation is arrested at the stage of promyelocytes, which – like myelocytes – are 
characterized by intense production of (primary) granules. Mechanistically, ELANE mutations in 
SCN are thought to cause mistrafficking of the protein and its accumulation in the ER. The 
resulting ER stress determines the activation of the UPR, ultimately leading to cellular 
apoptosis.35-37 Given that SDS, like SCN, appears to affect granule-producing cells, resulting in 
bone marrow failure, it is reasonable to hypothesize that Sbds deficiency equally determines ER 
stress and UPR activation, perhaps through inefficient translation and processing of secretable 
proteins. 
Recent studies already demonstrated the activation of UPR upon ribosomal stress. In zebrafish, 
loss of an essential component of the rRNA small subunit processome, kri1l, resulted in inefficient 
protein synthesis and accumulation of misfolded proteins, triggering PERK activity.38 Of note, 
inhibition of PERK rescued hematopoietic failure observed in kri1l mutants. Similarly, RPL22 
inactivation in T cell precursors, which is observed in ∼10% of pediatric T-ALL patients,39 was 
recently reported to activate the PERK-EIF2a-ATF4 stress pathway (Patel et al., Cancer Res 
2015;75(15 Suppl):Abstract nr 1269). Importantly, this finding could reflect the direct dependency 
of ATF4 translation on the availability of functional ribosomes. 
The translation of the key UPR transcription factors ATF4 is in fact normally inhibited by the 
presence of two upstream open reading frames (uORF) in its mRNA (reviewed in 40). During 
normal conditions, after the first uORF is translated, the 60S abandons the mRNA, but can rapidly 
be recruited to translate the second uORF. As the latter overlaps with the main coding sequence 
of ATF4, but has a different reading frame, this results in the inhibition of ATF4 translation. 
However, in conditions of scarce availability of 60S subunits, the recruiting of the latter on the 
second uORF is delayed. This results in bypassing the second uORF in favor of the main coding 
sequence, thus allowing the expression of ATF4. It is conceivable that RPL22 inactivation, or Sbds 
deficiency, similarly reduce the availability of 60S subunits and activate ATF4 expression. 
Although at this moment no study formally addressed the role of UPR in Sbds-deficiency, a study 
in HeLa cells showed that Sbds-knockdown induces hypersensitivity to tunicamycin, an ER stress 
inducer.41 Moreover, work from this thesis provides preliminary data supporting the concept of 
UPR activation in SDS (Figure 4). The gene expression profiling of c-Kitint cells described in chapter 
2, besides proving lineage progression arrest and p53 activation, also unraveled an enrichment of 
signatures for UPR in Sbds-deficient myelocytes (Figure 4A-C), including PERK regulated gene 
expression and transcriptional activation mediated by ATF4. RNA sequencing also showed a 
modest, although not significant, increase in the spliced isoform of X box-binding protein 1 
(Xbp1s) (Figure 4D), which is induced by activated IRE1 and drives the expression of several UPR 
targets. Finally, upregulation of specific UPR genes, including two activators of UPR sensors, 
Hspa5/BiP and calreticulin (Calr), characterized Sbds f/f myelocytes (Figure 4E).  
In conclusion, transcriptional evidence from the Cebpa-Cre model strongly suggests that Sbds 
deficiency may determine ER stress and activation of the UPR in granule producing cells. 
Importantly, UPR may also contribute to the increased rate of apoptosis observed in mutant 
myeloid cells, as programmed cell death is a possible outcome of irreversible ER stress. In this 
sense, it is important to consider that UPR induction also increases the binding of free ribosomal 
proteins to MDM2,42 thus ER stress may reinforce p53 activation to induce cell death and impaired 
differentiation in SDS affected lineages. Additional experiments to interrogate the role of UPR in 
the pathogenesis of SDS are ongoing in our laboratory.  
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Figure 4. Sbds deficient myelocytes are characterized by a signature of activated unfolded protein 
response (UPR). (A-C) Gene Set Enrichment Analysis plots indicating enrichment of data sets for UPR (A) 
and transcriptional regulation by PERK (B) and ATF4 (C). NES: normalized enrichment score. FDR: false 
discovery rate. (D) Tendency for upregulation of Xbp1 short isoform (Xbp1s, P = 0.17 by T test). (E) RNA 
sequencing data showing upregulation of different UPR genes. Data is mean ± s.e.m (n = 4). *P < 0.05. † 
FDR-adjusted P < 0.05.  
 
3. A ROLE FOR THE MICROENVIRONMENT IN LEUKEMIA PREDISPOSITION 
SYNDROMES 
The homeostasis of the hematopoietic tissue is guaranteed by the presence of hematopoietic 
stem cells (HSCs), but their maintenance and fate specification depends on signals from the bone 
marrow microenvironment (Figure 5A). Based on this notion, and on seminal work in 
experimental mouse models,1,2,43 this thesis evaluated the possibility that HSC niche cells 
contribute to two human pre-leukemic syndromes, SDS and MDS. 
First, by analyzing separately the effects of Sbds deficiency in hematopoietic and mesenchymal 
cells, it was possible to unravel a distinct contribution of the HSC niche to SDS pathogenesis. 
Specifically, the findings indicate that cell-autonomous events underlie bone marrow failure 
(neutropenia) in SDS, but do not readily explain leukemia predisposition. In fact, while all 
recipients of Sbds-deficient hematopoietic cells developed neutropenia, none of them progressed 
to MDS/AML, and only a benign and probably reactive expansion of myeloid progenitors was 
observed (chapter 2 and Figure 5B). On the contrary, in the OCS model, exposure of HSPCs to 
Sbds-deficient mesenchymal cells not only induced myelodysplasia,1 but caused oxidative and 
genotoxic stress in HSPCs (Figure 5C), thus supporting a concept of heterotypic contribution to 
the emergence of (malignant) mutations in SDS hematopoietic cells.  
Notably, however, the function of Sbds-proficient HSPCs was preserved in transplantation assays. 
Given also the absence of persistent DNA lesions in comet assays, the finding was explained in 
terms of rapid resolution of the damage and/or elimination of affected cells. However, the effect 
of a genotoxic microenvironment may be different on Sbds-deficient HSPCs. Previous in vitro 
 
  
Figure 5. A working model for hematopoietic and mesenchymal contributions to SDS pathogenesis. (A) 
In normal hematopoiesis, hematopoietic cells are supported by a healthy bone marrow niche and 
differentiate to secure the production of mature neutrophils. (B) Sbds deficiency in the hematopoietic 
lineage induces neutropenia and a reactive expansion of proliferating progenitors. This expansion, 
combined with genotoxic signals from Sbds-deficient mesenchymal cells (C), may predispose 
hematopoietic stem and progenitor cells to malignant transformation (D).  
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studies indicate in fact that Sbds deficiency reduces the ability of human cell lines to cope with 
DNA damaging agents.41 Moreover, Sbds knockdown was associated with accumulation of 
reactive oxygen species in myeloid cell lines,16 opening the possibility that intrinsic and extrinsic 
sources of oxidative stress combine in SDS hematopoietic cells, leading to stronger genotoxic 
insults. Therefore, it is intriguing to hypothesize that the coexistence of Sbds loss of function in 
the hematopoietic cells and their niche, combining environmental genotoxicity with an increased 
intrinsic sensitivity to DNA damage (with a possible further challenge represented by reactive 
progenitor proliferation), result in neoplastic transformation, thus explaining AML predisposition 
in the human disease (Figure 5D). Combining the two mouse models presented in this dissertation 
by genetic (Cebpacre/+;Osxcre/+ double knockout system) or transplantation experiments (Cebpacre/+ 
Sbdsf/f fetal liver cells transplanted in OCS mutant mice or S100-overexpressing mice44) will be 
required to fully demonstrate the codependency of hematopoietic and niche contributions to 
leukemogenesis in SDS.  
The second human pre-leukemic syndrome analyzed in this dissertation is MDS and, in particular, 
the subset associated with low-risk prognosis. Massive parallel RNA sequencing indicated that the 
gene expression programs of bone marrow niche cells are profoundly reshaped in low-risk MDS, 
with enriched signatures for cellular stress and senescence (chapter 4). More importantly, the 
same molecules proposed to underlie the genotoxic effects of the microenvironment on HSPCs in 
SDS, S100A8 and S100A9, were found overexpressed in a subset of low-risk MDS patients 
characterized by poor survival (chapter 3). These findings indicate a possible prognostic value of 
niche cell analysis in MDS (yet still to be demonstrated in larger cohorts of patients), and suggest 
that the genotoxic effect of the microenvironment on HSPCs may be of broader relevance to 
human leukemic predisposition syndromes. 
In summary, this thesis unraveled a new model of niche contribution to hematologic diseases via 
attenuation of genomic integrity of HSPCs. The study reinforces the importance of stromal cells 
for the homeostasis of the bone marrow and suggests that leukemogenesis should be interpreted 
at the tissue level (the bone marrow), rather than focusing solely on HSPCs. This notion, relatively 
novel for the hematology field, actually echoes the old concept of ‘field carcinogenesis’. Already 
in the late 50s, skin graft experiments demonstrated that the exposure of the dermal stroma to 
carcinogens was necessary to transform epithelial cells, while exposing epithelial cells alone was 
not sufficient to their transformation.45 
Carcinogenesis was thus proposed to result from “field effects” of chemical compounds on the 
whole tissue45-47 rather than from the genetic transformation of single cell types. From the first 
elaboration of the field carcinogenesis hypothesis, a body of literature has shown the importance 
of stromal elements in the field of solid tumors, with the remarkable emergence of so-called 
“cancer associated fibroblast”, shown to contribute to tumorigenesis and disease progression.48 
Data from this thesis similarly propose that mesenchymal cells may be important for 
leukemogenesis, at least in pre-leukemic syndromes, thus shifting the focus of 
hematology/oncology from the ‘cellular’ level (the HSC) to the ‘ecosystem’ level, i.e., the entire 
hematopoietic tissue. 
 
The S100A8/9 DAMPs as inducers of genotoxicity 
An important objective of this dissertation was to investigate the cellular and molecular 
mechanisms underlying the concept of niche-induced leukemogenesis. In chapter 1, two non-
mutually exclusive models were proposed to explain this phenomenon. According to the first, the 
niche would facilitate carcinogenesis by selecting premalignant HSC clones naturally emerging in 
the bone marrow, thus promoting disease progression to overt cancer. This ‘Darwinian’ model 
seems congruent with a number of studies demonstrating that niche cells in premalignant mouse 
models are able to maintain aberrant hematopoietic clones, while offering limited support to 
normal hematopoiesis (reviewed in 49). The second model considered instead the possibility that 
the very emergence of (pre)malignant clones, rather than their selection, directly depends on 
aberrant niche cells. This thesis demonstrated that this principle could be relevant for the human 
disorders SDS and MDS (chapter 3). 
The DAMP molecules S100A8 and S100A9 were found overexpressed both in a niche-restricted 
mouse model of SDS and in primary niche cells from human SDS and MDS patients. S100A8/9 
signaling was independently able to induce DNA damage in cultured murine and human HSPCs. 
Blockade of S100A8/9 receptor TLR4 was sufficient to rescue DNA damage in OCS mutant-derived 
HSPCs, demonstrating the critical role of these DAMPs in establishing a genotoxic 
microenvironment for hematopoietic cells. By destabilizing genomic integrity, S100A8/9 may 
promote accumulation of somatic mutations in SDS/MDS-derived HSPCs potentially favoring the 
emergence of leukemic clones, in agreement with the model of niche cells as inducers of 
leukemogenesis. 
The observation that single molecules from the microenvironment can destabilize the genomic 
integrity of parenchymal cells is not limited to the hematology field. In breast oncology, a similar 
scenario was described, demonstrating a role for the matrix metalloproteinase 3 (MMP3, or 
stromelysin) in inducing genomic instability of breast epithelial cells. While MMP3 is normally 
produced by stromal cells during mammary development, inducing its overexpression in vivo 
determined epithelial-to-mesenchymal transition (EMT) and development of tumors 
characterized by non-random cytogenetic changes.50 Subsequent in vitro studies further 
demonstrated that epithelial cells exposed to soluble MMP3 activate the GTPase Rac1, which in 
turn induces mitochondrial dysfunction, with consequent oxidative stress and DNA damage.51 The 
163
Summary and general discussion
C
ha
pt
er
 5
studies indicate in fact that Sbds deficiency reduces the ability of human cell lines to cope with 
DNA damaging agents.41 Moreover, Sbds knockdown was associated with accumulation of 
reactive oxygen species in myeloid cell lines,16 opening the possibility that intrinsic and extrinsic 
sources of oxidative stress combine in SDS hematopoietic cells, leading to stronger genotoxic 
insults. Therefore, it is intriguing to hypothesize that the coexistence of Sbds loss of function in 
the hematopoietic cells and their niche, combining environmental genotoxicity with an increased 
intrinsic sensitivity to DNA damage (with a possible further challenge represented by reactive 
progenitor proliferation), result in neoplastic transformation, thus explaining AML predisposition 
in the human disease (Figure 5D). Combining the two mouse models presented in this dissertation 
by genetic (Cebpacre/+;Osxcre/+ double knockout system) or transplantation experiments (Cebpacre/+ 
Sbdsf/f fetal liver cells transplanted in OCS mutant mice or S100-overexpressing mice44) will be 
required to fully demonstrate the codependency of hematopoietic and niche contributions to 
leukemogenesis in SDS.  
The second human pre-leukemic syndrome analyzed in this dissertation is MDS and, in particular, 
the subset associated with low-risk prognosis. Massive parallel RNA sequencing indicated that the 
gene expression programs of bone marrow niche cells are profoundly reshaped in low-risk MDS, 
with enriched signatures for cellular stress and senescence (chapter 4). More importantly, the 
same molecules proposed to underlie the genotoxic effects of the microenvironment on HSPCs in 
SDS, S100A8 and S100A9, were found overexpressed in a subset of low-risk MDS patients 
characterized by poor survival (chapter 3). These findings indicate a possible prognostic value of 
niche cell analysis in MDS (yet still to be demonstrated in larger cohorts of patients), and suggest 
that the genotoxic effect of the microenvironment on HSPCs may be of broader relevance to 
human leukemic predisposition syndromes. 
In summary, this thesis unraveled a new model of niche contribution to hematologic diseases via 
attenuation of genomic integrity of HSPCs. The study reinforces the importance of stromal cells 
for the homeostasis of the bone marrow and suggests that leukemogenesis should be interpreted 
at the tissue level (the bone marrow), rather than focusing solely on HSPCs. This notion, relatively 
novel for the hematology field, actually echoes the old concept of ‘field carcinogenesis’. Already 
in the late 50s, skin graft experiments demonstrated that the exposure of the dermal stroma to 
carcinogens was necessary to transform epithelial cells, while exposing epithelial cells alone was 
not sufficient to their transformation.45 
Carcinogenesis was thus proposed to result from “field effects” of chemical compounds on the 
whole tissue45-47 rather than from the genetic transformation of single cell types. From the first 
elaboration of the field carcinogenesis hypothesis, a body of literature has shown the importance 
of stromal elements in the field of solid tumors, with the remarkable emergence of so-called 
“cancer associated fibroblast”, shown to contribute to tumorigenesis and disease progression.48 
Data from this thesis similarly propose that mesenchymal cells may be important for 
leukemogenesis, at least in pre-leukemic syndromes, thus shifting the focus of 
hematology/oncology from the ‘cellular’ level (the HSC) to the ‘ecosystem’ level, i.e., the entire 
hematopoietic tissue. 
 
The S100A8/9 DAMPs as inducers of genotoxicity 
An important objective of this dissertation was to investigate the cellular and molecular 
mechanisms underlying the concept of niche-induced leukemogenesis. In chapter 1, two non-
mutually exclusive models were proposed to explain this phenomenon. According to the first, the 
niche would facilitate carcinogenesis by selecting premalignant HSC clones naturally emerging in 
the bone marrow, thus promoting disease progression to overt cancer. This ‘Darwinian’ model 
seems congruent with a number of studies demonstrating that niche cells in premalignant mouse 
models are able to maintain aberrant hematopoietic clones, while offering limited support to 
normal hematopoiesis (reviewed in 49). The second model considered instead the possibility that 
the very emergence of (pre)malignant clones, rather than their selection, directly depends on 
aberrant niche cells. This thesis demonstrated that this principle could be relevant for the human 
disorders SDS and MDS (chapter 3). 
The DAMP molecules S100A8 and S100A9 were found overexpressed both in a niche-restricted 
mouse model of SDS and in primary niche cells from human SDS and MDS patients. S100A8/9 
signaling was independently able to induce DNA damage in cultured murine and human HSPCs. 
Blockade of S100A8/9 receptor TLR4 was sufficient to rescue DNA damage in OCS mutant-derived 
HSPCs, demonstrating the critical role of these DAMPs in establishing a genotoxic 
microenvironment for hematopoietic cells. By destabilizing genomic integrity, S100A8/9 may 
promote accumulation of somatic mutations in SDS/MDS-derived HSPCs potentially favoring the 
emergence of leukemic clones, in agreement with the model of niche cells as inducers of 
leukemogenesis. 
The observation that single molecules from the microenvironment can destabilize the genomic 
integrity of parenchymal cells is not limited to the hematology field. In breast oncology, a similar 
scenario was described, demonstrating a role for the matrix metalloproteinase 3 (MMP3, or 
stromelysin) in inducing genomic instability of breast epithelial cells. While MMP3 is normally 
produced by stromal cells during mammary development, inducing its overexpression in vivo 
determined epithelial-to-mesenchymal transition (EMT) and development of tumors 
characterized by non-random cytogenetic changes.50 Subsequent in vitro studies further 
demonstrated that epithelial cells exposed to soluble MMP3 activate the GTPase Rac1, which in 
turn induces mitochondrial dysfunction, with consequent oxidative stress and DNA damage.51 The 
164
Chapter 5
C
ha
pt
er
 5
OCS models present evident parallels with this study: like MMP3,52,53 also S100A8/9 DAMPs bind 
parenchymal cells (via their interaction with TLR4) and induce DNA damage via mitochondrial 
oxidative stress induction. Importantly, work from this thesis not only identified molecules with 
genotoxic potential in a preleukemic mouse model, but verified their expression in primary niche 
cells from human patients and described their relation with disease outcome in the context of 
low-risk MDS. 
In conclusion, parallels between this thesis and previous work in breast cancer models suggest 
that niche-induced genotoxicity may unexpectedly be a common theme in oncology, and the 
prevalence and relevance of this phenomenon in human disease is worth to be tested. Equally 
important is trying to define what drives the expression of genotoxic molecules in niche cells and 
how they elicit mitochondrial dysfunction and DNA damage. The following sections will provide 
insights on these issues. 
 
What drives S100A8/9 expression in niche cells? 
The DAMP proteins S100A8 and S100A9 were found overexpressed in primary niche cells from 
SDS and a subgroup of low-risk MDS patients. At this moment, it is still unclear why upregulation 
of these molecules would characterize stromal cells in two related yet distinct pre-leukemic 
disorders. 
Because low risk MDS subtypes include the 5q- syndrome, which like SDS is a ribosomopathy, it 
is reasonable to hypothesize that S100A8/9 induction in the two diseases reflects stress signaling 
from (hematopoietic) cells with impaired ribosome biogenesis. However, this hypothesis seems 
confuted by the fact that the two patients with del(5q) in the investigated MDS cohort were 
equally distributed between the high and low S100A8/9 expression subgroups. 
A likelier hypothesis is that different stress signals in SDS and MDS niche cells converge to the 
activation of common pathways determining the overexpression of DAMP molecules. Signatures 
for p53 pathway activation were for instance observed in niche cells from both OCS mice (chapter 
3) and human low-risk MDS patients (chapter 4). Interestingly, the S100A9 promoter contains 
putative p53 binding sites and was proposed to be a novel p53 target based on luciferase reporter 
assays.54 It is thus possible that S100A8/9 overexpression in the two pre-leukemic disorders 
reflects common activation of the p53 pathway in niche cells. While in the SDS model p53 
activation likely depends on ribosomal biogenesis stress associated with Sbds deficiency, in MDS 
it could reflect activation of senescence programs, as suggested by the upregulation of SASP 
factors and NF-κB targets. 
The same activation of NF-κB pathway could be sufficient to induce S100A8/9 expression, as 
shown in a model of hepatocellular carcinoma, where production of the DAMP molecules was 
observed upon overexpression of p65.55 It is interesting to note that three out of the four patients 
with low-risk MDS investigated by immunohistochemistry showed abundant P-p65 staining in 
stromal cells, while the frequency of P-p65+ bone lining cells in a fourth patient was comparable 
to controls (chapter 4). It would be interesting to test S100A8/9 expression in these samples to 
verify whether the induction of alarmins correlates with P-p65 staining and thus with NF-κB 
activation. 
A wider body of evidence from the literature links S100A8/9 expression to inflammation signaling. 
S100A8/9 were initially discovered as associated with acute and chronic inflammatory diseases56-
58 and are now considered biomarkers of inflammation.59 Although they are abundant in immune 
cells, most notably in neutrophils, they  are also expressed in non-hematopoietic cells upon 
stimulation with inflammation factors, such as PGE260 and IL-1β.61 Importantly, high Il1b 
transcript levels characterized Osx::GFP+ cells from OCS mutants (fold change 6.34, P = 0.006), 
and inflammation cytokines IL6 and IL8 were overexpressed in niche cells from low-risk MDS 
patients (chapter 4). Interestingly, the latter also showed enriched signatures for response to UV 
irradiation, which was shown to induce S100A8 expression in keratinocytes.62,63 
In conclusion, inflammation and cellular stress could be responsible for increased S100A8/9 
production in the HSPC niche of SDS and MDS patients. The presence of low-risk MDS patients 
with high and low S100A8/9 expression in the niche offers the opportunity to further explore the 
molecular pathways leading to DAMP signaling. A differential expression analysis between the 
transcriptomes of the two subgroups could in fact lead to the definition of candidate molecules 
for S100A8/9 production. Blocking DAMP expression from the niche could represent a novel 
strategy to control progression of pre-leukemic disorders. 
 
How do S100A8/9 proteins establish a genotoxic microenvironment? 
Another insufficiently understood aspect of niche-induced genotoxicity is how S100A8/9 can drive 
DNA damage in HSPCs. Because in HSPCs from OCS mutants high levels of reactive oxygen species 
(ROS) were found associated with an increase in γH2AX foci, it was hypothesized that DNA 
damage resulted from oxidative stress. As neutrophil cytosolic molecules, S100A8/9 proteins are 
well-known ROS inducers via binding and activation of the NADPH oxidase,64 and this function 
was reported in some non-myeloid tumor cell lines as well.65 Also extracellular stimulation with 
S100A9 directly increases the production of ROS in neutrophils66 and different cell lines,67 and a 
proposed mechanism to explain this phenomenon is the formation of permeability pores in the 
outer membrane of mitochondria,67 which induce the release of ROS as well as the activation of 
165
Summary and general discussion
C
ha
pt
er
 5
OCS models present evident parallels with this study: like MMP3,52,53 also S100A8/9 DAMPs bind 
parenchymal cells (via their interaction with TLR4) and induce DNA damage via mitochondrial 
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Another insufficiently understood aspect of niche-induced genotoxicity is how S100A8/9 can drive 
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endogenous apoptotic programs. Although this dissertation shows a similar apoptotic effect of 
S100A8/9 (chapter 3), the presence of hyperpolarized mitochondria in HSPCs from OCS mutants 
is hard to reconcile with the model of mitochondrial permeability. Other mechanisms of S100-
induced genotoxicity should therefore be explored. 
Notably, the effects of S100A8/9 on DNA damage were rescued by treating OCS mice with a 
blocking anti-TLR4 antibody, indicating that the genotoxic signaling depends on this pattern 
recognition receptor (chapter 3). Interestingly, stimulation of TLR4 with its well-known ligand 
lipopolysaccharide was recently reported to induce HSC exhaustion in a ROS-dependent manner 
and with an associated accrual of DNA damage in HSCs (Takizawa et al., ASH meeting 2014, 
abstract 604). An intriguing hypothesis is that S100A8/9 may similarly elicit ROS production in 
HSPCs via direct stimulation of TLR4. 
The TLR4-mediated genotoxic effects of S100A8/9 may equally depend on indirect effects due to 
a signal amplification in HSPCs. A major effect of the S100A8/9 binding to its receptors TLR4 and 
RAGE is the activation of NF-κB and the consequent secretion of proinflammatory molecules,68-71 
including TNF-α, TGF-β, IL-1β, and metalloproteinases.44,70,72  In addition to recruiting immune 
cells, which reinforce S100A8/9 secretion,73 inflammation factors may be relevant for HSPC 
genotoxicity. For instance, lipocalin-2 (Lcn2), which is upregulated upon S100A8 stimulation,74 
was recently shown to promote oxidative stress and DNA damage of hematopoietic cells in 
myeloproliferative syndromes.75,76 Interestingly, Lcn2 was among the most upregulated genes in 
niche cells from both OCSf/f mice and SDS patients (chapter 3) and thus represents another 
candidate genotoxic factor in human pre-leukemic syndromes. 
In summary, direct stimulation and indirect effects mediated through the establishment of 
inflammatory milieus may contribute to the genotoxicity of S100A8/9. Further exploring the 
mechanisms of S100A8/9-mediated DNA damage may be of broader interest to the oncology 
field, as abundant expression of these DAMPs is found in numerous cancer types,77 and 
characterizes tumor cells as well as immune infiltrating cells and tumor-supporting stroma.55,78,79 
Attenuation of  genomic integrity could represent a novel paradigm for the role of S100A8/9 in 
carcinogenesis, adding to previously established contributions to tumor cell growth,80 immune 
protection81 and metastasis.71,82 
 
Contribution of inflammation to bone marrow failure and leukemogenesis 
While analyzing niche cells in OCS mice, as well as human SDS and low-risk MDS patients, a 
recurring theme was the presence of inflammatory signatures. Osx::GFP+ cells from OCSf/f mice 
overexpressed a number of molecules involved in inflammation (chapter 3 and Table 1), including 
the master regulators of the inflammasome cascade caspase 1 (fold-change 4.66, P = 0.03) and 
IL-1β (fold-change 6.34, P = 0.006). Importantly, of the ~25 common differentially expressed 
genes between niche cells from the OCS model and human SDS patients, 15 were related to 
inflammation and immunity (chapter 3). Signatures for inflammation also characterized CD271+ 
cells from low-risk MDS patients, probably resulting from NF-κB-mediated senescence signaling 
(chapter 4). Finally, the S100A8/9-TLR4 axis, typically marking local inflammatory activity,59 
characterized the studied pre-leukemic syndromes, with a proposed role in inducing DNA damage 
in HSPCs. Collectively, these findings suggest that inflammation may play a role in the 
pathogenesis of preleukemic disease. 
Further support for this concept comes from recent publications. In particular, it was reported 
that myelodysplastic syndromes often coexist with inflammatory manifestations, such as 
rheumatic disorders, arthritis and inflammatory bowel disease.83 Additionally, inflammation 
factors such as TNF-α and IFN-γ proteins accumulate in the bone marrow of MDS patients,84 with 
a proposed role in inducing TLR-4 upregulation in hematopoietic cells.85 As previously indicated 
(chapter 3, Discussion), the same TLR signaling pathway is often active in MDS86 and probably 
contributes to BMF and AML development in the 5q- syndrome subgroup.87 Finally, the 
proinflammatory molecules IFN-γ and TNF-α were found overexpressed in the bone marrow of 
patients affected by Fanconi anemia (FA), another BMF and AML predisposition syndrome.88 Of 
these factors, TNF-α appeared to play a role in impairing erythroid differentiation of patient bone 
marrow cells,88 and it stimulated ROS accumulation and leukemogenesis in the Fancc-/- FA mouse 
model.89 
Collectively, these observations indicate that inflammation is not only a trademark of preleukemic 
syndromes, but it may indeed have functional relevance for the pathogenesis of these disorders, 
including tumorigenesis. Leukemia predisposition syndromes thus reinforce the longstanding 
relationship between inflammation and cancer. Already in the 19th century, Rudolf Virchow 
hypothesized, based on the presence of leukocyte infiltrates in tumors, that cancer develops on 
inflamed tissues.90 Chronic inflammation is now considered a major risk factor of cancer 
development.91 Moreover, different tumors are characterized by inflammatory milieus, with 
secretion of cytokines, chemokines and tissue remodeling factors, the presence of which led some 
to refer to tumors as “wounds that do not heal”.92 
An emerging question is how inflammation milieus are established in pre-leukemic syndromes. In 
the context of low-risk MDS, proinflammation molecules produced by the niche coincide with a 
senescence-associated secretion profile (SASP), as suggested by this thesis (chapter 4) and by 
previous reports analyzing plastic-adherent stromal cultures from MDS patients.93-95 Moreover, 
especially in low-risk MDS, senescence programs are not limited to the mesenchymal 
compartment, but also characterize hematopoietic cells, including HSPCs.96,97 It cannot be 
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therefore excluded that senescence is initially established in the hematopoietic compartment, 
primarily affected by MDS, and next propagated to the bone marrow microenvironment via the 
SASP.98 Establishment of senescent milieus could next contribute to disease progression. In the 
context of solid tumors, it was already shown that senescent stromal cells sustain the growth of 
parenchymal cells,99-101 and promote malignant transformation, invasion and metastasis.102,103 
Whether a similar role is played by senescent niche cells in human MDS remains to be proven. 
Another intriguing hypothesis to explain inflammation phenotypes in preleukemic syndromes is 
that the presence of cytopenias contributes directly to sustained inflammation in these diseases. 
Peripheral cell deficiencies may mimic the elimination of differentiated cells observed upon 
infections, thus eliciting the release of proinflammatory molecules that signal directly to HSPCs to 
induce their mobilization, proliferation and differentiation.104-107 While these activation signals 
rapidly terminate upon elimination of pathogens, in BMF the inflammation would persist due to 
genetically-determined impairment of mature hematopoietic cell production. Chronic ‘sterile’ 
inflammation may thus lead to exhaustion of the stem cell pool and bone marrow failure,108 
ultimately contributing to hematopoietic dysfunction. Moreover, the exit from dormancy of HSCs 
was recently shown to induce oxidative stress and DNA damage,109 promoting malignant 
transformation. Data from this thesis suggest that inflammatory molecules in the 
microenvironment may equally contribute to HSPC DNA damage. 
In conclusion, while work described in this thesis demostrated that niche cells can directly induce 
genotoxic stress in hematopoietic cells, it is also possible that diseased hematopoietic clones 
contribute to niche reprogramming by establishing inflammatory environments (Figure 6). This 
model can explain why, in disorders such as MDS, mesenchymal cells would be affected even in 
the apparent absence of a primary genetic mutation. 
 
 
Figure 6. A model for inflammation contributions to human preleukemic syndromes. In MDS, a primary 
genetic event in HSPCs may drive establishment of a senescent/proinflammatory environment that 
reshapes the bone marrow niche. This alteration may be genetically determined in inherited BMF 
syndromes such as SDS. Inflammation and SASP factors coming from the microenvironment may next 
contribute to progression of preleukemic HSPC clones to overt malignant transformation. 
CONCLUSIONS AND PERSPECTIVES 
The worked described in this thesis was aimed at studying SDS and MDS pathogenesis with a 
particular focus on the role of HSPC niche cells in leukemia predisposition. Important conclusions 
can be drawn from the data presented. A first conclusion concerns the pathogenesis of SDS. In 
particular, it was shown that ribosome biogenesis defects do not affect all (proliferating) cells, but 
that the type and extent of ribosomopathy-induced stress strictly depends on the affected cellular 
types and their differentiation stage, with Sbds deficiency critically impairing the myelocyte-to-
metamyelocyte transition in the myeloid lineage. The availability of a transplantation model of 
neutropenia offers the opportunity to better investigate the molecular mechanisms underlying 
attenuated lineage progression in myelopoiesis. However, developing an in vitro model faithfully 
recapitulating cellular defects at the myelocyte stage would be of tremendous help, allowing the 
use of high-throughput screenings before engaging in transplantation studies, with evident 
advantages in terms of ethics, time and finances. 
A second major finding in this dissertation was the discovery that S100A8 and S100A9 mRNA 
levels in primary niche cells from low-risk MDS patients correlate with poor disease outcome, 
regardless of the mutational status of MDS clones, while previously established classification 
methods failed to identify patients with dismal prognosis.110 This finding suggests that S100A8/9 
levels in the niche could be used as prognostic markers in low-risk MDS. Notably, the prognostic 
value of S100A8 expression was already proposed in AML, with high S100A8 in myeloblasts 
predicting poor outcome.111 Moreover, the use of stromal cell signatures as prognostic factors 
has been already proposed in solid tumors, such as breast cancer, non-small cell lung carcinoma 
and intrahepatic cholangiocarcinoma.112-115 Importantly, a first report in hematology has shown 
that increased numbers of immunophenotypically-defined mesenchymal subsets in bone marrow 
aspirates predict relapse in AML patients.116 Given these precedents, future work will be aimed 
at confirming the prognostic value of S100A8 and S100A9 niche expression in extended cohorts 
of MDS patients, as well as developing diagnostic tests tailored for daily clinical practice. 
Finally, this thesis reports on a novel contribution of niche cells to leukemogenesis via induction 
of genotoxic milieus for HSPCs, thus potentially contributing to the occurrence of oncogenic 
mutations. Important follow-up studies should first clarify whether the crosstalk between 
preleukemic clones and aberrant niches results in leukemogenesis. As previously indicated, 
genetic or transplantation studies may help elucidating this aspect. If leukemia development is 
observed in such studies, it will be equally important to verify if increased S100A8/9 secretion 
from the niche is required for leukemogenesis. This could be achieved either by using anti-TLR4 
antibodies, as shown in chapter 3, or by using small molecule inhibitors blocking the capacity of 
S100A8/9 heterodimer to bind its receptor. Molecules of this type, namely quinolone-3-
carboxamide derivatives (ABR-215050 and ABR-215757), are currently tested as potential 
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preleukemic clones and aberrant niches results in leukemogenesis. As previously indicated, 
genetic or transplantation studies may help elucidating this aspect. If leukemia development is 
observed in such studies, it will be equally important to verify if increased S100A8/9 secretion 
from the niche is required for leukemogenesis. This could be achieved either by using anti-TLR4 
antibodies, as shown in chapter 3, or by using small molecule inhibitors blocking the capacity of 
S100A8/9 heterodimer to bind its receptor. Molecules of this type, namely quinolone-3-
carboxamide derivatives (ABR-215050 and ABR-215757), are currently tested as potential 
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treatment of prostate cancer and inflammatory diseases.117-119 Administering such molecules to 
established mouse models of MDS progression to leukemia will be seminal in exploring the 
feasibility of niche-targeting therapies in human disease. 
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  LIST OF ABBREVIATIONS 
 
µCT  Micro-computed tomography 
AD  Anauxetic dysplasia 
AG  Azurophilic granule 
AML  Acute myeloid leukemia 
ANC  Absolute neutrophil count 
BCS  Bowen-Conradi syndrome 
BMF  Bone marrow failure 
CAR  CXCL12-abundant reticular 
CFU-C  Colony forming unit culture 
CFU-F  Fibroblast colony forming unit 
CHH  Cartilage-hair hypoplasia 
CLP  Common lymphoid progenitor 
CMP  Common myeloid progenitor 
DAMP  Damage-associated molecular pattern 
DBA  Diamond-Blackfan anemia 
DC  Dendritic cell 
DCL  Donor cell leukemia 
DDR  DNA damage response 
EG  Eosinophilic granule 
EMT  Epithelial-mesenchymal transition 
ER  Endoplasmic reticulum 
ES  Enrichment score 
FA  Fanconi anemia 
FC  Fold change  
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FDR  False discovery rate 
FPKM  Fragments per kilobase of exon per million fragments mapped 
GG  Gelatinase granule 
GMP  Granulocyte-macrophage progenitor 
GSEA  Gene set enrichment analysis 
Hb  Hemoglobin 
HSC  Hematopoietic stem cell 
HSPC  Hematopoietic stem and progenitor cell 
IBMFS  Inherited bone marrow failure syndrome 
ICA  Isolated congenital asplenia 
iPSC  Induced pluripotent stem cell 
IPSS  International prognostic scoring system 
IRES  Internal ribosome entry site 
LR-PSS  Lower-risk prognostic scoring system 
MB  Myeloblast 
MC  Myelocyte 
MCV  Mean corpuscular volume 
MDS  Myelodysplastic syndrome 
MDSC  Myeloid-derived suppressor cell 
MEP  Megakaryocyte–erythroid progenitor 
MFI  Mean fluorescence intensity 
MM  Metamyelocyte 
MPC  Mesenchymal progenitor cell 
MPP  Multipotent progenitor 
MSC  Mesenchymal stromal cell 
MSigDB Molecular signature database 
NAIC  North American Indian childhood cirrhosis 
NES  Normalized enrichment score 
NET  Neutrophil extracellular trap 
NK  Natural killer 
OCS  Osx-cre Sbds-flox strain 
PCA  Principal component analysis 
PLT  Platelet 
PM  Promyelocyte 
RBC  Red blood cell 
ROS  Reactive oxygen species 
SASP  Senescence-associated secretory profile 
SC  Segmented cell 
SCN  Severe congenital neutropenia 
SDS  Shwachman-Diamond syndrome 
SEM  Standard error of the mean 
SG  Specific granule 
SLAM  Signaling lymphocyte activation molecule 
T-ALL  T-cell acute lymphoblastic leukemia 
TCS  Treacher Collins syndrome 
uORF  Upstream open reading frame 
UPR  Unfolded protein response 
WBC  White blood cell 
X-DC  X-linked dyskeratosis congenita 
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  ENGLISH SUMMARY 
The white blood cells, red blood cells and platelets circulating in the human blood are necessary 
for the survival of the entire organism, but their lifespan is limited. Sustaining a continuous 
production of new blood cells, or hematopoiesis, is the function of the so-called hematopoietic 
stem cells (HSC), located in the bone marrow. HSCs are undifferentiated, pluripotent cells capable 
of concurrently generating by cell division one differentiation-committed cell and another HSC, 
thus maintaining the hematopoietic potential throughout the lifespan of an organism. However, 
because sustained proliferation may result in the accumulation of genetic mutations, HSCs are 
often kept in a non-dividing, quiescent state to protect the genomic integrity in the blood lineage. 
The balance between HSC quiescence, proliferation and differentiation depends both on intrinsic 
programs and on signals coming from regulatory non-hematopoietic cells in the bone marrow 
microenvironment, cells which are collectively referred to as the HSC niche. The niche comprises 
several cell types among which mesenchymal progenitor cells. Disruption of the delicate 
mechanism regulating HSCs may lead to the development of acute myeloid leukemia, a form of 
cancer characterized by uncontrolled proliferation of immature myeloid cells that fail to fully 
differentiate.  
While numerous studies have focused on identifying genetic mutations in leukemic cells that 
intrinsically explain their malignant behavior, investigations on possible extrinsic contributions to 
HSC transformation have been so far limited. Genetically engineered mouse models have shown 
that aberrant niche cells can promote leukemogenesis, but the underlying molecular 
mechanisms, as well as their relevance to human disease states, remain to be elucidated. 
The aim of this thesis was to shed further light on these key issues, seeking answers to the 
following questions: 
1. What is the contribution of niche cells to leukemogenesis? 
2. What molecular mechanisms drive such contributions? 
3. What is the relevance of these concepts and mechanisms to human disease? 
To this end, two human bone marrow failure disorders were analyzed which confer a significantly 
increased risk of developing leukemia: Shwachman-Diamond syndrome (SDS) and the 
myelodysplastic syndromes (MDS).  
The first part of this thesis focuses on SDS, which was chosen as ‘index disease’ based on several 
considerations. First, as an inherited monogenic disorder, SDS is particularly suitable for 
experimental modeling. Moreover, SDS patients, besides suffering from severe neutropenia and 
leukemia predisposition, present skeletal abnormalities and osteoporosis, thus it was 
hypothesized that mesenchymal lineage cells may be involved in SDS pathogenesis. Finally, it was 
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previously shown that mice with reduced hematopoietic expression of Sbds, the ribosome 
biogenesis gene mutated in SDS, do not develop leukemia, suggesting that Sbds deficiency in 
hematopoietic cells is not sufficient for leukemia predisposition. 
In this thesis, cell intrinsic and extrinsic contributions to SDS pathogenesis were dissected using 
two conditional Sbds knockout mouse models targeting hematopoietic and niche cells, 
respectively. 
Chapter 2 describes the development and characterization of a hematopoietic lineage-specific 
mouse model, obtained by transplanting wild type mice with Sbds-deficient hematopoietic cells. 
Sbds deficiency in hematopoietic cells was achieved by deleting the gene through a cre-loxP 
system expressed under the control of the Cebpa promoter. Cebpa encodes for a hematopoietic 
transcription factor expressed in a subset of immunophenotypic hematopoietic stem and 
progenitor cells (HSPCs) and critical for myeloid development. Validation experiments on the 
transplanted mice confirmed highly efficient deletion of Sbds from HSPCs and throughout all 
hematopoietic differentiation stages, including the vast majority of myeloid-committed 
progenitor cells. Importantly, while previous attempts to recapitulate SDS disease characteristics 
in mice failed to induce neutropenia, all mice transplanted with Sbds-deficient cells demonstrated 
a profound reduction of circulating granulocytes, thus recapitulating for the first time SDS-
associated neutropenia in a mouse model. 
Analysis of this model subsequently allowed investigating the mechanisms linking Sbds deficiency 
to bone marrow failure. The general view on SDS and other ‘ribosomopathies’ is that ribosome 
biogenesis defects should mostly affect dividing progenitor cells due to the high demand of 
protein synthesis connected to cellular proliferation. At odds with this view, analysis of 
transplanted mice revealed that hematopoietic progenitor cells tolerate Sbds deficiency, while 
cells at terminal stages of myeloid differentiation respond to it with p53 activation and 
programmed cell death, thus providing cellular insights into the specific development of 
neutropenia in SDS. A final observation from transplanted mice was the fact that none of them 
showed signs of leukemia, further suggesting that non-hematopoietic cells may contribute to 
malignant transformation of HSPCs in SDS. 
In chapter 3 this hypothesis was tested in a second SDS mouse model, previously developed, 
where Sbds gene deletion is confined to mesenchymal progenitor cells in the bone marrow 
microenvironment. Mice with mesenchymal cell-restricted Sbds deficiency presented growth 
retardation and osteoporosis as observed in SDS patients. Low numbers of osteoblasts and 
reduced expression of late osteoblast markers in mutant mice suggested that, much like in the 
hematopoietic lineage, Sbds impairs terminal stages of mesenchymal differentiation. 
It was earlier reported that mutant mice display myelodysplastic alterations and increased 
frequency of apoptotic HSPCs, as observed in the human disease. To better understand the 
cellular and molecular basis for these hematopoietic alterations, a series of additional 
investigations was performed. These demonstrated that the exposure to the Sbds-deficient niche 
induces mitochondrial dysfunction, accumulation of free oxygen radicals and DNA damage in 
HSPCs, with consequent activation of cell cycle checkpoints. These findings reveal a concept of 
niche-induced genotoxic stress in HSPCs, perhaps contributing to the acquisition of genetic 
alterations and leukemic evolution in SDS. 
To identify candidate mechanisms for the niche genotoxic effects on HSPCs, the transcriptome of 
Sbds-deficient mesenchymal progenitors was profiled. Like in the myeloid lineage, Sbds deficiency 
was associated with p53 activation, however deletion of p53 did not improve the hematopoietic 
phenotype of mutant mice, while it rescued osteoporosis. Other candidate mechanisms were 
searched by comparing the transcriptome of mesenchymal cells from the mouse model and 
human patients suffering from SDS and other preleukemic conditions, namely low risk MDS and 
Diamond-Blackfan anemia. 
The damage-signaling molecules S100A8 and S100A9 were found upregulated both in the mouse 
model and in the two conditions mostly associated with leukemia progression, SDS and MDS. 
These molecules were able to directly induce DNA damage and apoptosis in HSPCs and blockade 
of their signaling through the TLR4 receptor was sufficient to partially rescue niche-induced 
genotoxicity in the mouse model. High mesenchymal expression of S100A8 and S100A9 identified 
low-risk MDS patients with poor outcome independently of known prognostic factors, indicating 
that increased S100A8/9 mesenchymal expression may represent a potential prognostic marker 
of human MDS. 
Collectively, the investigations in chapter 3 reveal a concept of mesenchymal niche-induced 
genotoxic stress in heterotypic stem and progenitor cells through inflammatory signaling as an 
actionable determinant of disease outcome in human preleukemia. They  provide proof of 
principle that concepts derived from studies in mice may be relevant to human disease and stress 
the potential importance of detailed insights into the molecular wiring of mesenchymal cells in 
human disease to guide prognostification and therapeutic strategies. However, thus far, insights 
into the molecular wiring of mesenchymal cells in human hematopoietic disease have been 
derived from ex vivo-expanded mesenchymal stromal cells, with unknown relevance to their 
actual transcriptional activity in the diseased tissue. 
Chapter 4 describes the first whole-transcriptome analysis of niche elements directly isolated 
from the marrow of low-risk MDS patients. A method was developed, optimized and validated to 
perform massive parallel sequencing on these rare cells. Downstream transcriptional network 
analyses indicated that niche cells from MDS patients are transcriptionally distinct from those of 
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normal individuals and characterized by upregulation of DNA damage, cellular stress and 
inflammation-associated pathways. Transcript analysis and immunohistochemistry also 
suggested that senescence characterizes niche cells in low-risk MDS. In particular, a number of 
transcripts for senescence-associated secretable molecules with known inflammatory potential 
were found upregulated in the MDS niche. The elucidation of the mesenchymal niche cell 
transcriptome is anticipated to facilitate the experimental definition of the molecular  programs 
upstream of S100A8/9 activation and the identification of other pathways involved in the 
disruption of hematopoiesis in MDS. 
In conclusion, the experiments described in this thesis provided novel insights into the 
contribution of niche cells to impaired hematopoiesis in preleukemic conditions and the 
underlying molecular mechanisms. They established human disease relevance of concepts and 
mechanisms uncovered in murine studies and stressed the view that alterations in HSPCs and in 
their niche may work in concert to drive leukemogenesis in human preleukemic disorders. The 
findings pave the way to future analyses determining whether such microenvironmental 
contributions are necessary for leukemogenesis and raise the perspective of niche-instructed 
therapeutic targeting to delay or prevent leukemogenesis in human preleukemic disorders. 
DUTCH SUMMARY 
Nederlandse samenvatting 
De witte bloedcellen, rode bloedcellen en bloedplaatjes die circuleren in het menselijk bloed zijn 
noodzakelijk voor de overleving van het gehele organisme, maar hun levensduur is beperkt. 
Behoud van een continue productie van nieuwe bloedcellen (hematopoiese), is de taak van de 
zogenaamde hematopoietische stamcellen (HSC), gelegen in het beenmerg. HSC zijn 
ongedifferentieerde, pluripotente cellen die in staat zijn zichzelf te delen in zowel een andere HSC 
als een meer uitgerijpte cel. Hierdoor blijven HSC gedurende het gehele leven intact en vormen 
ze de basis van de bloedcelvorming.  
Omdat aanhoudende celdeling kan resulteren in de opstapeling van afwijkingen in het DNA 
(mutaties) worden HSC overwegend in een niet-delende, rustende toestand gehouden om te 
voorkomen dat er DNA schade ontstaat.  Het evenwicht tussen HSC rust, celdeling en 
differentiatie wordt bepaald door zowel cel-intrinsieke factoren als signalen van regulerende, 
niet-hematopoietische, cellen in de beenmerg micro-omgeving, de zogenaamde HSC niche. De 
niche omvat verschillende celtypes, waaronder mesenchymale cellen. Verstoring van de delicate 
regelmechanisme van HSC (zowel intrinsiek als extrinsiek) kan leiden tot de ontwikkeling van 
acute myeloïde leukemie (AML), een vorm van bloedkanker gekenmerkt door een 
ongecontroleerde proliferatie van onrijpe cellen die niet volledig differentiëren.  
Hoewel een veelheid aan studies een belangrijke rol hebben aangetoond voor genetische 
afwijkingen in hematopoietische cellen in het ontstaan van AML, is het aantal studies wat heeft 
gekeken naar de rol van extrinsieke factoren beperkt. Recent hebben studies in genetisch 
gemanipuleerde muismodellen aangetoond dat afwijkende niche-cellen het ontstaan van 
leukemie kunnen bevorderen, maar de onderliggende moleculaire mechanismen en hun 
relevantie voor menselijke ziektetoestanden, moeten nog worden opgehelderd. 
Het doel van dit proefschrift was om meer licht te werpen op deze belangrijke kwesties, op zoek 
naar antwoorden op de volgende vragen: 
1. Wat is de bijdrage van niche cellen aan leukemie? 
2. Welke moleculaire mechanismen zijn verantwoordelijk voor deze bijdragen? 
3. Wat is de relevantie van deze concepten en mechanismen voor menselijke ziekte? 
Hiertoe werden twee beenmergziekten geanalyseerd die een significant verhoogd risico op het 
ontwikkelen van leukemie in zich dragen: Shwachman-Diamond Syndroom (SDS) en 
myelodysplastische syndromen (MDS).  
Het eerste deel van dit proefschrift richt zich op SDS. Deze ziekte leek bijzonder geschikt voor het 
onderzoek naar niche bijdragen aan het ontstaan van leukemie om de volgende redenen: ten 
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eerste wordt de ziekte veroorzaakt door een mutatie die leidt tot verlies van functie van een enkel 
gen (genaamd SBDS) in alle cellen van het lichaam, wat het goed mogelijk maakt de ziekte na te 
bootsen in muizen. Bovendien hebben SDS patiënten naast afwijkingen in bloedcellen (met name 
lage aantallen witte bloedcellen (granulocyten), neutropenie genoemd) en een verhoogde kans 
op leukemie, ook skeletafwijkingen, wat een direct verband legt tussen bloed en bot-niche cellen. 
Tenslotte werd eerder aangetoond in muizen dat mutatie van het Sbds gen in bloedcellen alleen, 
onvoldoende is voor het ontwikkelen van leukemie, wat suggereert dat andere cellen wellicht een 
rol spelen in het ontstaan hiervan.  
In dit proefschrift, werden cel intrinsieke en extrinsieke bijdragen aan het ontstaan van SDS 
ontleed met behulp van muismodellen waarin het Sbds gen specifiek werd aangedaan in 
bloedcellen danwel botcellen.  
Hoofdstuk 2 beschrijft de ontwikkeling van het muizenmodel met verlies van het Sbds gen, 
specifiek in bloedcellen, verkregen door het transplanteren van normale muizen met Sbds-
deficiënte bloedcellen. Sbds deficiëntie in hematopoietische cellen werd bereikt door het 
uitknippen van het gen via een zogenaamd Cre-loxP-systeem, wat aan wordt gezet door een gen 
wat specifiek in hematopoietische cellen tot expressie komt (Cebpa). Cebpa codeert een 
hemopoëtische transcriptiefactor die tot expressie komt in een deel van de HSC en in 
voorlopercellen van de witte reeks. Dit leidt tot verlies van het Sbds gen in de gehele lijn van 
bloedcellen die uiteindelijk leiden tot gedifferentieerde granulocyten. Verlies van het gen in al 
deze celtypen werd experimenteel bevestigd en de muizen ontwikkelden een uitgesproken 
neutropenie, waarmee we het eerste muismodel van neutropenie in SDS ontwikkeld hebben.  
Analyse van dit model stelde ons in staat onderzoek te doen naar de mechanismen die ten 
grondslag liggen aan neutropenie in SDS. Dit is belangrijk omdat neutropenie een ernstige 
ziektemanifestatie is die leidt tot ernstige infecties bij aangedane patienten. Over het algemeen 
wordt aangenomen dat in SDS, maar ook in andere ziekten die gepaard gaan met defecten in 
ribosomen, met name snel delende cellen zijn aangedaan omdat delende voorlopercellen een 
hoge behoefte hebben aan de aanmaak van eiwitten (de taak van ribosomen).  
In tegenstelling tot deze aanname, liet analyse van de getransplanteerde muizen zien dat snel 
delende hematopoietische voorlopercellen Sbds deficiëntie tolereren, terwijl cellen later in de 
uitrijping naar granulocyten reageren met p53 activatie en geprogrammeerde celdood. Deze 
specificiteit voor de ontwikkeling van witte bloedcellen is in overeenstemming met de observatie 
dat met name deze cellen zijn aangedaan in SDS. Een andere belangrijke observatie was dat 
getransplanteerde muizen geen leukemie ontwikkelden, wat verder suggereert dat niet-
hematopoïetische cellen mogelijk een noodzakelijke bijdrage leveren aan leukemische 
transformatie van HSC in SDS. 
In hoofdstuk 3 werd deze hypothese getoetst in een tweede SDS muismodel, waarbij het Sbds 
gen specifiek werd verwijderd uit mesenchymale cellen in het beenmerg micro-milieu. Deze 
muizen hadden een groeiachterstand en botontkalking (osteoporose), zoals waargenomen in SDS 
patiënten. De osteoporose werd veroorzaakt door een stoornis in de ontwikkeling richting 
uitgerijpte botvormende cellen (osteoblasten). Bloedvormende cellen in het beenmerg die 
blootgesteld werden aan dit micromilieu ontwikkelden mitochondriale dysfunctie, ophoping van 
vrije zuurstofradicalen en DNA schade. Deze bevindingen beschrijven een concept van ‘niche-
geïnduceerde genotoxische stress’ in HSC, waarbij veranderingen in het micromilieu leiden tot 
toegenomen schade aan het DNA van bloedcellen. Het is voorstelbaar dat dit concept bijdraagt 
aan de ophoping van genetische schade in bloedvormende cellen die nodig is voor leukemische 
evolutie. 
Om dit verder uit te werken en kandidaat mechanismen voor de niche-geinduceerde 
genotoxische effecten op HSC te identificeren, werd het transcriptoom (genexpressieprofiel) van 
Sbds-deficiënte mesenchymale cellen bestudeerd. Net als in hematopoietische cellen van de 
witte reeks, was Sbds-deficiëntie geassocieerd met p53 activatie. Genetische deletie van p53 
leidde tot herstel van de botafwijkingen en osteoporose, maar niet tot herstel van de DNA schade 
in bloedcellen. Andere kandidaat-mechanismen werden gezocht door het vergelijken van de 
genexpressie in mesenchymale cellen uit het muizenmodel met de expressie van genen in 
mesenchymale cellen geisoleerd uit patienten met SDS en een andere preleukemische ziekte, 
myelodysplastisch syndroom (MDS).  
De ontstekings-gerelateerde moleculen S100A8 en S100A9 bleken verhoogd tot expressie te 
komen in zowel het muismodel als deze beide preleukemische ziekten. Blootstelling van HSC aan 
S100A8/A9 leidde tot DNA schade en celdood via activatie van de TLR4 receptor en blokkade van 
deze receptor in de muizen verminderde de DNA schade. Hoge expressie van S100A8 en S100A9 
in mesenchymale cellen was bovendien sterk geassocieerd met de overleving van MDS-patiënten, 
onafhankelijk van bekende prognostische factoren, wat aangeeft dat verhoogde S100A8/A9 
expressie een potentiële prognostische marker in MDS is. 
Samengevat onthult het onderzoek, beschreven in hoofdstuk 3, een nieuw concept van niche-
geïnduceerde genotoxische stress in HSC via ontstekings-gerelateerde eiwitten, waaronder 
S100A8 en S100A9, via TLR4 receptor-activatie. De relatie met de overleving in MDS suggereert 
verder dat dit nieuwe mechanisme belangrijk is voor de pathogenese van MDS en opent de 
mogelijkheid dat het remmen van deze signalering zou kunnen leiden tot verbetering van de 
overleving in deze ziekte.  
Om meer inzicht te krijgen in de biologie van mesenchymale cellen in MDS werd in Hoofdstuk 4 
de moleculaire opmaak van deze cellen bestudeerd. Een methode (RNA sequencing) werd 
ontwikkeld, geoptimaliseerd en gevalideerd om mesenchymale cellen direct afkomstig uit het 
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eerste wordt de ziekte veroorzaakt door een mutatie die leidt tot verlies van functie van een enkel 
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deze receptor in de muizen verminderde de DNA schade. Hoge expressie van S100A8 en S100A9 
in mesenchymale cellen was bovendien sterk geassocieerd met de overleving van MDS-patiënten, 
onafhankelijk van bekende prognostische factoren, wat aangeeft dat verhoogde S100A8/A9 
expressie een potentiële prognostische marker in MDS is. 
Samengevat onthult het onderzoek, beschreven in hoofdstuk 3, een nieuw concept van niche-
geïnduceerde genotoxische stress in HSC via ontstekings-gerelateerde eiwitten, waaronder 
S100A8 en S100A9, via TLR4 receptor-activatie. De relatie met de overleving in MDS suggereert 
verder dat dit nieuwe mechanisme belangrijk is voor de pathogenese van MDS en opent de 
mogelijkheid dat het remmen van deze signalering zou kunnen leiden tot verbetering van de 
overleving in deze ziekte.  
Om meer inzicht te krijgen in de biologie van mesenchymale cellen in MDS werd in Hoofdstuk 4 
de moleculaire opmaak van deze cellen bestudeerd. Een methode (RNA sequencing) werd 
ontwikkeld, geoptimaliseerd en gevalideerd om mesenchymale cellen direct afkomstig uit het 
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beenmerg te bestuderen. Dit is een belangrijke aanvulling op bestaand onderzoek waarin deze 
cellen eerst buiten het lichaam worden gekweekt en dan onderzocht. Transcriptionele netwerk 
analyse liet zien dat deze cellen fundamenteel verschillen van normale mesenchymale cellen. 
Deze verschillen werden gekenmerkt door respons op DNA-schade, cellulaire stress en 
ontsteking-relateerde veranderingen.  
Concluderend hebben de experimenten beschreven in dit proefschrift nieuwe inzichten 
gegenereerd in de bijdrage van niche cellen aan de verstoring van de bloedvorming in 
preleukemische ziekten. De onderzoekingen brachten nieuwe moleculaire mechanismen aan het 
licht en lieten relevantie zien van deze bevindingen voor humane ziekten. Op grond van de 
resultaten hypothetiseren we dat ontsteking van mesenchymale cellen leidt tot uitscheiding van 
ontstekings (gerelateerde) eiwitten die de normale bloedvorming remmen en bijdragen aan het 
ontstaan van leukemie door het induceren van DNA schade.  
De uitkomsten passen in het beeld dat veranderingen in HSC en hun niche kunnen samenwerken 
in het ontstaan van leukemie. Toekomstige onderzoekingen zullen uit moeten maken of deze 
niche-bijdragen noodzakelijk zijn voor het ontstaan van leukemie en of in dat geval de moleculaire 
mechanismen geremd kunnen worden om het ontstaan van leukemie te verhinderen of uit te 
stellen. 
  
ITALIAN SUMMARY 
Riassunto in italiano 
 
I globuli bianchi, i globuli rossi e le piastrine che circolano nel sangue umano sono necessari alla 
sopravvivenza dell’intero organismo, ma tali cellule restano in vita per un periodo di tempo 
limitato. Garantire una produzione continuata di nuove cellule sanguigne, o emopoiesi, è la 
funzione delle cosiddette cellule staminali emopoietiche (CSE), situate nel midollo osseo. 
Le CSE sono cellule indifferenziate pluripotenti capaci di generare contemporaneamente, per 
divisione cellulare, una cellula destinata al differenziamento e un’ulteriore CSE, mantenendo 
quindi il potenziale emopoietico per tutta la durata di vita dell’organismo. Tuttavia, poiché una 
proliferazione cellulare continuata può causare a lungo andare l’accumulo di mutazioni genetiche, 
le CSE sono mantenute spesso in uno stato di non divisione (quiescenza) per proteggere l’integrità 
genomica nella linea emopoietica. 
Il bilancio tra quiescenza, proliferazione e differenziazione delle CSE dipende sia da programmi 
cellulari intrinseci, sia da segnali esterni provenienti da cellule regolatorie non emopoietiche 
situate nel microambiente midollare, cellule chiamate collettivamente ‘nicchia’ della CSE. La 
nicchia comprende diversi tipi cellulari, tra cui i progenitori mesenchimali. Un’alterazione del 
delicato meccanismo di regolazione delle CSE può portare allo sviluppo della leucemia mieloide 
acuta, un tumore maligno caratterizzato da proliferazione incontrollata di cellule mieloidi 
immature che non riescono a differenziarsi completamente. Mentre numerose ricerche si sono 
concentrate sull’identificazione delle mutazioni genetiche che spiegano a livello intrinseco il 
carattere tumorale delle cellule leucemiche, gli studi sui possibili contributi estrinseci alla 
trasformazione delle CSE sono stati finora limitati. Esperimenti su topi geneticamente modificati 
hanno dimostrato che cellule della nicchia anomale possono promuovere lo sviluppo di leucemie 
(leucemogenesi), ma rimangono da chiarire sia i meccanismi molecolari alla base di questo 
fenomeno, sia la sua rilevanza per l’uomo. 
Lo scopo di questa tesi è stato quello di far luce su tali punti chiave, cercando una risposta ai 
seguenti quesiti: 
1. Qual è il ruolo delle cellule della nicchia nello sviluppo della leucemia? 
2. Quali sono i relativi meccanismi molecolari? 
3. Come si applicano tali concetti all’uomo?  
A questo scopo, sono state analizzate due sindromi di aplasia midollare che conferiscono un alto 
rischio di sviluppare la leucemia mieloide acuta: la sindrome di Shwachman-Diamond (SSD) e la 
sindrome mielodisplastica (SMD). La prima parte di questa tesi si occupa della SSD, scelta come 
paradigma sulla base di diverse considerazioni. In primo luogo, essendo la SSD una malattia 
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quindi il potenziale emopoietico per tutta la durata di vita dell’organismo. Tuttavia, poiché una 
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le CSE sono mantenute spesso in uno stato di non divisione (quiescenza) per proteggere l’integrità 
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situate nel microambiente midollare, cellule chiamate collettivamente ‘nicchia’ della CSE. La 
nicchia comprende diversi tipi cellulari, tra cui i progenitori mesenchimali. Un’alterazione del 
delicato meccanismo di regolazione delle CSE può portare allo sviluppo della leucemia mieloide 
acuta, un tumore maligno caratterizzato da proliferazione incontrollata di cellule mieloidi 
immature che non riescono a differenziarsi completamente. Mentre numerose ricerche si sono 
concentrate sull’identificazione delle mutazioni genetiche che spiegano a livello intrinseco il 
carattere tumorale delle cellule leucemiche, gli studi sui possibili contributi estrinseci alla 
trasformazione delle CSE sono stati finora limitati. Esperimenti su topi geneticamente modificati 
hanno dimostrato che cellule della nicchia anomale possono promuovere lo sviluppo di leucemie 
(leucemogenesi), ma rimangono da chiarire sia i meccanismi molecolari alla base di questo 
fenomeno, sia la sua rilevanza per l’uomo. 
Lo scopo di questa tesi è stato quello di far luce su tali punti chiave, cercando una risposta ai 
seguenti quesiti: 
1. Qual è il ruolo delle cellule della nicchia nello sviluppo della leucemia? 
2. Quali sono i relativi meccanismi molecolari? 
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A questo scopo, sono state analizzate due sindromi di aplasia midollare che conferiscono un alto 
rischio di sviluppare la leucemia mieloide acuta: la sindrome di Shwachman-Diamond (SSD) e la 
sindrome mielodisplastica (SMD). La prima parte di questa tesi si occupa della SSD, scelta come 
paradigma sulla base di diverse considerazioni. In primo luogo, essendo la SSD una malattia 
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ereditaria monogenica, essa è particolarmente adatta ad essere riprodotta in modelli 
sperimentali. Per di più, i pazienti con SSD, oltre a soffrire di neutropenia severa e predisposizione 
alla leucemia, presentano anomalie scheletriche e osteoporosi, per cui è ipotizzabile che la linea 
mesenchimale sia coinvolta nella patogenesi della SSD. Inoltre, è stato in precedenza dimostrato 
che topi con ridotta espressione emopoietica del gene per la biogenesi dei ribosomi Sbds, mutato 
nella SSD, non sviluppano leucemie, il che suggerisce che il deficit di Sbds nelle sole cellule 
emopoietiche non è sufficiente per la trasformazione delle CSE stesse. 
In questa tesi, i fattori patogenetici intrinseci ed estrinseci per la SSD sono stati analizzati 
separatamente tramite l’uso di due topi conditional knockout in cui il gene Sbds è stato deleto 
rispettivamente nelle cellule emopoietiche e nella nicchia. Il capitolo 2 descrive lo sviluppo di un 
modello murino specifico per la linea emopoietica, ottenuto trapiantando cellule epatiche fetali 
con deficit di Sbds in topi wild type. Tali cellule sono state ottenute inducendo la delezione del 
gene Sbds tramite un sistema ‘cre-loxP’ espresso sotto il controllo del promotore di Cebpa. Il gene 
Cebpa codifica un fattore di trascrizione emopoietico espresso in una frazione di cellule staminali 
e progenitrici emopoietiche (CSPE), definite in base al loro immunofenotipo, e critico per il 
differenziamento mieloide. L’efficiente delezione del gene Sbds nei topi trapiantati è stata 
verificata sperimentalmente nelle CSPE e in ogni fase del differenziamento emopoietico, 
compresi i progenitori mieloidi. Mentre i tentativi precedenti di ottenere un modello murino per 
la neutropenia associata alla SSD erano risultati fallimentari, tutti i topi trapiantati hanno 
sviluppato una forte riduzione dei granulociti nel sangue, riproducendo quindi per la prima volta 
gli effetti della SSD sulla linea mieloide in un modello murino. L’analisi di tale modello ha 
successivamente permesso di analizzare i possibili meccanismi che legano il deficit di Sbds 
all’aplasia midollare. È opinione diffusa che, nella SSD come in altre ‘ribosomopatie’, i difetti della 
biogenesi dei ribosomi colpiscano maggiormente le cellule progenitrici a causa dell’alta richiesta 
di sintesi proteica di quest’ultime, connessa al loro elevato tasso di proliferazione. L’analisi dei 
topi trapiantati ha dimostrato invece come i progenitori emopoietici tollerino il deficit di Sbds, 
mentre cellule nelle fasi terminali del differenziamento mieloide vi rispondano con l’attivazione 
di p53 e la morte cellulare programmata, fornendo quindi un meccanismo cellulare per lo 
specifico sviluppo della neutropenia nella SSD. Un’ultima osservazione effettuata sui topi 
trapiantati è stata il fatto che nessuno di essi ha mostrato segni di leucemia, suggerendo 
nuovamente che cellule non ematopoietiche possono contribuire alla trasformazione delle CSE 
nella SSD. 
Nel capitolo 3 questa ipotesi è stata testata in un secondo modello murino, sviluppato 
precedentemente, dove la delezione del gene Sbds è confinata alle cellule progenitrici 
mesenchimali nel microambiente midollare. Come i pazienti con SSD, anche i topi con deficit di 
Sbds circoscritto alle cellule mesenchimali presentano ritardo di crescita e osteoporosi. Il basso 
numero di osteoblasti e la ridotta espressione di marker per osteoblasti terminalmente 
differenziati hanno indicato che, proprio come osservato nella linea emopoietica, il deficit di Sbds 
colpisce le fasi finali del differenziamento mesenchimale. 
Era stato precedentemente riportato in letteratura che i topi con deficit mesenchimale di Sbds 
presentano alterazioni mielodisplastiche ed alto tasso di apoptosi nelle CSPE, proprio come 
osservato nella malattia umana. Una serie di analisi descritte in questa tesi hanno permesso una 
migliore comprensione dei meccanismi cellulari e molecolari alla base di queste osservazioni. Si è 
infatti dimostrato che l’esposizione a una nicchia con deficit di Sbds induce disfunzione 
mitocondriale, accumulo di radicali liberi dell’ossigeno e danno al DNA in CSPE, con conseguente 
attivazione dei checkpoint del ciclo cellulare. Questi risultati introducono il concetto di 
genotossicità della nicchia per le CSPE, genotossicità che forse contribuisce all’acquisizione di 
mutazioni genetiche e alla progressione verso la leucemia nella SSD. 
Per identificare possibili meccanismi alla base degli effetti genotossici sulle CSPE, si è poi 
analizzato il trascrittoma dei progenitori mesenchimali Sbds-deleti. Come nella linea mieloide, il 
deficit di Sbds è risultato associato all’attivazione di p53, tuttavia proprio la delezione di p53, pur 
attenuando il fenotipo osteoporotico dei topi mutanti, non è sembrata migliorare le alterazioni 
del tessuto emopoietico. Si sono quindi investigati altri possibili meccanismi patogenetici 
comparando il trascrittoma di cellule mesenchimali del modello murino e di pazienti che soffrono 
di SSD ed altre condizioni preleucemiche, nella fattispecie la SMD a basso rischio e l’anemia di 
Diamond-Blackfan. Le molecole di segnale del danno S100A8 e S100A9 sono risultate 
overespresse sia nel modello murino che nelle due sindromi più associate con leucemia mieloide 
acuta, la SSD e la SMD. Si è poi dimostrato come queste molecole siano capaci di indurre 
direttamente danno al DNA e apoptosi nelle CSPE e il blocco del loro recettore TLR4 è stato 
sufficiente a limitare la genotossicità indotta dalla nicchia nel modello murino. Inoltre, un’alta 
espressione di S100A8 e S100A9 ha identificato, tra i pazienti con SMD a basso rischio, quelli con 
decorso sfavorevole, indipendentemente da fattori prognostici già noti, per cui l’elevata 
espressione di S100A8/9 nella nicchia potrebbe rappresentare un nuovo marker di prognosi nella 
SMD umana. 
Complessivamente, gli esperimenti descritti nel capitolo 3 rivelano come la nicchia possa indurre 
stress genotossico in cellule staminali e progenitrici eterotipiche attraverso segnali infiammatori. 
Questo concetto, critico per il decorso clinico della malattia preleucemica nell’uomo, rappresenta 
al contempo un possibile target d’intervento clinico. Data tale rilevanza per la malattia umana, è 
quindi importante ottenere una visione dettagliata dei segnali molecolari provenienti dalla 
nicchia nelle sindromi preleucemiche, al fine di guidare la loro prognosi e le relative strategie 
terapeutiche. Tuttavia, le conoscenze attuali sulla nicchia di soggetti malati derivano da studi 
effettuati su cellule mesenchimali stromali espanse ex vivo, mentre non è noto in quale misura 
tale sistema rispecchi lo stato delle cellule nel contesto del tessuto malato. 
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ereditaria monogenica, essa è particolarmente adatta ad essere riprodotta in modelli 
sperimentali. Per di più, i pazienti con SSD, oltre a soffrire di neutropenia severa e predisposizione 
alla leucemia, presentano anomalie scheletriche e osteoporosi, per cui è ipotizzabile che la linea 
mesenchimale sia coinvolta nella patogenesi della SSD. Inoltre, è stato in precedenza dimostrato 
che topi con ridotta espressione emopoietica del gene per la biogenesi dei ribosomi Sbds, mutato 
nella SSD, non sviluppano leucemie, il che suggerisce che il deficit di Sbds nelle sole cellule 
emopoietiche non è sufficiente per la trasformazione delle CSE stesse. 
In questa tesi, i fattori patogenetici intrinseci ed estrinseci per la SSD sono stati analizzati 
separatamente tramite l’uso di due topi conditional knockout in cui il gene Sbds è stato deleto 
rispettivamente nelle cellule emopoietiche e nella nicchia. Il capitolo 2 descrive lo sviluppo di un 
modello murino specifico per la linea emopoietica, ottenuto trapiantando cellule epatiche fetali 
con deficit di Sbds in topi wild type. Tali cellule sono state ottenute inducendo la delezione del 
gene Sbds tramite un sistema ‘cre-loxP’ espresso sotto il controllo del promotore di Cebpa. Il gene 
Cebpa codifica un fattore di trascrizione emopoietico espresso in una frazione di cellule staminali 
e progenitrici emopoietiche (CSPE), definite in base al loro immunofenotipo, e critico per il 
differenziamento mieloide. L’efficiente delezione del gene Sbds nei topi trapiantati è stata 
verificata sperimentalmente nelle CSPE e in ogni fase del differenziamento emopoietico, 
compresi i progenitori mieloidi. Mentre i tentativi precedenti di ottenere un modello murino per 
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migliore comprensione dei meccanismi cellulari e molecolari alla base di queste osservazioni. Si è 
infatti dimostrato che l’esposizione a una nicchia con deficit di Sbds induce disfunzione 
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deficit di Sbds è risultato associato all’attivazione di p53, tuttavia proprio la delezione di p53, pur 
attenuando il fenotipo osteoporotico dei topi mutanti, non è sembrata migliorare le alterazioni 
del tessuto emopoietico. Si sono quindi investigati altri possibili meccanismi patogenetici 
comparando il trascrittoma di cellule mesenchimali del modello murino e di pazienti che soffrono 
di SSD ed altre condizioni preleucemiche, nella fattispecie la SMD a basso rischio e l’anemia di 
Diamond-Blackfan. Le molecole di segnale del danno S100A8 e S100A9 sono risultate 
overespresse sia nel modello murino che nelle due sindromi più associate con leucemia mieloide 
acuta, la SSD e la SMD. Si è poi dimostrato come queste molecole siano capaci di indurre 
direttamente danno al DNA e apoptosi nelle CSPE e il blocco del loro recettore TLR4 è stato 
sufficiente a limitare la genotossicità indotta dalla nicchia nel modello murino. Inoltre, un’alta 
espressione di S100A8 e S100A9 ha identificato, tra i pazienti con SMD a basso rischio, quelli con 
decorso sfavorevole, indipendentemente da fattori prognostici già noti, per cui l’elevata 
espressione di S100A8/9 nella nicchia potrebbe rappresentare un nuovo marker di prognosi nella 
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Complessivamente, gli esperimenti descritti nel capitolo 3 rivelano come la nicchia possa indurre 
stress genotossico in cellule staminali e progenitrici eterotipiche attraverso segnali infiammatori. 
Questo concetto, critico per il decorso clinico della malattia preleucemica nell’uomo, rappresenta 
al contempo un possibile target d’intervento clinico. Data tale rilevanza per la malattia umana, è 
quindi importante ottenere una visione dettagliata dei segnali molecolari provenienti dalla 
nicchia nelle sindromi preleucemiche, al fine di guidare la loro prognosi e le relative strategie 
terapeutiche. Tuttavia, le conoscenze attuali sulla nicchia di soggetti malati derivano da studi 
effettuati su cellule mesenchimali stromali espanse ex vivo, mentre non è noto in quale misura 
tale sistema rispecchi lo stato delle cellule nel contesto del tessuto malato. 
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Il capitolo 4 descrive la prima analisi trascrittomica delle cellule della nicchia isolate direttamente 
dal midollo osseo di pazienti con SMD a basso rischio. È stato sviluppato, ottimizzato e validato 
un nuovo metodo per permettere il sequenziamento di nuova generazione (massive parallel 
sequencing) delle rare cellule della nicchia. Successivamente, l’analisi dei network trascrizionali 
ha indicato che le cellule della nicchia di pazienti con SMD hanno un profilo di espressione genica 
distinto da quello di individui sani e caratterizzato dall’attivazione di pathway associati a danno al 
DNA, stress cellulare e infiammazione. L’analisi trascrittomica ed esperimenti di 
immunoistochimica hanno anche indicato che le cellule della nicchia di pazienti con SMD a basso 
rischio possono essere soggette a senescenza cellulare. In particolare, diverse molecole 
tipicamente secrete da cellule senescenti e con note proprietà proinfiammatorie sono risultate 
overespresse nella nicchia dei pazienti con SMD. Si prevede che lo studio del trascrittoma delle 
cellule della nicchia aiuterà a definire sperimentalmente i programmi molecolari alla base 
dell’overespressione di S100A8/9 e ad identificare altri pathway che alterano l’emopoiesi nella 
SMD. 
In conclusione, gli esperimenti descritti in questa tesi hanno dimostrato che cellule della nicchia 
contribuiscono al fenotipo emopoietico delle sindromi preleucemiche, identificando al contempo 
i relativi meccanismi molecolari. I concetti elaborati sulla base del modello murino sono risultati 
applicabili alla malattia umana ed hanno evidenziato come possa esistere una sinergia tra le 
alterazioni nelle CSPE e nella loro nicchia, sinergia che può guidare lo sviluppo delle leucemie nelle 
sindromi preleucemiche umane. Questi risultati rappresentano la base per analisi future volte a 
determinare se il contributo della nicchia sia sufficiente alla leucemogenesi, e aprono al contempo 
nuove prospettive per terapie nicchia-specifiche che ritardino o prevengano la comparsa delle 
leucemie nelle sindromi preleucemiche. 
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During these years as a PhD student I was lucky enough to share my office with great colleagues 
from the Wagemaker, Delwel, Rijneveld/Valk and Sonneveld lab. Dear Helen, you were my first 
desk-mate and the first who really welcomed me in this department. You helped me out with 
administration when I couldn’t understand Dutch language, you invited me in the Wagemaker 
lunch groups (featuring the famous Trui!) and in no time you became a dear friend. I am so 
grateful I got to enjoy that friendship once you came back from Boston. Thanks to you and to Eric 
for great game dates (Arkham is a safer city thanks to us!) and look forward to see you both very 
soon. Dear Yvette, thanks for your help with managing the blood counter. You’re always welcome 
to visit for a Magic card game session! Dear Merel, we both found more than career development 
on this department and I’m so proud of all your achievements, professional and not! Thanks to 
you and to Roel for fun nights featuring mysterious murders! Dear Rana, thanks for sharing 
delicious treats at any given occasion and good luck with your papers and thesis. Dear Leonie, 
your work promoting science is really admirable. Thank you for giving me the opportunity to 
contribute to the Discovery Festival. Dear Niek, I’m glad your career proceeds well in Utrecht. 
Thank you for all your suggestions on lentiviral transduction. Dear Carla and Anikó, you girls make 
a great teamwork: always happy and very motivated. Anikó, thanks for your help in arranging the 
career workshop. Dear Tim and Sophie, I regret the opportunity to know you better but I wish 
you good luck in your PhD track! 
It is a true blessing when your colleagues become your dearest friends. I already mentioned quite 
a few of them, but I have more members of the ‘crazy 13’ club to thank! Dear Roberto, in spite of 
your reserved personality we managed to become dear friends. We are similar in many ways, and 
we similarly missed the warm Southern European vibe in the Netherlands. Thank you so much for 
many long and interesting conversations. I truly believe you are one of the most brilliant PhDs I 
have met in my journey, and I do not need to wish you success because that’s a given. Dear Onno, 
where shall I start thanking you from? Shall I be professional and mention your help with imaging 
and computer-related issues? Honestly, I prefer instead to thank you for all the fun you brought 
to us PhD student by organizing beerclubs, roadtrips, theme-nights and other memorable events. 
You are really the glue that kept us all together! I hope you will be visiting often…we need your 
help preparing party concoctions in the US! Dear Jana, I am close to my PhD defense and still I 
cannot find the birds! All joking aside, I am so happy to have met you and become your friend. 
Thanks for showing me that no matter what happens in the lab, you can still manage to be positive 
and relaxed…you just need to stroke a furry wall! Dear Joyce, regardless of your lab moving to 
the new building you never abandoned us, luckily! Thank you for all the fun times we had 
together, from preparing the Joker’s minion masks to the many dinners (also the ones in which I 
self-invited) and of course our little trip to Helmond! Dear Julia, my concert-pal! No matter how 
grumpy you try to be, you cannot help being helpful and kind. Thanks for your tips with many 
experiments and I look forward to the next metal music event together! Dear Patricia Olofsen, 
we knew each other for little time but still you shared a lot with me, from the laughter to some 
tears. Thanks for being a great friend, I am sure wonderful things await in your life! Dear Julien, 
Monica and Patricia Aparicio, you guys made me feel less lonely in my late sorting nights…because 
you were next to me waiting for the Aria to become available! Dear Patricia, thanks for all the 
tips in arranging my thesis! Monica, I regret not having spent more time with you. Let’s fix it when 
the Señora Tomasa is in town again! And obviously good luck in wrapping up your PhD! Dear 
Julien, I will try to bring some sun to Rotterdam for my defense…so we can all meet up in your 
garden again! Good luck with your career, and remember, Marseille is close! Dear Davine, the 
only one who can understand my need of focaccia! It was great finding someone who knew my 
city in the middle of the Netherlands, you made me feel at home! Thanks for your help with the 
career event and the many tips about Stockholm! Looking forward to having you as a guest in 
Bari!  
Dear Ferry, Farshid, Mark, Shiraaz, Shirley, Adil, Avinash, thank you all for being amazing 
colleagues and good luck in your research! Dear Claudia, Marije, Marijke, Hans, Jasper and all 
the department analysts, thank you all for your help! I was often running around in search of a 
reagent or some technical advice, and you always made time for me. I also want to express my 
gratitude to the supporting personnel, Jan, Egied, Natasha, Tomasia, and especially the 
secretaries Ans, Leenke and Annelies. Dear Annelies, you made it possible for me to arrange my 
thesis while staying in Italy. Thank you so much! 
Now would you please excuse a temporary language switch to thank my Italian friends and family. 
Care Claudia, Alessia e Katia, probabilmente non avrete modo di essere con me per la mia tesi di 
dottorato, e se ci riusciste forse vi annoiereste a morte. Ciononostante, vorrei ringraziarvi per 
essermi sempre state vicine, anche solo con una chiamata o un messaggio veloce. Questi anni 
lontano da casa non sono stati sempre facili e con il vostro aiuto mi sono sentita meno sola. Grazie 
per aver ritagliato un momento per incontrarci ogni volta che scendevo a Bari (o a Lisbona!). Non 
vedo l’ora che giugno arrivi per ricreare il gruppo. Vi voglio bene! 
Caro Manuel, il tempo passa ma la nostra amicizia cresce e si rinforza. Abbiamo sopportato e 
stiamo ancora sopportando insieme le difficoltà che nascono dall’essere ricercatori, dal duro 
lavoro all’insicurezza sul nostro futuro. Grazie per il tuo ascoltare ogni mio sfogo, anche 
se…diciamocelo…mi lamento sempre per le stesse cose! Grazie anche per avermi spronato ad 
uscire ogni volta che ero nei dintorni. È strano essere lontani da casa, torni e gli amici nel tuo 
gruppo cambiano, o ridono per eventi passati cui ovviamente non hai partecipato. Ecco, tu hai 
sempre fatto in modo che quei momenti non mi pesassero. Sei un grande amico, e sono sicuro 
che lo sarai anche con un oceano di mezzo. 
Cari mamma, papà e Lorenzo. Incredibile a dirsi, anche questa è fatta! Sembra ieri quando mi 
avete lasciato nella ‘casa con il bidet nel giardino’, ed eccomi qui a scrivere le ultime pagine della 
mia tesi. So che è stato difficile accettare l’idea che avrei vissuto in un altro Paese, ma suvvia…ve 
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Scherzi a parte, vi ringrazio davvero per avermi supportato (e sopportato) durante questi anni di 
lontanza. Grazie per i pacchi pieni di bontà ‘terroniche’, dall’olio buono, alla salsiccia barese, alla 
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aver ascoltato i miei sfoghi su Skype ogni volta che c’era un problema in casa o sul lavoro. Grazie 
per aver speso soldi e tempo per venirmi a trovare (anche se mi sorge il dubbio che Dino’s 
contribuiva molto alla vostra scelta!). E grazie per avermi riaccolto a casa mentre scrivevo la tesi. 
Per quanto possa spaventarmi l’idea di partire per l’America, sapere che potrò ancora contare su 
di voi mi rincuora! E chissà…magari questa Italia cambia rotta e ci permette di riunirci 
definitivamente! Incrociamo le dita! 
Sometimes life has unexpected plans for you. I moved to the Netherlands to pursue professional 
development, and I found love. These last words of thanks are for the person that rearranged my 
life plans and convinced me to move 10,000 kilometers (sorry, 6,500 miles) away from home. 
Dear Marshall, I could not have made it without you. You always believed that I would succeed 
as a researcher, and you encouraged me to go on and finish my PhD even when I was about to 
give up. You shared your own difficulties to remind me that I was not alone in this journey. You 
made me laugh when I was homesick and made your best to make me feel at home in Rotterdam. 
When I was running late in the lab, you got on your bike and came back to Erasmus MC just to 
share dinner with me. You were my safe haven and my peace sanctuary in all these years. I have 
no words to say how thankful I am to have you in my life. I do not know what my job will be, or 
where I will live, but as long as we are together, I will always look forward to our next great 
adventure. 
 
“The sky grew darker, painted blue on blue, one stroke at a time, 
into deeper and deeper shades of night.” 
Haruki Murakami, Dance Dance Dance. 
